|
4608 genotypes with 8927 annotations displayed
of selected term and subterms
|
|
Searched Term: neoplasm
|
2610035D17Rikem1Zhgn/2610035D17Rikem1Zhgn
Krasem1Gpt/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: C57BL/6JGpt * CBA)
|
decreased gland tumor incidence
|
J:339253
|
2610035D17Rikem2Zhgn/2610035D17Rikem2Zhgn
Krasem1Gpt/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53em3Gpt/Trp53+
(involves: C57BL/6JGpt * CBA)
|
decreased gland tumor incidence
|
J:339253
|
5730403I07Rikem8Gpt/5730403I07Rikem8Gpt
(involves: C57BL/6JGpt)
|
decreased tumor growth/size
|
J:329871
|
A4gnttm1Jnaka/A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka)
|
increased gastric adenocarcinoma incidence
|
J:184485
|
| increased tumor growth/size
|
J:184485
|
Avy/?
(129S1.C3-Avy)
|
neoplasm
|
J:146879
|
Avy/a
(involves: C3H/HeJ * C57BL/6)
|
increased tumor incidence
|
J:117156
|
Avy/Aw
(129S1.C3-Avy/Aw Chr 19MOLF/Ei)
|
neoplasm
|
J:146879
|
Ay/Aw
(129S1.C3-Ay/Aw Chr 19MOLF/Ei)
|
decreased incidence of induced tumors
|
J:146879
|
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
|
increased hepatocellular carcinoma incidence
|
J:21232
|
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
|
increased hepatocellular carcinoma incidence
|
J:217802
|
Abcb4tm1Bor/Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor)
|
increased hepatocellular carcinoma incidence
|
J:217802
|
Abi3bptm1.1Smoc/Abi3bptm1.1Smoc
(B6.129S6(FVB)-Abi3bptm1.1Smoc)
|
neoplasm
|
J:278622
|
Abraxas1tm1.1Bwng/Abraxas1+
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
|
increased histiocytic sarcoma incidence
|
J:269823
|
| increased lung adenocarcinoma incidence
|
J:269823
|
| increased lymphoma incidence
|
J:269823
|
| increased tumor incidence
|
J:269823
|
Abraxas1tm1.1Bwng/Abraxas1tm1.1Bwng
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
|
increased lymphoma incidence
|
J:269823
|
| increased tumor incidence
|
J:269823
|
Acadvltm1Vje/Acadvltm1Vje
(involves: 129/Sv * C57BL/6)
|
increased tumor incidence
|
J:102010
|
Acdtm1.1Blas/Acdtm1.1Blas
Tg(KRT5-cre)1Tak/?
(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * SJL)
|
preneoplasia
|
J:160600
|
Acetm6Keb/Ace+
(involves: 129 * C57BL/6)
|
decreased tumor growth/size
|
J:122178
|
Acetm6Keb/Acetm6Keb
(involves: 129 * C57BL/6)
|
abnormal tumor morphology
|
J:122178
|
| decreased tumor growth/size
|
J:122178
|
Acetm6Keb/Acetm6Keb
(involves: 129 * C57BL/6 * CD-1)
|
decreased tumor growth/size
|
J:122178
|
Acot12em1Holi/Acot12em1Holi
(involves: C57BL/6J * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:335836
|
| increased incidence of tumors by chemical induction
|
J:335836
|
| increased tumor growth/size
|
J:335836
|
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:174942
|
Acox1tm1Jkr/Acox1tm1Jkr
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:35794
|
| increased hepatoma incidence
|
J:48180
|
Acox2em1Jynz/Acox2em1Jynz
(involves: C57BL/6N)
|
increased liver tumor incidence
|
J:323193
|
Acp3tm1Pivi/Acp3tm1Pivi
(B6.Cg-Acp3tm1Pivi)
|
increased prostate gland adenocarcinoma incidence
|
J:207558
|
| increased prostate intraepithelial neoplasia incidence
|
J:207558
|
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv)
|
increased hemangioma incidence
|
J:87544
|
| increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm1(PyVT)Arge/Actb+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm2(Tag)Arge/Actb+
(involves: 129S1/Sv)
|
increased sarcoma incidence
|
J:87544
|
Actbtm2(Tag)Arge/Actb+
Tg(Hsp70-1-cre)1Arge/0
(involves: 129S1/Sv * C57BL/6J * CBA)
|
increased leiomyosarcoma incidence
|
J:87544
|
Actn4tm1a(EUCOMM)Wtsi/Actn4tm1a(EUCOMM)Wtsi
(C57BL/6N-Actn4tm1a(EUCOMM)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Acvr1tm1Emsh/Acvr1+
(chimera involves: BALB/c * C57BL/6 * CD-1)
|
increased osteochondroma incidence
|
J:194134
|
Acvr1tm1Mak/Acvr1+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
H3c2tm1Mak/H3c2+
Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129 * C57BL/6 * FVB/N)
|
increased brain tumor incidence
|
J:285841
|
| increased glioma incidence
|
J:285841
|
Acvr1tm1Mak/Acvr1+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129 * C57BL/6 * FVB/N)
|
increased brain tumor incidence
|
J:285841
|
| increased glioma incidence
|
J:285841
|
Acvr1tm1Mak/Acvr1+
H3c2tm1Mak/H3c2+
Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:285841
|
Acvr1tm1Mak/Acvr1+
Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:285841
|
Adam9tm1Bbl/Adam9tm1Bbl
(involves: 129)
|
decreased tumor growth/size
|
J:148993
|
Adam15tm1Bbl/Adam15tm1Bbl
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal tumor susceptibility
|
J:217858,
J:84800
|
| decreased tumor growth/size
|
J:217858
|
| decreased tumor incidence
|
J:217858
|
Adam15tm1Bbl/Adam15tm1Bbl
(B6.129X1-Adam15tm1Bbl)
|
decreased tumor growth/size
|
J:84800
|
Adam15tm2.1Bbl/Adam15tm2.1Bbl
(involves: 129 * 129P2/OlaHsd * C57BL/6J * SJL)
|
abnormal tumor susceptibility
|
J:217858
|
| decreased tumor growth/size
|
J:217858
|
| decreased tumor incidence
|
J:217858
|
Adam28tm1.2Dica/Adam28tm1.2Dica
(B6JRj.129-Adam28tm1.2Dica)
|
increased incidence of induced tumors
|
J:298188
|
Adam28tm1.2Dica/Adam28tm1.2Dica
(CJRj.129-Adam28tm1.2Dica)
|
increased incidence of induced tumors
|
J:298188
|
Adamts3tm1b(KOMP)Wtsi/Adamts3tm1b(KOMP)Wtsi
(C57BL/6N-Adamts3tm1b(KOMP)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Adamts12tm1Agno/Adamts12tm1Agno
(Not Specified)
|
abnormal tumor vascularization
|
J:160778
|
| increased tumor growth/size
|
J:160778
|
Adamts18tm1.1Wzha/Adamts18tm1.1Wzha
(involves: 129 * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:258487
|
Adap1tm1c(EUCOMM)Wtsi/Adap1tm1c(EUCOMM)Wtsi
Tg(tetO-HRAS)65Lc/0
(involves: C3H * C57BL/6N * FVB/N)
|
decreased tumor growth/size
|
J:284709
|
Adgrl4tm1Adbg/Adgrl4tm1Adbg
(involves: C57BL/6)
|
abnormal tumor vascularization
|
J:330927
|
| neoplasm
|
J:330927
|
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
|
abnormal tumor morphology
|
J:147458
|
| increased mammary gland tumor incidence
|
J:147458
|
| increased metastatic potential
|
J:147458
|
| increased tumor growth/size
|
J:147458
|
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0
(FVB.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
|
abnormal tumor morphology
|
J:147458
|
| increased mammary gland tumor incidence
|
J:147458
|
| increased metastatic potential
|
J:147458
|
| increased tumor growth/size
|
J:147458
|
Afptm1(Cebpa)Ndw/Afp+
(involves: 129S7/SvEvBrd)
|
decreased incidence of tumors by chemical induction
|
J:103404
|
Aggf1Gt(PT036)Byg/Aggf1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal tumor vascularization
|
J:239252
|
| decreased tumor incidence
|
J:239252
|
Aggf1tm1Qkw/Aggf1+
(involves: 129 * C57BL/6)
|
abnormal tumor vascularization
|
J:239252
|
| decreased tumor incidence
|
J:239252
|
Agktm1.1Smoc/Agktm1.1Smoc
(Not Specified)
|
increased tumor incidence
|
J:282052
|
Agtr2tm1Tin/Y
(SWR.129P2-Agtr2tm1Tin)
|
decreased incidence of tumors by chemical induction
|
J:101726
|
Ahrb-1/Ahrd
(involves: 129S1/SvImJ * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:113356
|
Ahrd/Ahrd
(involves: 129S1/SvImJ * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:113356
|
Ahrtm1Bra/Ahr+
Tg(TRAMP)8247Ng/0
(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
|
increased prostate gland tumor incidence
|
J:118152
|
Ahrtm1Bra/Ahrtm1Bra
Tg(TRAMP)8247Ng/0
(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
|
increased prostate gland tumor incidence
|
J:118152
|
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N)
|
increased hepatoma incidence
|
J:44690
|
| increased liver adenoma incidence
|
J:44690
|
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
|
increased urinary bladder carcinoma incidence
|
J:179919
|
Ahrrtm1Yfk/Ahrrtm1Yfk
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:130214
|
Aicdatm1(cre)Mnz/Aicda+
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:153656
|
| increased follicular lymphoma incidence
|
J:153656
|
| increased hemolymphoid system tumor incidence
|
J:153656
|
| increased leukemia incidence
|
J:153656
|
| increased medulloblastoma incidence
|
J:153656
|
| increased skin squamous cell carcinoma incidence
|
J:153656
|
| increased T cell derived lymphoma incidence
|
J:153656
|
| increased tumor incidence
|
J:153656
|
Aifm2tm1Hbsh/Aifm2tm1Hbsh
(involves: 129S6/SvEvTac)
|
neoplasm
|
J:105660
|
AipGt(RRI002)Byg/Aip+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:165349
|
| increased prolactinoma incidence
|
J:165349
|
Airetm1Pltn/Airetm1Pltn
(B6.129S4-Airetm1Pltn)
|
increased B cell derived lymphoma incidence
|
J:115076
|
Akr1b8tm1Dgen/Akr1b8tm1Dgen
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:301852
|
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased tumor latency
|
J:218587
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
(C57BL/6N-Aktiptm1a(EUCOMM)Hmgu)
|
neoplasm
|
J:276210
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N)
|
increased lymphoma incidence
|
J:276210
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N)
|
increased lymphoma incidence
|
J:276210
|
Albtm1(cre/ERT2)Mtz/Alb+
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6)
|
increased cholangiocarcinoma incidence
|
J:192740
|
Albtm1(cre/ERT2)Mtz/Alb+
Hes1tm1Kag/Hes1tm1Kag
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
neoplasm
|
J:192740
|
Albtm1(cre/ERT2)Mtz/Alb+
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae)
|
increased cholangiocarcinoma incidence
|
J:254370
|
| increased hepatocellular carcinoma incidence
|
J:254370
|
Aldh2tm1.1Mak/Aldh2+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:223796
|
Aldh2tm1.1Mak/Aldh2tm1.1Mak
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased tumor latency
|
J:223796
|
| increased incidence of tumors by chemical induction
|
J:223796
|
Aldh2tm1a(EUCOMM)Wtsi/Aldh2tm1a(EUCOMM)Wtsi
Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
|
increased acute lymphoblastic leukemia incidence
|
J:193232
|
| increased lymphoma incidence
|
J:193232
|
| increased T cell derived lymphoma incidence
|
J:193232
|
Alktm1.1(ALK*F1174L)Heno/Alk+
Tg(Mpz-cre)94Imeg/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL)
|
increased neuroblastoma incidence
|
J:294092
|
Alktm1.1(ALK*F1174L)Heno/Alktm1.1(ALK*F1174L)Heno
Tg(Mpz-cre)94Imeg/0
(involves: 129X1/SvJ * C57BL/6 * C57BL/6N * SJL)
|
neoplasm
|
J:294092
|
Alktm1.1(ALK*F1174L)Heno/Alktm1.1(ALK*F1174L)Heno
Tg(Mpz-cre)94Imeg/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL)
|
decreased tumor latency
|
J:294092
|
| increased neuroblastoma incidence
|
J:294092
|
Alktm1.1(ALK*F1174L)Heno/Alktm1.1(ALK*F1174L)Heno
Tmem163Tg(ACTB-cre)2Mrt/Tmem163+
(involves: 129X1/SvJ * C57BL/6 * C57BL/6N * FVB/N * SJL)
|
neoplasm
|
J:294092
|
Alktm1.1Ics/?
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033,
J:228124
|
Alktm2.1Ics/?
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033,
J:228124
|
Alox15tm1Fun/Alox15tm1Fun
(B6.129S2-Alox15tm1Fun/J)
|
increased chronic myelocytic leukemia incidence
|
J:119405
|
Altretm1.1Hbgl/Altretm1.1Hbgl
Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased liver tumor incidence
|
J:342907
|
Ambntm1Nid/Ambntm1Nid
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased tumor incidence
|
J:94844
|
Amelxtm1Kul/Amelxtm1Kul
Tg(AMELX*P70T)2Gibs/?
(involves: 129S1/Sv * 129X1/SvJ)
|
increased tumor incidence
|
J:122914
|
AmfrGt(IST12797A11)Tigm/AmfrGt(IST12797A11)Tigm
(C57BL/6-AmfrGt(IST12797A11)Tigm)
|
increased liver tumor incidence
|
J:221247
|
Amhtm1Bhr/Amh+
Amhr2tm1Bhr/Amhr2tm1Bhr
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm1Bhr/Amhr2tm1Bhr
Inhatm1Bay/Inha+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm1Bhr/Amhr2tm1Bhr
Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:36027
|
| increased Leydig cell tumor incidence
|
J:36027
|
| increased testis tumor incidence
|
J:36027
|
| increased tumor incidence
|
J:36027
|
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
| increased ovary tumor incidence
|
J:128934
|
| increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
| increased testis tumor incidence
|
J:186144
|
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ)
|
increased granulosa cell tumor incidence
|
J:149060
|
| increased metastatic potential
|
J:149060,
J:142150
|
| increased ovary tumor incidence
|
J:142150
|
| increased testis tumor incidence
|
J:149060
|
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
| increased testis tumor incidence
|
J:186144
|
Amhr2tm3(cre)Bhr/Amhr2+
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N)
|
increased granulosa cell tumor incidence
|
J:236161
|
| increased ovary adenoma incidence
|
J:236161
|
| increased ovary tumor incidence
|
J:236161
|
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
| increased ovary tumor incidence
|
J:128934
|
| increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
| increased ovary tumor incidence
|
J:128934
|
| increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
Smad9tm1Jfm/Smad9tm1Jfm
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
| increased ovary tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+
Stk11tm1Rdp/Stk11tm1Rdp
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:187754
|
Amhr2tm3(cre)Bhr/Amhr2+
Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
neoplasm
|
J:222579
|
Amhr2tm3(cre)Bhr/Amhr2+
Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:181774,
J:187754
|
Amhr2tm3(cre)Bhr/Amhr2+
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:187754
|
Amotl1tm1Laho/Amotl1tm1Laho
Tg(Cdh5-cre/ERT2)1Rha/0
(involves: C57BL/6)
|
abnormal tumor vascularization
|
J:253854
|
Amotl1tm1Laho/Amotl1tm1Laho
Tg(Cdh5-cre/ERT2)1Rha/0
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
abnormal tumor vascularization
|
J:253854
|
| increased tumor latency
|
J:253854
|
Anp32btm1Mak/Anp32btm1Mak
(C.129P2(B6)-Anp32btm1Mak)
|
increased incidence of tumors by chemical induction
|
J:227403
|
Antxr1tm1.2Bstc/Antxr1tm1.2Bstc
(B6.Cg-Antxr1tm1.2Bstc)
|
decreased tumor growth/size
|
J:150947
|
Anxa1tm1Rjf/Anxa1tm1Rjf
(involves: 129 * C57BL/6)
|
abnormal tumor vascularization
|
J:153690
|
| decreased metastatic potential
|
J:153690
|
| decreased tumor growth/size
|
J:153690
|
Anxa1tm1Rjf/Anxa1tm1Rjf
Tg(MMTV-PyVT)634Mul/?
(involves: FVB/N)
|
decreased metastatic potential
|
J:174635
|
| decreased tumor growth/size
|
J:174635
|
Anxa7tm1Pll/Anxa7+
(B6.Cg-Anxa7tm1Pll)
|
increased hepatocellular carcinoma incidence
|
J:93685
|
| increased lymphoma incidence
|
J:93685
|
| increased tumor incidence
|
J:93685
|
Apaf1tm1Her/Apaf1tm1Her
(involves: 129S6/SvEvTac * C57BL/6J)
|
neoplasm
|
J:60409
|
ApcGt(XA018)Byg/Apc+
(B6.129P2-ApcGt(XA018)Byg)
|
increased colon adenoma incidence
|
J:202877
|
| increased intestinal adenoma incidence
|
J:202877
|
| increased tumor growth/size
|
J:202877
|
ApcGt(XA018)Byg/Apc+
((B6.129P2-ApcGt(XA018)Byg x C3H/HeJ)F1)
|
decreased tumor growth/size
|
J:202877
|
ApcM1Tno/Apc+
(involves: C57BL/6 * DBA/2JJcl)
|
increased mammary gland tumor incidence
|
J:218227
|
| increased osteoma incidence
|
J:218227
|
| increased skin tumor incidence
|
J:218227
|
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl))
|
increased mammary adenocarcinoma incidence
|
J:218227
|
| increased mammary gland tumor incidence
|
J:218227
|
| increased osteoma incidence
|
J:218227
|
| increased osteosarcoma incidence
|
J:218227
|
| increased pilomatricoma incidence
|
J:218227
|
| increased skin tumor incidence
|
J:218227
|
| increased trichoepithelioma incidence
|
J:218227
|
ApcMin/Apc+
(involves: AKR/J * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:10209
|
| increased intestinal adenoma incidence
|
J:10209
|
ApcMin/Apc+
(C57BL/6J-ApcMin)
|
increased colon adenoma incidence
|
J:158733,
J:160399
|
| increased intestinal adenoma incidence
|
J:158733,
J:241611,
J:1879,
J:85142
|
ApcMin/Apc+
(involves: C57BL/6J)
|
abnormal tumor pathology
|
J:268691
|
| decreased intestinal adenoma incidence
|
J:268691
|
| decreased tumor growth/size
|
J:268691
|
| increased intestinal adenoma incidence
|
J:299895,
J:75393,
J:94108
|
| increased mammary adenocarcinoma incidence
|
J:94108
|
ApcMin/Apc+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased incidence of induced tumors
|
J:67445
|
| increased mammary gland tumor incidence
|
J:67445
|
ApcMin/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:95893
|
| neoplasm
|
J:95893
|
ApcMin/Apc+
(B6(AKR)-ApcMin)
|
increased intestinal adenocarcinoma incidence
|
J:10209
|
| increased intestinal adenoma incidence
|
J:10209
|
| increased mammary gland tumor incidence
|
J:15101
|
ApcMin/Apc+
((AKR/J x C57BL/6J-ApcMin)F1)
|
decreased intestinal adenoma incidence
|
J:1879
|
| increased incidence of tumors by chemical induction
|
J:15101
|
| increased intestinal adenocarcinoma incidence
|
J:21369
|
ApcMin/Apc+
((MA/MyJ x C57BL/6J-ApcMin)F1)
|
decreased intestinal adenoma incidence
|
J:1879
|
ApcMin/Apc+
(C57BL/6J-ApcMin/J)
|
increased colon adenoma incidence
|
J:331404
|
| increased intestinal adenoma incidence
|
J:331404
|
ApcMin/Apc+
Arhgef4tm1Taki/Arhgef4+
(B6J.Cg-Arhgef4tm1Taki ApcMin)
|
decreased intestinal adenoma incidence
|
J:157023
|
| decreased tumor growth/size
|
J:157023
|
ApcMin/Apc+
Arhgef4tm1Taki/Arhgef4tm1Taki
(B6J.Cg-Arhgef4tm1Taki ApcMin)
|
decreased intestinal adenoma incidence
|
J:157023
|
| decreased tumor growth/size
|
J:157023
|
ApcMin/Apc+
Arhgef4tm1Taki/Arhgef4tm1Taki
Spata13tm1Taki/Spata13tm1Taki
(B6J.Cg-Arhgef4tm1Taki Spata13tm1Taki ApcMin)
|
abnormal tumor pathology
|
J:157023
|
| abnormal tumor vascularization
|
J:157023
|
| decreased intestinal adenoma incidence
|
J:157023
|
| decreased tumor growth/size
|
J:157023
|
ApcMin/Apc+
Atp5f1aMom2/Atp5f1a+
(involves: C57BL/6J * DBA/2J)
|
decreased tumor incidence
|
J:73854
|
ApcMin/Apc+
Atp5f1aMom2/Atp5f1aMom2
(involves: C57BL/6J * DBA/2J)
|
decreased tumor incidence
|
J:73854
|
ApcMin/Apc+
Bcl2l14tm1.1Boui/Bcl2l14tm1.1Boui
(involves: C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:296081
|
ApcMin/Apc+
Blmtm1Grdn/Blm+
(involves: 129P2/OlaHsd * 129S/SvEv * Black Swiss * C57BL/6J)
|
increased colon adenoma incidence
|
J:79058
|
| increased gastrointestinal tumor incidence
|
J:79058
|
| increased intestinal adenoma incidence
|
J:79058
|
ApcMin/Apc+
Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased incidence of induced tumors
|
J:67445
|
| increased incidence of tumors by chemical induction
|
J:67445
|
| increased mammary gland tumor incidence
|
J:67445
|
ApcMin/Apc+
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * C57BL/6J * C57BL/6N)
|
increased colon adenocarcinoma incidence
|
J:216704
|
| increased colon adenoma incidence
|
J:216704
|
| increased colon tumor incidence
|
J:216704
|
| increased gastrointestinal tumor incidence
|
J:216704
|
ApcMin/Apc+
Ccnd1tm1Dsn/Ccnd1tm1Dsn
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:78500
|
ApcMin/Apc+
Cd44tm1Mak/Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased intestinal adenoma incidence
|
J:135025
|
ApcMin/Apc+
Cd44tm1Mak/Cd44tm1Mak
(involves: C57BL/6J)
|
decreased intestinal adenoma incidence
|
J:204874
|
ApcMin/Apc+
Cd44tm1Stpa/Cd44tm1Stpa
(involves: C57BL/6J * C57BL/6JIco)
|
increased intestinal adenoma incidence
|
J:204874
|
ApcMin/Apc+
Cd44tm1Stpa/Cd44tm2Stpa
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:204874
|
ApcMin/Apc+
Cd44tm2Stpa/Cd44tm2Stpa
(involves: C57BL/6J)
|
decreased intestinal adenoma incidence
|
J:204874
|
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:134301
|
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL)
|
decreased tumor incidence
|
J:134301
|
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:127808
|
| increased tumor growth/size
|
J:127808
|
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
neoplasm
|
J:127808
|
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
neoplasm
|
J:127808
|
ApcMin/Apc+
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:231166
|
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
neoplasm
|
J:127808
|
ApcMin/Apc+
Dcctm1Wbg/Dcc+
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:39765
|
ApcMin/Apc+
Dclk1tm1.1(cre/ERT2)Seno/Dclk1+
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1(HBEGF)Awai
(involves: 129S4/SvJaeSor * C57BL/6)
|
abnormal tumor morphology
|
J:193873
|
ApcMin/Apc+
Del(15Rr357-Rr303293)2Jta/Del(15Rr357-Rr303293)2Jta
(involves: C57BL/6)
|
decreased colon tumor incidence
|
J:257088
|
ApcMin/Apc+
Dnd1Ter/Dnd1+
(involves: 129P3/J * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:221231
|
ApcMin/Apc+
Dnmt3btm1Jae/Dnmt3btm1Jae
Tg(Fabp1-cre)1Jig/0
(involves: 129 * C57BL/6 * C57BL/6J * FVB/N)
|
decreased tumor incidence
|
J:107386
|
ApcMin/Apc+
Dp(17Nfkbil1-Or2h1)1Cogr/0
(involves: 129S6/SvEvTac * C57BL/6J)
|
neoplasm
|
J:190754
|
ApcMin/Apc+
EgfrWa5/Egfr+
(involves: BALB/cAnN * C3H/HeN * C57BL/6J)
|
decreased tumor incidence
|
J:92308
|
ApcMin/Apc+
Elp3tm1.1Tac/Elp3tm1.1Tac
Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * C57BL/6NTac * SJL)
|
decreased intestinal adenoma incidence
|
J:227334
|
| increased tumor latency
|
J:227334
|
ApcMin/Apc+
Erbb3tm1.1Dwt/Erbb3tm2.1Dwt
Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
|
decreased tumor incidence
|
J:152703
|
ApcMin/Apc+
Eregtm1Dwt/Eregtm1Dwt
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:93327
|
ApcMin/Apc+
Esr1tm1.1Mma/Esr1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased carcinoma incidence
|
J:118600
|
| increased colon adenoma incidence
|
J:118600
|
| increased gastrointestinal tumor incidence
|
J:118600
|
ApcMin/Apc+
Esr2tm1Mma/Esr2+
(involves: 129S2/SvPas * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:118600
|
ApcMin/Apc+
Esr2tm1Mma/Esr2tm1Mma
(involves: 129S2/SvPas * C57BL/6J)
|
increased colon adenoma incidence
|
J:118600
|
| increased gastrointestinal tumor incidence
|
J:118600
|
ApcMin/Apc+
Foxl1tm1Khk/Foxl1tm1Khk
(involves: 129P2/OlaHsd * C57BL/6)
|
increased colon adenoma incidence
|
J:95893
|
| neoplasm
|
J:95893
|
ApcMin/Apc+
Fxyd5em1Namje/Fxyd5em1Namje
(C57BL/6J-Fxyd5em1Namje Apcmin)
|
increased gastrointestinal tumor incidence
|
J:325989
|
ApcMin/Apc+
Glp2rtm1Ddr/Glp2r+
(involves: C57BL/6J)
|
abnormal tumor morphology
|
J:141821
|
| increased intestinal adenoma incidence
|
J:141821
|
ApcMin/Apc+
Glp2rtm1Ddr/Glp2rtm1Ddr
(involves: C57BL/6J)
|
abnormal tumor morphology
|
J:141821
|
| increased intestinal adenoma incidence
|
J:141821
|
ApcMin/Apc+
Gpa33tm1(GNAS)Wtsi/Gpa33+
Hprt1tm1(CMV-cre)Brd/?
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:168378
|
ApcMin/Apc+
Gt(ROSA)26Sor/Gt(ROSA)26Sor+
(B6.Cg-Gt(ROSA)26Sor ApcMin)
|
abnormal tumor susceptibility
|
J:66060
|
| decreased alimentary system tumor incidence
|
J:66060
|
| decreased incidence of tumors by chemical induction
|
J:66060
|
| decreased mammary gland tumor incidence
|
J:66060
|
ApcMin/Apc+
Gt(ROSA)26Sortm2(Rnf187)Jhai/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased gastrointestinal tumor incidence
|
J:173145
|
| increased tumor growth/size
|
J:173145
|
ApcMin/Apc+
Hdac2Gt(W035F03)Joe/Hdac2Gt(W035F03)Joe
(involves: 129S2/SvPas * C57BL/6J)
|
decreased tumor incidence
|
J:152134
|
| increased small intestine adenocarcinoma incidence
|
J:152134
|
ApcMin/Apc+
Hltftm1.1Hdin/Hltftm1.1Hdin
(involves: 129 * C57BL/6 * FVB/N)
|
increased metastatic potential
|
J:252991
|
| neoplasm
|
J:252991
|
ApcMin/Apc+
Hptm1Skl/Hptm1Skl
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:75249
|
ApcMin/Apc+
Hpgdstm1Urad/Hpgds+
(involves: 129 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+
Hpgdstm1Urad/Hpgdstm1Urad
(involves: 129 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+
Hsd11b2tm1.1Mzz/Hsd11b2tm1.1Mzz
Tg(Vil1-cre)997Gum/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
decreased tumor growth/size
|
J:205456
|
| increased intestinal adenoma incidence
|
J:205456
|
ApcMin/Apc+
Igf2bp1tm1Vssp/Igf2bp1tm1Vssp
Tg(Vil1-cre)997Gum/0
(involves: C57BL/6J * SJL)
|
abnormal tumor incidence
|
J:202774
|
ApcMin/Apc+
Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor incidence
|
J:130429
|
ApcMin/Apc+
Il22tm1Flv/Il22tm1Flv
(involves: 129/Sv * C57BL/6 * C57BL/6J)
|
decreased alimentary system tumor incidence
|
J:189217
|
ApcMin/Apc+
Il22ra2tm2Vlcg/Il22ra2tm2Vlcg
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)
|
increased intestinal adenoma incidence
|
J:189217
|
| increased tumor growth/size
|
J:189217
|
ApcMin/Apc+
Map9tm1.2Bcgen/Map9+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:299895
|
ApcMin/Apc+
Map9tm1.2Bcgen/Map9tm1.2Bcgen
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:299895
|
ApcMin/Apc+
Mapkapk2tm1.1Gkl/Mapkapk2tm1.1Gkl
Tg(Tie1-cre)9Ref/0
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6J)
|
decreased tumor growth/size
|
J:262876
|
ApcMin/Apc+
Mapkapk2tm1.1Gkl/Mapkapk2tm1.1Gkl
Twist2tm1.1(cre)Dor/Twist2+
(involves: 129X1/SvJ * BALB/cJ * C57BL/6J)
|
decreased tumor growth/size
|
J:262876
|
| decreased tumor incidence
|
J:262876
|
ApcMin/Apc+
Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6J)
|
abnormal tumor vascularization
|
J:262876
|
| decreased tumor growth/size
|
J:262876
|
| decreased tumor incidence
|
J:262876
|
| increased intestinal adenoma incidence
|
J:262876
|
ApcMin/Apc+
Mbd2tm1Bh/Mbd2+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
decreased tumor incidence
|
J:83087
|
ApcMin/Apc+
Mbd2tm1Bh/Mbd2tm1Bh
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
decreased tumor growth/size
|
J:83087
|
| decreased tumor incidence
|
J:83087
|
ApcMin/Apc+
Mbd4tm1Bird/Mbd4tm1Bird
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:77896
|
ApcMin/Apc+
Mir10atm1.1Ahl/Mir10atm1.1Ahl
(B6.Cg-Mir10atm1.1Ahl Apcmin)
|
increased gastrointestinal tumor incidence
|
J:205135
|
| increased intestinal adenoma incidence
|
J:205135
|
ApcMin/Apc+
Mir708tm1Wtsi/Mir708tm1Wtsi
(involves: C57BL/6J * C57BL/6N)
|
increased colon adenoma incidence
|
J:317482
|
ApcMin/Apc+
Mmom1C57BL/6J/Mmom1FVB/NTac
(involves: C57BL/6J * FVB/NTac)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmom1C57BL/6J/Mmom1FVB/NTac
Mmom3C57BL/6J/Mmom3FVB/NTac
(involves: C57BL/6J * FVB/NTac)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmom2129X1/SvJ/Mmom2C57BL/6J
(involves: 129X1/SvJ * C57BL/6J)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmom2C57BL/6J/Mmom2FVB/NTac
(involves: C57BL/6J * FVB/NTac)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmom2C57BL/6J/Mmom2FVB/NTac
Mmom3C57BL/6J/Mmom3FVB/NTac
(involves: C57BL/6J * FVB/NTac)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmom2C57BL/6J/Mmom2FVB/NTac
Mmom4C57BL/6J/Mmom4FVB/NTac
(involves: C57BL/6J * FVB/NTac)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmom4C57BL/6J/Mmom4FVB/NTac
(involves: C57BL/6J * FVB/NTac)
|
decreased mammary gland tumor incidence
|
J:128481
|
ApcMin/Apc+
Mmp7tm1Lmm/Mmp7tm1Lmm
(involves: C57BL/6 * C57BL/6J)
|
abnormal tumor morphology
|
J:38609
|
| increased tumor incidence
|
J:38609
|
ApcMin/Apc+
Mom5129P2/OlaHsd/?
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased incidence of induced tumors
|
J:152194
|
ApcMin/Apc+
Mom5C57BL/6J/Mom5C57BL/6J
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:152194
|
ApcMin/Apc+
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * BALB/c * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:45433
|
ApcMin/Apc+
Msh2tm1Mak/Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:75393
|
ApcMin/Apc+
MthfsGt(RRK291)Byg/Mthfs+
(B6.Cg-MthfsGt(RRK291)Byg ApcMin)
|
neoplasm
|
J:185874
|
ApcMin/Apc+
Nos2tm1Lau/Nos2+
(B6.Cg-Nos2tm1Lau ApcMin)
|
decreased tumor growth/size
|
J:73152
|
| decreased tumor incidence
|
J:73152
|
ApcMin/Apc+
Nos2tm1Lau/Nos2tm1Lau
(B6.Cg-Nos2tm1Lau ApcMin)
|
decreased tumor growth/size
|
J:73152
|
| decreased tumor incidence
|
J:73152
|
ApcMin/Apc+
Phgdhtm1.1Shfu/Phgdh+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
neoplasm
|
J:183477
|
ApcMin/Apc+
Pla2g2aMom1-r/?
Prkdcdxnph/Prkdcdxnph
(involves: BALB/cByJ * C57BL/6)
|
increased incidence of tumors by ionizing radiation induction
|
J:83497
|
ApcMin/Apc+
Pla2g2aMom1-r/Pla2g2a+
(either: (AKR/J x C57BL/6J-ApcMin)F1 or (MA/MyJ x C57BL/6J-ApcMin)F1 or (CAST/EiJ x C57BL/6J-ApcMin)F1)
|
decreased alimentary system tumor incidence
|
J:15703
|
| decreased intestinal adenoma incidence
|
J:15703
|
ApcMin/Apc+
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:46419
|
ApcMin/Apc+
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * AKR/J * C57BL/6 * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:90337
|
ApcMin/Apc+
Ptentm1Hwu/Ptentm1Hwu
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:150553
|
ApcMin/Apc+
Ptgdstm1Ohy/Ptgdstm1Ohy
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+
Ptgs1tm1Unc/Ptgs1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased tumor incidence
|
J:64401
|
ApcMin/Apc+
Ptgs1tm1Unc/Ptgs1tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased tumor incidence
|
J:64401
|
ApcMin/Apc+
Ptgs2tm1Unc/Ptgs2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased tumor incidence
|
J:64401
|
ApcMin/Apc+
Ptprhtm1.1Mato/Ptprhtm1.1Mato
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
decreased incidence of induced tumors
|
J:146871
|
ApcMin/Apc+
Rab11atm1.1Ngao/Rab11atm1.1Ngao
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased intestinal adenoma incidence
|
J:278932
|
ApcMin/Apc+
Rab25tm1Jrgo/Rab25+
(B6.Cg-Rab25tm1Jrgo ApcMin)
|
increased intestinal adenoma incidence
|
J:158733
|
ApcMin/Apc+
Rab25tm1Jrgo/Rab25tm1Jrgo
(B6.Cg-Rab25tm1Jrgo ApcMin)
|
increased colon adenoma incidence
|
J:158733
|
| increased intestinal adenoma incidence
|
J:158733
|
ApcMin/Apc+
Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased adenoma incidence
|
J:97101
|
| increased colon adenoma incidence
|
J:97101
|
| increased tumor growth/size
|
J:97101
|
ApcMin/Apc+
Shmt1Gt(AD0236)Wtsi/Shmt1Gt(AD0236)Wtsi
(B6.Cg-Shmt1Gt(AD0236)Wtsi ApcMin)
|
neoplasm
|
J:183477
|
ApcMin/Apc+
Slc5a8tm1.1Boet/Slc5a8tm1.1Boet
(involves: C57BL/6 * C57BL/6J)
|
increased colon adenoma incidence
|
J:139883
|
ApcMin/Apc+
Spata13tm1Taki/Spata13+
(B6J.Cg-Spata13tm1Taki ApcMin)
|
decreased intestinal adenoma incidence
|
J:157023
|
| decreased tumor growth/size
|
J:157023
|
ApcMin/Apc+
Spata13tm1Taki/Spata13tm1Taki
(B6J.Cg-Spata13tm1Taki ApcMin)
|
decreased intestinal adenoma incidence
|
J:157023
|
| decreased tumor growth/size
|
J:157023
|
ApcMin/Apc+
Spata18tm1.2Hifa/Spata18+
(involves: C57BL/6J)
|
abnormal tumor susceptibility
|
J:254117
|
| increased classified tumor incidence
|
J:254117
|
| increased colon adenocarcinoma incidence
|
J:254117
|
| increased colon adenoma incidence
|
J:254117
|
| increased intestinal adenocarcinoma incidence
|
J:254117
|
| increased intestinal adenoma incidence
|
J:254117
|
| increased small intestine adenocarcinoma incidence
|
J:254117
|
ApcMin/Apc+
Spata18tm1.2Hifa/Spata18tm1.2Hifa
(involves: C57BL/6J)
|
abnormal tumor susceptibility
|
J:254117
|
| increased classified tumor incidence
|
J:254117
|
| increased colon adenocarcinoma incidence
|
J:254117
|
| increased colon adenoma incidence
|
J:254117
|
| increased intestinal adenocarcinoma incidence
|
J:254117
|
| increased intestinal adenoma incidence
|
J:254117
|
| increased small intestine adenocarcinoma incidence
|
J:254117
|
ApcMin/Apc+
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:57721
|
| increased mammary adenoacanthoma incidence
|
J:57721
|
| increased salivary gland tumor incidence
|
J:57721
|
ApcMin/Apc+
Tcf7l2tm1(EGFP/cre)Mrc/Tcf7l2tm2.1Mrc
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J * C57BL/6NCrl)
|
neoplasm
|
J:170088
|
ApcMin/Apc+
Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:170088
|
ApcMin/Apc+
Tcf7l2tm2.2Mrc/Tcf7l2+
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:170088
|
ApcMin/Apc+
Tg(CAG-PGDS)S-55Hjl/0
(involves: C57BL/6J * FVB/N)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+
Tg(Vil1-PPARGC1A)#Amos/0
(involves: C57BL/6J * FVB/N)
|
decreased alimentary system tumor incidence
|
J:171361
|
| decreased tumor growth/size
|
J:171361
|
ApcMin/Apc+
Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:143706
|
| increased intestinal adenocarcinoma incidence
|
J:143706
|
ApcMin/Apc+
Tgfbr1tm1Bopa/Tgfbr1+
(B6.Cg-Tgfbr1tm1Bopa ApcMin)
|
increased gastrointestinal tumor incidence
|
J:143706
|
| increased intestinal adenocarcinoma incidence
|
J:143706
|
ApcMin/Apc+
Thbs1tm1Hyn/Thbs1tm1Hyn
(involves: C57BL/6J)
|
increased carcinoma incidence
|
J:79641
|
| increased intestinal adenoma incidence
|
J:79641
|
| increased tumor incidence
|
J:79641
|
ApcMin/Apc+
Tmem9tm1d(EUCOMM)Wtsi/Tmem9+
(involves: C57BL/6J * C57BL/6N)
|
decreased intestinal adenoma incidence
|
J:268691
|
ApcMin/Apc+
Tmem9tm1d(EUCOMM)Wtsi/Tmem9tm1d(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
abnormal tumor pathology
|
J:268691
|
| decreased intestinal adenoma incidence
|
J:268691
|
| decreased tumor growth/size
|
J:268691
|
ApcMin/Apc+
Tnfaip8l1em1Huwa/Tnfaip8l1em1Huwa
(involves: C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:342074
|
ApcMin/Apc+
Tniktm1Teya/Tniktm1Teya
(involves: C57BL/6J)
|
decreased alimentary system tumor incidence
|
J:241611
|
ApcMin/Apc+
Trp53tm1Mlh/Trp53tm1Mlh
(involves: 129P2/OlaHsd * C57BL/6 * SWR)
|
increased pancreatic acinar cell carcinoma incidence
|
J:29664
|
ApcMin/Apc+
Trp53tm2.1Tyj/Trp53tm2.1Tyj
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2)
|
decreased alimentary system tumor incidence
|
J:291671
|
| increased colon adenoma incidence
|
J:291671
|
| increased intestinal adenoma incidence
|
J:291671
|
ApcMin/Apc+
Zbtb33tm1.1Bird/Y
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
decreased tumor growth/size
|
J:104155
|
| increased intestinal adenoma incidence
|
J:104155
|
ApcMin/Apc+
Zfp82tm1.2Cya/Zfp82+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6NTac)
|
increased colon tumor incidence
|
J:316087
|
ApcMin/Apc+
Zfp82tm1.2Cya/Zfp82tm1.2Cya
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6NTac)
|
increased colon tumor incidence
|
J:316087
|
ApcMin/Apc+
Zfp280cem1Xss/Zfp280cem1Xss
(C57BL/6J-ApcMin Zfp280cem1Xss)
|
decreased alimentary system tumor incidence
|
J:331404
|
ApcMin/ApcMin
Asphtm1Jed/Asphtm1Jed
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6J * C57BL/6NTac)
|
increased gastrointestinal tumor incidence
|
J:75888
|
ApcMin/ApcMin
Ppardtm1.1Rev/Ppardtm1.1Rev
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:73557
|
ApcMin/ApcMin
Rr27tm1Rohl/Rr27+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased colon adenoma incidence
|
J:97083
|
| increased intestinal adenoma incidence
|
J:97083
|
ApcMin/ApcMin
Sat1tm1Alh/Y
(involves: 129X1/SvJ * C57BL/6J)
|
decreased tumor incidence
|
J:99381
|
ApcMin/Apctm1Tno
Ctnnb1tm4.1Wbm/Ctnnb1+
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1.1Alew/Apc+
(B6.129-Apctm1.1Alew)
|
abnormal tumor morphology
|
J:180275
|
| increased adenoma incidence
|
J:180057
|
| increased intestinal adenoma incidence
|
J:180057,
J:180275
|
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd)
|
increased gastrointestinal tumor incidence
|
J:149225
|
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased desmoid tumor incidence
|
J:159883
|
| increased gastrointestinal tumor incidence
|
J:159883
|
| increased intestinal adenoma incidence
|
J:159883
|
| increased large intestine adenocarcinoma incidence
|
J:159883
|
| increased small intestine adenocarcinoma incidence
|
J:159883
|
Apctm1.1Tno/Apc+
(involves: 129S4/SvJae * C57BL/6)
|
increased intestinal adenoma incidence
|
J:127452
|
Apctm1.1Tno/Apc+
Ctnna1del/Ctnna1+
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:127452
|
Apctm1.1Tyj/Apc+
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased colon adenoma incidence
|
J:160399
|
| increased intestinal adenoma incidence
|
J:160399
|
| increased tumor growth/size
|
J:160399
|
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased colon adenoma incidence
|
J:94108
|
| increased intestinal adenocarcinoma incidence
|
J:94108
|
| increased intestinal adenoma incidence
|
J:94108
|
| increased mammary adenocarcinoma incidence
|
J:94108
|
Apctm1Cip/Apc+
Cdhr5tm1Lex/Cdhr5tm1Lex
(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:301471
|
| increased tumor growth/size
|
J:301471
|
Apctm1Cip/Apc+
H19tm1Lda/H19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
|
increased adenoma incidence
|
J:138826
|
| increased intestinal adenocarcinoma incidence
|
J:138826
|
Apctm1Cip/Apc+
H19tm1Lda/H19+
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased adenoma incidence
|
J:138826
|
Apctm1Cip/Apc+
Mki67em1Dfis/Mki67em1Dfis
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:304800
|
| decreased tumor growth/size
|
J:304800
|
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:61978
|
| increased mammary adenocarcinoma incidence
|
J:61978
|
| increased mammary gland tumor incidence
|
J:61978
|
| increased stomach tumor incidence
|
J:61978
|
Apctm1Kk/Apctm1Kk
Tg(Lck-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased intestinal adenoma incidence
|
J:104334
|
Apctm1Mmt/Apc+
(involves: 129S2/SvPas * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:25200,
J:79668
|
Apctm1Mmt/Apc+
Mmp7tm1Lmm/Mmp7tm1Lmm
Smad4tm1Mmt/Smad4+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
decreased tumor growth/size
|
J:142797
|
| decreased tumor incidence
|
J:142797
|
Apctm1Mmt/Apc+
Smad2tm1Kato/Smad2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:79668
|
Apctm1Mmt/Apc+
Smad2tm2Kato/Smad2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:79668
|
Apctm1Mmt/Apc+
Smad4tm1Mmt/Smad4+
(involves: 129S2/SvPas * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:46242
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:46242
|
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:20443
|
| increased intestinal adenocarcinoma incidence
|
J:20443
|
| increased intestinal adenoma incidence
|
J:20443
|
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:65142
|
| increased stomach tumor incidence
|
J:65142
|
Apctm1Rak/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
|
increased desmoid tumor incidence
|
J:151494
|
| increased gastrointestinal tumor incidence
|
J:151494
|
| increased stomach tumor incidence
|
J:151494
|
Apctm1Rak/Apc+
Cdh1tm1Cbm/Cdh1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:65142
|
| increased stomach tumor incidence
|
J:65142
|
Apctm1Rak/Apc+
Dcctm1.1Mehl/Dcctm1.1Mehl
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:181517
|
| increased intestinal adenocarcinoma incidence
|
J:181517
|
| increased metastatic potential
|
J:181517
|
Apctm1Rak/Apc+
Hmmrtm1Baa/Hmmrtm1Baa
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased tumor incidence
|
J:86065
|
Apctm1Rak/Apc+
Mbd4tm1Wed/Mbd4tm1Wed
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:80319
|
Apctm1Rak/Apc+
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:53451
|
| increased tumor incidence
|
J:53451
|
Apctm1Rak/Apc+
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:53451
|
| increased adenoma incidence
|
J:53451
|
| increased carcinoma incidence
|
J:53451
|
| increased gastrointestinal tumor incidence
|
J:53451
|
| increased lymphoma incidence
|
J:53451
|
| increased skin tumor incidence
|
J:53451
|
| increased tumor incidence
|
J:53451
|
Apctm1Rak/Apc+
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd)
|
increased tumor incidence
|
J:64667
|
Apctm1Rak/Apc+
Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak Smad4E6sad/+ +)
|
increased intestinal adenoma incidence
|
J:107273
|
Apctm1Rak/Apc+
Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak +/+ Smad4E6sad)
|
increased intestinal adenocarcinoma incidence
|
J:107273
|
| increased intestinal adenoma incidence
|
J:107273
|
Apctm1Rfo/Apctm1Rfo
(involves: 129P2/OlaHsd * C57BL/6J)
|
neoplasm
|
J:55416
|
Apctm1Rsmi/Apc+
Ctnnb1tm1Wvv/Ctnnb1+
Tg(Fabp1-cre)1Jig/?
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:185942
|
Apctm1Rsmi/Apc+
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:159883
|
| increased intestinal adenocarcinoma incidence
|
J:159883
|
| increased intestinal adenoma incidence
|
J:159883
|
| increased large intestine adenocarcinoma incidence
|
J:159883
|
| increased small intestine adenocarcinoma incidence
|
J:159883
|
Apctm1Rsmi/Apctm1Rsmi
(involves: 129P2/OlaHsd)
|
neoplasm
|
J:149225
|
Apctm1Rsmi/Apctm1Rsmi
Pgrtm2(cre)Lyd/Pgr+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:210095
|
| increased ovary tumor incidence
|
J:210095
|
| increased reproductive system tumor incidence
|
J:210095
|
Apctm1Tno/Apc+
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1Tno/Apc+
Brf1tm1Arte/Brf1tm1Arte
Tg(Cyp1a1-cre)1Dwi/0
(involves: C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Apctm1Tno/Apc+
Il17ratm1Koll/Il17ratm1Koll
Tg(CDX2-cre)101Erf/0
(involves: 129 * 129S4/SvJae * C57BL/6J * SJL/J)
|
decreased tumor growth/size
|
J:189226
|
Apctm1Tno/Apc+
Il23atm1Ngh/Il23atm1Ngh
Tg(CDX2-cre)101Erf/0
(involves: 129 * 129S4/SvJae * C57BL/6J * SJL/J)
|
decreased tumor growth/size
|
J:189226
|
Apctm1Tno/Apc+
Il23rtm1.2Trin/Il23rtm1.2Trin
Tg(CDX2-cre)101Erf/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL/J)
|
decreased tumor growth/size
|
J:189226
|
Apctm1Tno/Apc+
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
increased intestinal adenocarcinoma incidence
|
J:143082
|
Apctm1Tno/Apc+
Rac3tm1.1Bea/Rac3tm1.1Bea
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)
|
abnormal tumor susceptibility
|
J:306088
|
| decreased alimentary system tumor incidence
|
J:306088
|
| decreased intestinal adenoma incidence
|
J:306088
|
| decreased tumor growth/size
|
J:306088
|
Apctm1Tno/Apc+
Tg(CDX2-cre)101Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:126018
|
| increased mammary adenocarcinoma incidence
|
J:126018
|
| increased tumor incidence
|
J:126018
|
Apctm1Tno/Apc+
Tg(CDX2-cre*)189Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
neoplasm
|
J:148161
|
Apctm1Tno/Apc+
Tg(CDX2-cre/ERT)#Erf/0
(involves: 129S4/SvJae)
|
increased gastrointestinal tumor incidence
|
J:189226
|
Apctm1Tno/Apc+
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:126018
|
| increased small intestine adenocarcinoma incidence
|
J:126018
|
Apctm1Tno/Apctm1Tno
(involves: 129S4/SvJae * C57BL/6)
|
increased colon adenoma incidence
|
J:43301
|
Apctm1Tno/Apctm1Tno
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
| increased incidence of tumors by chemical induction
|
J:156864
|
Apctm1Tno/Apctm1Tno
Ctnnb1tm4.1Wbm/Ctnnb1+
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased tumor incidence
|
J:156864
|
Apctm1Tno/Apctm1Tno
Elp3tm1.1Tac/Elp3tm1.1Tac
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
decreased tumor growth/size
|
J:227334
|
Apctm1Tno/Apctm1Tno
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased intestinal adenoma incidence
|
J:227334
|
Apctm1Tno/Apctm1Tno
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased ovarian carcinoma incidence
|
J:120955
|
Apctm1Tno/Apctm1Tno
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR)
|
increased renal cystadenoma incidence
|
J:95502
|
Apctm1Tno/Apctm1Tno
Tg(CDX2-cre*)189Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased colon adenoma incidence
|
J:148161
|
Apctm1Tno/Apctm1Tno
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:120308
|
| increased prostate intraepithelial neoplasia incidence
|
J:120308
|
| increased tumor incidence
|
J:120308
|
Apctm1Tyj/Apc+
Tg(Vil1-cre)20Syr/0
(involves: C57BL/6 * DBA/2)
|
increased colon adenoma incidence
|
J:160399
|
| increased intestinal adenoma incidence
|
J:160399
|
Apctm2.1Alew/Apc+
(B6.129-Apctm2.1Alew)
|
abnormal tumor pathology
|
J:180057
|
| increased adenoma incidence
|
J:180057
|
| increased intestinal adenoma incidence
|
J:180057
|
Apctm2.1Cip/Apc+
Atg7tm1Tchi/Atg7tm1Tchi
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)
|
decreased intestinal adenoma incidence
|
J:227287
|
Apctm2.1Cip/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB)
|
increased intestinal adenocarcinoma incidence
|
J:132357
|
Apctm2.1Cip/Apc+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:186084
|
Apctm2.1Cip/Apc+
Lrig1tm1.1(cre/ERT2)Rjc/Lrig1+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:186084
|
Apctm2.1Cip/Apc+
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:132357
|
Apctm2.1Cip/Apc+
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased colon adenoma incidence
|
J:160399
|
| increased intestinal adenoma incidence
|
J:160399
|
Apctm2.1Cip/Apc+
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased colon adenoma incidence
|
J:227287
|
| increased intestinal adenoma incidence
|
J:227287
|
Apctm2.1Cip/Apctm2.1Cip
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:94721
|
Apctm2.1Rak/Apc+
(involves: 129/Sv * C57BL/6J * SJL)
|
increased gastrointestinal tumor incidence
|
J:114152
|
| increased intestinal adenoma incidence
|
J:114152
|
Apctm2Mmt/Apc+
(involves: 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:81402
|
Apctm2Rak/Apc+
Krastm1.1Khai/Kras+
Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased colon adenoma incidence
|
J:276349
|
Apctm2Rak/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL)
|
increased colon adenoma incidence
|
J:276349
|
Apctm2Rak/Apc+
Tg(Car1-cre)5Flt/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased incidence of tumors by chemical induction
|
J:164247
|
| increased intestinal adenoma incidence
|
J:164247
|
| neoplasm
|
J:164247
|
Apctm2Rak/Apc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased cystadenoma incidence
|
J:234310
|
| increased metastatic potential
|
J:234310
|
| increased pancreas tumor incidence
|
J:234310
|
Apctm2Rak/Apctm2Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased carcinoma incidence
|
J:156532
|
| increased colon adenoma incidence
|
J:156532
|
| increased organ/body region tumor incidence
|
J:156532
|
Apctm2Rak/Apctm2Rak
Krastm4Tyj/Kras+
(involves: 129 * 129S4/SvJae * C57BL/6J * SJL)
|
increased adenocarcinoma incidence
|
J:156532
|
| increased carcinoma incidence
|
J:156532
|
| increased colon adenoma incidence
|
J:156532
|
| increased organ/body region tumor incidence
|
J:156532
|
Apctm2Rak/Apctm2Rak
Tg(Car1-cre)5Flt/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:164247
|
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo)
|
increased liver tumor incidence
|
J:151494
|
| increased mammary adenocarcinoma incidence
|
J:151494
|
| increased mammary gland tumor incidence
|
J:151494
|
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
|
increased desmoid tumor incidence
|
J:151494
|
| increased liver tumor incidence
|
J:151494
|
| increased mammary adenocarcinoma incidence
|
J:204440,
J:151494
|
| increased mammary gland tumor incidence
|
J:151494
|
| increased metastatic potential
|
J:204440
|
| increased tumor incidence
|
J:151494
|
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo)
|
increased gastrointestinal tumor incidence
|
J:151494
|
| increased liver tumor incidence
|
J:151494
|
| increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Rfo/Apc+
Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:151494
|
| increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Tno/Apc+
(Not Specified)
|
increased intestinal adenoma incidence
|
J:47857
|
Apctm3Mmt/Apc+
(B6.129X1-Apctm3Mmt)
|
increased intestinal adenoma incidence
|
J:101604
|
Apctm4Mmt/Apc+
(B6.129X1-Apctm4Mmt)
|
increased intestinal adenoma incidence
|
J:101604
|
Apex1tm1Ecf/Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased carcinoma incidence
|
J:70397
|
| increased lymphoma incidence
|
J:70397
|
| increased sarcoma incidence
|
J:70397
|
| increased tumor incidence
|
J:70397
|
Apex1tm1Ecf/Apex1+
Xpctm1Ecf/Xpctm1Ecf
(involves: 129)
|
increased tumor incidence
|
J:70397
|
Apmt1FVB/NJ/Apmt1FVB/NJ
(involves: FVB/NJ * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt1FVB/NJ/Apmt1FVB/NJ
Apmt2I/LnJ/Apmt2FVB/NJ
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt1FVB/NJ/Apmt1I/LnJ
(involves: FVB/NJ * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt2I/LnJ/?
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apobec3Rfv3-r/Apobec3+
((B10.A x A)F1)
|
abnormal tumor morphology
|
J:6147
|
Aptxtm1Pmc/Aptx+
Atmtm2.1Mfgc/Atmtm2.1Mfgc
(involves: 129 * C57BL/6)
|
increased thymoma incidence
|
J:316365
|
Aptxtm1Pmc/Aptxtm1Pmc
Atmtm2.1Mfgc/Atmtm2.1Mfgc
(involves: 129 * C57BL/6)
|
increased thymoma incidence
|
J:316365
|
ArTfm/Y
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
|
increased testis tumor incidence
|
J:140803
|
ArTfm/Y
Tg(TSPY)9Jshm/0
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
|
increased testis tumor incidence
|
J:140803
|
Artm1(AR)Dmr/Y
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Artm1.1Chc/Y
(involves: 129S/SvEv * C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:120844
|
| decreased incidence of tumors by chemical induction
|
J:120844
|
| preneoplasia
|
J:120844
|
Artm1.1Chc/Artm1.1Chc
(involves: 129S/SvEv * C57BL/6 * FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:120844
|
| preneoplasia
|
J:120844
|
Artm1Verh/Y
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:172730
|
Artm2(AR)Dmr/Y
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Artm3(AR)Dmr/Y
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
decreased tumor incidence
|
J:108849
|
Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0
Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
abnormal tumor morphology
|
J:170092
|
| decreased tumor latency
|
J:170092
|
| increased prostate gland tumor incidence
|
J:170092
|
| increased tumor growth/size
|
J:170092
|
Arhgef4tm1Taki/Arhgef4tm1Taki
(involves: C57BL/6 * C57BL/6J * CBA)
|
abnormal tumor morphology
|
J:159959
|
| abnormal tumor vascularization
|
J:159959
|
| decreased tumor growth/size
|
J:159959
|
Arhgef15tm1(KOMP)Vlcg/Arhgef15tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
neoplasm
|
J:188649
|
Arid1atm1.1Mag/Arid1a+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
neoplasm
|
J:219794
|
Arid1atm1.1Mag/Arid1atm1.1Mag
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
increased metastatic potential
|
J:219794
|
| increased ovarian carcinoma incidence
|
J:219794
|
| increased ovary tumor incidence
|
J:219794
|
Arid4atm1Alb/Arid4atm1Alb
(involves: 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:141004
|
| increased sarcoma incidence
|
J:141004
|
Arid4atm1Alb/Arid4atm1Alb
Arid4btm1Alb/Arid4b+
(involves: 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:141004
|
| increased sarcoma incidence
|
J:141004
|
Arl6ip5tm1.2Jwzh/Arl6ip5tm1.2Jwzh
(B6.129X1-Arl6ip5tm1.2Jwzh)
|
decreased incidence of tumors by chemical induction
|
J:187133
|
| decreased tumor growth/size
|
J:187133
|
| neoplasm
|
J:187133
|
Armcx3tm1.1Eso/Y
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
(involves: 129S/SvEv * C57BL/6)
|
abnormal tumor morphology
|
J:345411
|
| decreased incidence of tumors by chemical induction
|
J:345411
|
Arnttm1Bra/Arnttm1Bra
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
(involves: 129 * BALB/c * C57BL/6)
|
neoplasm
|
J:97652
|
Asap1Gt(RRS873)Byg/Asap1Gt(RRS873)Byg
(FVB.129P2(B6)-Asap1Gt(RRS873)Byg)
|
neoplasm
|
J:277387
|
Asxl1tm1.1Mjxu/Asxl1+
(involves: 129 * C57BL/6)
|
increased leukemia incidence
|
J:208085
|
| increased malignant tumor incidence
|
J:208085
|
| increased sarcoma incidence
|
J:208085
|
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd)
|
increased gland tumor incidence
|
J:176672
|
| increased granulosa cell tumor incidence
|
J:176672
|
| increased Harderian gland adenocarcinoma incidence
|
J:176672
|
| increased hemangiosarcoma incidence
|
J:176672
|
| increased liver adenocarcinoma incidence
|
J:176672
|
| increased lung adenocarcinoma incidence
|
J:176672
|
| increased lung carcinoma incidence
|
J:176672
|
| increased lymphoma incidence
|
J:176672
|
| increased sarcoma incidence
|
J:176672
|
| increased spindle cell carcinoma incidence
|
J:176672
|
| increased T cell derived lymphoma incidence
|
J:176672
|
| increased tumor incidence
|
J:176672
|
Atf2Tg(Gzma-Klra1)7Wum/Atf2+
(involves: C57BL/6)
|
increased metastatic potential
|
J:61178
|
Atf2tm3Nicj/Atf2tm3Nicj
Tg(KRT14-cre)1Efu/?
(involves: C57BL/6 * FVB/N)
|
increased skin papilloma incidence
|
J:131564
|
Atf3tm1.1Hai/Atf3tm1.1Hai
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * FVB/N)
|
decreased metastatic potential
|
J:201626
|
Atf3tm1Dron/Atf3tm1Dron
(involves: 129X1/SvJ * C57BL/6)
|
decreased metastatic potential
|
J:201626
|
| neoplasm
|
J:201626
|
Atf3tm1Dron/Atf3tm1Dron
Tg(MMTV-PyVT)634Mul/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
decreased metastatic potential
|
J:201626
|
| decreased tumor growth/size
|
J:201626
|
Atg4ctm1Otin/Atg4ctm1Otin
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:123386
|
Atg5em1Smoc/Atg5em1Smoc
S100a4em1(cre)Zhyg/S100a4+
(involves: C57BL/6J)
|
abnormal tumor morphology
|
J:330821
|
| decreased tumor growth/size
|
J:330821
|
Atmtm1.1Mmpl/Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:226414
|
Atmtm1Awb/Atm+
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased T cell derived lymphoma incidence
|
J:34193
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:90941
|
Atmtm1Awb/Atmtm1Awb
(CByJ.129S6-Atmtm1Awb)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(B6.129S6-Atmtm1Awb)
|
abnormal tumor incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(A.129S6-Atmtm1Awb)
|
abnormal tumor susceptibility
|
J:208539
|
| increased hepatocellular carcinoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (A.129S6-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x A.129S6-Atmtm1Awb)F1)
|
abnormal tumor incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J)
|
increased T cell derived lymphoma incidence
|
J:226414
|
Atmtm1Awb/Atmtm1Awb
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
(involves: 129 * C57BL * FVB/N * SJL)
|
increased tumor incidence
|
J:120284
|
Atmtm1Awb/Atmtm1Awb
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb
Rad50tm4.1Jpt/Rad50+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
|
increased tumor latency
|
J:209141
|
Atmtm1Awb/Atmtm1Awb
Rad52tm1Aps/Rad52tm1Aps
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
decreased lymphoma incidence
|
J:90941
|
| increased T cell derived lymphoma incidence
|
J:90941
|
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:35914
|
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:61201
|
Atmtm1Led/Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss)
|
increased T cell derived lymphoma incidence
|
J:69726
|
| increased thymoma incidence
|
J:36561
|
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J)
|
increased adenoma incidence
|
J:78527
|
| increased leukemia incidence
|
J:78527
|
| increased lymphoma incidence
|
J:78527
|
| increased ovary tumor incidence
|
J:78527
|
| increased sarcoma incidence
|
J:78527
|
| increased tumor incidence
|
J:78527
|
Atmtm1Mfl/Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:69726
|
| increased tumor incidence
|
J:69726
|
Atmtm1Pmc/Atmtm1Pmc
(involves: 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:47752
|
Atmtm2.1Fwa/Atmtm2.1Fwa
Tg(VAV1-cre)1Graf/0
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:277750
|
Atmtm2.1Mfgc/Atmtm2.1Mfgc
(C57BL/6-Atmtm2.1Mfgc)
|
increased thymoma incidence
|
J:316365
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
(B6.Cg-Bcl2l11tm1.1Ast Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
|
increased lymphoma incidence
|
J:230105
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
|
decreased lymphoma incidence
|
J:230105
|
| increased tumor latency
|
J:230105
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Ighmtm1(Bcl6)Rdf/Ighm+
Tg(Fcer2a-cre)5Mbu/0
(B6.Cg-Atmintm1.1Jhh Ighmtm1(Bcl6)Rdf Tg(Fcer2a-cre)5Mbu)
|
abnormal tumor susceptibility
|
J:230105
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Tg(Fcer2a-cre)5Mbu/0
(B6.Cg-Atmintm1.1Jhh Tg(Fcer2a-cre)5Mbu)
|
neoplasm
|
J:230105
|
Atp2a2tm1Ges/Atp2a2+
(involves: 129X1/SvJ * Black Swiss)
|
increased esophageal papilloma incidence
|
J:69754
|
| increased skin papilloma incidence
|
J:69754
|
| increased squamous cell carcinoma incidence
|
J:69754
|
| increased tongue papilloma incidence
|
J:69754
|
| increased tumor incidence
|
J:69754
|
Atp2c1tm1Ges/Atp2c1+
(involves: 129X1/SvJ * Black Swiss)
|
increased esophageal papilloma incidence
|
J:124662
|
| increased skin papilloma incidence
|
J:124662
|
| increased squamous cell carcinoma incidence
|
J:124662
|
Atp4atm1.1Ocalv/Atp4atm1.1Ocalv
(involves: 129S6/SvEv * C57BL/6J * C57BL/6NCrl)
|
neoplasm
|
J:235360
|
Atp6v0a2tm1Kdb/Atp6v0a2tm1Kdb
Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
decreased tumor latency
|
J:274048
|
| increased incidence of induced tumors
|
J:274048
|
| increased metastatic potential
|
J:274048
|
Atp11atm1a(KOMP)Wtsi/Atp11atm1a(KOMP)Wtsi
(C57BL/6N-Atp11atm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Atp11cambr/Y
(C57BL/6-Atp11cambr)
|
increased hepatocellular carcinoma incidence
|
J:171924
|
Atrtm1Akl/Atr+
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:61732
|
Atrtm1Bal/Atr+
(involves: 129 * C57BL/6)
|
increased tumor incidence
|
J:60768
|
Atrxtm1Rjg/Y
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
decreased tumor latency
|
J:329449
|
| increased osteosarcoma incidence
|
J:329449
|
Atrxtm1Rjg/Atrxtm1Rjg
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
decreased tumor latency
|
J:329449
|
| increased osteosarcoma incidence
|
J:329449
|
AurkaGt(XQ0149)Wtsi/Aurka+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatoma incidence
|
J:143099
|
| increased lung carcinoma incidence
|
J:143099
|
| increased lymphoma incidence
|
J:143099
|
| increased squamous cell carcinoma incidence
|
J:143099
|
| increased tumor incidence
|
J:143099
|
Aurkbtm1.2Mama/Aurkb+
(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL)
|
increased adenocarcinoma incidence
|
J:173575
|
| increased liver adenocarcinoma incidence
|
J:173575
|
| increased skin papilloma incidence
|
J:173575
|
| increased tumor incidence
|
J:173575
|
Auts2em1(IMPC)Wtsi/Auts2em1(IMPC)Wtsi
(C57BL/6N-Auts2em1(IMPC)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased hemangioma incidence
|
J:239583
|
B2mtm1Unc/B2mtm1Unc
Il2tm1Hor/Il2tm1Hor
(involves: 129 * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:51450
|
B2mtm1Unc/B2mtm1Unc
Prkdcscid/Prkdcscid
(NOD.Cg-B2mtm1Unc Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:102141
|
B3gnt6tm1Lx/B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J)
|
increased adenocarcinoma incidence
|
J:123826
|
| increased carcinoma incidence
|
J:123826
|
| increased gastrointestinal tumor incidence
|
J:123826
|
| increased incidence of tumors by chemical induction
|
J:123826
|
| increased intestinal adenoma incidence
|
J:123826
|
| increased tumor growth/size
|
J:123826
|
B3gnt6tm1Lx/B3gnt6tm1Lx
C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc
Tg(Vil1-cre)997Gum/0
(involves: 129S1/Sv * C57BL/6J * SJL)
|
increased duodenum glandular epithelium tumor incidence
|
J:239765
|
B3gnt6tm1Lx/B3gnt6tm1Lx
C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2)
|
increased duodenum adenocarcinoma incidence
|
J:239765
|
| increased duodenum glandular epithelium tumor incidence
|
J:239765
|
B9d2tm1a(EUCOMM)Wtsi/B9d2tm1a(EUCOMM)Wtsi
(C57BL/6N-B9d2tm1a(EUCOMM)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased hemangioma incidence
|
J:239583
|
Badtm1Sjk/Badtm1Sjk
(either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))
|
increased B cell derived lymphoma incidence
|
J:84987
|
| increased lymphoma incidence
|
J:84987
|
| increased tumor incidence
|
J:84987
|
Bag1tm1Msd/Bag1+
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: C57BL/6)
|
decreased lung tumor incidence
|
J:95491
|
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Krastm4Tyj/Kras+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased adenocarcinoma incidence
|
J:125101
|
Bap1em1Test/Bap1+
(involves: FVB)
|
increased colon tumor incidence
|
J:231692
|
| increased granulosa cell tumor incidence
|
J:231692
|
| increased incidence of tumors by chemical induction
|
J:213725
|
| increased lung carcinoma incidence
|
J:231692
|
| increased mammary adenocarcinoma incidence
|
J:231692
|
| increased mesothelioma incidence
|
J:231692
|
| increased ovary tumor incidence
|
J:231692
|
| increased skin tumor incidence
|
J:231692
|
| increased squamous cell carcinoma incidence
|
J:213725
|
Bap1em2Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
| increased incidence of tumors by chemical induction
|
J:231692
|
| increased lung carcinoma incidence
|
J:231692
|
| increased mammary adenocarcinoma incidence
|
J:231692
|
| increased mesothelioma incidence
|
J:231692
|
| increased ovary tumor incidence
|
J:231692
|
| increased pancreatic islet cell carcinoma incidence
|
J:231692
|
| increased skin tumor incidence
|
J:231692
|
Bap1em3Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
| increased incidence of tumors by chemical induction
|
J:231692
|
| increased lung carcinoma incidence
|
J:231692
|
| increased lymphoma incidence
|
J:231692
|
| increased mammary adenocarcinoma incidence
|
J:231692
|
| increased ovary tumor incidence
|
J:231692
|
| increased skin tumor incidence
|
J:231692
|
Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased leukemia incidence
|
J:187380
|
Bard1tm1.1Rjbr/Bard1tm1.1Rjbr
(involves: 129S6/SvEvTac * C57BL/6J)
|
neoplasm
|
J:269011
|
Bard1tm1Thl/Bard1tm2Thl
Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2.1Rjbr/Bard1tm2.1Rjbr
(involves: 129S6/SvEvTac * C57BL/6J)
|
neoplasm
|
J:269011
|
Bard1tm2Thl/Bard1tm2Thl
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl
Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bcl2tm1Mpin/Bcl2+
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Bcl2tm1Mpin/Bcl2tm1Mpin
Tg(H2-K-BCL2)1Josd/0
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Bcl2tm1Mpin/Bcl2tm1Mpin
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
decreased tumor incidence
|
J:79696
|
| increased lung adenoma incidence
|
J:79696
|
Bcl2tm2.1Lbox/Bcl2+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:175730
|
| increased follicular lymphoma incidence
|
J:175730
|
Bcl2tm2.1Lbox/Bcl2tm2.1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:175730
|
| increased follicular lymphoma incidence
|
J:175730
|
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam
Tg(Ins2-cre)25Mgn/0
Tg(RIP1-Tag)2Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:146436
|
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam
Tg(RIP1-Tag)2Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:146436
|
Bcl2l11tm1.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
| increased T cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm2.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm3.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l14tm1.1Boui/Bcl2l14tm1.1Boui
(involves: C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:296081
|
Bcl11btm1Peli/Bcl11btm1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J)
|
decreased metastatic potential
|
J:161373
|
Bcl11btm2.1Jpk/Bcl11b+
Tg(Lck-cre)1Jtak/0
(involves: C57BL/6)
|
increased lymphoma incidence
|
J:210122
|
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased follicular lymphoma incidence
|
J:86953
|
| increased hepatocellular carcinoma incidence
|
J:86953
|
| increased histiocytic sarcoma incidence
|
J:86953
|
| increased lung adenocarcinoma incidence
|
J:86953
|
| increased lung adenoma incidence
|
J:86953
|
| increased lung carcinoma incidence
|
J:86953
|
| increased lymphoma incidence
|
J:86953
|
| increased malignant tumor incidence
|
J:86953
|
| increased mammary gland tumor incidence
|
J:86953
|
| increased plasmacytoma incidence
|
J:86953
|
| increased tumor incidence
|
J:86953
|
Becn1tm1Blev/Becn1+
Tg(Alb1HBV)44Bri/0
(involves: 129X1/SvJ * C57BL/6J)
|
increased tumor incidence
|
J:86953
|
Becn1tm1Htz/Becn1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:86982
|
| increased hepatocellular carcinoma incidence
|
J:86982
|
| increased lung adenocarcinoma incidence
|
J:86982
|
| increased tumor incidence
|
J:86982
|
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:105076
|
| increased liver adenoma incidence
|
J:105076
|
| increased pancreas adenoma incidence
|
J:105076
|
| increased pancreatic acinar cell carcinoma incidence
|
J:105076
|
| increased tumor incidence
|
J:105076
|
Bhlha15tm2(Kras)Skz/Bhlha15+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:105076
|
| increased metastatic potential
|
J:105076
|
Bhmttm1.2Zei/Bhmttm1.2Zei
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:177569
|
| increased liver adenoma incidence
|
J:177569
|
| increased liver tumor incidence
|
J:177569
|
Bin1tm1Gcp/Bin1tm2Gcp
Tg(MMTV-Myc)141-3Led/0
Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased lymphoma incidence
|
J:117330
|
| increased mammary adenocarcinoma incidence
|
J:117330
|
Bin1tm1Gcp/Bin1tm2Gcp
Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased granulosa cell tumor incidence
|
J:117330
|
| increased incidence of tumors by chemical induction
|
J:117330
|
| increased mammary gland tumor incidence
|
J:117330
|
Bin1tm2Gcp/Bin1+
Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased incidence of tumors by chemical induction
|
J:117330
|
| increased mammary gland tumor incidence
|
J:117330
|
Bin3tm1Gcp/Bin3tm1Gcp
(involves: 129 * C57BL/6)
|
increased incidence of tumors by ionizing radiation induction
|
J:133313
|
| increased lung adenocarcinoma incidence
|
J:133313
|
| increased lymphoma incidence
|
J:133313
|
Blmtm1Ches/Blmtm3Brd
(involves: 129S/SvEv * C57BL/6 * NIH Black Swiss)
|
increased lymphoma incidence
|
J:86827
|
| increased tumor incidence
|
J:86827
|
Blmtm1Ches/Blmtm4Ches
Tg(Hsp70-1-cre)6Arge/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:112115
|
Blmtm1Ches/Blmtm4Ches
Tg(KLK3-cre)1Ches/0
(involves: 129S6/SvEvTac)
|
increased mammary gland tumor incidence
|
J:112115
|
Blmtm1Ches/Blmtm4Ches
Tg(LGB-cre)74Acl/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:112115
|
Blmtm1Grdn/Blm+
(involves: 129P2/OlaHsd * Black Swiss)
|
increased incidence of induced tumors
|
J:79058
|
Blmtm3Brd/Blmtm3Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:66261
|
| increased tumor incidence
|
J:66261
|
Blnktm1Dkit/Blnktm1Dkit
(involves: C57BL/6)
|
increased leukemia incidence
|
J:84040
|
Blnktm1Dkit/Blnktm1Dkit
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
(involves: 129P2/OlaHsd * C57BL/6 * NZB)
|
increased leukemia incidence
|
J:84040
|
Blnktm1Pjln/Blnktm1Pjln
(involves: BALB/c)
|
increased tumor incidence
|
J:80332
|
Blnktm1Pjln/Blnktm1Pjln
Btktm1Gsv/Y
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:94768
|
Blnktm1Pjln/Blnktm1Pjln
Btktm1Gsv/Y
Tg(CD19-BTK*K430R)XK24Rwhe/?
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB)
|
neoplasm
|
J:94768
|
Bmftm1.1Ast/Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst)
|
increased T cell derived lymphoma incidence
|
J:133084
|
| neoplasm
|
J:133084
|
Bmi1tm1(cre/ERT)Mrc/Bmi1+
Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:138364
|
Bmi1tm1.1Lees/Bmi1tm1.1Lees
Apctm2Cip/Apc+
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)
|
decreased alimentary system tumor incidence
|
J:204354
|
| decreased colon tumor incidence
|
J:204354
|
| decreased intestinal adenoma incidence
|
J:204354
|
Bmi1tm1Brn/Bmi1tm1Brn
Apctm2Cip/Apc+
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased intestinal adenoma incidence
|
J:204354
|
Bmi1tm1Brn/Bmi1tm1Brn
Apctm2Cip/Apc+
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased alimentary system tumor incidence
|
J:204354
|
| decreased colon tumor incidence
|
J:204354
|
| decreased intestinal adenoma incidence
|
J:204354
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr
Ctnnb1tm1Mmt/Ctnnb1+
Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ)
|
increased salivary gland tumor incidence
|
J:199091
|
| increased squamous cell carcinoma incidence
|
J:199091
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr
Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
neoplasm
|
J:199091
|
Bmpr1atm2Bhr/Bmpr1atm2Bhr
Tg(KRT14-cre/ERT2)1Ipc/?
(involves: 129S7/SvEvBrd * C57BL/6)
|
preneoplasia
|
J:91054
|
Bmyctm1Mpo/Bmyctm1Mpo
(involves: 129S7/SvEvBrd * C57BL/6N)
|
neoplasm
|
J:191587
|
Boktm1.1Ast/Boktm1.1Ast
Tg(IghMyc)22Bri/0
(involves: BALB/cJ * C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:203179
|
Bomb1NSF/N/Bomb1NSF/N
(involves: NFS/N * SL/Kh)
|
increased lymphoma incidence
|
J:55364
|
Bomb1SL/Kh/Bomb1SL/Kh
(involves: NFS/N * SL/Kh)
|
increased lymphoma incidence
|
J:55364
|
Braftm1.1Brd/Braf+
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased carcinoma incidence
|
J:199307
|
| increased intestinal adenoma incidence
|
J:199307
|
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased carcinoma incidence
|
J:199307
|
| increased gastrointestinal tumor incidence
|
J:199307
|
| increased intestinal adenoma incidence
|
J:199307
|
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
Trp53tm2Tyj/Trp53tm2Tyj
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL)
|
abnormal tumor pathology
|
J:199307
|
| increased metastatic potential
|
J:199307
|
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
|
increased gland tumor incidence
|
J:170095
|
| increased lung adenoma incidence
|
J:170095
|
| increased metastatic potential
|
J:170095
|
| increased pheochromocytoma incidence
|
J:170095
|
Braftm1Cpri/Braf+
(involves: 129P2/OlaHsd)
|
increased lung adenoma incidence
|
J:187371
|
| increased lung tumor incidence
|
J:187371
|
Braftm1Cpri/Braf+
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:104375
|
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
|
increased incidence of tumors by chemical induction
|
J:147434
|
| increased melanoma incidence
|
J:147434
|
| increased skin tumor incidence
|
J:147434
|
Braftm1Cpri/Braftm1Cpri
Gnastm3Lsw/Gnastm3Lsw
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/NCr)
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:168249
|
| increased thyroid tumor incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased melanoma incidence
|
J:147434
|
| increased skin tumor incidence
|
J:147434
|
Braftm1Cpri/Braftm1Cpri
Tshrtm1Rmar/Tshrtm1Rmar
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB/NCr)
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:121715
|
| increased lung adenoma incidence
|
J:121715
|
| increased lung tumor incidence
|
J:121715
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+
Cdkn2atm4Rdp/Cdkn2atm4Rdp
(involves: 129P2/OlaHsd)
|
increased lung tumor incidence
|
J:121715
|
Braftm1Mmcm/Braf+
Ezh2tm1.1Nesh/Ezh2+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:239472
|
Braftm1Mmcm/Braf+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased lung adenoma incidence
|
J:121715
|
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
(B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro)
|
increased cutaneous melanoma incidence
|
J:188523
|
Braftm1Mmcm/Braf+
Ptentm1Rdp/Ptentm1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased cutaneous melanoma incidence
|
J:151023
|
| increased metastatic potential
|
J:151023
|
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Pten+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
|
increased cutaneous melanoma incidence
|
J:151023
|
| increased metastatic potential
|
J:151023
|
Braftm1Mmcm/Braf+
Tg(Tg-cre/ERT2)#Mmcm/0
(involves: 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:172205
|
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased metastatic potential
|
J:208854
|
| increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
neoplasm
|
J:239472
|
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:121715
|
| increased lung tumor incidence
|
J:121715
|
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braftm1Mmcm
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Pten+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased metastatic potential
|
J:191327
|
| increased prostate gland adenocarcinoma incidence
|
J:191327
|
| increased prostate gland tumor incidence
|
J:191327
|
| increased prostate intraepithelial neoplasia incidence
|
J:191327
|
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased tumor incidence
|
J:161180
|
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased melanoma incidence
|
J:161180
|
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:161180
|
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Braftm1Tuv/Braftm1Tuv
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
TgTn(sb-T2/Onc)#Dla/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased melanoma incidence
|
J:177503
|
Braftm2Cpri/Braf+
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:187371
|
Braftm2Cpri/Braf+
Tg(CMV-cre)1Cgn/0
(B6.Cg-Braftm2Cpri Tg(CMV-cre)1Cgn)
|
increased intestinal adenoma incidence
|
J:187371
|
| increased skin papilloma incidence
|
J:187371
|
Brca1tm1Aash/Brca1tm1Aash
Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:119996
|
| increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Aash/Brca1tm1Aash
Trp53tm1Brd/Trp53+
Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland ductal carcinoma incidence
|
J:119996
|
| increased mammary gland tumor incidence
|
J:119996
|
| increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Arge/Brca1tm1Thl
Waptm1(cre)Arge/0
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm1Bhk/Brca1+
(C.129P2-Brca1tm1Bhk)
|
increased mammary gland tumor incidence
|
J:198018
|
Brca1tm1Bhk/Brca1+
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk)
|
increased mammary adenocarcinoma incidence
|
J:198018
|
| increased mammary gland tumor incidence
|
J:198018
|
| increased metastatic potential
|
J:198018
|
Brca1tm1Brn/Brca1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1.1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
abnormal tumor morphology
|
J:178595
|
| abnormal tumor pathology
|
J:178595
|
| decreased mammary gland tumor incidence
|
J:178595
|
| decreased skin tumor incidence
|
J:178595
|
| decreased tumor latency
|
J:178595
|
Brca1tm1Brn/Brca1tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
neoplasm
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased carcinoma incidence
|
J:189304
|
| increased metastatic potential
|
J:189304
|
| increased ovarian carcinoma incidence
|
J:189304
|
| increased ovary tumor incidence
|
J:189304
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
abnormal tumor morphology
|
J:178595
|
| abnormal tumor pathology
|
J:178595
|
| increased mammary gland tumor incidence
|
J:178595
|
| increased skin tumor incidence
|
J:178595
|
| increased tumor latency
|
J:178595
|
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-cre)5132Jlj/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased mouth tumor incidence
|
J:85354
|
| increased skin tumor incidence
|
J:85354
|
| increased squamous cell carcinoma incidence
|
J:85354
|
| increased tumor incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-cre)5132Jlj/0
Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
decreased tumor latency
|
J:85354
|
| increased skin tumor incidence
|
J:85354
|
| increased squamous cell carcinoma incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased mouth tumor incidence
|
J:85354
|
| increased papilloma incidence
|
J:85354
|
| increased reproductive system tumor incidence
|
J:85354
|
| increased skin tumor incidence
|
J:85354
|
| increased squamous cell carcinoma incidence
|
J:85354
|
| increased tumor incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * Black Swiss * FVB)
|
increased mammary adenocarcinoma incidence
|
J:54533
|
| increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Cxd/Brca1tm2Cxd
Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * Black Swiss)
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Thl/Brca1tm1Thl
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased tumor latency
|
J:177853
|
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm1Thl/Brca1tm2Rjbr
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased tumor latency
|
J:177853
|
Brca1tm1Thl/Brca1tm3.1Rjbr
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased tumor latency
|
J:177853
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:122899
|
| increased incidence of tumors by chemical induction
|
J:122899
|
| increased mammary gland tumor incidence
|
J:70271
|
| increased T cell derived lymphoma incidence
|
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
|
increased tumor incidence
|
J:81559
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
decreased tumor latency
|
J:177853
|
Brca1tm2.1Cxd/Brca1tm2Rjbr
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
decreased tumor latency
|
J:177853
|
Brca1tm2.1Cxd/Brca1tm3.1Rjbr
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased tumor latency
|
J:177853
|
Brca1tm2.1Cxd/Brca1tm3.1Rjbr
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:177853
|
Brca1tm2Arge/Brca1tm2Arge
(129-Brca1tm2Arge)
|
increased mammary gland tumor incidence
|
J:69187
|
| increased tumor incidence
|
J:69187
|
Brca1tm2Arge/Brca1tm2Arge
(involves: 129/Sv * C57BL/6J * MF1)
|
increased mammary gland tumor incidence
|
J:69187
|
| increased tumor incidence
|
J:69187
|
Brca1tm2Arge/Brca1tm2Arge
(involves: 129 * C57BL/6)
|
increased tumor incidence
|
J:177853
|
Brca1tm2Arge/Brca1tm3.1Rjbr
(involves: 129 * C57BL/6)
|
neoplasm
|
J:177853
|
Brca1tm2Cxd/Brca1+
Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased skin tumor incidence
|
J:85354
|
| increased squamous cell carcinoma incidence
|
J:85354
|
| increased tumor incidence
|
J:85354
|
Brca1tm2Cxd/Brca1tm2Cxd
Pkmtm1.1Mgvh/Pkmtm1.1Mgvh
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N)
|
increased liver tumor incidence
|
J:205213
|
| increased mammary gland tumor incidence
|
J:205213
|
| increased metastatic potential
|
J:205213
|
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
| preneoplasia
|
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
| preneoplasia
|
J:132088
|
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Lck-cre)548Jxm/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased tumor incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary gland tumor incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53+
Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased tumor incidence
|
J:90512
|
Brca1tm2Rjbr/Brca1tm2Rjbr
(involves: 129 * C57BL/6)
|
increased tumor incidence
|
J:177853
|
Brca1tm2Rjbr/Brca1tm2Rjbr
(involves: 129)
|
increased tumor incidence
|
J:197743
|
Brca1tm3.1Rjbr/Brca1tm3.1Rjbr
(involves: 129 * C57BL/6)
|
neoplasm
|
J:177853
|
Brca1tm3Cxd/Brca1tm3Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
increased hepatoma incidence
|
J:94114
|
| increased incidence of tumors by ionizing radiation induction
|
J:94114
|
| increased lipoma incidence
|
J:94114
|
| increased lymphoma incidence
|
J:94114
|
| increased mammary gland tumor incidence
|
J:94114
|
| increased tumor incidence
|
J:94114
|
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
increased mammary gland ductal carcinoma incidence
|
J:112308
|
| increased mammary gland tumor incidence
|
J:112308
|
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
increased incidence of tumors by ionizing radiation induction
|
J:155810
|
| increased liver tumor incidence
|
J:155810
|
| increased lymphoma incidence
|
J:155810
|
| increased mammary gland tumor incidence
|
J:155810
|
| increased T cell derived lymphoma incidence
|
J:155810
|
Brca2tm1Arge/Brca2+
(involves: 129S/SvEv * C57BL/6)
|
neoplasm
|
J:40594
|
Brca2tm1Arge/Brca2tm2Arge
Waptm1(cre)Arge/Wap+
(involves: 129S/SvEv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brca2tm1Brn/Brca2+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
| increased mammary gland tumor incidence
|
J:73028
|
| increased skin tumor incidence
|
J:73028
|
| increased tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Brca2tm1Brn/Brca2tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
| increased mammary gland tumor incidence
|
J:73028
|
| increased skin tumor incidence
|
J:73028
|
| increased tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
| increased mammary gland tumor incidence
|
J:73028
|
| increased skin tumor incidence
|
J:73028
|
| increased tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
abnormal tumor morphology
|
J:144617
|
| increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Cam
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic acinar cell carcinoma incidence
|
J:166678
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Brn
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased malignant tumor incidence
|
J:166678
|
| increased sarcoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Cam
(involves: 129S/SvEv * MF1)
|
increased T cell derived lymphoma incidence
|
J:46812
|
Brca2tm1Cbl/Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))
|
increased T cell derived lymphoma incidence
|
J:44386
|
Brca2tm1Hst/Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased tumor latency
|
J:82434
|
| increased carcinoma incidence
|
J:82434
|
| increased lymphoma incidence
|
J:82434
|
Brca2tm1Kamc/Brca2tm1Kamc
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased tumor incidence
|
J:75026
|
| neoplasm
|
J:109193
|
Brca2tm1Kamc/Brca2tm1Kamc
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
|
increased mammary gland tumor incidence
|
J:109193
|
| increased osteosarcoma incidence
|
J:109193
|
| increased stomach tumor incidence
|
J:109193
|
Brca2tm1Mak/Brca2tm2Mak
Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
neoplasm
|
J:79697
|
Brca2tm1Mak/Brca2tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:79697
|
| increased malignant tumor incidence
|
J:79697
|
| increased osteosarcoma incidence
|
J:79697
|
| increased tumor incidence
|
J:79697
|
Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
Brca2tm1Mhun/Brca2+
(involves: 129S7/SvEvBrd * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:89083
|
| decreased tumor incidence
|
J:89083
|
Brca2tm2.1Sks/Brca2tm1Brd
(B6.Cg-Brca2tm1Brd Brca2tm2.1Sks)
|
neoplasm
|
J:323630
|
Brca2tm2.1Sks/Brca2tm2.1Sks
(Not Specified)
|
neoplasm
|
J:323630
|
Brca2tm2Arge/Brca2tm2Arge
Waptm1(cre)Arge/Waptm1(cre)Arge
(involves: 129S1/Sv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brf1tm1Arte/Brf1tm1Arte
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd)
|
increased adenocarcinoma incidence
|
J:227115
|
| increased adenoma incidence
|
J:227115
|
| increased Harderian gland adenoma incidence
|
J:227115
|
| increased lymphoma incidence
|
J:227115
|
| increased pituitary adenoma incidence
|
J:227115
|
| increased tumor incidence
|
J:227115
|
Btg3tm1Tya/Btg3tm1Tya
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenoma incidence
|
J:149382
|
| increased lung carcinoma incidence
|
J:149382
|
| increased lung tumor incidence
|
J:149382
|
Btn2a2tm1.2Wrth/Btn2a2tm1.2Wrth
(C57BL/6-Btn2a2tm1.2Wrth)
|
abnormal tumor susceptibility
|
J:232636
|
Btnl2em1Wche/Btnl2em1Wche
(C57BL/6-Btnl2em1Wche)
|
neoplasm
|
J:321348
|
Btrctm1Kin/Btrctm1Kin
(involves: C57BL/6)
|
neoplasm
|
J:84639
|
Bts1C57BL/6JShi/?
(involves: C57BL/6JShi * NON/Shi)
|
decreased incidence of tumors by chemical induction
|
J:51984
|
Bts1NON/Shi/?
(involves: C57BL/6JShi * NON/Shi)
|
increased tumor incidence
|
J:51984
|
Bts2C57BL/6JShi/?
(involves: C57BL/6JShi * NON/Shi)
|
decreased incidence of tumors by chemical induction
|
J:51984
|
Bts2NON/Shi/?
(involves: C57BL/6JShi * NON/Shi)
|
increased tumor incidence
|
J:51984
|
Bub1tm1.1Jvd/Bub1+
(involves: 129/Sv * C57BL/6)
|
decreased tumor incidence
|
J:135093
|
| increased incidence of tumors by chemical induction
|
J:135093
|
Bub1tm1.1Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
|
decreased tumor latency
|
J:135093
|
| increased lung tumor incidence
|
J:135093
|
| increased lymphoma incidence
|
J:135093
|
| increased sarcoma incidence
|
J:135093
|
Bub1tm1.1Tvd/Bub1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased brain tumor incidence
|
J:143035
|
| increased lung tumor incidence
|
J:143035
|
Bub1tm1.1Tvd/Bub1tm1.1Tvd
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased incidence of induced tumors
|
J:143035
|
| increased liver tumor incidence
|
J:143035
|
| increased lung tumor incidence
|
J:143035
|
Bub1tm2Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
|
decreased tumor latency
|
J:135093
|
| increased hepatocellular carcinoma incidence
|
J:135093
|
| increased sarcoma incidence
|
J:135093
|
Bub1tm3.1Jvd/Bub1tm3.1Jvd
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:195237
|
Bub1bGt(neo-btk)1Dai/Bub1b+
(involves: 129S4/SvJae)
|
increased colon adenoma incidence
|
J:88094
|
| increased intestinal adenocarcinoma incidence
|
J:88094
|
Bub1btm1.1Hsl/Bub1b+
(involves: 129 * C57BL/6)
|
increased adenocarcinoma incidence
|
J:201641
|
| increased B cell derived lymphoma incidence
|
J:201641
|
| increased fibrosarcoma incidence
|
J:201641
|
| increased hemangiosarcoma incidence
|
J:201641
|
| increased hepatocellular carcinoma incidence
|
J:201641
|
| increased incidence of induced tumors
|
J:201641
|
| increased leukemia incidence
|
J:201641
|
| increased lung adenocarcinoma incidence
|
J:201641
|
| increased lymphoma incidence
|
J:201641
|
| increased rectum adenocarcinoma incidence
|
J:201641
|
| increased sarcoma incidence
|
J:201641
|
Bub1btm1.1Jvd/Bub1b+
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased tumor latency
|
J:293084
|
| increased tumor growth/size
|
J:293084
|
| neoplasm
|
J:293084
|
Bub1btm1Jvd/Bub1btm3.1Jvd
(involves: 129S6/SvEvTac * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:293084
|
| increased tumor growth/size
|
J:293084
|
| neoplasm
|
J:293084
|
Bub1btm2.1Jvd/Bub1b+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased tumor growth/size
|
J:194926
|
| neoplasm
|
J:194926
|
Bub1btm3.1Jvd/Bub1b+
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased tumor latency
|
J:293084
|
| increased tumor growth/size
|
J:293084
|
| neoplasm
|
J:293084
|
Bub3tm1Jvd/Bub3+
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:81546
|
Bub3tm1Jvd/Bub3+
Rae1tm1Jvd/Rae1+
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:81546
|
Cab39ltm1d(EUCOMM)Wtsi/Cab39ltm1d(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6NCr * CBA)
|
increased incidence of tumors by chemical induction
|
J:350956
|
Cables1tm1Lrz/Cables1tm1Lrz
(involves: 129S1/Sv)
|
increased endometrial carcinoma incidence
|
J:87478
|
Cacfd1tm1.1Geno/Cacfd1tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:184968
|
| increased tumor latency
|
J:184968
|
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased lung small cell carcinoma incidence
|
J:190366
|
| increased thyroid tumor incidence
|
J:190366
|
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N)
|
increased lung small cell carcinoma incidence
|
J:190366
|
| increased metastatic potential
|
J:190366
|
| increased thyroid tumor incidence
|
J:190366
|
Camk2gtm1.1Irt/Camk2gtm1.1Irt
(involves: C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:243363
|
Camta1tm1.2Eno/Camta1tm1.2Eno
(involves: C57BL/6)
|
neoplasm
|
J:212232
|
Capza2tm1b(KOMP)Wtsi/Capza2tm1b(KOMP)Wtsi
(C57BL/6N-Capza2tm1b(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Casp1tm1Flv/Casp1tm1Flv
Casp4del/Casp4del
(involves: 129S2/SvPas)
|
decreased metastatic potential
|
J:59893
|
| decreased tumor growth/size
|
J:59893
|
Casp1tm1Flv/Casp1tm1Flv
Casp4del/Casp4del
(involves: 129S2/SvPas * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:191239
|
Casp1tm1Sesh/Casp1tm1Sesh
Casp4del/Casp4del
(involves: 129S2/SvPas * C57BL/6)
|
neoplasm
|
J:22964,
J:40691
|
Casp8tm1Clie/Casp8tm1Clie
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr
Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
neoplasm
|
J:218665
|
Casp12tm1Yuan/Casp12tm1Yuan
(involves: 129S4/SvJae * C57BL/6J)
|
neoplasm
|
J:59337
|
Catb/Catb
(C3.Cg-Catb/Anl)
|
decreased mammary gland tumor incidence
|
J:5971
|
| increased hepatoma incidence
|
J:154291
|
| increased incidence of tumors by chemical induction
|
J:5971
|
Cav1tm1.1Aia/Cav1tm1.1Aia
(involves: 129S7/SvEvBrd * C57BL/6J)
|
neoplasm
|
J:174719
|
Cav1tm1.1Aia/Cav1tm1.1Aia
crsp/+
(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
|
neoplasm
|
J:174719
|
Cav1tm1.1Aia/Cav1tm1.1Aia
crsp/crsp
(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
|
neoplasm
|
J:174719
|
Cav1tm1.1Aia/Cav1tm1.1Aia
Rxfp2tm1Aia/Rxfp2+
(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
|
neoplasm
|
J:174719
|
Cav1tm1Mls/Cav1+
Tg(MMTV-PyVT)634Mul/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:132472
|
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:83485
|
| neoplasm
|
J:109251
|
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:147439
|
Cav1tm1Mls/Cav1tm1Mls
Tg(MMTV-PyVT)634Mul/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:132472
|
Cav1tm1Mls/Cav1tm1Mls
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6 * SJL)
|
decreased tumor incidence
|
J:133066
|
Cav2tm1(KOMP)Mbp/Cav2tm1(KOMP)Mbp
(C57BL/6N-Cav2tm1(KOMP)Mbp)
|
abnormal tumor morphology
|
J:217189
|
| abnormal tumor pathology
|
J:217189
|
| abnormal tumor vascularization
|
J:217189
|
| decreased tumor growth/size
|
J:217189
|
| tumor regression
|
J:217189
|
Cbfbtm5Ppl/Cbfb+
(Not Specified)
|
neoplasm
|
J:193140
|
Cbfbtm6Ppl/Cbfb+
(involves: 129S/SvEv * C57BL/6)
|
neoplasm
|
J:252447
|
Cbx6tm1a(EUCOMM)Wtsi/Cbx6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cbx6tm1a(EUCOMM)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Cbx7tm1Afus/Cbx7+
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184383
|
| increased liver adenoma incidence
|
J:184383
|
| increased lung adenoma incidence
|
J:184383
|
Cbx7tm1Afus/Cbx7tm1Afus
(involves: C57BL/6J)
|
increased carcinoma incidence
|
J:184383
|
| increased hepatocellular carcinoma incidence
|
J:184383
|
| increased liver adenoma incidence
|
J:184383
|
| increased liver tumor incidence
|
J:184383
|
| increased lung carcinoma incidence
|
J:184383
|
| increased lung tumor incidence
|
J:184383
|
| increased tumor incidence
|
J:184383
|
Ccar2tm1Dac/Ccar2tm1Dac
(involves: 129 * C57BL/6J)
|
neoplasm
|
J:228688
|
Ccdc25em1Smoc/Ccdc25em1Smoc
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6NTac * FVB/N)
|
decreased metastatic potential
|
J:291299
|
Ccdc65em11Gpt/Ccdc65+
(C57BL/6J-Ccdc65em11Gpt)
|
increased incidence of tumors by chemical induction
|
J:327251
|
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:216704
|
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified)
|
increased metastatic potential
|
J:217742
|
| increased ovarian carcinoma incidence
|
J:217742
|
| increased thyroid adenoma incidence
|
J:217742
|
Ccl2tm1Rol/Ccl2tm1Rol
(involves: 129S4/SvJae * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:56068
|
Ccm2ltm1Mlkn/Ccm2ltm1Mlkn
(involves: 129 * C57BL/6)
|
abnormal tumor vascularization
|
J:187714
|
| decreased metastatic potential
|
J:187714
|
| decreased tumor growth/size
|
J:187714
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl
Tg(MMTV-cre)1Mam/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
| increased metastatic potential
|
J:241259
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl
Tg(MMTV-cre)1Mam/0
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
| increased metastatic potential
|
J:241259
|
Ccnctm1.1Pisc/Ccnctm1.1Pisc
Tg(Lck-LMO1)11Sjk/0
Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:217695
|
Ccnctm1.1Pisc/Ccnctm1.1Pisc
Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
neoplasm
|
J:217695
|
Ccnd1tm1Dsn/Ccnd1tm1Dsn
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129 * C57BL/6)
|
increased pituitary adenoma incidence
|
J:66707
|
Ccnd1tm1Phin/Ccnd1tm1Phin
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased mammary gland tumor incidence
|
J:105045
|
Ccnd1tm1Wbg/Ccnd1+
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1+
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Smarcb1tm1Gvk/Smarcb1+
(involves: 129/Sv * 129S2/SvPas * C57BL/6J * SJL/J)
|
decreased tumor incidence
|
J:101185
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
| increased tumor latency
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
| increased tumor latency
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm5.1Pisc
Tg(CAG-cre/Esr1*)5Amc/0
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S2/SvPas * C57BL/6 * CBA * FVB/N)
|
decreased tumor growth/size
|
J:192032
|
Ccnd1tm4Pisc/Ccnd1tm4Pisc
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:156591
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
|
decreased lymphoma incidence
|
J:88120
|
| increased T cell derived lymphoma incidence
|
J:88120
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Ccndbp1tm1Riet/Ccndbp1tm1Riet
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:121623
|
| increased liver adenoma incidence
|
J:121623
|
Ccne1tm1Jro/?
Trp53tm1Tyj/Trp53tm1Tyj
(either: (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6J) or (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * C57BL/6J))
|
decreased tumor latency
|
J:99695
|
Ccng1tm1Sst/Ccng1tm1Sst
(involves: 129S/SvEv * C57BL/6)
|
decreased hepatoma incidence
|
J:106007
|
| decreased incidence of induced tumors
|
J:106007
|
| increased hepatoma incidence
|
J:106007
|
Ccr2tm1Ifc/Ccr2tm1Ifc
(B6.129S4-Ccr2tm1Ifc/J)
|
decreased tumor growth/size
|
J:122119
|
Ccr5tm1Kuz/Ccr5tm1Kuz
Tg(CAG-EGFP)1Osb/?
(involves: 129P2/OlaHsd * C3H * C57BL/6)
|
decreased metastatic potential
|
J:97833
|
Ccs1C57BL/6Ha/?
(involves: C57BL/6Ha * ICR/Ha)
|
decreased tumor incidence
|
J:19675
|
Ccs1ICR/Ha/?
(involves: C57BL/6Ha * ICR/Ha)
|
increased tumor incidence
|
J:19675
|
Cd1tm1Gru/Cd1tm1Gru
(involves: 129S2/SvPas * BALB/c)
|
decreased metastatic potential
|
J:118828
|
Cd3etm1Mal/Cd3etm1Mal
Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:95693
|
| increased leukemia incidence
|
J:95693
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
|
decreased tumor growth/size
|
J:280854
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
increased T cell derived lymphoma incidence
|
J:160931
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:228288
|
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased follicular lymphoma incidence
|
J:166155
|
| increased lymphoma incidence
|
J:166155
|
| increased malignant tumor incidence
|
J:166155
|
| increased plasmacytoma incidence
|
J:166155
|
| increased splenic marginal zone lymphoma incidence
|
J:166155
|
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
| increased leukemia incidence
|
J:156946
|
Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:177285
|
| increased B cell derived lymphoma incidence
|
J:177285
|
Cd19tm1(cre)Cgn/Cd19+
Tbl1xr1tm1c(EUCOMM)Hmgu/Tbl1xr1tm1c(EUCOMM)Hmgu
Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)
|
increased organ/body region tumor incidence
|
J:292118
|
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc
(involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6)
|
neoplasm
|
J:195018
|
Cd28tm1Mak/Cd28tm1Mak
Rc3h1san/Rc3h1+
(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)
|
decreased lymphoma incidence
|
J:189087
|
| increased T cell derived lymphoma incidence
|
J:189087
|
Cd34tm1Szk/Cd34tm1Szk
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:121305
|
| increased skin papilloma incidence
|
J:121305
|
Cd44tm1Mak/Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased tumor growth/size
|
J:110162
|
Cd44tm1Mak/Cd44tm1Mak
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased metastatic potential
|
J:100774
|
Cd44tm1Mak/Cd44tm1Mak
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-Cd44tm1Mak Tg(MMTV-PyVT)634Mul)
|
increased metastatic potential
|
J:100774
|
Cd44tm1Mak/Cd44tm1Mak
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J)
|
decreased metastatic potential
|
J:76201
|
| increased lymphoma incidence
|
J:76201
|
Cd47tm1Fpl/Cd47tm1Fpl
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased tumor incidence
|
J:147367
|
Cd79atm1(cre)Reth/Cd79a+
Dynll1tm1.1Jhh/Dynll1tm1.1Jhh
Tg(IghMyc)22Bri/0
(B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth Tg(IghMyc)22Bri)
|
decreased lymphoma incidence
|
J:230105
|
Cd79atm1(cre)Reth/Cd79a+
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
|
neoplasm
|
J:209928
|
Cd82tm1.1Xaz/Cd82tm1.1Xaz
(B6NCr.Cg-Cd82tm1.1Xaz)
|
abnormal tumor vascularization
|
J:234155
|
Cd96tm1.1Mjs/Cd96tm1.1Mjs
(B6.129P2(Cg)-Cd96tm1.1Mjs)
|
decreased incidence of tumors by chemical induction
|
J:209990
|
| decreased metastatic potential
|
J:209990
|
Cd151tm1Mhe/Cd151tm1Mhe
(B6.129S-Cd151tm1Mhe)
|
decreased incidence of induced tumors
|
J:141595
|
Cd151tm2Nki/Cd151tm2Nki
Itga3tm1Son/Itga3+
Krt14tm1(cre)Wbm/?
(FVB.129P2-Cd151tm2Nki Itga3tm1Son Krt14tm1(cre)Wbm)
|
decreased incidence of tumors by chemical induction
|
J:205736
|
| decreased tumor growth/size
|
J:205736
|
Cd151tm2Nki/Cd151tm2Nki
Krt14tm1(cre)Wbm/?
(FVB.129P2-Cd151tm2Nki Krt14tm1(cre)Wbm)
|
decreased incidence of tumors by chemical induction
|
J:205736
|
| decreased tumor growth/size
|
J:205736
|
Cd160tm1Yxf/Cd160tm1Yxf
(C57BL/6-Cd160tm1Yxf)
|
increased tumor growth/size
|
J:222131
|
Cd160tm1Yxf/Cd160tm1Yxf
Rag1tm1Mom/Rag1tm1Mom
(B6.Cg-Rag1tm1Mom Cd160tm1Yxf)
|
increased tumor growth/size
|
J:222131
|
Cd226tm1.1Cln/Cd226tm1.1Cln
(B6.129P2-Cd226tm1.1Cln)
|
abnormal tumor susceptibility
|
J:209990
|
| increased metastatic potential
|
J:159749
|
| increased tumor growth/size
|
J:159749
|
Cd226tm1Shib/Cd226tm1Shib
(involves: BALB/c)
|
increased incidence of induced tumors
|
J:165704
|
| increased incidence of tumors by chemical induction
|
J:165704
|
Cd248tm1Huso/Cd248tm1Huso
(involves: 129S/SvEv * C57BL/6)
|
decreased tumor growth/size
|
J:107172
|
Cdatm1d(EUCOMM)Wtsi/Cdatm1d(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6J * C57BL/6N)
|
decreased incidence of tumors by chemical induction
|
J:332259
|
| decreased tumor growth/size
|
J:332259
|
| neoplasm
|
J:332259
|
Cdc20tm1.1Mama/Cdc20tm1.2Mama
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL)
|
decreased tumor growth/size
|
J:167609
|
| tumor regression
|
J:167609
|
Cdc20tm1.1Pzg/Cdc20+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hepatoma incidence
|
J:150421
|
| increased lymphoma incidence
|
J:150421
|
| increased tumor incidence
|
J:150421
|
Cdc25atm1Dvb/Cdc25atm1Dvb
(involves: 129)
|
increased incidence of tumors by ionizing radiation induction
|
J:144548
|
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-Erbb2)NK1Mul/?
(involves: 129/Sv * C57BL/6 * FVB/N)
|
decreased incidence of induced tumors
|
J:123144
|
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-Myc)141-3Led/?
(involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1)
|
neoplasm
|
J:123144
|
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-vHaras)SH1Led/?
(involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1)
|
decreased incidence of induced tumors
|
J:123144
|
Cdc73Gt(RRE190)Byg/Cdc73+
(B6.129P2-Cdc73Gt(RRE190)Byg)
|
increased parathyroid adenoma incidence
|
J:243366
|
| increased parathyroid gland tumor incidence
|
J:243366
|
| increased uterus tumor incidence
|
J:243366
|
Cdc73tm1Btt/Cdc73+
Tg(PTH-cre)4167Slib/0
(Not Specified)
|
increased parathyroid adenoma incidence
|
J:243366
|
| increased parathyroid gland tumor incidence
|
J:243366
|
Cdc73tm1Btt/Cdc73tm1Btt
Tg(PTH-cre)4167Slib/0
(Not Specified)
|
increased parathyroid adenoma incidence
|
J:243366
|
| increased parathyroid gland tumor incidence
|
J:243366
|
Cdcp1tm1.2Moas/Cdcp1+
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased tumor incidence
|
J:194368
|
Cdcp1tm1.2Moas/Cdcp1tm1.2Moas
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129X1/SvJ * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased tumor growth/size
|
J:194368
|
| increased tumor incidence
|
J:194368
|
Cdcp1tm1.2Moas/Cdcp1tm1.2Moas
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased tumor growth/size
|
J:194368
|
| increased tumor incidence
|
J:194368
|
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
| increased pilomatricoma incidence
|
J:116152
|
| increased skin tumor incidence
|
J:116152
|
| increased squamous cell carcinoma incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
| increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
neoplasm
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
abnormal tumor vascularization
|
J:116152
|
| increased mammary adenocarcinoma incidence
|
J:116152
|
| increased metastatic potential
|
J:116152
|
| increased skin tumor incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary gland tumor incidence
|
J:171765
|
| increased metastatic potential
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
abnormal tumor vascularization
|
J:116152
|
| increased mammary adenocarcinoma incidence
|
J:116152
|
| increased metastatic potential
|
J:116152
|
| increased skin tumor incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary gland tumor incidence
|
J:171765
|
| increased metastatic potential
|
J:171765
|
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
| increased metastatic potential
|
J:212549
|
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased duodenum adenocarcinoma incidence
|
J:212549
|
| increased gastric adenocarcinoma incidence
|
J:212549
|
| increased metastatic potential
|
J:212549
|
| increased squamous cell carcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased intestinal adenocarcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
neoplasm
|
J:212549
|
Cdh1tm2Kem/Cdh1tm2Kem
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased gastric adenocarcinoma incidence
|
J:212549
|
Cdh13tm1Brns/Cdh13tm1Brns
(involves: 129)
|
neoplasm
|
J:132759
|
Cdh13tm1Brns/Cdh13tm1Brns
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:132759
|
| abnormal tumor vascularization
|
J:132759
|
| decreased incidence of induced tumors
|
J:132759
|
| decreased tumor growth/size
|
J:132759
|
| increased mammary gland tumor incidence
|
J:132759
|
| increased metastatic potential
|
J:132759
|
Cdhr5tm1Lex/Cdhr5tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
neoplasm
|
J:301471
|
Cdiptosem1Sunb/Cdiptosem1Sunb
(C57BL/6J-Cdiptosem1Sunb)
|
decreased incidence of tumors by chemical induction
|
J:321215
|
Cdk1tm2.1Kald/Cdk1tm2.1Kald
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * DBA * SJL)
|
decreased incidence of induced tumors
|
J:182141
|
Cdk1tm2.1Kald/Cdk1tm2.1Kald
Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129 * C57BL/6 * CBA * SJL)
|
decreased tumor growth/size
|
J:182141
|
Cdk2tm1Sgo/Cdk2tm1Sgo
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased tumor incidence
|
J:161780
|
Cdk2tm2Sgo/Cdk2tm2Sgo
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased tumor incidence
|
J:161780
|
Cdk4+/Cdk4+
Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
|
increased incidence of tumors by chemical induction
|
J:111992
|
| increased metastatic potential
|
J:111992
|
| increased skin tumor incidence
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:86101
|
| increased lung adenoma incidence
|
J:86101
|
| increased papilloma incidence
|
J:86101
|
| increased pituitary adenoma incidence
|
J:86101
|
| increased sarcoma incidence
|
J:86101
|
Cdk4tm1.1Bbd/Cdk4+
Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
|
decreased tumor growth/size
|
J:111992
|
| increased incidence of tumors by chemical induction
|
J:111992
|
| increased metastatic potential
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
(B6.129(Cg)-Cdk4tm1.1Bbd)
|
neoplasm
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Krt14tm1(cre)Wbm/Krt14+
Pard3tm1Shoh/Pard3tm1Shoh
Tg(Mt1-Hgf)#Lmb/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:240961
|
| increased metastatic potential
|
J:240961
|
| increased tumor growth/size
|
J:240961
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
|
increased cutaneous melanoma incidence
|
J:111992
|
| increased incidence of tumors by chemical induction
|
J:111992
|
| increased metastatic potential
|
J:111992
|
| increased skin tumor incidence
|
J:111992
|
| increased tumor growth/size
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee)
|
increased cutaneous melanoma incidence
|
J:222847
|
| increased incidence of tumors by UV-induction
|
J:222847
|
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased tumor growth/size
|
J:161780
|
| increased adenocarcinoma incidence
|
J:161780
|
Cdk4tm2.2Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased tumor growth/size
|
J:161780
|
| decreased tumor incidence
|
J:161780
|
| increased tumor incidence
|
J:161780
|
Cdk4tm2.2Bbd/Cdk4tm2.2Bbd
Krastm1Bbd/Krastm1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased tumor incidence
|
J:161780
|
Cdk5rap2an/Cdk5rap2an
(Not Specified)
|
increased ovary adenoma incidence
|
J:15165
|
Cdk5rap2an/Cdk5rap2an
Tyrp1B-lt/Tyrp1B-lt
(WBB6F1)
|
increased histiocytic sarcoma incidence
|
J:102334
|
Cdk6tm1Bbd/Cdk6tm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased adenoma incidence
|
J:161780
|
| increased lung non-small cell carcinoma incidence
|
J:161780
|
Cdk6tm1Phin/Cdk6+
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:144975
|
Cdk6tm1Phin/Cdk6tm1Phin
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: 129S4/SvJae)
|
neoplasm
|
J:144975
|
Cdk11bGt(XG836)Byg/Cdk11bGt(XG836)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased skin papilloma incidence
|
J:125424
|
Cdkn1atm1(HBsAg)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm1(HBsAg)Xya/Cdkn1atm1(HBsAg)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm1Led/Cdkn1atm1Led
(NIH.Cg-Cdkn1atm1Led)
|
abnormal tumor incidence
|
J:87536
|
| decreased lymphoma incidence
|
J:87536
|
Cdkn1atm1Led/Cdkn1atm1Led
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Cdkn1atm1Led/Cdkn1atm1Led
Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * FVB/N)
|
neoplasm
|
J:234236
|
Cdkn1atm1Led/Cdkn1atm1Led
Wrntm1Led/Wrntm1Led
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased tumor incidence
|
J:68488
|
Cdkn1atm1Tyj/Cdkn1a+
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J)
|
increased incidence of tumors by ionizing radiation induction
|
J:83967
|
| increased malignant tumor incidence
|
J:83967
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
decreased incidence of tumors by ionizing radiation induction
|
J:70894
|
| increased B cell derived lymphoma incidence
|
J:70894
|
| increased carcinoma incidence
|
J:70894
|
| increased hemangiosarcoma incidence
|
J:70894
|
| increased histiocytic sarcoma incidence
|
J:70894
|
| increased incidence of tumors by chemical induction
|
J:80271
|
| increased Leydig cell tumor incidence
|
J:70894
|
| increased lung carcinoma incidence
|
J:70894
|
| increased sebaceous gland adenoma incidence
|
J:70894
|
| increased skin tumor incidence
|
J:70894
|
| increased T cell derived lymphoma incidence
|
J:70894
|
| increased tumor incidence
|
J:70894
|
| increased urinary system tumor incidence
|
J:70894
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129/Sv * 129S2/SvPas * C57BL/6)
|
increased squamous cell carcinoma incidence
|
J:72780
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J)
|
increased incidence of tumors by ionizing radiation induction
|
J:83967
|
| increased malignant tumor incidence
|
J:83967
|
| increased metastatic potential
|
J:83967
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL)
|
increased squamous cell carcinoma incidence
|
J:72780
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129 * C57BL/6 * CD-1 * DBA/2)
|
increased carcinoma incidence
|
J:204886
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:138701
|
| increased renal carcinoma incidence
|
J:138701
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:106662
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Tg(MMTV-vHaras)SH1Led/0
(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
|
decreased tumor latency
|
J:66183
|
| increased mammary adenocarcinoma incidence
|
J:66183
|
| increased salivary adenocarcinoma incidence
|
J:66183
|
| increased tumor incidence
|
J:66183
|
Cdkn1atm2(HBx)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm2(HBx)Xya/Cdkn1atm2(HBx)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1btm1Ako/Cdkn1b+
KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J)
|
increased ovary adenoma incidence
|
J:236161
|
| increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1b+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid adenoma incidence
|
J:165293
|
| increased thyroid carcinoma incidence
|
J:165293
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:50053
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv)
|
increased lung adenocarcinoma incidence
|
J:120835
|
| increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1btm1Ako
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
|
increased carcinoma incidence
|
J:50053
|
| increased pituitary adenoma incidence
|
J:50053
|
Cdkn1btm1Ako/Cdkn1btm1Ako
KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J)
|
increased ovary adenoma incidence
|
J:236161
|
| increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1btm1Ako
Men1tm1.1Ctre/Men1+
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
| increased lung adenoma incidence
|
J:120835
|
| increased pancreas tumor incidence
|
J:120835
|
| increased parathyroid gland tumor incidence
|
J:120835
|
| increased pituitary gland tumor incidence
|
J:120835
|
| increased testis tumor incidence
|
J:120835
|
| increased thyroid tumor incidence
|
J:120835
|
| increased tumor incidence
|
J:120835
|
Cdkn1btm1Jro/Cdkn1btm1Jro
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
abnormal tumor pathology
|
J:318035
|
| decreased tumor growth/size
|
J:318035
|
| increased osteosarcoma incidence
|
J:318035
|
Cdkn1btm1Kin/Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:33402
|
Cdkn1btm1Mlf/Cdkn1b+
(involves: 129S4/SvJaeSor)
|
increased incidence of tumors by chemical induction
|
J:103819
|
Cdkn1btm1Mlf/Cdkn1b+
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * CBA * FVB)
|
increased T cell derived lymphoma incidence
|
J:88323
|
Cdkn1btm1Mlf/Cdkn1b+
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:205254
|
| increased hemangiosarcoma incidence
|
J:205254
|
| increased lymphoma incidence
|
J:205254
|
| increased medulloblastoma incidence
|
J:205254
|
| increased rhabdomyosarcoma incidence
|
J:205254
|
| increased tumor incidence
|
J:205254
|
Cdkn1btm1Mlf/Cdkn1b+
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
|
increased pituitary adenoma incidence
|
J:33400
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor)
|
increased incidence of tumors by chemical induction
|
J:103819
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:89571
|
| preneoplasia
|
J:89571
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:205254
|
| increased hemangiosarcoma incidence
|
J:205254
|
| increased lymphoma incidence
|
J:205254
|
| increased medulloblastoma incidence
|
J:205254
|
| increased rhabdomyosarcoma incidence
|
J:205254
|
| increased tumor incidence
|
J:205254
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Tg(MMTV-vHaras)SH1Led/0
(involves: 129S4/SvJaeSor * C57BL/6J * CD-1)
|
increased tumor growth/size
|
J:80271
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd
(involves: C3H * C57BL/6J * NIH)
|
increased sarcoma incidence
|
J:87536
|
| increased T cell derived lymphoma incidence
|
J:87536
|
| increased tumor incidence
|
J:87536
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased sarcoma incidence
|
J:87536
|
| increased T cell derived lymphoma incidence
|
J:87536
|
| increased tumor incidence
|
J:87536
|
Cdkn1btm2Jro/Cdkn1btm2Jro
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:103819
|
Cdkn1btm2Kin/Cdkn1btm2Kin
Rassf5tm1Kina/Rassf5tm1Kina
(involves: C57BL/6 * CBA)
|
neoplasm
|
J:168749
|
Cdkn1btm2Mlf/Cdkn1btm2Mlf
Tg(Pomc1-cre)1Mlf/0
(involves: 129S4/SvJaeSor)
|
increased pituitary gland tumor incidence
|
J:107588
|
Cdkn1btm3Mlf/Cdkn1btm3Mlf
(involves: 129S4/SvJaeSor)
|
increased pituitary gland tumor incidence
|
J:107588
|
Cdkn1btm3Mlf/Cdkn1btm3Mlf
Tg(Pomc1-cre)1Mlf/0
(involves: 129S4/SvJaeSor)
|
decreased tumor incidence
|
J:107588
|
Cdkn2aem1Cjs/Cdkn2aem1Cjs
(B6.Cg-Cdkn2aem1Cjs)
|
increased acute lymphoblastic leukemia incidence
|
J:244260
|
Cdkn2aem2Cjs/Cdkn2aem2Cjs
(C57BL/6-Cdkn2aem2Cjs)
|
neoplasm
|
J:244260
|
Cdkn2aPctr1-DBA/2N/?
(involves: BALB/cAnPt * DBA/2N)
|
decreased tumor incidence
|
J:16958
|
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
(involves: 129S1/Sv * C57BL/6)
|
increased gastrointestinal stromal tumor incidence
|
J:87339
|
| increased hemangiosarcoma incidence
|
J:87339
|
| increased histiocytic sarcoma incidence
|
J:87339
|
| increased incidence of tumors by ionizing radiation induction
|
J:87339
|
| increased lymphoma incidence
|
J:87339
|
| increased sarcoma incidence
|
J:87339
|
| increased tumor incidence
|
J:87339
|
Cdkn2atm1.1Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased mesothelioma incidence
|
J:132943
|
| increased metastatic potential
|
J:132943
|
| increased rhabdomyosarcoma incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:125189
|
| neoplasm
|
J:71393
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Cdkn2btm2Brn/Cdkn2btm2Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:125189
|
| increased skin tumor incidence
|
J:125189
|
| neoplasm
|
J:125189
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd * FVB/N)
|
increased liver tumor incidence
|
J:131179
|
| increased meningioma incidence
|
J:131179
|
| increased osteoma incidence
|
J:131179
|
| osseous metaplasia
|
J:131179
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
(involves: 129P2/OlaHsd * FVB/N)
|
increased meningioma incidence
|
J:173718
|
| neoplasm
|
J:173718
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased mesothelioma incidence
|
J:132943
|
| increased rhabdomyosarcoma incidence
|
J:132943
|
| increased Schwannoma incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased mesothelioma incidence
|
J:132943
|
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
increased adenocarcinoma incidence
|
J:198619
|
| increased pancreas adenoma incidence
|
J:198619
|
| increased pancreas tumor incidence
|
J:198619
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:198619
|
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
neoplasm
|
J:198619
|
Cdkn2atm1Cjs/Cdkn2a+
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
|
increased carcinoma incidence
|
J:93298
|
| increased incidence of tumors by chemical induction
|
J:93298
|
| increased papilloma incidence
|
J:93298
|
Cdkn2atm1Cjs/Cdkn2a+
Kat5tm1Jwl/Kat5+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased tumor latency
|
J:125164
|
Cdkn2atm1Cjs/Cdkn2a+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
(involves: 129 * C57BL * FVB/N * SJL)
|
decreased tumor incidence
|
J:120284
|
Cdkn2atm1Cjs/Cdkn2a+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:244260
|
| increased carcinoma incidence
|
J:44427
|
| increased fibrohistocytoma incidence
|
J:44427
|
| increased fibrosarcoma incidence
|
J:44427
|
| increased incidence of tumors by chemical induction
|
J:44427
|
| increased incidence of tumors by ionizing radiation induction
|
J:44427
|
| increased lymphoma incidence
|
J:44427
|
| increased T cell derived lymphoma incidence
|
J:44427
|
| increased tumor incidence
|
J:44427
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
|
increased carcinoma incidence
|
J:93298
|
| increased incidence of tumors by chemical induction
|
J:93298
|
| increased metastatic potential
|
J:93298
|
| increased papilloma incidence
|
J:93298
|
| increased squamous cell carcinoma incidence
|
J:93298
|
| increased tumor growth/size
|
J:93298
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
| increased sarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7tm1Pgr
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
| increased sarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)68Dla/0
(involves: 129X1/SvJ * FVB/N)
|
increased leukemia incidence
|
J:99991
|
| increased lung adenocarcinoma incidence
|
J:99991
|
| increased lymphoma incidence
|
J:99991
|
| increased osteosarcoma incidence
|
J:99991
|
| increased sarcoma incidence
|
J:99991
|
| increased tumor incidence
|
J:99991
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)76Dla/0
(involves: 129X1/SvJ * FVB/N)
|
increased leukemia incidence
|
J:99991
|
| increased lung adenocarcinoma incidence
|
J:99991
|
| increased lymphoma incidence
|
J:99991
|
| increased osteosarcoma incidence
|
J:99991
|
| increased sarcoma incidence
|
J:99991
|
| increased tumor incidence
|
J:99991
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tacstd2tm1Lsm/Tacstd2tm1Lsm
(involves: 129X1/SvJ * C57BL/6)
|
increased carcinoma incidence
|
J:182647
|
| increased skin squamous cell carcinoma incidence
|
J:182647
|
| increased spindle cell carcinoma incidence
|
J:182647
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(GFAP-TVA)5Hev/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(NES-TVA)J12Ech/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
|
abnormal tumor incidence
|
J:93298
|
| increased carcinoma incidence
|
J:93298
|
| increased tumor growth/size
|
J:93298
|
Cdkn2atm1Nesh/Cdkn2atm1Nesh
(involves: 129S6/SvEvTac * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:88365
|
| increased lung carcinoma incidence
|
J:88365
|
| increased osteosarcoma incidence
|
J:88365
|
| increased sarcoma incidence
|
J:88365
|
| increased small lymphocytic lymphoma incidence
|
J:88365
|
| increased tumor incidence
|
J:88365
|
Cdkn2atm1Nesh/Cdkn2atm1Nesh
X/Tg(Tyr-HRAS)60Lc
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB)
|
increased melanoma incidence
|
J:85075
|
Cdkn2atm1Rdp/Cdkn2a+
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Cdkn2atm1Rdp/Cdkn2a+
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:120065
|
| increased sarcoma incidence
|
J:120065
|
| increased tumor incidence
|
J:120065
|
Cdkn2atm1Rdp/Cdkn2a+
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased metastatic potential
|
J:197052
|
| increased pancreas tumor incidence
|
J:197052
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
Cdkn2atm1Rdp/Cdkn2a+
Tg(NES-TVA)J12Ech/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:52161
|
Cdkn2atm1Rdp/Cdkn2a+
Tg(S100b-v-erbB)4496Waw/0
(involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL)
|
increased glioma incidence
|
J:82649
|
Cdkn2atm1Rdp/Cdkn2a+
X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * FVB/N * SJL)
|
increased incidence of tumors by UV-induction
|
J:140820
|
| increased intraocular melanoma incidence
|
J:140820
|
Cdkn2atm1Rdp/Cdkn2a+
Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:53805
|
| increased cutaneous melanoma incidence
|
J:98545
|
| increased fibrosarcoma incidence
|
J:53805
|
| increased hemangiosarcoma incidence
|
J:53805
|
| increased sarcoma incidence
|
J:53805
|
| increased tumor incidence
|
J:53805
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased lymphoma incidence
|
J:88365
|
| increased sarcoma incidence
|
J:88365
|
| increased tumor incidence
|
J:88365
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
|
increased squamous cell carcinoma incidence
|
J:72780
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased brain tumor incidence
|
J:163931
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char
Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * C57BL/6J * FVB * SJL)
|
increased melanoma incidence
|
J:155731
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
(involves: 129 * C57BL/6J * SJL)
|
increased fibrosarcoma incidence
|
J:146617
|
| increased sarcoma incidence
|
J:146617
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptentm1Rdp/Ptentm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * C57BL/6J * FVB * SJL)
|
increased melanoma incidence
|
J:221902
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Krastm4Tyj/Kras+
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Mxi1tm1Rdp/Mxi1tm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased tumor incidence
|
J:48236
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased leukemia incidence
|
J:131914
|
| increased lymphoma incidence
|
J:131914
|
| increased neurofibrosarcoma incidence
|
J:131914
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL)
|
increased melanoma incidence
|
J:155731
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Rnf2tm1Mvi/Rnf2tm1Mvi
Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL)
|
increased lymphoma incidence
|
J:130397
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Sox10tm1Weg/Sox10+
Tg(Tyr-NRAS*Q61K)1Bee/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * SJL)
|
neoplasm
|
J:193443
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:120065
|
| increased sarcoma incidence
|
J:120065
|
| increased tumor incidence
|
J:120065
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(GFAP-TVA)5Hev/0
(involves: 129/Sv * BALB/c * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(GFAP-TVA)10Ech/0
(involves: 129 * BALB/c * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:52161
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Mt1-Hgf)19Lmb/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased melanoma incidence
|
J:79704
|
| increased rhabdomyosarcoma incidence
|
J:79704
|
| increased tumor incidence
|
J:79704
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(NES-TVA)J12Ech/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:52161
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(NES-TVA)J12Ech/0
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:153220
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(S100b-v-erbB)4496Waw/0
(involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL)
|
decreased tumor latency
|
J:82649
|
| increased glioma incidence
|
J:82649
|
| increased oligodendroglioma incidence
|
J:82649
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6J * FVB/N * SJL)
|
increased lung adenocarcinoma incidence
|
J:166963,
J:73468
|
| increased lung tumor incidence
|
J:73468
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-rtTA)37Lc/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased prostate gland adenocarcinoma incidence
|
J:144358
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-Nras*Q61K)#Lc/0
Tg(Tyr-rtTA)37Lc/0
(FVB.Cg-Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc Tg(Tyr-rtTA)37Lc)
|
increased cutaneous melanoma incidence
|
J:238049
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)470Fgh/0
(involves: 129/Sv * C57BL/6J * CBA * SJL)
|
increased melanoma incidence
|
J:151455
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)476Fgh/0
(involves: 129/Sv * C57BL/6J * CBA * SJL)
|
increased melanoma incidence
|
J:151455
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * SJL)
|
decreased tumor growth/size
|
J:164588
|
| increased melanoma incidence
|
J:164588
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
| increased metastatic potential
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/0
(involves: 129/Sv * C57BL/6J * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:193443
|
Cdkn2atm1Sxs/Cdkn2atm1Sxs
(involves: 129/Sv * C57BL/6)
|
abnormal tumor incidence
|
J:149526
|
Cdkn2atm2.1Brn/Cdkn2atm2.1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased carcinoma incidence
|
J:71393
|
| increased incidence of tumors by chemical induction
|
J:71393
|
| increased lymphoma incidence
|
J:71393
|
| increased melanoma incidence
|
J:71393
|
| increased metastatic potential
|
J:71393
|
| increased sarcoma incidence
|
J:71393
|
| increased tumor incidence
|
J:71393
|
Cdkn2atm2.1Nesh/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
| increased spindle cell carcinoma incidence
|
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Ezh2tm1.1Nesh/Ezh2+
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:239472
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
| increased spindle cell carcinoma incidence
|
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2atm2.1Nesh Krastm4Tyj)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
| increased spindle cell carcinoma incidence
|
J:164588
|
| increased tumor growth/size
|
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:239472
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh Stk11tm1.1Rdp)
|
increased cutaneous melanoma incidence
|
J:220627
|
| increased metastatic potential
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1Tyj Cdkn2atm2.1Nesh)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
Cdkn2atm2.1Rdp/Cdkn2a+
(involves: 129S6/SvEvTac * FVB/N)
|
increased tumor incidence
|
J:71394
|
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:71394,
J:88365
|
| increased lymphoma incidence
|
J:88365
|
| increased osteosarcoma incidence
|
J:88365
|
| increased sarcoma incidence
|
J:88365
|
| increased small lymphocytic lymphoma incidence
|
J:88365
|
| increased tumor incidence
|
J:71394,
J:88365
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
| increased metastatic potential
|
J:124682
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased adenocarcinoma incidence
|
J:198619
|
| increased pancreas adenoma incidence
|
J:198619
|
| increased pancreas tumor incidence
|
J:198619
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:198619
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:131914
|
| neoplasm
|
J:131914
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(GFAP-TVA)5Hev/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(NES-TVA)J12Ech/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
X/Tg(Tyr-HRAS)60Lc
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB)
|
increased melanoma incidence
|
J:85075
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:124682
|
Cdkn2atm2Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
| increased uterus leiomyoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2+
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
| increased uterus leiomyoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:132943
|
| increased rhabdomyosarcoma incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
| increased uterus leiomyoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn
Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0
(involves: C57BL/6 * FVB/N)
|
increased classified tumor incidence
|
J:107175
|
| increased cutaneous melanoma incidence
|
J:107175
|
| increased neurofibrosarcoma incidence
|
J:107175
|
Cdkn2atm4Cjs/Cdkn2atm4Cjs
(involves: 129S1/Sv * C57BL/6)
|
neoplasm
|
J:147752
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
| increased tumor incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
| increased stomach tumor incidence
|
J:116130
|
| increased tumor incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm4Rdp/Cdkn2a+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
|
neoplasm
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:195492
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:125101
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
| increased stomach tumor incidence
|
J:116130
|
| increased tumor incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased malignant tumor incidence
|
J:87196
|
| increased metastatic potential
|
J:108298,
J:87196
|
| increased pancreas tumor incidence
|
J:108298,
J:87196
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:108298,
J:87196
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:87196
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:187012
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:151781
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Nf1tm1Par/Nf1tm1Par
(involves: 129S1/Sv * 129X1/SvJ)
|
increased neurofibrosarcoma incidence
|
J:234760
|
| increased rhabdomyosarcoma incidence
|
J:234760
|
| increased sarcoma incidence
|
J:234760
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: C57BL/6 * CBA * FVB/N)
|
neoplasm
|
J:87196
|
Cdkn2btm1Bbd/Cdkn2btm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased adenocarcinoma incidence
|
J:63299
|
| increased sarcoma incidence
|
J:63299
|
| increased tumor incidence
|
J:63299
|
Cdkn2btm1Bbd/Cdkn2btm1Bbd
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:63299
|
| increased pituitary adenoma incidence
|
J:63299
|
| increased sarcoma incidence
|
J:63299
|
| increased testis tumor incidence
|
J:63299
|
| increased tumor incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:63299
|
| increased hemangiosarcoma incidence
|
J:63299
|
| increased pheochromocytoma incidence
|
J:63299
|
| increased pituitary adenoma incidence
|
J:63299
|
| increased renal carcinoma incidence
|
J:63299
|
| increased T cell derived lymphoma incidence
|
J:63299
|
| increased testis tumor incidence
|
J:63299
|
| neoplasm
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Cdkn2dtm1Maro/Cdkn2dtm1Maro
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
|
increased pheochromocytoma incidence
|
J:68829
|
| increased pituitary adenoma incidence
|
J:68829
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased medulloblastoma incidence
|
J:205254
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:50053
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(B6.129-Cdkn2ctm1Yxi)
|
increased lung adenocarcinoma incidence
|
J:120835
|
| increased lung adenoma incidence
|
J:120835
|
| increased lung tumor incidence
|
J:120835
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi)
|
increased mammary gland tumor incidence
|
J:198018
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
|
decreased tumor latency
|
J:120835
|
| increased adenocarcinoma incidence
|
J:120835
|
| increased adrenal gland tumor incidence
|
J:120835
|
| increased Leydig cell tumor incidence
|
J:120835
|
| increased lung adenocarcinoma incidence
|
J:120835
|
| increased lung adenoma incidence
|
J:120835
|
| increased lung tumor incidence
|
J:120835
|
| increased pancreas tumor incidence
|
J:120835
|
| increased parathyroid gland tumor incidence
|
J:120835
|
| increased testis tumor incidence
|
J:120835
|
| increased thyroid tumor incidence
|
J:120835
|
Cdsntm1.1Ics/Cdsntm1.1Ics
Tg(KRT14-cre)1Ipc/0
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
increased skin papilloma incidence
|
J:153292
|
Cdx2tm1Fbe/Cdx2+
(involves: 129S1/Sv * C57BL/6J)
|
increased colon adenoma incidence
|
J:38772
|
| increased intestinal adenoma incidence
|
J:38772
|
Cdx2tm1Mmt/Cdx2+
(involves: 129X1/SvJ * C57BL/6)
|
increased colon hamartoma incidence
|
J:47050
|
Ceacam1tm2Bcn/Ceacam1tm2Bcn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:115838
|
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT5-cre)5132Jlj/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2J)
|
increased skin papilloma incidence
|
J:123139
|
| increased skin tumor incidence
|
J:123139
|
| increased squamous cell carcinoma incidence
|
J:123139
|
| increased tumor growth/size
|
J:123139
|
Cebpatm1Timc/Cebpatm1Timc
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:163725
|
Cebpatm8.1Nerl/Cebpatm8.1Nerl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased leukemia incidence
|
J:136134
|
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT5-cre)5132Jlj/?
(involves: 129S1/Sv * C57BL/6J * DBA/2J)
|
decreased incidence of tumors by chemical induction
|
J:107334
|
Cebpbtm1Pfj/Cebpb+
(B6.Cg-Cebpbtm1Pfj)
|
decreased incidence of tumors by chemical induction
|
J:73558
|
Cebpbtm1Pfj/Cebpbtm1Pfj
(B6.Cg-Cebpbtm1Pfj)
|
decreased incidence of induced tumors
|
J:73558
|
| decreased incidence of tumors by chemical induction
|
J:73558
|
Cebpbtm1Pfj/Cebpbtm1Pfj
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:73558
|
| decreased tumor growth/size
|
J:73558
|
Cep57em1Jvd/Cep57+
(involves: 129 * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:264300
|
| increased lung adenoma incidence
|
J:264300
|
| increased tumor incidence
|
J:264300
|
Cep57em2Jvd/Cep57+
(involves: FVB/N)
|
increased lung adenoma incidence
|
J:264300
|
| increased tumor incidence
|
J:264300
|
Cers2Gt(S16-4B1)Sor/Cers2Gt(S16-4B1)Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156841
|
| increased liver tumor incidence
|
J:156841
|
Chd1lGt(E305F08)Wrst/Chd1lGt(E305F08)Wrst
(involves: 129 * 129P2/OlaHsd)
|
decreased incidence of tumors by chemical induction
|
J:302849
|
| decreased tumor incidence
|
J:302849
|
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:146176
|
| increased T cell derived lymphoma incidence
|
J:146176
|
Chek1tm1Sje/Chek1+
(Not Specified)
|
neoplasm
|
J:62919
|
Chek1tm1Sje/Chek1+
Tg(Wnt1)1Hev/0
(Not Specified)
|
increased mammary adenocarcinoma incidence
|
J:62919
|
Chek1tm2.1Sje/Chek1+
Tg(MMTV-cre)#Mam/0
(involves: FVB)
|
neoplasm
|
J:162126
|
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
abnormal tumor morphology
|
J:162126
|
| abnormal tumor vascularization
|
J:162126
|
| increased mammary adenocarcinoma incidence
|
J:162126
|
| increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
decreased tumor incidence
|
J:162126
|
| increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje
Tg(MMTV-cre)#Mam/0
(involves: FVB)
|
neoplasm
|
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
abnormal tumor morphology
|
J:162126
|
| decreased tumor incidence
|
J:162126
|
Chek2tm1Mak/Chek2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:78491
|
Chek2tm1Mak/Chek2tm1Mak
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Chfrtm1Jc/Chfr+
(involves: 129S/SvEv * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:97428
|
| increased lymphoma incidence
|
J:97428
|
| increased tumor incidence
|
J:97428
|
Chfrtm1Jc/Chfrtm1Jc
(involves: 129S/SvEv * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:97428
|
| increased lymphoma incidence
|
J:97428
|
| increased tumor incidence
|
J:97428
|
Chordc1tm1Mbra/Chordc1+
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:159109
|
Chordc1tm1Mbra/Chordc1+
(involves: 129 * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:222040
|
Chuktm1Yhu/Chuktm1Yhu
Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased skin tumor incidence
|
J:141162
|
Chuktm1Yhu/Chuktm1Yhu
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased carcinoma incidence
|
J:141162
|
| increased skin papilloma incidence
|
J:141162
|
| increased skin tumor incidence
|
J:141162
|
Chuktm1Yhu/Chuktm1Yhu
Tg(MMTV-cre)4Mam/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)
|
increased skin tumor incidence
|
J:141162
|
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased lung tumor incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin squamous cell carcinoma incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu
Tg(KRT5-CHUK)#Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
neoplasm
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu
Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased lung squamous cell carcinoma incidence
|
J:197037
|
| increased lung tumor incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu
Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased squamous cell carcinoma incidence
|
J:197037
|
Cibar1tm1b(KOMP)Wtsi/Cibar1tm1b(KOMP)Wtsi
(C57BL/6N-Cibar1tm1b(KOMP)Wtsi/Wtsi)
|
increased osteoma incidence
|
J:274784
|
Cimap2Retro/Cimap2Retro
(involves: C57BL/6J)
|
decreased lung tumor incidence
|
J:223336
|
Ciz1tm1.1Homy/Ciz1tm1.1Homy
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased tumor incidence following infection
|
J:198470
|
Cks1btm1Sir/Cks1b+
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:121564
|
Cks1btm1Sir/Cks1btm1Sir
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
decreased metastatic potential
|
J:121564
|
| increased lymphoma incidence
|
J:121564
|
Clcn2em1Uis/Clcn2+
(C57BL/6N-Clcn2em1Uis)
|
neoplasm
|
J:282228
|
Clp1tm1.1Pngr/Clp1tm1.1Pngr
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J)
|
increased tumor incidence
|
J:196364
|
Clspntm1(KOMP)Vlcg/Clspn+
(C57BL/6N-Clspntm1(KOMP)Vlcg)
|
decreased tumor latency
|
J:332163
|
| increased incidence of tumors by chemical induction
|
J:332163
|
Cmiptm1a(EUCOMM)Wtsi/Cmiptm1a(EUCOMM)Wtsi
(C57BL/6N-Cmiptm1a(EUCOMM)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:235747
|
Col1a1tm1(CAG-Ezh2*)Meln/Col1a1+
Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:199122
|
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp
Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
increased leukemia incidence
|
J:199366
|
| increased T cell derived lymphoma incidence
|
J:199366
|
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129 * C57BL/6)
|
abnormal tumor pathology
|
J:166724
|
| increased lung carcinoma incidence
|
J:166724
|
| increased lung tumor incidence
|
J:166724
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:194505
|
| tumor regression
|
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(CAG-cat,-lacZ)11Miya/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2)
|
increased sarcoma incidence
|
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:194505
|
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:201145
|
| increased papilloma incidence
|
J:201145
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
| increased incidence of tumors by chemical induction
|
J:217463
|
| increased liver adenoma incidence
|
J:217463
|
| increased metastatic potential
|
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Trp53tm1Gev/Trp53+
(B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1tm1(tetO-URI1)Ndj
Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:171057
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
| increased prostate gland tumor incidence
|
J:222916
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
(involves: 129 * C57BL/6)
|
increased leukemia incidence
|
J:210097
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:210097
|
| neoplasm
|
J:210097
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Foxd1tm1(GFP/cre)Amc/Foxd1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Six2-EGFP/cre)1Amc/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CD-1)
|
neoplasm
|
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased kidney tumor incidence
|
J:211179
|
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased skin tumor incidence
|
J:98920
|
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:171191
|
| increased lymphoma incidence
|
J:171191
|
| increased T cell derived lymphoma incidence
|
J:171191
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung tumor incidence
|
J:214230
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:214230
|
| increased lung tumor incidence
|
J:214230
|
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:171191
|
| increased lymphoma incidence
|
J:171191
|
| increased T cell derived lymphoma incidence
|
J:171191
|
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung tumor incidence
|
J:214230
|
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased lung adenoma incidence
|
J:171191
|
| increased tumor incidence
|
J:171191
|
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:163322
|
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:231166
|
| increased tumor incidence
|
J:231166
|
Col1a1tm13(tetO-Nup88)Jvd/Col1a1+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:231166
|
| increased tumor incidence
|
J:231166
|
Col4a2em1(IMPC)Wtsi/Col4a2em1(IMPC)Wtsi
(C57BL/6N-Col4a2em1(IMPC)Wtsi/WtsiOulu)
|
embryo tumor
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Col18a1tm1Hms/Col18a1tm1Hms
(B6.129S4-Col18a1tm1Hms)
|
neoplasm
|
J:75861
|
Cop1Gt(XR0653)1.1Wtsi/Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:178271
|
| increased histiocytic sarcoma incidence
|
J:178271
|
| increased incidence of induced tumors
|
J:178271
|
| increased T cell derived lymphoma incidence
|
J:178271
|
| increased testicular teratoma incidence
|
J:178271
|
| increased tumor incidence
|
J:178271
|
| increased uterus tumor incidence
|
J:178271
|
Cop1tm2.1Vmd/Cop1+
Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
| increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Cop1tm2.1Vmd/Cop1tm2.1Vmd
Tg(Pbsn-cre)4Prb/0
(B6N.Cg-Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb)
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Cops6Gt(RRI087)Byg/Cops6+
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased incidence of tumors by ionizing radiation induction
|
J:172038
|
Cops6Gt(RRI087)Byg/Cops6+
Trp53tm1Glo/Trp53+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased incidence of tumors by ionizing radiation induction
|
J:172038
|
Coro1ctm1a(KOMP)Wtsi/Coro1ctm1a(KOMP)Wtsi
(C57BL/6N-Coro1ctm1a(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
Coro1ctm1c(KOMP)Wtsi/Coro1ctm1c(KOMP)Wtsi
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ)
|
increased glioblastoma incidence
|
J:290447
|
Cpb2tm1Jcmm/Cpb2tm1Jcmm
(involves: 129P2/OlaHsd * C57BL/6J)
|
neoplasm
|
J:102166
|
Cpt1cGt(XL823)Byg/Cpt1c+
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased metastatic potential
|
J:228258
|
| decreased sarcoma incidence
|
J:228258
|
Crebbptm1Dli/Crebbp+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hemolymphoid system tumor incidence
|
J:60630
|
| increased histiocytic sarcoma incidence
|
J:60630
|
| increased leukemia incidence
|
J:60630
|
Crebbptm1Jvd/Crebbptm1Jvd
Tg(Lck-cre)548Jxm/0
(involves: 129 * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:105505
|
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * FVB)
|
increased T cell derived lymphoma incidence
|
J:88323
|
Crebbptm2Pkb/Crebbp+
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal tumor incidence
|
J:103607
|
Crkltm1Hkp/Crkltm1Hkp
Tg(BCR/ABL)623Hkp/?
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:76680
|
| increased leukemia incidence
|
J:76680
|
Crtac1em1(IMPC)H/Crtac1em1(IMPC)H
(C57BL/6NTac-Crtac1em1(IMPC)H/H)
|
neoplasm
|
J:322410
|
Csf2tm1Dran/Csf2tm1Dran
Ifngtm1Ts/Ifngtm1Ts
Il3tm1Glli/Il3tm1Glli
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:83086
|
| increased carcinoma incidence
|
J:83086
|
| increased ovarian carcinoma incidence
|
J:83086
|
Csf2tm1Mlg/Csf2tm1Mlg
Ifngtm1Ts/Ifngtm1Ts
Il3tm1Glli/Il3tm1Glli
(B6.129S-Csf2tm1Mlg Il3tm1Glli Ifngtm1TsIfngtm1Ts)
|
increased pituitary adenoma incidence
|
J:145518
|
Csnk1a1tm1.1Ybn/Csnk1a1+
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6 * CD-1 * DBA/2)
|
increased carcinoma incidence
|
J:204886
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
neoplasm
|
J:253611
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6 * CD-1 * DBA/2)
|
increased carcinoma incidence
|
J:204886
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.2Ybn
(involves: 129 * BALB/c * C57BL/6 * CD-1)
|
neoplasm
|
J:204886
|
Cst3tm1Karl/Cst3tm1Karl
(involves: 129S/SvEv * C57BL/6)
|
increased metastatic potential
|
J:62407
|
Ct55em1Xdzg/Ct55em1Xdzg
(involves: C57BL/6)
|
decreased incidence of induced tumors
|
J:280149
|
Ctnnb1tm1.1Smoc/Ctnnb1tm1.1Smoc
Sox9em1(cre/ERT2)Tchn/Sox9+
(involves: C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:322311
|
Ctnnb1tm1.2Wvv/Ctnnb1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:185942
|
| increased intestinal adenocarcinoma incidence
|
J:185942
|
| increased intestinal adenoma incidence
|
J:185942
|
Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:169830
|
Ctnnb1tm1Mmt/Ctnnb1+
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Tg(Wap-cre)11738Mam/0
Tg(Wap-Hgf)402Mig/0
(FVB.Cg-Cxcr4tm2Yzo Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam Tg(Wap-Hgf)402Mig)
|
decreased mammary gland tumor incidence in breeding females
|
J:206839
|
Ctnnb1tm1Mmt/Ctnnb1+
Dclk1tm1.1(cre/ERT2)Seno/Dclk1+
(involves: 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:193873
|
Ctnnb1tm1Mmt/Ctnnb1+
Fgfr3tm4Cxd/Fgfr3+
Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N)
|
increased lung tumor incidence
|
J:174242
|
| neoplasm
|
J:174242
|
Ctnnb1tm1Mmt/Ctnnb1+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Prom1tm1(cre/ERT2)Gilb/Prom1+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased intestinal adenocarcinoma incidence
|
J:144215
|
Ctnnb1tm1Mmt/Ctnnb1+
Igs2tm1(CAG-Met)Zsu/Igs2+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:284956
|
| increased prostate intraepithelial neoplasia incidence
|
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:143034
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
| increased testis tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
| increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased lung tumor incidence
|
J:174242
|
Ctnnb1tm1Mmt/Ctnnb1+
Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
neoplasm
|
J:199091
|
Ctnnb1tm1Mmt/Ctnnb1+
Krt19tm1(cre)Mmt/Krt19+
(involves: 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:58367
|
Ctnnb1tm1Mmt/Ctnnb1+
Pik3catm1Gilb/Pik3ca+
Trp53tm1Brn/Trp53+
Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
| increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1+
Sox2tm1.1(cre/ERT2)Jpmb/Sox2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:201265
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Col1a1-cre)1Kry/0
(involves: 129X1/SvJ * FVB)
|
increased osteoma incidence
|
J:98430
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(CYP19A1-cre)1Jri/0
(involves: 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
| increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Fabp1-cre)1Mmt/?
(involves: 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:58367
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Msx2-rtTA)885Lma/0
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129X1/SvJ * C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:202618
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased hepatoblastoma incidence
|
J:112659
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Pbsn-cre)4Prb/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034,
J:284956
|
| increased prostate intraepithelial neoplasia incidence
|
J:143034,
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Upk2-cre)6Xrw/0
(involves: 129X1/SvJ * FVB/N)
|
neoplasm
|
J:164579,
J:174242
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Wap-cre)11738Mam/0
(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam)
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Wap-cre)11738Mam/0
Tg(Wap-Hgf)402Mig/0
(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam Tg(Wap-Hgf)402Mig)
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
| increased mammary gland tumor incidence in virgin females
|
J:206839
|
Ctnnb1tm1Mmt/Ctnnb1+
Trp53tm1Brn/Trp53+
Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Hwu/Ptentm1Hwu
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased hepatoblastoma incidence
|
J:112659
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Upk2-cre)6Xrw/0
(involves: 129X1/SvJ * FVB/N)
|
neoplasm
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Upk2-cre)6Xrw/0
Tg(Upk2-HRAS*Q61L)5Xrw/0
(involves: 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Ctnnb1tm2Kem/Ctnnb1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
Tg(tetO-Vegfa)90Ala/0
(involves: 129 * C57BL/6 * FVB/N * ICR * SJL)
|
increased hemangioma incidence
|
J:156474
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Tcf21tm1(cre)Seq/Tcf21+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased tumor incidence
|
J:189643
|
Ctnnd1tm1Abre/Ctnnd1tm1Abre
Tg(KRT14-cre)1Efu/?
(involves: 129S6/SvEvTac)
|
increased skin tumor incidence
|
J:143096
|
Ctsbtm1Jde/Ctsbtm1Jde
Ctsztm1Thre/Ctsztm1Thre
Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsztm1Thre Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
|
abnormal tumor morphology
|
J:157541
|
| decreased metastatic potential
|
J:157541
|
| decreased tumor growth/size
|
J:157541
|
| increased mammary gland tumor incidence
|
J:157541
|
| increased tumor latency
|
J:157541
|
Ctsbtm1Jde/Ctsbtm1Jde
Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
|
abnormal tumor morphology
|
J:157541
|
| decreased metastatic potential
|
J:157541
|
| decreased tumor growth/size
|
J:157541
|
| increased mammary gland tumor incidence
|
J:157541
|
| increased tumor latency
|
J:157541
|
Ctsgtm1Ley/Ctsgtm1Ley
(Not Specified)
|
neoplasm
|
J:84230
|
Ctsgtm1Ley/Ctsgtm2.1(PML/RARA)Ley
(involves: 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:84230
|
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
(involves: 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:84230,
J:86458
|
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
(involves: 129 * 129X1/SvJ * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:166479
|
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
Elanetm1Sds/Elanetm1Sds
(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:86458
|
Ctsgtm2.1(PML/RARA)Ley/Ctsgtm2.1(PML/RARA)Ley
(involves: 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:84230
|
Ctsgtm3.1(PML/RARA)Ley/Ctsg+
(involves: 129 * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:166479
|
Ctsztm1Thre/Ctsztm1Thre
Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsztm1Thre Tg(MMTV-PyVT)634Mul)
|
decreased metastatic potential
|
J:157541
|
| increased mammary gland tumor incidence
|
J:157541
|
| increased tumor growth/size
|
J:157541
|
| increased tumor latency
|
J:157541
|
Cuedc2tm1Qxia/Cuedc2tm1Qxia
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased incidence of tumors by chemical induction
|
J:211782
|
Cul4atm1.1Pz/Cul4atm1.1Pz
Tg(KRT14-cre/ERT)20Efu/?
(involves: C57BL/6 * CD-1)
|
decreased incidence of tumors by UV induction
|
J:150427
|
Cul9tm1.2Yxi/Cul9+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:170976
|
| increased insulinoma incidence
|
J:170976
|
| increased lung tumor incidence
|
J:170976
|
| increased lymphoma incidence
|
J:170976
|
| increased pituitary gland tumor incidence
|
J:170976
|
| increased sarcoma incidence
|
J:170976
|
| increased tumor incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9+
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL)
|
abnormal tumor pathology
|
J:170976
|
| increased B cell derived lymphoma incidence
|
J:170976
|
| increased lymphoma incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:170976
|
| increased liver tumor incidence
|
J:170976
|
| increased lung tumor incidence
|
J:170976
|
| increased lymphoma incidence
|
J:170976
|
| increased ovary tumor incidence
|
J:170976
|
| increased pituitary gland tumor incidence
|
J:170976
|
| increased sarcoma incidence
|
J:170976
|
| increased tumor incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL)
|
abnormal tumor pathology
|
J:170976
|
| increased B cell derived lymphoma incidence
|
J:170976
|
| increased lymphoma incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB/N)
|
neoplasm
|
J:170976
|
Cxcl16tm1Syon/Cxcl16tm1Syon
(B6.129P2-Cxcl16tm1Syon)
|
increased tumor growth/size
|
J:155199
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
(B6.Cg-Il8rbtm1Mwm)
|
abnormal tumor morphology
|
J:88233
|
| decreased metastatic potential
|
J:88233
|
| decreased tumor growth/size
|
J:88233
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
Tg(TRAMP)8247Ng/?
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
decreased tumor growth/size
|
J:115957
|
Cxcr3tm1Wwh/Y
Tg(TRAMP)8247Ng/?
(involves: C57BL/6)
|
increased tumor growth/size
|
J:115957
|
Cxcr3tm1Wwh/Cxcr3tm1Wwh
(Not Specified)
|
increased tumor incidence
|
J:163822
|
Cxcr6tm1Lex/Cxcr6+
(involves: 129S/SvEvBrd * C57BL/6J)
|
increased medulloblastoma incidence
|
J:120952
|
Cxcr6tm1Lex/Cxcr6tm1Lex
(involves: 129S/SvEvBrd * C57BL/6J)
|
increased medulloblastoma incidence
|
J:120952
|
Cybbtm1Din/Cybbtm1Din
(B6.129S-Cybbtm1Din)
|
decreased metastatic potential
|
J:110181
|
| decreased tumor growth/size
|
J:110181
|
Cygbtm1Nka/Cygb+
(B6.Cg-Cygbtm1Nka)
|
increased incidence of tumors by chemical induction
|
J:174134
|
| increased tumor growth/size
|
J:174134
|
Cygbtm1Nka/Cygbtm1Nka
(B6.Cg-Cygbtm1Nka)
|
abnormal tumor pathology
|
J:174134
|
| increased incidence of tumors by chemical induction
|
J:174134
|
| increased tumor growth/size
|
J:174134
|
Cyldtm1Lex/Cyldtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:114972
|
Cyldtm1Ref/Cyld+
(B6.129-Cyldtm1Ref)
|
increased skin papilloma incidence
|
J:108769
|
Cyldtm1Ref/Cyldtm1Ref
(B6.129-Cyldtm1Ref)
|
increased skin papilloma incidence
|
J:108769
|
Cyp1a2tm1Dwn/Cyp1a2tm1Dwn
(B6.129P2-Cyp1a2tm1Dwn)
|
decreased incidence of tumors by chemical induction
|
J:97596
|
Cyp1b1tm1Gonz/Cyp1b1tm1Gonz
(involves: 129X1/SvJ * C57BL/6N)
|
decreased incidence of tumors by chemical induction
|
J:53827
|
Cyp2c23Gt(OST85045)Lex/Cyp2c23Gt(OST85045)Lex
(129-Cyp2c23Gt(OST85045)Lex)
|
decreased incidence of induced tumors
|
J:207597
|
Cyp2e1tm1Gonz/Cyp2e1tm1Gonz
(involves: 129S4/SvJae)
|
decreased incidence of tumors by chemical induction
|
J:118150
|
Cytiptm1Tes/Cytiptm1Tes
(involves: 129S1/Sv * FVB/N)
|
increased sarcoma incidence
|
J:110320
|
Dancrem1.1Bcgen/Dancrem1.1Bcgen
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:329926
|
Dcctm1.1Mehl/Dcctm1.1Mehl
(Not Specified)
|
increased intestinal adenocarcinoma incidence
|
J:181517
|
| increased intestinal adenoma incidence
|
J:181517
|
Dcctm1Nki/Dcctm1Nki
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N)
|
abnormal tumor latency
|
J:181090
|
| increased classified tumor incidence
|
J:181090
|
| increased mammary adenocarcinoma incidence
|
J:181090
|
| increased metastatic potential
|
J:181090
|
| increased spindle cell carcinoma incidence
|
J:181090
|
| increased tumor incidence
|
J:181090
|
Dcctm1Wbg/Dcc+
(involves: 129S2/SvPas * C57BL/6)
|
neoplasm
|
J:39765
|
Dclre1atm1Rleg/Dclre1a+
(involves: 129S7/SvEvBrd)
|
decreased tumor latency
|
J:102381
|
| increased histiocytic sarcoma incidence
|
J:102381
|
| increased lymphoma incidence
|
J:102381
|
| increased tumor incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1a+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased sarcoma incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
|
decreased tumor latency
|
J:102381
|
| increased adenoma incidence
|
J:102381
|
| increased histiocytic sarcoma incidence
|
J:102381
|
| increased lung adenoma incidence
|
J:102381
|
| increased lymphoma incidence
|
J:102381
|
| increased ovarian teratoma incidence
|
J:102381
|
| increased sarcoma incidence
|
J:102381
|
| increased tumor incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:102381
|
| increased T cell derived lymphoma incidence
|
J:102381
|
Dcntm1Ioz/Dcn+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53511
|
| increased tumor incidence
|
J:53511
|
Dcntm1Ioz/Dcntm1Ioz
(involves: 129/Sv * Black Swiss * C57BL/6)
|
neoplasm
|
J:53511
|
Dcntm1Ioz/Dcntm1Ioz
Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:53511
|
| increased T cell derived lymphoma incidence
|
J:53511
|
| increased tumor incidence
|
J:53511
|
Ddb2tm1Linn/Ddb2+
(involves: 129S/SvEv * C57BL/6)
|
increased incidence of tumors by UV-induction
|
J:88125
|
Ddb2tm1Linn/Ddb2tm1Linn
(involves: 129S/SvEv * C57BL/6)
|
increased incidence of tumors by UV-induction
|
J:88125
|
Ddb2tm1Pra/Ddb2+
(involves: C57BL/6)
|
increased tumor incidence
|
J:95633
|
Ddb2tm1Pra/Ddb2tm1Pra
(involves: C57BL/6)
|
increased tumor incidence
|
J:95633
|
Ddb2tm1Vri/Ddb2+
(involves: 129P2/Ola * SKH1)
|
increased squamous cell carcinoma incidence
|
J:103406
|
Ddb2tm1Vri/Ddb2tm1Vri
(involves: 129P2/Ola * SKH1)
|
increased squamous cell carcinoma incidence
|
J:103406
|
Ddit3tm1.1Irt/Ddit3tm1.1Irt
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(Mup3-Plau)350-2Eps/?
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:233146
|
Ddr2tm1a(EUCOMM)Wtsi/Ddr2tm1a(EUCOMM)Wtsi
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
decreased metastatic potential
|
J:236031
|
| increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1b(EUCOMM)Wtsi/Ddr2tm1b(EUCOMM)Wtsi
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
decreased metastatic potential
|
J:236031
|
| increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi
Tg(KRT14-cre)1Amc/0
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * C57BL/6N * CBA * FVB/N)
|
decreased metastatic potential
|
J:236031
|
| increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi
Tg(MMTV-cre)#Mam/0
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Dektm1Siwe/Dektm1Siwe
(involves: 129P2/OlaHsd)
|
decreased incidence of tumors by chemical induction
|
J:146608
|
Del(4C4-C5)1Lap/Del(4C4-C5)1Lap
(involves: 129S6/SvEvTac)
|
increased hemangiosarcoma incidence
|
J:158126
|
| increased osteosarcoma incidence
|
J:158126
|
| increased sarcoma incidence
|
J:158126
|
| increased teratoma incidence
|
J:158126
|
| increased tumor incidence
|
J:158126
|
Del(4Cdkn2a-Cdkn2b)1Brn/+
(involves: 129P2/OlaHsd)
|
increased intestinal adenoma incidence
|
J:125189
|
| increased leukemia incidence
|
J:125189
|
| increased lymphoma incidence
|
J:125189
|
| increased sarcoma incidence
|
J:125189
|
| increased skin tumor incidence
|
J:125189
|
| increased tumor incidence
|
J:125189
|
Del(4Cdkn2a-Cdkn2b)1Brn/Del(4Cdkn2a-Cdkn2b)1Brn
(involves: 129P2/OlaHsd)
|
increased tumor incidence
|
J:125189
|
Del(4Cdkn2a-Cdkn2b)2Brn/+
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:125189
|
| increased leukemia incidence
|
J:125189
|
| increased lymphoma incidence
|
J:125189
|
| increased melanoma incidence
|
J:125189
|
| increased sarcoma incidence
|
J:125189
|
| increased skin tumor incidence
|
J:125189
|
| increased tumor incidence
|
J:125189
|
Del(4Cdkn2a-Cdkn2b)2Brn/Del(4Cdkn2a-Cdkn2b)2Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased tumor incidence
|
J:125189
|
| increased tumor latency
|
J:125189
|
Del(4D4Mit190-D4Mit51)2Aam/+
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:121726
|
| increased squamous cell carcinoma incidence
|
J:121726
|
Del(5Gtf2i-Fkbp6)1Vcam/+
(B6.129-Del(5Gtf2i-Fkbp6)1Vcam(J:204278))
|
abnormal tumor susceptibility
|
J:216195
|
Del(11Stat5a-Stat5b)1Mam/+
(involves: 129 * 129S6/SvEvTac * C57BL/6)
|
decreased tumor incidence
|
J:122463
|
Del(11Stat5a-Stat5b)1Mam/Del(11Stat5a-Stat5b)1Mam
(involves: 129 * 129S6/SvEvTac * C57BL/6)
|
decreased tumor incidence
|
J:122463
|
Del(14Trim13-Dleu2)4Rdf/+
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
Del(14Trim13-Dleu2)4Rdf/Del(14Trim13-Dleu2)4Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
| increased leukemia incidence
|
J:156946
|
Del(14Trim13-Rnaseh2b)6Rdf/+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:179879
|
| increased lymphoma incidence
|
J:179879
|
| increased small lymphocytic lymphoma incidence
|
J:179879
|
Del(15Krt7-Krt18)1Tmm/+
Igs11tm1Tmm/Igs11+
Krt1ctm1Tmm/Krt1c+
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:199528
|
| increased lung adenoma incidence
|
J:199528
|
| increased lung tumor incidence
|
J:199528
|
Del(15Krt7-Krt18)1Tmm/+
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:199528
|
Del(15Rr357-Rr303293)2Jta/Del(15Rr357-Rr303293)2Jta
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:257088
|
Del(16Tmprss2-Erg)1Sho/Del(16Tmprss2-Erg)1Sho
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:212219
|
Del(16Tmprss2-Erg)1Sho/Del(16Tmprss2-Erg)1Sho
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Deptortm1.2Ysun/Deptortm1.2Ysun
Krastm4Tyj/Kras+
Ube2cem1Gpt/Ube2cem1Gpt
(involves: 129S4/SvJae * C57BL/6J)
|
increased lung tumor incidence
|
J:333347
|
DgkdGt(RRT600)Byg/Dgkd+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased sarcoma incidence
|
J:126380
|
DgkdGt(RRT600)Byg/DgkdGt(RRT600)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased tumor incidence
|
J:126380
|
Dgkitm1Mtop/Dgkitm1Mtop
(involves: 129S1/Sv * 129X1/SvJ)
|
neoplasm
|
J:99817
|
Dgkitm1Mtop/Dgkitm1Mtop
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NTac)
|
decreased incidence of induced tumors
|
J:99817
|
Dh/Dh+
H2d/H2d
(NZB.Cg-Dh)
|
decreased lymphoma incidence
|
J:12036
|
Dhx33em1Yazh/Dhx33+
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
decreased lung tumor incidence
|
J:299900
|
Dhx33em1Yazh/Dhx33em1Yazh
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
decreased lung tumor incidence
|
J:299900
|
Dicer1tm1Mmk/Dicer1tm1Mmk
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
increased facial tumor incidence
|
J:158901
|
| increased hemolymphoid system tumor incidence
|
J:158901
|
| increased leukemia incidence
|
J:158901
|
| increased myeloid sarcoma incidence
|
J:158901
|
Dicer1tm1Snj/Dicer1tm1Snj
Tg(KRT5-cre/PGR)1Der/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * ICR)
|
neoplasm
|
J:216813
|
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR)
|
increased basal cell carcinoma incidence
|
J:216813
|
| increased skin tumor incidence
|
J:216813
|
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR)
|
increased skin squamous cell carcinoma incidence
|
J:216813
|
| increased skin tumor incidence
|
J:216813
|
Dicer1tm1Tara/Dicer1tm1Tara
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
neoplasm
|
J:222579
|
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:182161
|
| increased metastatic potential
|
J:182161
|
| increased ovarian carcinoma incidence
|
J:182161
|
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:222579
|
| increased metastatic potential
|
J:222579
|
| increased ovarian carcinoma incidence
|
J:222579
|
Dicer1tm1Tara/Dicer1tm1Tara
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
neoplasm
|
J:222579
|
Diras2em1Gpt/Diras2em1Gpt
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * C57BL/6J * C57BL/6JGpt)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:348744
|
Diras2em1Gpt/Diras2em1Gpt
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
Ube2ftm1c(EUCOMM)Hmgu/Ube2ftm1c(EUCOMM)Hmgu
(involves: 129S4/SvJae * C57BL/6)
|
increased pancreas tumor incidence
|
J:348744
|
Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
|
increased B cell derived lymphoma incidence
|
J:81054
|
| increased fibrosarcoma incidence
|
J:81054
|
| increased lung carcinoma incidence
|
J:81054
|
| increased malignant tumor incidence
|
J:81054
|
| increased mammary adenocarcinoma incidence
|
J:81054
|
| increased pheochromocytoma incidence
|
J:81054
|
| increased renal carcinoma incidence
|
J:81054
|
Dkc1tm1Ppp/Dkc1+
(involves: 129S1/Sv)
|
increased tumor incidence
|
J:81054
|
Dlg2tm1a(EUCOMM)Wtsi/Dlg2tm1a(EUCOMM)Wtsi
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N)
|
decreased tumor latency
|
J:269943
|
| increased osteosarcoma incidence
|
J:269943
|
| increased tumor growth/size
|
J:269943
|
Dmbt1tm1Kumc/Dmbt1tm1Kumc
(involves: 129X1/SvJ * C57BL/6J)
|
neoplasm
|
J:132597
|
Dmbt1tm1Kumc/Dmbt1tm1Kumc
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J)
|
neoplasm
|
J:132597
|
Dmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Dmq2FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Dmq3M16i/?
(involves: FVB/NJ * M16i)
|
increased metastatic potential
|
J:136011
|
Dmq4FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased metastatic potential
|
J:136011
|
Dmtf1tm1Cjs/Dmtf1+
(involves: 129/Sv * C57BL/6)
|
increased incidence of induced tumors
|
J:63444
|
| increased tumor incidence
|
J:63444,
J:72617
|
Dmtf1tm1Cjs/Dmtf1+
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal metastatic potential
|
J:126002
|
| decreased tumor latency
|
J:126002
|
| increased cholangiocarcinoma incidence
|
J:126002
|
| increased lung adenocarcinoma incidence
|
J:126002
|
| increased lung adenoma incidence
|
J:126002
|
| increased lung tumor incidence
|
J:126002
|
| increased neurofibroma incidence
|
J:126002
|
| increased osteosarcoma incidence
|
J:126002
|
| increased skin papilloma incidence
|
J:126002
|
| increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1+
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal metastatic potential
|
J:126002
|
| decreased tumor latency
|
J:126002
|
| increased lung adenocarcinoma incidence
|
J:126002
|
| increased lung adenoma incidence
|
J:126002
|
| increased lung tumor incidence
|
J:126002
|
| increased skin papilloma incidence
|
J:126002
|
| increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1+
Tg(IghMyc)22Bri/0
(involves: 129/Sv * C57BL * C57BL/6 * SJL)
|
decreased tumor latency
|
J:72617
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs
(involves: 129/Sv * C57BL/6)
|
increased incidence of induced tumors
|
J:63444
|
| increased tumor incidence
|
J:63444,
J:72617
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal metastatic potential
|
J:126002
|
| decreased tumor latency
|
J:126002
|
| increased lung adenocarcinoma incidence
|
J:126002
|
| increased lung adenoma incidence
|
J:126002
|
| increased lung tumor incidence
|
J:126002
|
| increased ovary tumor incidence
|
J:126002
|
| increased skin papilloma incidence
|
J:126002
|
| increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
decreased tumor latency
|
J:126002
|
| increased lung adenocarcinoma incidence
|
J:126002
|
| increased lung adenoma incidence
|
J:126002
|
| increased lung tumor incidence
|
J:126002
|
| increased skin papilloma incidence
|
J:126002
|
| increased T cell derived lymphoma incidence
|
J:126002
|
Dmxl2tm1a(EUCOMM)Wtsi/Dmxl2tm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd Dmxl2tm1a(EUCOMM)Wtsi/WtsiH)
|
embryo tumor
|
J:239583
|
Dna2tm1.1Lzhg/Dna2+
(involves: 129S1/Sv)
|
increased hepatoma incidence
|
J:198831
|
| increased lung adenocarcinoma incidence
|
J:198831
|
| increased lymphoma incidence
|
J:198831
|
Dnai7Gt(VICTR21)709Lex/Dnai7+
(involves: 129S5/SvEvBrd)
|
increased incidence of tumors by chemical induction
|
J:111629
|
| increased lung adenocarcinoma incidence
|
J:111629
|
Dnai7Gt(VICTR21)709Lex/Dnai7Gt(VICTR21)709Lex
(involves: 129S5/SvEvBrd)
|
increased incidence of tumors by chemical induction
|
J:111629
|
| increased lung adenocarcinoma incidence
|
J:111629
|
| increased lung adenoma incidence
|
J:111629
|
Dnajc27Gt(OST374030)Lex/Dnajc27Gt(OST374030)Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
|
decreased incidence of tumors by chemical induction
|
J:210622
|
| decreased tumor growth/size
|
J:210622
|
Dnd1Ter/?
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:29502
|
Dnd1Ter/Dnd1+
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1+
(involves: 129S1/Sv * C57BL/6)
|
increased testicular teratoma incidence
|
J:7954
|
| increased testis tumor incidence
|
J:7954
|
Dnd1Ter/Dnd1+
(involves: 129P3/J)
|
increased testis tumor incidence
|
J:221231
|
Dnd1Ter/Dnd1Ter
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1Ter
(involves: 129S1/Sv * C57BL/6)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1Ter
Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * 129T1/Sv)
|
decreased tumor incidence
|
J:164224
|
| increased testis tumor incidence
|
J:164224
|
Dnd1tm1Na/Dnd1+
(129S1.129S6-Dnd1tm1Na)
|
neoplasm
|
J:221231
|
Dnmt1tm1(tetO-BCL2)Sjk/Dnmt1+
Tg(IghMyc)22Bri/0
Tg(MMTVtTA)1Mam/0
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:93549
|
| increased leukemia incidence
|
J:93549
|
Dnmt1tm1Jae/Dnmt1+
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
| increased intestinal adenoma incidence
|
J:75745
|
| increased lymphoma incidence
|
J:75745
|
Dnmt1tm1Jae/Dnmt1tm1Pwl
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:75745
|
| neoplasm
|
J:75745
|
Dnmt1tm1Pwl/Dnmt1+
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
| increased intestinal adenoma incidence
|
J:75745
|
| increased lymphoma incidence
|
J:75745
|
Dnmt1tm3Jae/Dnmt1tm2Enl
(involves: 129S4/SvJae * BALB/c)
|
increased tumor incidence
|
J:82979
|
Dock1tm2.1Jfco/Dock1+
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
| increased mammary gland tumor incidence
|
J:196659
|
| increased tumor latency
|
J:196659
|
Dock1tm2.1Jfco/Dock1tm2.1Jfco
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
decreased metastatic potential
|
J:196659
|
| decreased tumor growth/size
|
J:196659
|
| increased mammary adenocarcinoma incidence
|
J:196659
|
| increased mammary gland tumor incidence
|
J:196659
|
| increased tumor latency
|
J:196659
|
Dock4tm1(NCOM)Mfgc/Dock4+
(involves: C57BL/6J * C57BL/6NCrl)
|
abnormal tumor vascularization
|
J:224385
|
Dok1tm1Ppp/Dok1+
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok1tm1Ppp/Dok1tm1Ppp
(129S1/Sv-Dok1tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp)
|
increased leukemia incidence
|
J:95334
|
| increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp
Dok2tm1Ppp/Dok2tm1Ppp
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp Dok3tm1Ppp)
|
increased chronic myelocytic leukemia incidence
|
J:158011
|
| increased lung adenocarcinoma incidence
|
J:158011
|
| increased lung tumor incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok1tm1Yyam/Dok1tm1Yyam
Dok2tm1Yyam/Dok2tm1Yyam
(B6.129-Dok1tm1Yyam Dok2tm1Yyam)
|
increased leukemia incidence
|
J:95335
|
| increased sarcoma incidence
|
J:95335
|
Dok1tm1Yyam/Dok1tm1Yyam
Dok2tm1Yyam/Dok2tm1Yyam
Dok3tm1Brs/Dok3tm1Brs
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:163407
|
| increased tumor incidence
|
J:163407
|
Dok1tm1Yyam/Dok1tm1Yyam
Dok2tm1Yyam/Dok2tm1Yyam
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:95335
|
Dok1tm1Yyam/Dok1tm1Yyam
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:95335
|
Dok2tm1Ppp/Dok2+
(129S1/Sv-Dok2tm1Ppp)
|
increased lung tumor incidence
|
J:158011
|
Dok2tm1Ppp/Dok2+
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok2tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok2tm1Ppp/Dok2tm1Ppp
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok2tm1Yyam/Dok2tm1Yyam
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:95335
|
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dot1ltm1.1Saam/Dot1ltm1.1Saam
(involves: 129S1/Sv * C57BL/6)
|
decreased tumor growth/size
|
J:193161
|
Dp(16Cbr1-Fam3b)1Rhr/0
(involves: 129S6/SvEvTac)
|
neoplasm
|
J:184564
|
Dph1tm1Bhr/Dph1+
(involves: 129/Sv * C57BL/6)
|
increased tumor incidence
|
J:88090
|
Dph1tm2Bhr/Dph1+
(involves: 129/Sv * C57BL/6)
|
increased tumor incidence
|
J:88090
|
Dph1tm2Bhr/Dph1+
Trp53tm1Tyj/Trp53+
(involves: 129/Sv * C57BL/6)
|
decreased tumor latency
|
J:88090
|
Drd2tm1Ebo/Drd2tm1Ebo
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:41857
|
Droshatm1Litt/Droshatm1Litt
Wt1tm2(cre/ERT2)Wtp/Wt1+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
neoplasm
|
J:321428
|
Ds/Ds+
(involves: 129T1/Sv * DA/Hu * DBA/1J)
|
increased skin hamartoma incidence
|
J:13012
|
Dusp5tm1.1Skey/Dusp5+
(involves: C57BL/6 * C57BL/6NTac)
|
increased incidence of tumors by chemical induction
|
J:216939
|
Dusp5tm1.1Skey/Dusp5tm1.1Skey
(involves: C57BL/6 * C57BL/6NTac)
|
increased incidence of tumors by chemical induction
|
J:216939
|
Dusp5tm1.1Skey/Dusp5tm1.1Skey
Serpinb2tm1Dgi/Serpinb2tm1Dgi
(involves: 129S1/Sv * C57BL/6 * C57BL/6NTac)
|
neoplasm
|
J:216939
|
E2f1tm1.1Dgj/E2f1tm1.1Dgj
(FVB.Cg-E2f1tm1.1Dgj)
|
increased incidence of tumors by UV-induction
|
J:212453
|
E2f1tm1Meg/E2f1tm1Meg
(either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
|
increased T cell derived lymphoma incidence
|
J:33100
|
E2f1tm1Meg/E2f1tm1Meg
Rb1tm2.1Fad/Rb1tm2.1Fad
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:215358
|
E2f1tm1Njd/E2f1+
Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
increased thyroid adenoma incidence
|
J:47108
|
| increased tumor incidence
|
J:47108
|
E2f1tm1Njd/E2f1tm1Njd
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:33099
|
| increased lung adenocarcinoma incidence
|
J:33099
|
| increased lung non-small cell carcinoma incidence
|
J:33099
|
| increased lymphoma incidence
|
J:33099
|
| increased metastatic potential
|
J:33099
|
| increased reproductive system tumor incidence
|
J:33099
|
| increased tumor incidence
|
J:33099
|
E2f1tm1Njd/E2f1tm1Njd
Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
increased hemangioma incidence
|
J:47108
|
| increased pituitary gland tumor incidence
|
J:47108
|
| increased thyroid adenoma incidence
|
J:47108
|
E2f4tm1Lees/E2f4+
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:81082
|
| increased thyroid tumor incidence
|
J:81082
|
E2f4tm1Lees/E2f4tm1Lees
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor incidence
|
J:81082
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow
Eaf2tm1Zhow/Eaf2tm1Zhow
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow
Tg(Pbsn-cre)4Prb/0
(B6(Cg)-Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eaf2tm1Zhow/Eaf2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:145228
|
| increased lymphoma incidence
|
J:145228
|
| increased tumor incidence
|
J:145228
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:145228
|
| increased hepatocellular carcinoma incidence
|
J:145228
|
| increased lung adenocarcinoma incidence
|
J:145228
|
| increased prostate intraepithelial neoplasia incidence
|
J:145228
|
| increased skin tumor incidence
|
J:145228
|
| increased tumor incidence
|
J:145228
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Ednrbtm1Ywa/Ednrb+
Tg(Mt1-RET)304Ina/0
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6)
|
increased melanoma incidence
|
J:155735
|
| increased metastatic potential
|
J:155735
|
Eef1a1tm1(FBXW7*)Iaai/Eef1a1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
decreased tumor latency
|
J:200006
|
| neoplasm
|
J:200006
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Igf1rtm2Arge/Igf1r+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Igf1rtm2Arge/Igf1rtm2Arge
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:146290
|
| increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm2Arge/Eef1a1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:197167
|
Eef1e1Gt(OST377244)Lex/Eef1e1+
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased malignant tumor incidence
|
J:96923
|
Efna1tm1a(EUCOMM)Wtsi/Efna1tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased hibernoma incidence
|
J:213427
|
Egfrwa2/Egfr+
Fostm2(Fosl1)Wag/Fostm2(Fosl1)Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased tumor growth/size
|
J:175064
|
| increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+
Fostm3.1Wag/Fostm3.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
decreased tumor growth/size
|
J:175064
|
| increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+
Fostm4.1Wag/Fostm4.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+
Fostm5.1Wag/Fostm5.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
decreased tumor growth/size
|
J:175064
|
| increased skin papilloma incidence
|
J:175064
|
| increased skin tumor incidence
|
J:175064
|
Egfrwa2/Egfr+
Fostm6.1Wag/Fostm6.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased skin papilloma incidence
|
J:175064
|
| increased tumor growth/size
|
J:175064
|
Egfrwa2/Egfr+
Nf1tm1Fcr/Nf1+
Trp53tm1Brd/Trp53+
(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * C57BL/6JEi * C3H/HeSnJ)
|
decreased tumor incidence
|
J:95933
|
Egfrwa2/Egfr+
Rps6ka3tm1.1Kry/Y
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
decreased tumor growth/size
|
J:175064
|
| increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+
Tg(KRT5-SOS1)892A6Wag/0
(involves: C57BL/6 * CBA)
|
increased skin papilloma incidence
|
J:175064
|
| increased skin tumor incidence
|
J:175064
|
Egr1tm1Jmi/Egr1tm1Jmi
(involves: 129 * C57BL/6)
|
decreased tumor latency
|
J:99386
|
| increased incidence of tumors by chemical induction
|
J:123870
|
| increased skin papilloma incidence
|
J:99386
|
| increased T cell derived lymphoma incidence
|
J:123870
|
| neoplasm
|
J:123870
|
Egr1tm1Jmi/Egr1tm1Jmi
Tg(Defcr2-TAg)#Jig/?
(involves: 129 * C57BL/6 * FVB/N)
|
decreased prostate gland tumor incidence
|
J:67125
|
| decreased tumor incidence
|
J:67125
|
Egr1tm1Jmi/Egr1tm1Jmi
Tg(TRAMP)8247Ng/?
(involves: 129 * C57BL/6)
|
increased tumor latency
|
J:67125
|
Ehbp1l1tm1a(EUCOMM)Wtsi/Ehbp1l1tm1a(EUCOMM)Wtsi
(C57BL/6N-Ehbp1l1tm1a(EUCOMM)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Eif2ak2tm1Jcbe/Eif2ak2tm1Jcbe
(involves: 129S4/SvJae * BALB/c)
|
neoplasm
|
J:53258
|
Eif2ak3tm1.2Drc/Eif2ak3tm1.2Drc
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
|
decreased prostate gland tumor incidence
|
J:261540
|
Eif2s2Gt(XH413)Byg/Eif2s2+
(129-Eif2s2Gt(XH413)Byg Chr 19MOLF/Ei)
|
decreased incidence of induced tumors
|
J:146879
|
Eif4eGt(RRO036)Byg/Eif4e+
Krastm3Tyj/Kras+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased lung tumor incidence
|
J:224214
|
| decreased tumor growth/size
|
J:224214
|
Eif4etm1.1Lfur/Eif4etm1.1Lfur
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
decreased tumor incidence
|
J:163589
|
Elac2em1Afi/Elac2em1Afi
Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6N)
|
increased prostate intraepithelial neoplasia incidence
|
J:336403
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon
Lyz2tm1(cre)Ifo/Lyz2+
(B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo)
|
increased colon adenocarcinoma incidence
|
J:184388
|
| increased colon adenoma incidence
|
J:184388
|
| increased incidence of tumors by chemical induction
|
J:184388
|
| increased tumor growth/size
|
J:184388
|
Emv30b/Emv30b
Prkdcscid/Prkdcscid
(NOD.Cg-Emv30b Prkdcscid/Dvs)
|
increased T cell derived lymphoma incidence
|
J:29951
|
Emv72a/Emv72a
(involves: BALB/cAnNCr * C57BL/6NCr)
|
increased tumor growth/size
|
J:194735
|
Emv72b/Emv72b
(CAnNCr.B6NCr-Emv72b)
|
decreased tumor growth/size
|
J:194735
|
Endovtm1Ial/Endovtm1Ial
(involves: C57BL/6J * C57BL/6N)
|
decreased incidence of tumors by chemical induction
|
J:293118
|
Enpp7tm1Rudd/Enpp7tm1Rudd
(involves: 129S1/Sv * C57BL/6)
|
neoplasm
|
J:170667
|
Entpd5tm1Rre/Entpd5tm1Rre
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:163795
|
| increased liver adenoma incidence
|
J:163795
|
Eomestm1.1Bflu/Eomestm1.1Bflu
Tbx21tm1Glm/Tbx21tm1Glm
Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)
|
increased tumor incidence
|
J:163822
|
Eomestm1.1Bflu/Eomestm1.1Bflu
Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
increased tumor incidence
|
J:163822
|
Ep300tm1Dli/Ep300+
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:60630
|
Ep300tm2Pkb/Ep300tm2Pkb
Tg(MMTV-cre)4Mam/0
(involves: 129P2/OlaHsd * FVB)
|
neoplasm
|
J:105505
|
Ep300tm3Pkb/Ep300+
Tg(IghMyc)22Bri/0
(involves: 129S6/SvEvTac * C57BL * SJL)
|
abnormal tumor susceptibility
|
J:103607
|
Ep300tm3Pkb/Ep300+
Tg(IghMyc)22Bri/0
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal tumor incidence
|
J:103607
|
Epb41l3tm1Jkis/Epb41l3tm1Jkis
(involves: 129S4/SvJae)
|
neoplasm
|
J:102380
|
Epb41l3tm1Sohn/Epb41l3tm1Sohn
(involves: 129S4/SvJaeSor * C57BL/6)
|
neoplasm
|
J:148708
|
Epha2Gt(KST085)Byg/Epha2+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:112120
|
Epha2Gt(KST085)Byg/Epha2Gt(KST085)Byg
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:112120
|
| increased metastatic potential
|
J:112120
|
Epha2tm1Jrui/Epha2tm1Jrui
Krastm4Tyj/Kras+
Trp53tm2.1Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * FVB/N)
|
decreased metastatic potential
|
J:244261
|
| neoplasm
|
J:244261
|
Ephb6tm1Tom/Ephb6tm1Tom
(involves: 129S4/SvJae * C57BL/6J)
|
neoplasm
|
J:79747
|
Ephb6tm2Tom/Ephb6tm2Tom
(involves: 129S4/SvJae * C57BL/6J)
|
neoplasm
|
J:79747
|
Ephx1tm1Gonz/Ephx1tm1Gonz
(involves: 129X1/SvJ * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:56886
|
Epm2aTg(TcraK,TcrbK)TG-BFlv/Epm2a+
(involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)
|
increased T cell derived lymphoma incidence
|
J:112696
|
Epn1tm1.1Wami/Epn1tm1.1Wami
Epn2tm1Ocr/Epn2tm1Ocr
Tg(Cdh5-cre)7Mlia/0
(involves: C57BL/6J * FVB/N)
|
decreased tumor growth/size
|
J:193966
|
Epn1tm1.1Wami/Epn1tm1.1Wami
Epn2tm1Ocr/Epn2tm1Ocr
Tg(Cdh5-cre/ERT2)CIVE23Mlia/0
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal tumor vascularization
|
J:193966
|
| decreased incidence of tumors by chemical induction
|
J:193966
|
| decreased tumor growth/size
|
J:193966
|
Epn1tm1.1Wami/Epn1tm1.1Wami
Epn2tm1Ocr/Epn2tm1Ocr
Tg(Cdh5-cre/ERT2)CIVE23Mlia/0
Tg(TRAMP)8247Ng/0
(involves: 129X1/SvJ * C57BL/6 * C57BL/6J)
|
decreased tumor growth/size
|
J:193966
|
Erbb2tm8(Erbb2)Mul/Erbb2+
Ptentm1Hwu/Pten+
Tg(MMTV-cre)7Mul/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133305
|
| increased metastatic potential
|
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)7Mul/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+
Tg(MMTV-cre)7Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:89255
|
Erbb3tm1.1(ERBB3)Mul/Erbb3+
Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:189292
|
| increased tumor latency
|
J:189292
|
Erbb3tm1.1(ERBB3)Mul/Erbb3tm1.1(ERBB3)Mul
Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased metastatic potential
|
J:189292
|
| increased mammary gland tumor incidence
|
J:189292
|
| increased tumor latency
|
J:189292
|
Ercc1tm1Dwm/Ercc1tm2Dwm
Hrhr/Hrhr
Tg(KRT5-cre)5132Jlj/0
(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J * MF1)
|
increased incidence of tumors by UV-induction
|
J:115849
|
Ercc2tm1Jhjh/Ercc2tm2(ERCC2)Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:48256
|
| increased incidence of tumors by UV-induction
|
J:48256
|
| increased skin tumor incidence
|
J:48256
|
Ercc2tm2(ERCC2)Jhjh/Ercc2tm2(ERCC2)Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of induced tumors
|
J:48256
|
| neoplasm
|
J:112689
|
Ercc2tm3Jhjh/Ercc2tm3Jhjh
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
decreased tumor latency
|
J:112689
|
| increased incidence of tumors by UV-induction
|
J:112689
|
Ercc3tm1.1Gima/Ercc3tm1.1Gima
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB))
|
neoplasm
|
J:154596
|
Ercc6tm1Gvh/Ercc6tm1Gvh
(involves: 129P2/OlaHsd * FVB)
|
increased incidence of induced tumors
|
J:40211
|
Ercc8tm1Jhjh/Ercc8tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased incidence of tumors by UV-induction
|
J:74959
|
Ercc8tm1Jhjh/Ercc8tm1Jhjh
Xpctm1Ecf/Xpc+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased incidence of tumors by UV-induction
|
J:74959
|
Ergtm1.1Sho/Ergtm1.1Sho
Ptentm1Hwu/Ptentm1Hwu
Tmprss2tm3Sho/Tmprss2tm3Sho
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Errfi1tm1.1Jwj/Errfi1tm1.1Jwj
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased skin papilloma incidence
|
J:129106
|
Errfi1tm1Jwj/Errfi1tm1Jwj
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased skin papilloma incidence
|
J:153715
|
Errfi1tm1Jwj/Errfi1tm1Jwj
Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:150007
|
Errfi1tm1Jwj/Errfi1tm1Jwj
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:162027
|
| increased metastatic potential
|
J:162027
|
Errfi1tm1Kln/Errfi1tm1Kln
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased adenoma incidence
|
J:109556
|
| increased carcinoma incidence
|
J:109556
|
| increased incidence of tumors by chemical induction
|
J:109556
|
| increased skin papilloma incidence
|
J:109556
|
Esamtm1Tq/Esamtm1Tq
(B6.129S6-Esamtm1Tq)
|
decreased tumor incidence
|
J:85314
|
Esl1NFS/N/Esl1SL/Kh
(involves: SL/Kh * NFS/N)
|
increased B cell derived lymphoma incidence
|
J:16441
|
Esl1SL/Kh/Esl1SL/Kh
(involves: SL/Kh * NFS/N)
|
increased B cell derived lymphoma incidence
|
J:16441
|
Esm1tm1.1Rha/Esm1tm1.1Rha
(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6NTac)
|
abnormal tumor vascularization
|
J:246778
|
Espl1Gt(XL058)Byg/Espl1+
(B6.129P2-Espl1Gt(XL058)Byg)
|
decreased tumor incidence
|
J:174926
|
Espl1Gt(XL058)Byg/Espl1+
Trp53tm1Tyj/Trp53+
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
|
increased carcinoma incidence
|
J:174926
|
Espl1Gt(XL058)Byg/Espl1+
Trp53tm1Tyj/Trp53tm1Tyj
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
|
abnormal tumor pathology
|
J:174926
|
| increased carcinoma incidence
|
J:174926
|
| increased lymphoma incidence
|
J:174926
|
| increased metastatic potential
|
J:174926
|
Esr1tm1Ksk/Esr1tm1Ksk
Esr2tm1Unc/Esr2tm1Unc
Inhatm1Bay/Inha+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk
Esr2tm1Unc/Esr2tm1Unc
Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
| increased testis tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk
Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
| increased testis tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased mammary gland tumor incidence
|
J:76653
|
| increased tumor latency
|
J:76653
|
Esr1tm1Ksk/Esr1tm1Ksk
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
| increased tumor latency
|
J:54215
|
Esr2tm1Unc/Esr2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased chronic myelocytic leukemia incidence
|
J:83617
|
Esr2tm1Unc/Esr2tm1Unc
Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
| increased testis tumor incidence
|
J:84989
|
Etn3Ppd/Y
(either: (involves: CD-1) or (involves: C3H/HeJ * CD-1))
|
increased skin papilloma incidence
|
J:112867
|
Etn3Ppd/?
(either: (involves: CD-1) or (involves: C3H/HeJ * CD-1))
|
increased skin papilloma incidence
|
J:112867
|
Ets2tm1Rgo/Ets2+
Tg(MMTV-PyVT)634Mul/0
(involves: 129S2/SvPas * Black Swiss * FVB/N)
|
decreased tumor growth/size
|
J:57272
|
Ets2tm1Rgo/Ets2tm5.1Rgo
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(S100a4-cre)1Gle/0
(involves: 129S2/SvPas * FVB/N)
|
abnormal tumor morphology
|
J:153747
|
| decreased mammary gland tumor incidence
|
J:153747
|
| increased mammary gland tumor incidence
|
J:153747
|
Ets2tm1Rgo/Ets2tm5.1Rgo
Tg(MMTV-PyVT)634Mul/0
Tg(S100a4-cre)1Gle/0
(involves: 129S2/SvPas * FVB/N)
|
decreased mammary gland tumor incidence
|
J:153747
|
Ets2tm2Rgo/Ets2tm2Rgo
(involves: FVB/N)
|
decreased tumor growth/size
|
J:86530
|
Ets2tm3Rgo/Ets2+
Meox2tm1(cre)Sor/?
Tg(MMTV-cre)7Mul/?
(involves: 129S4/SvJaeSor * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2+
Meox2tm1(cre)Sor/?
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2tm3.1Rgo
Meox2tm1(cre)Sor/?
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2tm3Rgo
Meox2tm1(cre)Sor/?
Tg(MMTV-cre)7Mul/?
(involves: 129S4/SvJaeSor * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Etv4tm1Hass/Etv4tm1Hass
Tg(MMTVneu)202Mul/Tg(MMTVneu)202Mul
(involves: FVB/N)
|
decreased metastatic potential
|
J:87017
|
| increased mammary gland tumor incidence
|
J:87017
|
Etv6tm1(RUNX1)Haho/Etv6+
Tg(Gata1-cre)1Sho/0
(involves: 129S1/Sv * C57BL/6 * CD-1 * Swiss Webster)
|
neoplasm
|
J:151639
|
Etv6tm1(RUNX1)Haho/Etv6+
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased incidence of tumors by chemical induction
|
J:151639
|
| increased leukemia incidence
|
J:151639
|
Etv6tm1.1(RUNX1,hsb5)Lvdw/Etv6+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)
|
increased leukemia incidence
|
J:174866
|
Etv6tm1.1(RUNX1,hsb5)Lvdw/Etv6+
TgTn(sb-T2/Onc)76Dla/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
increased leukemia incidence
|
J:174866
|
Etv6tm3(NTRK3)Sho/Etv6+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:130323
|
Etv6tm3(NTRK3)Sho/Etv6+
Tg(MMTV-cre)FMam/0
(involves: 129S1/Sv * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:130323
|
Etv6tm3(NTRK3)Sho/Etv6+
Tg(Wap-cre)11738Mam/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:130323
|
Ewsr1tm1(ERG)Thr/Ewsr1+
Rag1tm1(cre)Thr/Rag1+
(involves: 129S/SvEv)
|
increased leukemia incidence
|
J:98679
|
| increased T cell derived lymphoma incidence
|
J:98679
|
Exo1tm1Wed/Exo1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:82426
|
| increased tumor incidence
|
J:82426
|
Exo1tm2Wed/Exo1tm2Wed
(involves: 129 * C57BL/6)
|
increased adenoma incidence
|
J:198719
|
| increased lymphoma incidence
|
J:198719
|
| increased sarcoma incidence
|
J:198719
|
| increased tumor incidence
|
J:198719
|
Exo1tm2Wed/Exo1tm2Wed
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased tumor incidence
|
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed
(involves: 129 * C57BL/6)
|
increased adenoma incidence
|
J:198719
|
| increased lymphoma incidence
|
J:198719
|
| increased sarcoma incidence
|
J:198719
|
| increased tumor incidence
|
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:198719
|
| increased sarcoma incidence
|
J:198719
|
Ext1tm1.1Vcs/Ext1tm1.1Vcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
neoplasm
|
J:157599
|
Ext1tm1.1Vcs/Ext1tm1.1Vcs
Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteochondroma incidence
|
J:242977
|
Ext1tm1.1Vcs/Ext1tm1.1Vcs
Tg(Col2a1-rtTA,tetO-cre)22Pjro/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased osteochondroma incidence
|
J:157599
|
Ext1tm1.1Yama/Ext1+
(involves: 129S4/SvJaeSor * 129S5/SvEvBrd)
|
increased osteochondroma incidence
|
J:161395
|
Ext1tm1Vcs/Ext1+
Tg(Col2a1-rtTA,tetO-cre)22Pjro/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:157599
|
Ext1tm1Vcs/Ext1tm1Vcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:157599
|
Ext1tm1Vcs/Ext1tm1Vcs
Tg(Col2a1-rtTA,tetO-cre)22Pjro/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteochondroma incidence
|
J:157599
|
Ext1tm1Vcs/Ext1tm1Vcs
Tg(Sp7-cre/ERT)1Hmk/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:157599
|
Ext1tm1Yama/Ext1tm1Yama
Acantm1(cre/ERT2)Crm/Acan+
(involves: 129S5/SvEvBrd * 129S6/SvEvTac * C57BL/6NCrl)
|
increased osteochondroma incidence
|
J:242977
|
Ext1tm1Yama/Ext1tm1Yama
Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: 129S5/SvEvBrd * FVB/N)
|
increased osteochondroma incidence
|
J:161395
|
Ezh2tm1.1Nesh/Ezh2+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:239472
|
| increased leukemia incidence
|
J:239472
|
Ezh2tm1.1Nesh/Ezh2+
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB)
|
neoplasm
|
J:239472
|
Ezh2tm1.1Nesh/Ezh2tm1.1Nesh
Cd19tm1(cre)Cgn/Cd19+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:239472
|
Ezh2tm2Sho/Ezh2tm2.1Sho
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:182211
|
Ezh2tm2Sho/Ezh2tm2Sho
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:182211
|
F2rtm1Ajc/F2rtm1Ajc
(B6.129S4-F2rtm1Ajc)
|
neoplasm
|
J:92278
|
F2rtm1Pago/F2rtm1Pago
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul)
|
increased adenoma incidence
|
J:138924
|
| increased mammary adenocarcinoma incidence
|
J:138924
|
F2rl1tm1Bpd/F2rl1tm1Bpd
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul)
|
abnormal tumor vascularization
|
J:138924
|
| decreased mammary gland tumor incidence
|
J:138924
|
| increased adenoma incidence
|
J:138924
|
| increased mammary adenocarcinoma incidence
|
J:138924
|
F3tm1(F3)Lasn/F3tm1(F3)Lasn
(involves: 129S/SvEvBrd * C57BL/6)
|
increased lung adenoma incidence
|
J:133293
|
| increased lung carcinoma incidence
|
J:133293
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:138701
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL)
|
increased hepatocellular carcinoma incidence
|
J:27735
|
| increased hepatoma incidence
|
J:27735
|
| increased liver adenoma incidence
|
J:27735
|
| increased liver tumor incidence
|
J:27735
|
Fam3dem1Wko/Fam3dem1Wko
(C57BL/6-Fam3dem1Wko)
|
increased incidence of tumors by chemical induction
|
J:300819
|
Fancatm1Wong/Fancatm1Wong
(either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * CD-1))
|
neoplasm
|
J:85108
|
Fancd2Gt(OST57859)Lex/Fancd2Gt(OST57859)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased adenoma incidence
|
J:146616
|
| increased carcinoma incidence
|
J:146616
|
Fancd2tm1Hou/Fancd2tm1Hou
(129S4/SvJae-Fancd2tm1Hou)
|
increased adenoma incidence
|
J:84892
|
| increased carcinoma incidence
|
J:84892
|
Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J)
|
increased adenoma incidence
|
J:84892
|
| increased carcinoma incidence
|
J:84892
|
Fancftm1Nki/Fancftm1Nki
(involves: 129P2/OlaHsd * FVB)
|
increased adenoma incidence
|
J:180025
|
| increased granulosa cell tumor incidence
|
J:180025
|
| increased ovary tumor incidence
|
J:180025
|
| increased tumor incidence
|
J:180025
|
Fancmem1Qsh/Fancmem1Qsh
(C57BL/6-Fancmem1Qsh)
|
neoplasm
|
J:301639
|
Fancmtm1.1Htr/Fancm+
(involves: C57BL/6 * FVB)
|
increased tumor incidence
|
J:151714
|
Fancmtm1.1Htr/Fancmtm1.1Htr
(involves: C57BL/6 * FVB)
|
increased hepatoma incidence
|
J:151714
|
| increased tumor incidence
|
J:151714
|
Faslpr/Faslpr
(MRL/Mp-Agtpbp1atms Faslpr)
|
increased tumor incidence
|
J:103944
|
Fastm1Ach/Fastm1Ach
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
decreased ovarian tumor incidence
|
J:161953
|
Fasldel1Hong/Fasldel1Hong
(either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6))
|
increased lymphoma incidence
|
J:112563
|
| increased metastatic potential
|
J:112563
|
Faslgld/Faslgld
(C3H/HeJ-Faslgld/J)
|
neoplasm
|
J:108303
|
Faslgld/Faslgld
(involves: C3H/HeJ * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153501
|
Fasltm1.1Ast/Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153501
|
| increased liver tumor incidence
|
J:153501
|
Fbln5tm1.1Hiya/Fbln5tm1.1Hiya
(involves: 129S6/SvEvTac)
|
decreased tumor growth/size
|
J:159246
|
Fbln5tm1Eno/Fbln5tm1Eno
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased metastatic potential
|
J:159246
|
| decreased tumor growth/size
|
J:159246
|
Fbxo4tm1.1Jadi/Fbxo4+
(Not Specified)
|
increased hemangioma incidence
|
J:178645
|
| increased hepatic hemangioma incidence
|
J:178645
|
| increased hepatocellular carcinoma incidence
|
J:178645
|
| increased histiocytic sarcoma incidence
|
J:178645
|
| increased lymphoma incidence
|
J:178645
|
| increased mammary gland tumor incidence
|
J:178645
|
| increased myeloid sarcoma incidence
|
J:178645
|
| increased tumor incidence
|
J:178645
|
| increased uterus tumor incidence
|
J:178645
|
Fbxo4tm1.1Jadi/Fbxo4tm1.1Jadi
(Not Specified)
|
increased hemangioma incidence
|
J:178645
|
| increased hepatic hemangioma incidence
|
J:178645
|
| increased hepatocellular carcinoma incidence
|
J:178645
|
| increased histiocytic sarcoma incidence
|
J:178645
|
| increased lymphoma incidence
|
J:178645
|
| increased mammary gland tumor incidence
|
J:178645
|
| increased myeloid sarcoma incidence
|
J:178645
|
| increased tumor incidence
|
J:178645
|
| increased uterus tumor incidence
|
J:178645
|
Fbxo43tm1.2Kald/Fbxo43tm1.2Kald
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
neoplasm
|
J:251984
|
Fbxw7tm1Iaai/Fbxw7tm1Iaai
Tg(Lck-cre)1Cwi/0
(involves: 129/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:137138
|
Fbxw7tm1Iken/Fbxw7tm1Iken
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA)
|
increased cholangiocarcinoma incidence
|
J:258194
|
Fbxw7tm1Kei/Fbxw7tm1Kei
Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:128523
|
Fbxw7tm1Kei/Fbxw7tm1Kei
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:128523
|
| increased T cell derived lymphoma incidence
|
J:128523
|
Fbxw7tm1Sje/Fbxw7+
(involves: 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:88903
|
Fbxw7tm2Iaai/Fbxw7+
Tg(EIIa-cre)C5379Lmgd/0
(involves: C57BL/6 * FVB/N)
|
neoplasm
|
J:200006
|
Fbxw7tm2Iaai/Fbxw7+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
decreased tumor latency
|
J:200006
|
| neoplasm
|
J:200006
|
Fbxw7as1tm1Opaz/Fbxw7as1tm1Opaz
(B6.Cg-Fbxw7as1tm1Opaz)
|
decreased tumor growth/size
|
J:103174
|
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch)
|
increased B cell derived lymphoma incidence
|
J:244082
|
| increased hemangioma incidence
|
J:244082
|
| increased hemangiosarcoma incidence
|
J:244082
|
| increased hepatocellular carcinoma incidence
|
J:244082
|
| increased liver tumor incidence
|
J:244082
|
| increased lung carcinoma incidence
|
J:244082
|
| increased lymphoma incidence
|
J:244082
|
| increased myeloid sarcoma incidence
|
J:244082
|
| increased plasmacytoma incidence
|
J:244082
|
| increased sarcoma incidence
|
J:244082
|
| increased T cell derived lymphoma incidence
|
J:244082
|
| increased tumor incidence
|
J:244082
|
Fem1atm1Seno/Fem1atm1Seno
(C57BL/6-Fem1atm1Seno)
|
increased colon tumor incidence
|
J:228893
|
Fen1tm1Rak/Fen1+
(involves: 129/Sv * C57BL/6 * SJL/J)
|
increased B cell derived lymphoma incidence
|
J:77962
|
Fen1tm1Rak/Fen1+
Apctm1Rak/Apc+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL/J)
|
increased gastrointestinal tumor incidence
|
J:77962
|
| increased malignant tumor incidence
|
J:77962
|
Fen1tm2.1Bhsh/Fen1tm2.1Bhsh
(involves: 129S1/Sv)
|
increased liver tumor incidence
|
J:218627
|
| increased lung tumor incidence
|
J:218627
|
| increased thymus tumor incidence
|
J:218627
|
| increased tumor incidence
|
J:218627
|
Fen1tm2Klng/Fen1tm2Klng
(involves: 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:138901
|
| increased lung adenoma incidence
|
J:138901
|
| increased sarcoma incidence
|
J:138901
|
Fen1tm3.1Bhsh/Fen1+
(Not Specified)
|
increased lung adenoma incidence
|
J:231218
|
Fen1tm3.1Bhsh/Fen1tm3.1Bhsh
(Not Specified)
|
increased gonad tumor incidence
|
J:231218
|
| increased liver tumor incidence
|
J:231218
|
| increased lung adenocarcinoma incidence
|
J:231218
|
| increased lung adenoma incidence
|
J:231218
|
Festm1Pag/Festm1Pag
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
decreased tumor latency
|
J:98281
|
Festm2Pag/Festm2Pag
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
decreased tumor latency
|
J:98281
|
Fgf2tm1Bee/Fgf2tm1Bee
Tg(Tyrp1-TAg)3434Bee/?
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased eye tumor incidence
|
J:75629
|
Fgf22tm1Rpgr/Fgf22tm1Rpgr
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:187809
|
Fgfr2tm1Dsn/Fgfr2tm1Dsn
Tg(KRT5-cre)5132Jlj/0
(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
|
increased incidence of tumors by chemical induction
|
J:119723
|
| increased skin papilloma incidence
|
J:119723
|
Fgfr3tm1Dor/Fgfr3tm1Dor
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-Fgf9,-EGFP)#Dor/0
(involves: 129S6/SvEvTac * C57BL/6J * FVB)
|
decreased organ/body region tumor incidence
|
J:204282
|
Fgfr3tm1Iwa/Fgfr3+
Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * FVB/N)
|
neoplasm
|
J:174242
|
Fgfr3tm4Cxd/Fgfr3+
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased skin papilloma incidence
|
J:174242
|
| neoplasm
|
J:174242
|
Fgfr3tm4Cxd/Fgfr3+
Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * FVB/N)
|
neoplasm
|
J:174242
|
Fgfr4tm1Axul/Fgfr4+
Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
| increased metastatic potential
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal tumor susceptibility
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
| increased metastatic potential
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(WapTgfa)215Bri/0
(FVB.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Cxd/Fgfr4tm1Cxd
Tg(Myl2-FGF19)1Dfre/0
(involves: 129S6/SvEvTac * FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:187236
|
| decreased liver tumor incidence
|
J:187236
|
Fgl1tm1b(EUCOMM)Hmgu/Fgl1tm1b(EUCOMM)Hmgu
(involves: BALB/cJ * C57BL/6N)
|
decreased tumor growth/size
|
J:269578
|
Fhip2bem1Wwan/Fhip2bem1Wwan
(involves: C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:285283
|
Fhittm1Hbn/Fhit+
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:61946,
J:71303,
J:110096
|
| increased tumor incidence
|
J:71303
|
Fhittm1Hbn/Fhittm1Hbn
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:71303
|
| increased tumor incidence
|
J:71303
|
Fhittm1Hbn/Fhittm1Hbn
Hint1tm1.1Tpm/Hint1+
(involves: 129X1/SvJ * BALB/c * C57BL/6)
|
increased tumor incidence
|
J:83562
|
Fhittm1Hbn/Fhittm1Hbn
Hint1tm1.1Tpm/Hint1tm1.1Tpm
(involves: 129X1/SvJ * BALB/c * C57BL/6)
|
increased tumor incidence
|
J:83562
|
Fhittm1Tko/Fhit+
(involves: 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:93269
|
| increased lymphoma incidence
|
J:93269
|
| increased papilloma incidence
|
J:93269
|
Fhittm1Tko/Fhittm1Tko
(involves: 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:93269
|
| increased hepatocellular carcinoma incidence
|
J:93269
|
| increased lymphoma incidence
|
J:93269
|
| increased papilloma incidence
|
J:93269
|
Fkbpltm1(KOMP)Wtsi/Fkbpl+
(involves: C57BL/6N)
|
abnormal tumor vascularization
|
J:226964
|
| increased tumor growth/size
|
J:226964
|
Fkbpltm1.1(KOMP)Wtsi/Fkbpl+
(involves: C57BL/6N * C57BL/6NTac)
|
abnormal tumor vascularization
|
J:226964
|
| increased tumor growth/size
|
J:226964
|
FlcnGt(RRX115)Byg/Flcn+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:147582
|
| increased kidney tumor incidence
|
J:147582
|
| increased lymphoma incidence
|
J:147582
|
Flcntm1Btt/Flcntm1Btt
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJaeSor * C57BL/6 * ICR)
|
increased renal carcinoma incidence
|
J:143922
|
Fli1tm1Ber/Fli1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
increased leukemia incidence
|
J:33052
|
Fli1tm1Ber/Fli1tm1Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
increased leukemia incidence
|
J:33052
|
Flot2tm1Mak/Flot2tm1Mak
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased metastatic potential
|
J:203238
|
| increased mammary gland tumor incidence
|
J:203238
|
Flt3tm1Dgg/Flt3+
Kmt2atm1Clgr/Kmt2a+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
|
increased leukemia incidence
|
J:189096
|
Flt3tm1Dgg/Flt3tm1Dgg
Kmt2atm1Clgr/Kmt2a+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
|
increased leukemia incidence
|
J:189096
|
Flt3tm2.1Dosm/Flt3+
(B6.129(C)-Flt3tm2.1Dosm)
|
increased B cell derived lymphoma incidence
|
J:205200
|
| increased hemangiosarcoma incidence
|
J:205200
|
| increased histiocytic sarcoma incidence
|
J:205200
|
Flvcr2tm1a(EUCOMM)Hmgu/Flvcr2tm1a(EUCOMM)Hmgu
(C57BL/6N-Flvcr2tm1a(EUCOMM)Hmgu/Wtsi)
|
embryo tumor
|
J:239583
|
| increased hemangioma incidence
|
J:239583
|
Fn1tm1Bwg/Fn1tm1Bwg
(involves: 129S4/SvJae * BALB/c * C57BL/6J)
|
neoplasm
|
J:93027
|
Fn1tm1Bwg/Fn1tm1Bwg
Tg(RIP1-Tag)2Dh/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J)
|
increased carcinoma incidence
|
J:93027
|
Fn1tm1Ksek/Fn1tm1Ksek
(involves: 129P2/OlaHsd * 129/Sv)
|
neoplasm
|
J:93027
|
Fn1tm1Ksek/Fn1tm1Ksek
Tg(RIP1-Tag)2Dh/0
(involves: 129S4/SvJae * C57BL/6J)
|
increased carcinoma incidence
|
J:93027
|
Fnip1LPAB.1/Fnip1LPAB.1
Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6J * SJL)
|
neoplasm
|
J:187318
|
Fnip1tm1.2Baba/Fnip1+
Fnip2tm1.2Lss/Fnip2tm1.2Lss
(involves: C57BL/6)
|
increased kidney tumor incidence
|
J:220672
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
decreased tumor growth/size
|
J:158937
|
| increased lung tumor incidence
|
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
decreased tumor growth/size
|
J:158937
|
| increased lung adenoma incidence
|
J:158937
|
| increased lung carcinoma incidence
|
J:158937
|
| increased lung tumor incidence
|
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
decreased tumor growth/size
|
J:158937
|
| increased lung tumor incidence
|
J:158937
|
Fntbtm1Bbd/Fntbtm1.1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
decreased incidence of tumors by chemical induction
|
J:98944
|
Fntbtm1Bbd/Fntbtm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:98944
|
| increased lung adenoma incidence
|
J:98944
|
Fntbtm1Bbd/Fntbtm1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
decreased incidence of tumors by chemical induction
|
J:98944
|
Foc1NFS/N/Foc1NFS/N
(involves: SL/Kh * NFS/N)
|
increased B cell derived lymphoma incidence
|
J:16441
|
Folr1tm1Fnn/Folr1+
(involves: 129 * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:96380
|
Fostm1Pa/Fostm1Pa
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal tumor morphology
|
J:78834
|
| decreased metastatic potential
|
J:78834
|
Fostm1Wag/Fostm1Wag
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased rhabdomyosarcoma incidence
|
J:89283
|
Fostm1Wag/Fostm1Wag
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased rhabdomyosarcoma incidence
|
J:89283
|
Fostm7Wag/Fostm7Wag
Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased tumor growth/size
|
J:190150
|
Foxa1tm1Khk/Foxa1tm1Khk
Foxa2tm1Khk/Foxa2tm1Khk
Tg(Alb1-cre)1Khk/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
decreased incidence of tumors by chemical induction
|
J:181296
|
| increased hepatocellular carcinoma incidence
|
J:181296
|
| increased incidence of tumors by chemical induction
|
J:181296
|
Foxl1tm1Khk/Foxl1tm1Khk
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:95893
|
Foxm1tm1Rhc/Foxm1tm1Rhc
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:89472
|
| increased incidence of tumors by chemical induction
|
J:89472
|
Foxm1tm1Rhc/Foxm1tm1Rhc
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129X1/SvJ * C57BL/6 * DBA)
|
decreased incidence of tumors by chemical induction
|
J:89472
|
| decreased liver tumor incidence
|
J:89472
|
Foxm1tm1Rhc/Foxm1tm1Rhc
Tg(Tek-cre)1Ywa/0
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:167773
|
| increased lung adenoma incidence
|
J:167773
|
Foxn1nu-str/Foxn1nu-str
(AKR/J-Foxn1nu-str/J)
|
decreased incidence of tumors by chemical induction
|
J:43880
|
| decreased lymphoma incidence
|
J:30715
|
| increased sarcoma incidence
|
J:30715
|
Foxn1nu/Foxn1nu
(involves: BALB/c)
|
increased plasmacytoma incidence
|
J:40405
|
Foxn1nu/Foxn1nu
Gpc1tm1.1Alan/Gpc1tm1.1Alan
(involves: CD-1)
|
decreased metastatic potential
|
J:130809
|
Foxn1nu/Foxn1nu
Srcr/Srcr+
(involves: BALB/c * C57BL/6)
|
decreased tumor incidence
|
J:83618
|
Foxo1tm1Mrc/Foxo1tm1Mrc
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
neoplasm
|
J:93444
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Tg(CYP19A1-cre)1Jri/0
(involves: 129S6/SvEvTac)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo3tm1Rdp/Foxo3tm1Rdp
Foxo4tm1Rdp/Foxo4tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hamartoma incidence
|
J:118179
|
| increased hemangioma incidence
|
J:118179
|
| increased hemangiosarcoma incidence
|
J:118179
|
| increased T cell derived lymphoma incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo3tm1Rdp/Foxo3tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hemangioma incidence
|
J:118179
|
| increased hemangiosarcoma incidence
|
J:118179
|
| increased hepatic hemangioma incidence
|
J:118179
|
| increased tumor incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo4tm1Rdp/Foxo4tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hamartoma incidence
|
J:118179
|
| increased hemangioma incidence
|
J:118179
|
| increased hemangiosarcoma incidence
|
J:118179
|
| increased hepatic hemangioma incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA * FVB/N)
|
increased hemangioma incidence
|
J:118179
|
Foxo3mommeR1/Foxo3mommeR1
(B6.FVB-Foxo3mommeR1)
|
neoplasm
|
J:170710
|
Foxo3mommeR1/Foxo3mommeR1
Tg(HBA1-GFP)1Ew/Tg(HBA1-GFP)1Ew
(FVB/NJ-Foxo3mommeR1 Tg(HBA1-Gfp)1Ew)
|
increased ovarian teratoma incidence
|
J:170710
|
Foxo3mommeR1/Foxo3tm1.1Rdp
Tg(HBA1-GFP)1Ew/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ)
|
neoplasm
|
J:170710
|
Foxo3tm1.1Rdp/Foxo3+
Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
|
increased Harderian gland tumor incidence
|
J:118179
|
| increased ovary tumor incidence
|
J:118179
|
| increased pituitary adenoma incidence
|
J:118179
|
| increased tumor incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
decreased tumor latency
|
J:118179
|
| increased hemangiosarcoma incidence
|
J:118179
|
| increased ovary tumor incidence
|
J:118179
|
| increased prolactinoma incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
|
increased Harderian gland tumor incidence
|
J:118179
|
| increased lung adenoma incidence
|
J:118179
|
| increased ovarian teratoma incidence
|
J:118179
|
| increased ovary tumor incidence
|
J:118179
|
| increased pituitary adenoma incidence
|
J:118179
|
| increased tumor incidence
|
J:118179
|
Foxp3tm4(YFP/icre)Ayr/Y
Zfp91tm1Smoc/Zfp91tm1Smoc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:306129
|
Foxq1sa/Foxq1sa
Lystbg/Lystbg
(involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl)
|
increased lymphoma incidence
|
J:5311
|
Fpr2tm1.2Jimw/Fpr2tm1.2Jimw
(involves: 129X1/SvJ)
|
increased colon adenoma incidence
|
J:197568
|
| increased incidence of tumors by chemical induction
|
J:197568
|
Frktm1Liu/Frktm1Liu
(involves: 129P2/OlaHsd * C57BL/6J)
|
neoplasm
|
J:77207
|
Frmd8em2Smoc/Frmd8em2Smoc
Tg(Vil1-cre)997Gum/0
(involves: C57BL/6J * SJL)
|
increased incidence of tumors by chemical induction
|
J:338904
|
Fshrtm1Saco/Fshr+
(involves: 129)
|
increased ovary tumor incidence
|
J:140008
|
Fshrtm1Saco/Fshr+
(involves: 129T2/SvEmsJ)
|
increased uterus tumor incidence
|
J:81460
|
Fshrtm1Saco/Fshrtm1Saco
(involves: 129)
|
increased ovarian carcinoma incidence
|
J:70933
|
Fut7tm1Jbl/Fut7tm1Jbl
(B6.129S2-Fut7tm1Jbl)
|
decreased metastatic potential
|
J:106671
|
Fut8em1(IMPC)Wtsi/Fut8em1(IMPC)Wtsi
(C57BL/6N-Fut8em1(IMPC)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
Fxyd5em1Namje/Fxyd5em1Namje
(C57BL/6J-Fxyd5em1Namje)
|
decreased incidence of tumors by chemical induction
|
J:325989
|
| neoplasm
|
J:325989
|
Fzr1tm1.1Mama/Fzr1+
(involves: BALB/cJ * C57BL/6 * SJL)
|
decreased incidence of tumors by chemical induction
|
J:137456
|
| decreased tumor growth/size
|
J:137456
|
| increased liver tumor incidence
|
J:137456
|
| increased lung tumor incidence
|
J:137456
|
| increased mammary adenocarcinoma incidence
|
J:137456
|
| increased mammary gland tumor incidence
|
J:137456
|
| increased testis tumor incidence
|
J:137456
|
| increased tumor incidence
|
J:137456
|
G6pc1tm1.1Ics/G6pc1tm1.1Ics
Albtm1(cre/ERT2)Mtz/Alb+
(involves: 129S2/SvPas * C57BL/6J)
|
increased liver adenoma incidence
|
J:195257
|
Gadd45atm1Ajf/Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
|
increased incidence of tumors by ionizing radiation induction
|
J:57882
|
Gadd45atm1Ajf/Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * C57BL/6 * SKH1) or (involves: 129X1/SvJ * C57BL/6 * SKH1))
|
increased incidence of tumors by UV-induction
|
J:81080
|
Gadd45atm1Ajf/Gadd45atm1Ajf
Xpctm1Ecf/Xpctm1Ecf
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129X1/SvJ * C57BL/6))
|
increased lung adenocarcinoma incidence
|
J:101421
|
| increased lung adenoma incidence
|
J:101421
|
| increased lung tumor incidence
|
J:101421
|
| increased metastatic potential
|
J:101421
|
Gas2l2tm1a(KOMP)Wtsi/Gas2l2tm1a(KOMP)Wtsi
(C57BL/6N-Gas2l2tm1a(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Gasttm1Lcs/Gasttm1Lcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased stomach tumor incidence
|
J:97527
|
Gasttm1Psi/Gasttm1Psi
(involves: C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:77985
|
Gata6osem1Zfa/Gata6osem1Zfa
(C57BL/6-1010001N08Rikem1Zfa)
|
decreased incidence of tumors by chemical induction
|
J:268724
|
Gata6osem1Zfa/Gata6osem1Zfa
ApcMin/Apc+
(involves: C57BL/6J)
|
decreased intestinal adenoma incidence
|
J:268724
|
Gcgrtm1Jcp/Gcgrtm1Jcp
(DBA/1LacJ-Gcgrtm1Jcp)
|
increased glucagonoma incidence
|
J:176507
|
| increased pancreas tumor incidence
|
J:176507
|
Gct1SJL/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct1SWR/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct4CAST/Ei/Gct4CAST/Ei
(involves: CAST/Ei * SJL * SWR)
|
decreased tumor incidence
|
J:87114
|
Gct4SJL/Bm/?
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct4SJL/Bm/Gct4SJL/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:87114
|
Gct4SJL/Bm/Gct4SJL/Bm
Gct6SJL/Gct6SJL
(involves: CAST/Ei * SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:87114
|
Gct5SWXJ9/BmJ/Gct5SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct7SWXJ9/BmJ/Gct7SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct8SWXJ9/BmJ/Gct8SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct9SWXJ9/BmJ/Gct9SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gfertm1.1Crg/Gfertm1.1Crg
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:227242
|
Ggctem1.2Smoc/Ggctem1.2Smoc
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6J)
|
decreased tumor incidence
|
J:317466
|
Ggta1tm1Jbl/Ggta1tm1Jbl
(involves: 129S2/SvPas)
|
decreased lung tumor incidence
|
J:90851
|
Gins4tm1Ntak/Gins4+
Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0
Tg(Krt19-Wnt1)2Maos/0
(involves: 129P2/OlaHsd * C3H * C57BL/6)
|
decreased tumor growth/size
|
J:209708
|
Gkn2tm1.1(KOMP)Vlcg/Gkn2tm1.1(KOMP)Vlcg
Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6NTac)
|
increased stomach tumor incidence
|
J:234656
|
Gli1tm3(cre/ERT2)Alj/Gli1+
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Glipr1tm1Tt/Glipr1+
(Not Specified)
|
increased tumor incidence
|
J:131419
|
Glipr1tm1Tt/Glipr1+
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd)
|
increased tumor incidence
|
J:131419
|
Glipr1tm1Tt/Glipr1tm1Tt
(Not Specified)
|
increased tumor incidence
|
J:131419
|
Glipr1tm1Tt/Glipr1tm1Tt
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd)
|
increased tumor incidence
|
J:131419
|
Gm5544tm1a(KOMP)Wtsi/Gm5544tm1a(KOMP)Wtsi
(C57BL/6N-Gm5544tm1a(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:24434
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd)
|
increased intestinal adenocarcinoma incidence
|
J:24434
|
Gnai2tm2.1Lbi/Gnai2tm2.1Lbi
Tg(Cd4-cre)1Cwi/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA)
|
increased incidence of tumors by chemical induction
|
J:194587
|
Gnmttm1Ymac/Gnmttm1Ymac
(involves: 129 * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:146081
|
| increased hepatocellular carcinoma incidence
|
J:146081
|
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
|
increased salivary adenocarcinoma incidence
|
J:197352
|
Gpa33tm1Jkhh/Gpa33tm1Jkhh
(B6.129-Gpa33tm1Jkhh)
|
increased incidence of tumors by chemical induction
|
J:224768
|
Gpnmbtm1Ari/Gpnmbtm1Ari
(C57BL/6-Gpnmbtm1Ari)
|
decreased tumor growth/size
|
J:215931
|
Gpr4tm1Mglg/Gpr4tm1Mglg
(either: BALB/c-Gpr4tm1Mglg or B6.C-Gpr4tm1Mglg)
|
abnormal tumor vascularization
|
J:232324
|
| decreased tumor growth/size
|
J:232324
|
Gpr37l1tm1.2Gtva/Gpr37l1tm1.2Gtva
Ptch1tm1Zim/Ptch1+
(STOCK Gpr37l1tm1.2Gtva Ptch1tm1Zim/Cnrm)
|
increased medulloblastoma incidence
|
J:272049
|
| increased tumor incidence
|
J:272049
|
| increased tumor latency
|
J:272049
|
Gpr68tm1.1Yaxu/Gpr68tm1.1Yaxu
(B6.Cg-Gpr68tm1.1Yaxu)
|
decreased tumor growth/size
|
J:149315
|
Gpr68tm1.1Yaxu/Gpr68tm1.1Yaxu
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased tumor growth/size
|
J:149315
|
Gpr68tm1Yaxu/Gpr68tm1Yaxu
(involves: C57BL/6)
|
increased tumor growth/size
|
J:149315
|
Gprc5atm1Rlo/Gprc5a+
(involves: 129 * C57BL/6)
|
increased lung tumor incidence
|
J:127821
|
Gprc5atm1Rlo/Gprc5atm1Rlo
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:127821
|
| increased lung adenoma incidence
|
J:127821
|
| increased lung tumor incidence
|
J:127821
|
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
increased leukemia incidence
|
J:193993
|
| increased lung adenocarcinoma incidence
|
J:193993
|
| increased lymphoma incidence
|
J:193993
|
| increased mammary adenocarcinoma incidence
|
J:193993
|
| increased salivary gland tumor incidence
|
J:193993
|
| increased sarcoma incidence
|
J:193993
|
| increased tumor incidence
|
J:193993
|
Grb2tm1Paw/Grb2+
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:93530
|
| increased endometrial carcinoma incidence
|
J:93530
|
| increased lymphoma incidence
|
J:93530
|
| increased tumor incidence
|
J:93530
|
Grb2tm1Paw/Grb2+
Ptentm2Mak/Ptentm2Mak
Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:93530
|
Grb2tm1Paw/Grb2+
Tg(MMTV-PyVT)634Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:51424
|
Grhl3tm1Jane/Grhl3+
(involves: 129S1/Sv)
|
neoplasm
|
J:178952
|
Grhl3tm1Jane/Grhl3+
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv)
|
increased skin papilloma incidence
|
J:178952
|
| increased skin squamous cell carcinoma incidence
|
J:178952
|
Grhl3tm1Jane/Grhl3tm3.1Jane
Tg(KRT14-cre)8Brn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:178952
|
| increased skin papilloma incidence
|
J:178952
|
| increased skin squamous cell carcinoma incidence
|
J:178952
|
Grhl3tm1Jane/Grhl3tm3.1Jane
Tg(MMTV-cre)4Mam/0
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased tumor incidence
|
J:178952
|
Grm1Tg(p18A4.B)1352Szc/0
(Not Specified)
|
increased cutaneous melanoma incidence
|
J:83183,
J:32786
|
Gstp1/Gstp2tm1Wolf/Gstp1/Gstp2tm1Wolf
(involves: 129P2/OlaHsd * MF1)
|
increased skin papilloma incidence
|
J:47638
|
Gstp1/Gstp2tm1Wolf/Gstp1/Gstp2tm1Wolf
(involves: 129P2/OlaHsd * MF1)
|
increased skin papilloma incidence
|
J:47638
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+
Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased malignant tumor incidence
|
J:234601
|
| increased prostate gland adenocarcinoma incidence
|
J:234601
|
| increased prostate intraepithelial neoplasia incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu
Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
| increased prostate intraepithelial neoplasia incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:184533
|
| increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased pituitary gland tumor incidence
|
J:187257
|
| neoplasm
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased carcinoma incidence
|
J:187257
|
| increased medulloblastoma incidence
|
J:187257
|
| increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Tg(Gfap-cre)2Brn/0
(either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased mammary gland tumor incidence
|
J:187257
|
| increased pituitary gland tumor incidence
|
J:187257
|
| increased tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
| neoplasm
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/Gt(ROSA)26Sor+
Tg(Vil1-cre)997Gum/0
(involves: 129 * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:243363
|
Gt(ROSA)26Sortm1(CAG-Errfi1)Jwj/?
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased papilloma incidence
|
J:218222
|
Gt(ROSA)26Sortm1(CAG-Mir182)Dgk/Gt(ROSA)26Sortm1(CAG-Mir182)Dgk
Krastm4Tyj/Krastm4Tyj
Trp53tm1Brn/Trp53tm1Brn
(involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased metastatic potential
|
J:217635
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1+
Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:307910
|
| increased prostate gland tumor incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased neuroblastoma incidence
|
J:222527
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(MMTV-cre)7Mul/0
(involves: BALB/c * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(Wap-cre)1Gsc/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
| increased mammary gland tumor incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PTPN1,-EGFP)Mtr/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:231906
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
(involves: 129S6/SvEv * C57BL/6)
|
neoplasm
|
J:161806
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+
Tg(Sftpc-cre)1Blh/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:161806
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
(involves: 129S6/SvEv * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:161806
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
Trp53tm5Tyj/Trp53tm5Tyj
(involves: 129S4/SvJae * C57BL/6)
|
tumor regression
|
J:118233
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
decreased lymphoma incidence
|
J:179414
|
| increased T cell derived lymphoma incidence
|
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
(involves: 129 * C57BL/6)
|
increased sarcoma incidence
|
J:146617
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:130367
|
| increased incidence of tumors by chemical induction
|
J:130367
|
| increased prostate gland tumor incidence
|
J:130367
|
| increased prostate intraepithelial neoplasia incidence
|
J:130367
|
| increased skin squamous cell carcinoma incidence
|
J:130367
|
| increased T cell derived lymphoma incidence
|
J:130367
|
| increased tumor incidence
|
J:130367
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
(involves: 129 * 129S1/Sv * 129X1/SvJ)
|
increased sarcoma incidence
|
J:147728
|
| increased tumor incidence
|
J:147728
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:217462
|
| increased tumor incidence
|
J:194308
|
| increased tumor latency
|
J:194308
|
Gt(ROSA)26Sortm1(EWSR1/FLI1)Sbk/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:129039
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:167612
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:280854
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi
(involves: 129 * C57BL/6 * CBA)
|
decreased gland tumor incidence
|
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Brn/Trp53+
(involves: 129 * C57BL/6 * CBA)
|
increased pancreas tumor incidence
|
J:289183
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:289183
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:289183
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
Tg(Mitf-cre)7114Gsb/0
(C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvkr Tg(Mitf-cre)7114Gsb/Cvrk)
|
increased intraocular melanoma incidence
|
J:225597
|
| increased metastatic potential
|
J:225597
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
(C3FeJ.Cg-Tg(Tyr-cre/ERT2)13Bos Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Cvrk)
|
neoplasm
|
J:225597
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased histiocytic sarcoma incidence
|
J:172031
|
| increased sarcoma incidence
|
J:172031
|
| increased tumor incidence
|
J:172031
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased histiocytic sarcoma incidence
|
J:172031
|
| increased sarcoma incidence
|
J:172031
|
| increased tumor incidence
|
J:172031
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
|
increased lymphoma incidence
|
J:170965
|
| increased thyroid adenoma incidence
|
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:170965
|
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:160931
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
| increased prostate intraepithelial neoplasia incidence
|
J:238768
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+
Tg(Tagln-cre)1Jjl/0
(involves: CD-1 * FVB/N)
|
increased squamous cell carcinoma incidence
|
J:112093
|
Gt(ROSA)26Sortm1(Myc)Rcse/Gt(ROSA)26Sortm1(Myc)Rcse
Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
neoplasm
|
J:169403
|
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev
(involves: C57BL/6 * FVB/N)
|
preneoplasia
|
J:142030
|
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev
Krastm4Tyj/Krastm4Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenoma incidence
|
J:142030
|
| increased lung tumor incidence
|
J:142030
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Hes1tm1.1Frad/Hes1tm1.1Frad
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
|
decreased lymphoma incidence
|
J:167000
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae * 129S4/SvJaeSor)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/NJ)
|
increased liposarcoma incidence
|
J:237232
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJaeSor * C57BL/6J * FVB/NJ)
|
increased liposarcoma incidence
|
J:237232
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:167000
|
Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/Gt(ROSA)26Sor+
Tg(Lck-cre)548Jxm/0
(B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm)
|
increased T cell derived lymphoma incidence
|
J:185287
|
Gt(ROSA)26Sortm1(Ntn4)Dyl/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
(involves: 129/Sv * C57BL/6 * CBA)
|
abnormal tumor vascularization
|
J:162807
|
| increased metastatic potential
|
J:162807
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)H5Brd/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal tumor susceptibility
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)S1Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
abnormal tumor susceptibility
|
J:166063
|
| increased carcinoma incidence
|
J:166063
|
| increased sarcoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)S2Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
abnormal tumor susceptibility
|
J:166063
|
| increased carcinoma incidence
|
J:166063
|
| increased sarcoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H27Brd/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal tumor susceptibility
|
J:166063
|
| increased leukemia incidence
|
J:166063
|
| increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H32Brd/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal tumor susceptibility
|
J:166063
|
| increased leukemia incidence
|
J:166063
|
| increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)S1Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
abnormal tumor susceptibility
|
J:166063
|
| increased leukemia incidence
|
J:166063
|
| increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)S2Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
abnormal tumor susceptibility
|
J:166063
|
| increased leukemia incidence
|
J:166063
|
| increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP3)S1Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
abnormal tumor susceptibility
|
J:166063
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
neoplasm
|
J:219794
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
H3c2tm1Mak/H3c2+
Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129 * C57BL/6 * FVB/N)
|
neoplasm
|
J:285841
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129 * C57BL/6 * FVB/N)
|
neoplasm
|
J:285841
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)1Mam/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:170898
|
| increased tumor incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
(involves: 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
| increased mammary gland tumor incidence
|
J:170898
|
| increased tumor incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:170898
|
| increased mammary adenocarcinoma incidence
|
J:170898
|
| increased mammary gland tumor incidence
|
J:170898
|
| increased T cell derived lymphoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:170898
|
| increased mammary gland tumor incidence
|
J:170898
|
| increased T cell derived lymphoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+
(involves: 129)
|
neoplasm
|
J:187582
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:187582
|
| increased tumor growth/size
|
J:187582
|
Gt(ROSA)26Sortm1(RICTOR)Jger/Gt(ROSA)26Sortm1(RICTOR)Jger
Tg(GFAP-cre)25Mes/0
(involves: 129 * FVB/N)
|
abnormal tumor vascularization
|
J:192206
|
| increased glioma incidence
|
J:192206
|
| increased oligodendroglioma incidence
|
J:192206
|
Gt(ROSA)26Sortm1(RICTOR)Jger/Gt(ROSA)26Sortm1(RICTOR)Jger
Tg(GFAP-cre)25Mes/0
Tg(GFAP-EGFR*,-lacZ)#Agu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased tumor latency
|
J:192206
|
| increased astrocytoma incidence
|
J:192206
|
| increased glioma incidence
|
J:192206
|
| increased oligodendroglioma incidence
|
J:192206
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreas tumor incidence
|
J:184378
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:184378
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Y
(involves: 129S7/SvEvBrd)
|
increased hemangioma incidence
|
J:166283
|
| increased hemangiosarcoma incidence
|
J:166283
|
| increased lung adenocarcinoma incidence
|
J:166283
|
| increased lung adenoma incidence
|
J:166283
|
| increased lymphoma incidence
|
J:166283
|
| increased medulloblastoma incidence
|
J:166283
|
| increased rhabdomyosarcoma incidence
|
J:166283
|
| increased skin squamous cell carcinoma incidence
|
J:166283
|
| increased tumor incidence
|
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Hprt1+
(involves: 129S7/SvEvBrd)
|
increased hemangioma incidence
|
J:166283
|
| increased hemangiosarcoma incidence
|
J:166283
|
| increased lung adenocarcinoma incidence
|
J:166283
|
| increased lung adenoma incidence
|
J:166283
|
| increased lymphoma incidence
|
J:166283
|
| increased medulloblastoma incidence
|
J:166283
|
| increased rhabdomyosarcoma incidence
|
J:166283
|
| increased skin squamous cell carcinoma incidence
|
J:166283
|
| increased tumor incidence
|
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6057Njen/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:102234
|
| increased lymphoma incidence
|
J:102234
|
| increased medulloblastoma incidence
|
J:102234
|
| increased T cell derived lymphoma incidence
|
J:102234
|
| increased tumor incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:102234
|
| increased lymphoma incidence
|
J:102234
|
| increased medulloblastoma incidence
|
J:102234
|
| increased T cell derived lymphoma incidence
|
J:102234
|
| increased tumor incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6113Njen/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:102234
|
| increased lymphoma incidence
|
J:102234
|
| increased T cell derived lymphoma incidence
|
J:102234
|
| increased tumor incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc3)12740Njen/0
(involves: C3H * C57BL/6J)
|
increased adenoma incidence
|
J:153656
|
| increased B cell derived lymphoma incidence
|
J:153656
|
| increased basal cell carcinoma incidence
|
J:153656
|
| increased blastoma incidence
|
J:153656
|
| increased carcinoma incidence
|
J:153656
|
| increased hemangioma incidence
|
J:153656
|
| increased hemangiosarcoma incidence
|
J:153656
|
| increased hepatocellular carcinoma incidence
|
J:153656
|
| increased liver adenoma incidence
|
J:153656
|
| increased liver tumor incidence
|
J:153656
|
| increased lung carcinoma incidence
|
J:153656
|
| increased lymphoma incidence
|
J:153656
|
| increased melanoma incidence
|
J:153656
|
| increased pheochromocytoma incidence
|
J:153656
|
| increased sarcoma incidence
|
J:153656
|
| increased skin squamous cell carcinoma incidence
|
J:153656
|
| increased squamous cell carcinoma incidence
|
J:153656
|
| increased T cell derived lymphoma incidence
|
J:153656
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
(involves: 129X1/SvJ)
|
neoplasm
|
J:114992
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased basal cell carcinoma incidence
|
J:114992
|
| increased medulloblastoma incidence
|
J:114992
|
| increased rhabdomyosarcoma incidence
|
J:114992
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Hk2tm1.1Uku/Hk2+
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Hk2tm1.1Uku/Hk2tm1.1Uku
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
|
abnormal tumor vascularization
|
J:210113
|
| decreased tumor growth/size
|
J:210113
|
| increased medulloblastoma incidence
|
J:210113
|
| increased tumor latency
|
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Olig2tm2(TVA,cre)Rth/Olig2+
(involves: 129 * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Shhtm2(cre/ERT2)Cjt/Shh+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
neoplasm
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129X1/SvJ * FVB/N)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(GFAP-cre)25Mes/0
(involves: 129X1/SvJ * FVB/N)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
increased basal cell carcinoma incidence
|
J:158915
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tlx3tm1(cre)Qima/Tlx3+
(involves: 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm2(EGFP/cre)Alj
Pgbd5tm1.1Aken/Pgbd5tm1.1Aken
(involves: 129 * C57BL/6J * C57BL/6NTac * SW)
|
increased medulloblastoma incidence
|
J:346387
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
| increased prostate intraepithelial neoplasia incidence
|
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:200002
|
| increased prostate intraepithelial neoplasia incidence
|
J:200002
|
Gt(ROSA)26Sortm1(tTA,tetO-Mir21)Fjsl/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wmz/0
(involves: C57BL/6 * C57BL/6J * SJL/J)
|
abnormal tumor morphology
|
J:163919
|
| increased lymphoma incidence
|
J:163919
|
| increased tumor incidence
|
J:163919
|
Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wmz/0
(involves: 129 * C57BL/6 * FVB/N * SJL/J)
|
increased B cell derived lymphoma incidence
|
J:185598
|
| tumor regression
|
J:185598
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased incidence of induced tumors
|
J:140423
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:140423
|
Gt(ROSA)26Sortm1.1(CAG-YFP/DROSHA*E1147K)Gess/Gt(ROSA)26Sortm1.1(CAG-YFP/DROSHA*E1147K)Gess
Tg(Six2-EGFP/cre)1Amc/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1)
|
neoplasm
|
J:321428
|
Gt(ROSA)26Sortm1.1(Loxl2)Acan/Gt(ROSA)26Sortm1.1(Loxl2)Acan
(Not Specified)
|
abnormal tumor pathology
|
J:220689
|
| decreased tumor latency
|
J:220689
|
| increased incidence of tumors by chemical induction
|
J:220689
|
Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu/Gt(ROSA)26Sor+
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129S6/SvEvTac * C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:227748
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(Lck-icre)3779Nik/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)
|
neoplasm
|
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(MMTV-cre)4Mam/0
(involves: C57BL/6J * C57BL/6N * FVB/N)
|
increased acute lymphoblastic leukemia incidence
|
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:202090
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Pms2tm2(cre)Lisk/Pms2tm2(cre)Lisk
(involves: 129S4/SvJae * 129S4/SvJaeSor)
|
increased lung tumor incidence
|
J:204653
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Srctm1Mul/Srctm1Mul
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * FVB/N)
|
neoplasm
|
J:181822
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
(involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB)
|
neoplasm
|
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased nervous system tumor incidence
|
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Slc1a3tm1(cre/ERT2)Mgoe/Slc1a3+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJaeSor)
|
increased astrocytoma incidence
|
J:229481
|
| increased glioma incidence
|
J:229481
|
| increased oligodendroglioma incidence
|
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB)
|
increased astrocytoma incidence
|
J:204385
|
| increased glioma incidence
|
J:204385
|
| increased oligodendroglioma incidence
|
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJaeSor)
|
increased astrocytoma incidence
|
J:229481
|
| increased glioma incidence
|
J:229481
|
| increased oligodendroglioma incidence
|
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased nervous system tumor incidence
|
J:204385
|
Gt(ROSA)26Sortm2(CAG-Lin28b,-luc)Jhsc/Gt(ROSA)26Sor+
Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
increased neuroblastoma incidence
|
J:241988
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Ptentm2Mak/Ptentm2Mak
Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased lung tumor incidence
|
J:226601
|
| increased pancreas tumor incidence
|
J:226601
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(GFP/KRAS2/ALPP)1Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased keratoacanthoma incidence
|
J:127226
|
| increased lung tumor incidence
|
J:127226
|
| increased lymphoma incidence
|
J:127226
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:226601
|
| increased lung tumor incidence
|
J:226601
|
| increased pancreas tumor incidence
|
J:226601
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:226601
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:226601
|
| increased sebaceous gland tumor incidence
|
J:226601
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:170965
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:137122
|
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse
Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
increased brain tumor incidence
|
J:169403
|
| increased mammary adenocarcinoma incidence
|
J:169403
|
| increased pituitary gland tumor incidence
|
J:169403
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
neoplasm
|
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac)
|
neoplasm
|
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:197054
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S6/SvEvTac)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197054
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:147264
|
| increased liver adenoma incidence
|
J:147264
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:146887
|
| increased intestinal adenoma incidence
|
J:146887
|
| increased small intestine adenocarcinoma incidence
|
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
TgTn(sb-T2/Onc)76Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:146887
|
| increased intestinal adenoma incidence
|
J:146887
|
| increased small intestine adenocarcinoma incidence
|
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Trp53tm3Tyj/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:147264
|
| increased liver adenoma incidence
|
J:147264
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:120967
|
| increased tumor incidence
|
J:120967
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Myf6tm1(cre)Mrc/Myf6tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:120967
|
Gt(ROSA)26Sortm2.1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
increased hemolymphoid system tumor incidence
|
J:153656
|
| increased leukemia incidence
|
J:153656
|
| increased T cell derived lymphoma incidence
|
J:153656
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Thl/Trp53tm1Thl
Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6)
|
increased glioblastoma incidence
|
J:172585
|
| increased tumor growth/size
|
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6)
|
increased glioblastoma incidence
|
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * C57BL/6)
|
neoplasm
|
J:172585
|
Gt(ROSA)26Sortm3(myc*S62A)Rcse/Gt(ROSA)26Sortm3(myc*S62A)Rcse
Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
increased brain tumor incidence
|
J:169403
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:120967
|
| increased tumor incidence
|
J:120967
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Myf6tm1(cre)Mrc/Myf6tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:120967
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Npm1tm1Gsva/Npm1+
TgTn(pb-sb-GrOnc)#aGsva/0
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased acute promyelocytic leukemia incidence
|
J:172071
|
| increased B cell derived lymphoma incidence
|
J:172071
|
| increased hemangiosarcoma incidence
|
J:172071
|
| increased leukemia incidence
|
J:172071
|
| increased lymphoma incidence
|
J:172071
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(Tal1-tTA)19Dgt/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:227558
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * FVB/N)
|
increased leukemia incidence
|
J:227558
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
(involves: C57BL/6)
|
abnormal tumor latency
|
J:194308
|
| abnormal tumor morphology
|
J:194308
|
| increased incidence of tumors by chemical induction
|
J:194308
|
| increased tumor growth/size
|
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Bmi1tm1(cre/ERT)Mrc/Bmi1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased tumor incidence
|
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Pax7tm1(cre/ERT2)Gaka/Pax7+
(involves: 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Tg(Prrx1-cre/ERT2)1Mlgn/?
(involves: C57BL/6)
|
increased tumor incidence
|
J:194308
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:167612
|
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sor+
Tg(Prrx1-cre/ERT2)1Mlgn/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased organ/body region tumor incidence
|
J:217462
|
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sortm1(cre/ERT)Nat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:217462
|
| increased tumor incidence
|
J:217462
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sor+
Tg(CAG-cre/Esr1*)5Amc/0
(B6.Cg-Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky Tg(CAG-cre/Esr1*)5Amc)
|
increased classified tumor incidence
|
J:264410
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky
Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:191824
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Hmga2tm1.1Mmw/Hmga2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N)
|
increased metastatic potential
|
J:245611
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Prdm1tm1Clme/Prdm1tm1Clme
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased metastatic potential
|
J:245611
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:245611
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:170965
|
Gt(ROSA)26Sortm9(Rac1*,EGFP)Rsky/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: C57BL/6)
|
neoplasm
|
J:197054
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
neoplasm
|
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)
|
increased B cell derived lymphoma incidence
|
J:181546
|
| increased plasmacytoma incidence
|
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:181546
|
| increased plasmacytoma incidence
|
J:181546
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * CD-1 * DBA/2)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * CD-1 * SJL)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:263520
|
| increased thymus tumor incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased leukemia incidence
|
J:263520
|
| increased T cell derived lymphoma incidence
|
J:263520
|
| increased thymoma incidence
|
J:263520
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/0
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:4527
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:34434,
J:101128
|
| increased liver adenoma incidence
|
J:34434
|
| increased liver tumor incidence
|
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:101128
|
| increased liver tumor incidence
|
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
| increased liver adenoma incidence
|
J:34434
|
Gzmatm1Ley/Gzmatm1Ley
(involves: 129X1/SvJ)
|
increased tumor growth/size
|
J:126114
|
Gzmatm1Simn/Gzmatm1Simn
(B6.Cg-Gzmatm1Simn)
|
neoplasm
|
J:28773
|
Gzmbtm1Ley/Gzmbtm1Ley
(involves: 129X1/SvJ)
|
decreased tumor growth/size
|
J:126114
|
H2-Obvic1/H2-Obvic1
(I/LnJ)
|
decreased incidence of induced tumors
|
J:81554,
J:60602
|
H2d/H2d
Trap1atm1.1Jvde/Y
(involves: 129 * BALB/cJ * C57BL/10 * DBA/2)
|
tumor regression
|
J:180807
|
H2u/H2u
Tg(TCRA)B1Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J)
|
increased T cell derived lymphoma incidence
|
J:92992
|
H2u/H2u
Tg(TCRA)B1Jg/0
Tg(TCRB)C14Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)
|
increased T cell derived lymphoma incidence
|
J:92992
|
H2axtm1Fwa/H2ax+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:84879
|
| increased lymphoma incidence
|
J:84879
|
| increased sarcoma incidence
|
J:84879
|
| increased T cell derived lymphoma incidence
|
J:84879
|
| increased teratoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:84879
|
| increased colon adenocarcinoma incidence
|
J:84879
|
| increased sarcoma incidence
|
J:84879
|
| increased T cell derived lymphoma incidence
|
J:84879
|
| increased tumor incidence
|
J:84879
|
H2axtm1Nus/H2ax+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased incidence of induced tumors
|
J:86590
|
H2axtm1Nus/H2axtm1Nus
(Not Specified)
|
abnormal tumor vascularization
|
J:149487
|
| decreased tumor growth/size
|
J:149487
|
H2axtm1Nus/H2axtm1Nus
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased lymphoma incidence
|
J:86590
|
H2axtm1Nus/H2axtm2.1Fwa
Tg(Cdh5-cre)7Mlia/0
(involves: 129S6/SvEvTac * FVB/N)
|
abnormal tumor vascularization
|
J:149487
|
| decreased tumor growth/size
|
J:149487
|
H13tm1b(KOMP)Wtsi/H13tm1b(KOMP)Wtsi
(C57BL/6N-H13tm1b(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
H19tm1Lda/H19tm1Lda
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased tumor growth/size
|
J:138826
|
H19tm1Tilg/H19+
Sdhdtm1Jpb/Sdhd+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
neoplasm
|
J:155380
|
H19tm1Tilg/H19+
Tg(CRP-TAg)60-3Urt/0
(involves: 129S/SvEv * BALB/c * C57BL/6 * SJL)
|
decreased tumor incidence
|
J:90036
|
| increased liver tumor incidence
|
J:90036
|
Habp4em1Jkob/Habp4em1Jkob
(involves: C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:310581
|
Hace1tm1Pngr/Hace1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung tumor incidence
|
J:125183
|
Hace1tm1Pngr/Hace1tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung tumor incidence
|
J:125183
|
| increased T cell derived lymphoma incidence
|
J:125183
|
| increased tumor incidence
|
J:125183
|
Hat1tm1.1Mrpa/Hat1+
(B6.Cg-Hat1tm1.1Mrpa)
|
increased histiocytic sarcoma incidence
|
J:296531
|
| increased kidney tumor incidence
|
J:296531
|
| increased liver tumor incidence
|
J:296531
|
| increased spleen neoplasm incidence
|
J:296531
|
| increased tumor incidence
|
J:296531
|
Hcif1C57BL/6J/Hcif1C57BR/cdJ
Hcif2C57BL/6J/Hcif2C57BR/cdJ
(involves: C57BL/6J * C57BR/cdJ)
|
increased hepatoma incidence
|
J:33543
|
| increased incidence of induced tumors
|
J:33543
|
Hcif1C57BR/cdJ/?
(involves: C57BL/6J * C57BR/cdJ)
|
increased hepatoma incidence
|
J:33543
|
| increased incidence of induced tumors
|
J:33543
|
Hcktm1Ern/Hcktm1Ern
(involves: 129S1/Sv * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:111432
|
Hcs1C3H/He/?
(involves: A/J * C3H/He)
|
increased hepatoma incidence
|
J:3657
|
Hcs2C3H/He/?
(involves: A/J * C3H/He)
|
increased hepatoma incidence
|
J:3657
|
Hcs3A/J/?
(involves: A/J * C3H/He)
|
increased hepatoma incidence
|
J:3657
|
Hcs4C3H/He/Hcs4C57BL/6ByJ
(involves: C3H/He * C57BL/6JBy * M. spretus)
|
increased hepatoma incidence
|
J:20738
|
Hcs5C3H/He/?
(involves: C3H/He * C57BL/6ByJ * M. spretus)
|
increased hepatoma incidence
|
J:20738
|
Hcs6M. spretus/?
(involves: C3H/He * C57BL/6ByJ * M. spretus)
|
increased hepatoma incidence
|
J:20738
|
Hcs7C3H/HeJ/?
(involves: C3H/HeJ * C57BL/6J)
|
increased hepatoma incidence
|
J:31507
|
Hcs7C3H/HeJ/Hcs7C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
increased hepatoma incidence
|
J:91132
|
| increased incidence of induced tumors
|
J:91132
|
Hcs7C3H/HeJ/Hcs7C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
increased hepatoma incidence
|
J:91132
|
| increased incidence of induced tumors
|
J:91132
|
Hcs7C57BL/6J/?
(involves: C3H/HeJ * C57BL/6J)
|
decreased liver tumor incidence
|
J:31507
|
Hcs8CBA/J/Hcs8CBA/J
(involves: C57BL/6J * CBA/J)
|
increased hepatoma incidence
|
J:91132
|
| increased incidence of induced tumors
|
J:91132
|
Hcs9C57BR/cdJ/Hcs9C57BR/cdJ
(B6.BR-(D1Mit5-D1Mit17))
|
increased hepatoma incidence
|
J:91132
|
| increased incidence of induced tumors
|
J:91132
|
Hcsttm1.1Dnax/Hcsttm1.1Dnax
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:148086
|
| decreased metastatic potential
|
J:148086
|
| decreased tumor growth/size
|
J:148086
|
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc
Hdac2tm1.1Shmc/Hdac2+
Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased tumor incidence
|
J:194769
|
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc
Hdac2tm1.1Shmc/Hdac2tm1.1Shmc
Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:194769
|
| increased tumor incidence
|
J:194769
|
Hdac11tm1.2Mrl/Hdac11tm1.2Mrl
(involves: C57BL/6NTac)
|
increased tumor growth/size
|
J:222335
|
HelqGt(RRF112)Byg/Helq+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased Harderian gland tumor incidence
|
J:206104
|
| increased intestinal adenoma incidence
|
J:206104
|
| increased pituitary adenoma incidence
|
J:206104
|
HelqGt(RRF112)Byg/HelqGt(RRF112)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gland tumor incidence
|
J:206104
|
| increased granulosa cell tumor incidence
|
J:206104
|
| increased Harderian gland tumor incidence
|
J:206104
|
| increased mammary gland tumor incidence
|
J:206104
|
| increased ovary tumor incidence
|
J:206104
|
| increased pituitary adenoma incidence
|
J:206104
|
Hephl1cw/Hephl1cw
(CWD/LeJ)
|
increased B cell derived lymphoma incidence
|
J:24875
|
| increased lymphoma incidence
|
J:24875
|
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6)
|
increased carcinoma incidence
|
J:81448
|
| increased hepatocellular carcinoma incidence
|
J:81448
|
| increased lung adenocarcinoma incidence
|
J:81448
|
| increased lymphoma incidence
|
J:81448
|
| increased malignant tumor incidence
|
J:81448
|
| increased metastatic potential
|
J:81448
|
| increased pancreatic islet cell carcinoma incidence
|
J:81448
|
| increased sarcoma incidence
|
J:81448
|
| increased squamous cell carcinoma incidence
|
J:81448
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
(involves: 129 * BALB/c * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:97652
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Tg(Tek-cre)1Ywa/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
decreased tumor growth/size
|
J:94773
|
Hint1tm1Ibw/Hint1tm1Ibw
(involves: 129 * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:84504
|
Hip1tm4Tsr/Hip1+
Runx1tm3Dow/Runx1+
Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
abnormal tumor morphology
|
J:151974
|
| increased chronic myelocytic leukemia incidence
|
J:151974
|
Hip1tm4Tsr/Hip1+
Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
abnormal tumor incidence
|
J:151974
|
| increased hepatocellular carcinoma incidence
|
J:151974
|
| increased liver tumor incidence
|
J:151974
|
| increased T cell derived lymphoma incidence
|
J:151974
|
Hipk1tm1Mak/Hipk1tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:99823
|
Hivep3tm1Lcw/Hivep3tm1Lcw
(chimera involves: 129S/SvEv * 129X1/SvJ)
|
increased teratoma incidence
|
J:79652
|
Hmga1tm1Afus/Hmga1tm1Afus
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:106702
|
| increased leukemia incidence
|
J:106702
|
Hmga1tm1Mina/Hmga1tm1Mina
Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0
Tg(Krt19-Wnt1)2Maos/0
(involves: C3H * C57BL/6 * CBA)
|
increased stomach tumor incidence
|
J:153058
|
Hmgn1tm1Mbus/Hmgn1tm1Mbus
(involves: 129X1/SvJ)
|
increased hemangioma incidence
|
J:100773
|
| increased incidence of tumors by ionizing radiation induction
|
J:100773
|
| increased malignant tumor incidence
|
J:100773
|
| increased metastatic potential
|
J:100773
|
| increased pheochromocytoma incidence
|
J:100773
|
| increased tumor incidence
|
J:100773
|
Hmgxb3tm1a(EUCOMM)Wtsi/Hmgxb3tm1a(EUCOMM)Wtsi
(C57BL/6N-Hmgxb3tm1a(EUCOMM)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Hpcal1em1Ylzg/Hpcal1em1Ylzg
(C57BL/6J-Hpcal1em1Ylzg)
|
abnormal tumor morphology
|
J:331711
|
| increased incidence of tumors by chemical induction
|
J:331711
|
Hpcr1C57BL/6J/Hpcr1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased hepatoma incidence
|
J:22501
|
| decreased incidence of tumors by chemical induction
|
J:22501
|
Hpcr1C57BL/6J/Hpcr1DBA/2J
Hpcr2C57BL/6J/Hpcr2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased hepatoma incidence
|
J:22501
|
| decreased incidence of tumors by chemical induction
|
J:22501
|
Hpcr1DBA/2J/Hpcr1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased hepatoma incidence
|
J:22501
|
| decreased incidence of tumors by chemical induction
|
J:22501
|
Hpcr2C57BL/6J/Hpcr2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased hepatoma incidence
|
J:22501
|
| decreased incidence of tumors by chemical induction
|
J:22501
|
Hpcr2DBA/2J/Hpcr2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased hepatoma incidence
|
J:22501
|
| decreased incidence of tumors by chemical induction
|
J:22501
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Hprt1tm1(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm1(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
| increased mammary gland tumor incidence
|
J:152682
|
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:144357
|
| increased prostate intraepithelial neoplasia incidence
|
J:144357
|
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:97652
|
Hprt1tm1(Rcan1)Zyga/Hprt1+
(B6.129P2-Hprt1tm1(Rcan1)Zyga)
|
decreased tumor growth/size
|
J:150286
|
Hprt1tm2(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm2(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
| increased mammary gland tumor incidence
|
J:152682
|
Hrhr/Hrhr
(HRS/J)
|
increased leukemia incidence
|
J:5726,
J:5908,
J:24786
|
Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
increased incidence of tumors by UV-induction
|
J:79734
|
| increased lymphoma incidence
|
J:79734
|
| increased skin papilloma incidence
|
J:79734
|
| increased skin squamous cell carcinoma incidence
|
J:79734
|
| increased skin tumor incidence
|
J:79734
|
Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
Xpatm1Tnka/Xpatm1Tnka
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased incidence of tumors by UV-induction
|
J:79734
|
| increased lymphoma incidence
|
J:79734
|
| increased skin papilloma incidence
|
J:79734
|
| increased skin squamous cell carcinoma incidence
|
J:79734
|
| increased skin tumor incidence
|
J:79734
|
Hrhr/Hrhr
Ptger2tm1Brey/Ptger2+
(involves: 129S6/SvEvTac * C57BL/6 * SKH1)
|
neoplasm
|
J:117581
|
Hrhr/Hrhr
Ptger2tm1Brey/Ptger2tm1Brey
(involves: 129S6/SvEvTac * C57BL/6 * SKH1)
|
abnormal tumor morphology
|
J:117581
|
| decreased incidence of tumors by UV induction
|
J:117581
|
| increased tumor growth/size
|
J:117581
|
Hrhr/Hrhr
Ptgs1tm1Unc/Ptgs1+
(involves: 129P2/OlaHsd * C57BL/6 * SKH1)
|
neoplasm
|
J:121635
|
Hrhr/Hrhr
Ptgs2tm1Unc/Ptgs2+
(involves: 129P2/OlaHsd * C57BL/6 * SKH1)
|
decreased incidence of tumors by UV induction
|
J:121635
|
Hrhr/Hrhr
Tg(KRT14-Birc5)19Gros/0
(involves: C3H * C57BL/6 * SKH1)
|
decreased incidence of tumors by UV induction
|
J:95011
|
| increased squamous cell carcinoma incidence
|
J:95011
|
Hrhr/Hrhr
Tg(KRT14-Ptgs2)1Sumf/0
(involves: C57BL/6 * DBA/2 * FVB/N * SKH1)
|
increased incidence of tumors by UV-induction
|
J:121635
|
Hrhr/Hrhr
Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA)
|
increased skin tumor incidence
|
J:79734
|
Hrastm1Jaf/?
Tg(TPO-cre)1Shk/0
(involves: 129S6/SvEvTac * FVB/NCr)
|
neoplasm
|
J:168249
|
Hrastm1Jaf/Hras+
Tg(CAG-cre)13Miya/0
(involves: 129S6/SvEvTac * Black Swiss * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:148393
|
| increased papilloma incidence
|
J:148393
|
| increased skin papilloma incidence
|
J:148393
|
| increased stomach tumor incidence
|
J:148393
|
Hrastm1Jaf/Hrastm1Jaf
Nf2tm2Gth/Nf2tm2Gth
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf
Tg(TPO-cre)1Shk/0
(involves: 129S6/SvEvTac * FVB/NCr)
|
neoplasm
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Mok/Hrastm1Mok
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
decreased incidence of tumors by chemical induction
|
J:62962
|
Hrastm2Xbr/Hrastm2Xbr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:137729
|
| neoplasm
|
J:137729
|
Hspa5tm1Alee/Hspa5+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
| increased prostate intraepithelial neoplasia incidence
|
J:142106
|
Hspa5tm1Alee/Hspa5tm1.1Alee
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
neoplasm
|
J:142106
|
Hspa5tm1Alee/Hspa5tm1Alee
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
neoplasm
|
J:142106
|
Htatip2tm1Hx/Htatip2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:87066
|
| increased hemangiosarcoma incidence
|
J:87066
|
| increased hepatocellular carcinoma incidence
|
J:87066
|
| increased malignant tumor incidence
|
J:87066
|
| increased metastatic potential
|
J:87066
|
| increased neuroblastoma incidence
|
J:87066
|
| increased ovary tumor incidence
|
J:87066
|
| increased thymoma incidence
|
J:87066
|
| increased tumor incidence
|
J:87066
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:87066
|
Htatip2tm1Hx/Htatip2tm1Hx
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:87066
|
| increased duodenum adenocarcinoma incidence
|
J:87066
|
| increased hepatocellular carcinoma incidence
|
J:87066
|
| increased malignant tumor incidence
|
J:87066
|
| increased sarcoma incidence
|
J:87066
|
| increased tumor incidence
|
J:87066
|
| increased uterus leiomyoma incidence
|
J:87066
|
Hunktm1Lach/Hunk+
Tg(MMTV-Myc)#Led/0
(involves: 129P2/OlaHsd * C57BL/6J * CD-1)
|
decreased metastatic potential
|
J:153075
|
Hunktm1Lach/Hunktm1Lach
Tg(MMTV-Myc)#Led/0
(involves: 129P2/OlaHsd * C57BL/6J * CD-1)
|
decreased metastatic potential
|
J:153075
|
Hus1tm1Led/Hus1tm2Rsw
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:118898
|
Icam1tm1Bay/Icam1tm1Bay
(B6.129S7-Icam1tm1Bay)
|
increased tumor growth/size
|
J:108135
|
Icam1tm1Bay/Icam1tm1Bay
Selltm1Tft/Selltm1Tft
(B6.129-Selltm1Tft Icam1tm1Bay)
|
increased tumor growth/size
|
J:108135
|
Icostm1Flv/Icostm1Flv
Rc3h1san/Rc3h1+
(involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)
|
decreased lymphoma incidence
|
J:189087
|
| increased T cell derived lymphoma incidence
|
J:189087
|
Id1tm1Zhu/Id1+
(involves: 129S1/Sv * 129S4/SvJaeSor)
|
decreased metastatic potential
|
J:86480
|
| decreased tumor growth/size
|
J:86480
|
| tumor regression
|
J:86480
|
Id1tm1Zhu/Id1+
Id3tm1Zhu/Id3tm1Zhu
(involves: 129S1/Sv * 129S4/SvJaeSor)
|
abnormal tumor vascularization
|
J:86480
|
| decreased metastatic potential
|
J:86480
|
| decreased tumor growth/size
|
J:86480
|
| tumor regression
|
J:86480
|
Id1tm1Zhu/Id1tm1Zhu
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44278
|
Id2tm1Yyk/Id2+
Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Id2tm1Yyk/Id2tm1Yyk
Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Idh2tm1Jwpk/Idh2tm1Jwpk
(involves: 129S4/SvJae * C57BL/6)
|
abnormal tumor pathology
|
J:210036
|
| abnormal tumor vascularization
|
J:210036
|
| decreased tumor growth/size
|
J:210036
|
Ido2tm1.2Gcp/Ido2tm1.2Gcp
(involves: C57BL/6J * FVB/N)
|
neoplasm
|
J:211949
|
Ier3tm1Mxw/Ier3tm1Mxw
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:194587
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(B6.129S2-Ifnar1tm1Agt)
|
increased tumor growth/size
|
J:118750
|
Ifnar1tm1Pjh/Ifnar1tm1Pjh
(B6.129S2-Ifnar1tm1Pjh)
|
increased incidence of induced tumors
|
J:125812
|
| increased incidence of tumors by chemical induction
|
J:125812
|
Ifnar2tm1Pjh/Ifnar2tm1Pjh
(B6.Cg-Ifnar2tm1Pjh)
|
increased incidence of induced tumors
|
J:125812
|
| increased incidence of tumors by chemical induction
|
J:125812
|
Ifnb1tm1Acgp/Ifnb1tm1Acgp
(involves: 129P2/OlaHsd)
|
increased tumor growth/size
|
J:86527
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased tumor incidence
|
J:138466
|
| increased metastatic potential
|
J:152785
|
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
|
decreased tumor latency
|
J:77491
|
| increased lymphoma incidence
|
J:77491
|
| increased sarcoma incidence
|
J:77491
|
| increased T cell derived lymphoma incidence
|
J:77491
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
|
increased lung adenocarcinoma incidence
|
J:77491
|
| increased tumor latency
|
J:77491
|
| neoplasm
|
J:77491
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7(B6)-Ifngtm1Ts/J)
|
abnormal tumor pathology
|
J:115144
|
| decreased tumor latency
|
J:115144
|
Ifngtm1Ts/Ifngtm1Ts
Prf1tm1Sdz/Prf1tm1Sdz
(C.Cg-Prf1tm1Sdz Ifngtm1Ts)
|
abnormal tumor morphology
|
J:77491
|
| decreased tumor latency
|
J:77491
|
| increased B cell derived lymphoma incidence
|
J:77491
|
| increased lymphoma incidence
|
J:77491
|
Ifngr1tm1.1Rost/Ifngr1tm1.1Rost
(involves: BALB/cJ * C57BL/6)
|
decreased metastatic potential
|
J:152785
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd)
|
abnormal tumor susceptibility
|
J:63089
|
| abnormal tumor vascularization
|
J:63089
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal tumor susceptibility
|
J:138466
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(B6.129S7-Ifngr1tm1Agt/J)
|
increased metastatic potential
|
J:152785
|
Ifngr1tm1Agt/Ifngr1tm1Agt
Tg(GZMB-Tax)#Lera/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased skeletal tumor incidence
|
J:147601
|
| increased tumor incidence
|
J:147601
|
Igf1tm1Dlr/Igf1tm1Dlr
Tg(Alb1-cre)1Dlr/0
(involves: 129/Sv * C57BL/6J * FVB/N)
|
decreased tumor growth/size
|
J:155733
|
Igf1tm1Dlr/Igf1tm1Dlr
Tg(Serpina1e-cre/ERT)1Sykr/0
(involves: 129/Sv * C57BL/6J * FVB/N)
|
neoplasm
|
J:155733
|
Igf1rtm1.2Mhz/Igf1r+
Zfand2btm1Otin/Zfand2btm1Otin
(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:233169
|
Igf2bp2tm1Mini/Igf2bp2tm1Mini
(B6.129P2-Igf2bp2tm1Mini)
|
decreased tumor incidence
|
J:271356
|
Igh-Vtm1(Igh-Vx24)Hmb/Igh-Vtm1(Igh-Vx24)Hmb
(involves: 129/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:54380
|
| increased T cell derived lymphoma incidence
|
J:54380
|
Ightm1(Myc)Janz/Igh+
(involves: 129X1/SvJ * C57BL/6)
|
abnormal tumor morphology
|
J:160845
|
| increased B cell derived lymphoma incidence
|
J:160845,
J:96785
|
| increased plasmacytoma incidence
|
J:160845,
J:96785
|
| increased tumor incidence
|
J:160845,
J:96785
|
Ightm1(Myc)Janz/Igh+
Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:150341
|
| increased lymphoma incidence
|
J:150341
|
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)A5Wmk/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:160845
|
| increased B cell derived lymphoma incidence
|
J:160845
|
| increased plasmacytoma incidence
|
J:160845
|
| increased tumor incidence
|
J:160845
|
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)D3Wmk/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:160845
|
| increased B cell derived lymphoma incidence
|
J:160845
|
| increased plasmacytoma incidence
|
J:160845
|
| increased tumor incidence
|
J:160845
|
Ightm1(PAX5)Mbu/Igh+
(B6.Cg-Ightm1(PAX5)Mbu)
|
increased lymphoma incidence
|
J:118111
|
| increased T cell derived lymphoma incidence
|
J:118111
|
Ightm1(PAX5)Mbu/Ightm1(PAX5)Mbu
(B6.Cg-Ightm1(PAX5)Mbu)
|
increased lymphoma incidence
|
J:118111
|
| increased T cell derived lymphoma incidence
|
J:118111
|
Ightm1.1(Tag)Rwhe/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
| increased leukemia incidence
|
J:150315
|
Ightm1.1(Tag)Rwhe/Igh+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
| increased leukemia incidence
|
J:150315
|
Ightm2.1(Tag)Rwhe/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
| increased leukemia incidence
|
J:150315
|
Ightm2.1(Tag)Rwhe/Igh+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
| increased leukemia incidence
|
J:150315
|
Ighatm1(Myc)Janz/Igha+
(involves: 129S1/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:90901
|
Ighatm1(Myc)Janz/Igha+
Tg(Igk-V21-Bax)1967Bvn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased leukemia incidence
|
J:90901
|
| increased plasmacytoma incidence
|
J:90901
|
Ighatm1(Myc)Janz/Igha+
Tg(Tnfsf13b)1Fma/0
(involves: 129S1/Sv * C57BL/6 * DBA/2J)
|
increased chronic lymphocytic leukemia incidence
|
J:166158
|
Ighg1em1Wliu/Ighg1em1Wliu
(C57BL/6-Ighg1em1Wliu)
|
neoplasm
|
J:322180
|
Ighg2cem1Wliu/Ighg2cem1Wliu
(C57BL/6J-Ighg2cem1Wliu)
|
decreased incidence of induced tumors
|
J:322180
|
| decreased incidence of tumors by chemical induction
|
J:322180
|
| decreased tumor growth/size
|
J:322180
|
Ighg2cem2Wliu/Ighg2cem2Wliu
(C57BL/6J-Ighg2cem2Wliu)
|
increased tumor growth/size
|
J:322180
|
Ighmtm1(Bcl6)Rdf/?
(involves: 129/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:98937
|
Ighmtm1Cgn/Ighmtm1Cgn
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ)
|
increased lymphoma incidence
|
J:80859
|
Ighmtm1Cgn/Ighmtm1Cgn
Tg(IghMyc)22Bri/0
(involves: 129S2/SvPas * C57BL * SJL)
|
increased lymphoma incidence
|
J:187318
|
Igs2em1(Alb-Golm1)Jdon/Igs2+
(involves: C57BL/6N)
|
increased incidence of tumors by chemical induction
|
J:306528
|
Igs2tm1(CAG-Met)Zsu/Igs2+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2 * FVB/N)
|
increased carcinoma incidence
|
J:268934
|
| increased metastatic potential
|
J:268934
|
| increased prostate gland adenocarcinoma incidence
|
J:268934
|
| increased prostate gland tumor incidence
|
J:268934
|
| increased prostate intraepithelial neoplasia incidence
|
J:268934
|
Igs2tm1(CAG-Met)Zsu/Igs2+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:268934
|
Ikbkgtm1.1Chtr/Y
Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased hepatocellular carcinoma incidence
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr
Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased hepatocellular carcinoma incidence
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr
Tg(Alb1-cre)7Gsc/0
(involves: FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:160521
|
Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa
Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:118336
|
Ikzf1plstc/Ikzf1+
(C57BL/6JSfdAnu-Ikzf1plstc)
|
increased leukemia incidence
|
J:84569
|
| increased T cell derived lymphoma incidence
|
J:84569
|
Ikzf1tm1(Pax5)Mbu/Ikzf1+
Tg(Lck-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ikzf1tm1.1(Pax5)Mbu/Ikzf1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:118111
|
| increased T cell derived lymphoma incidence
|
J:118111
|
Ikzf1tm1.1Smale/Ikzf1tm1.1Smale
(B6.Cg-Ikzf1tm1.1Smale)
|
neoplasm
|
J:208211
|
Ikzf1tm1Kast/Ikzf1+
Tg(BCR/ABL)623Hkp/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:160846
|
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:29355
|
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * BALB/c)
|
increased leukemia incidence
|
J:29355
|
Ikzf1tm2.1Smale/Ikzf1tm2.1Smale
(B6.Cg-Ikzf1tm2.1Smale)
|
increased lymphoma incidence
|
J:208211
|
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu
Il7rtm1.1(icre)Hrr/Il7r+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:209928
|
Ikzf1tm3Kge/Ikzf1tm3Kge
Tg(CD2-icre)4Kio/?
(involves: C57BL/10 * CBA/Ca)
|
increased T cell derived lymphoma incidence
|
J:209927
|
Ikzf3tm1Kge/Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:50626
|
Il1atm1Yiw/Il1atm1Yiw
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal tumor vascularization
|
J:82394
|
| decreased metastatic potential
|
J:82394
|
Il1btm1Lvp/Il1btm1Lvp
(involves: 129S7/SvEvBrd)
|
abnormal tumor vascularization
|
J:82394
|
| decreased metastatic potential
|
J:59893,
J:82394
|
| decreased tumor growth/size
|
J:59893,
J:82394
|
Il1r1tm1Roml/Il1r1tm1Roml
(involves: 129S1/Sv * BALB/c)
|
decreased incidence of tumors by chemical induction
|
J:191239
|
Il2rgtm1Wjl/Il2rgtm1Wjl
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz)
|
decreased incidence of tumors by ionizing radiation induction
|
J:109833
|
Il5tm1Ktk/Il5tm1Ktk
(B6.129S4-Il5tm1Ktk)
|
increased metastatic potential
|
J:180790
|
Il5ratm1Ktk/Il5ratm1Ktk
(involves: 129P2/OlaHsd)
|
increased metastatic potential
|
J:180790
|
Il6tm1Kopf/Il6+
Ncoa5tm1Hxia/Ncoa5+
(involves: 129S2/SvPas * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:122816
|
Il6tm1Poli/Il6tm1Poli
(CAnNCrl.129S(Cg)-Il6tm1Poli)
|
decreased incidence of induced tumors
|
J:42869
|
Il6ratm1.2Jcbr/Il6ratm1.2Jcbr
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:202764
|
| decreased tumor growth/size
|
J:202764
|
Il6sttm1Ern/Il6st+
Smad3tm1Par/Smad3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased adenoma incidence
|
J:100160
|
Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6)
|
increased adenoma incidence
|
J:87206,
J:79073
|
Il6sttm1Ern/Il6sttm1Ern
Stat3tm1Aki/Stat3+
(involves: 129P2/OlaHsd * 129S1/Sv)
|
neoplasm
|
J:100160
|
Il6sttm1Ern/Il6sttm1Ern
Tg(RP11-H2112)5Trme/0
(involves: 129S1/Sv * C57BL/6J * DBA/2J)
|
decreased stomach tumor incidence
|
J:234656
|
Il6sttm1Ern/Il6sttm1Ern
Tg(RP11-H2112)9Trme/0
(involves: 129S1/Sv * C57BL/6J * DBA/2J)
|
decreased stomach tumor incidence
|
J:234656
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by UV induction
|
J:125760
|
| decreased tumor incidence
|
J:125760
|
| increased intestinal adenocarcinoma incidence
|
J:68476
|
| increased large intestine adenocarcinoma incidence
|
J:35020
|
Il10tm1Cgn/Il10tm1Cgn
(B6.129P2-Il10tm1Cgn/J)
|
increased colon adenocarcinoma incidence
|
J:149347
|
Il10tm1Cgn/Il10tm1Cgn
Tg(MUC1)79.24Gend/0
(B6.Cg-Il10tm1Cgn Tg(MUC1)79.24Gend)
|
increased colon adenocarcinoma incidence
|
J:149347
|
Il12atm1Jm/Il12atm1Jm
(B6.129S1-Il12atm1Jm/J)
|
increased incidence of tumors by chemical induction
|
J:111568
|
Il12btm1Jm/Il12btm1Jm
(B6.129S1-Il12btm1Jm/J)
|
decreased incidence of tumors by chemical induction
|
J:111568
|
Il12rb2tm1Jm/Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
|
abnormal tumor morphology
|
J:120061
|
| abnormal tumor vascularization
|
J:120061
|
| decreased tumor growth/size
|
J:120061
|
| increased lung carcinoma incidence
|
J:106805
|
| increased plasmacytoma incidence
|
J:106805
|
Il22tm1Flv/Il22tm1Flv
(involves: 129/Sv * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:189217
|
Il22tm1Flv/Il22tm1Flv
Il22ra2tm2Vlcg/Il22ra2tm2Vlcg
(involves: 129 * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased incidence of tumors by chemical induction
|
J:189217
|
Il22ra2tm2Vlcg/Il22ra2tm2Vlcg
(B6.Cg-Il22ra2tm2Vlcg)
|
decreased tumor latency
|
J:189217
|
| increased incidence of tumors by chemical induction
|
J:189217
|
| increased tumor growth/size
|
J:189217
|
Il23atm1Dnax/Il23atm1Dnax
(B6.Cg-Il23atm1Dnax)
|
decreased incidence of tumors by chemical induction
|
J:111568
|
Immp2lTg(HLA-A/H2-D)2Enge/0
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * CBA/Ca)
|
increased eye tumor incidence
|
J:130879
|
| increased melanoma incidence
|
J:130879
|
| increased metastatic potential
|
J:130879
|
| increased organ/body region tumor incidence
|
J:130879
|
| increased tumor incidence
|
J:130879
|
Ing1Gt(OST206270)Lex/Ing1+
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:118602
|
Ing1Gt(OST206270)Lex/Ing1Gt(OST206270)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:118602
|
Ing1tm1Avg/Ing1tm1Avg
(involves: 129S1/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:105658
|
Ing2tm1.1Ccha/Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N)
|
increased Harderian gland adenoma incidence
|
J:167311
|
| increased histiocytic sarcoma incidence
|
J:167311
|
| increased sarcoma incidence
|
J:167311
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:125349,
J:20450
|
| increased gonad tumor incidence
|
J:3315
|
| increased ovary tumor incidence
|
J:125349,
J:3315
|
| increased testis tumor incidence
|
J:125349
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
| increased testis tumor incidence
|
J:84989
|
Inhatm1Bay/Inhatm1Bay
Smad3tm1Par/Smad3+
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:125349
|
| increased ovary tumor incidence
|
J:125349
|
Inhatm1Bay/Inhatm1Bay
Smad3tm1Par/Smad3tm1Par
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
|
increased ovary tumor incidence
|
J:125349
|
Ino80tm1.1Schg/Ino80+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
decreased lymphoma incidence
|
J:221224
|
| increased sarcoma incidence
|
J:221224
|
| increased T cell derived lymphoma incidence
|
J:221224
|
Ino80tm1Schg/Ino80tm1Schg
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * CBA)
|
neoplasm
|
J:221224
|
Inpp5dm1Anu/Inpp5dm1Anu
(C57BL/6JAnu-Inpp5dm1Anu)
|
increased B cell derived lymphoma incidence
|
J:104190
|
Inpp5jtm1.1Cmit/Inpp5jtm1.1Cmit
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6)
|
abnormal tumor pathology
|
J:224914
|
| decreased metastatic potential
|
J:224914
|
| increased mammary gland tumor incidence
|
J:224914
|
| increased tumor growth/size
|
J:224914
|
Ints15em1Takas/Ints15em1Takas
(involves: C57BL/6 * DBA/2)
|
increased retina hemangioma incidence
|
J:337973
|
Ints15em2Takas/Ints15+
(involves: C57BL/6 * DBA/2)
|
increased retina hemangioma incidence
|
J:337973
|
Ip6k2tm1Dlin/Ip6k2tm1Dlin
(involves: 129X1/SvJ * Black Swiss * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:151345
|
Iqgap1tm1Aber/Iqgap1tm1Aber
Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae)
|
decreased tumor growth/size
|
J:132670
|
| increased hepatocellular carcinoma incidence
|
J:132670
|
Iqgap2tm1Vs/Iqgap2tm1Vs
(either: 129S4/SvJae-Iqgap2tm1Vs or B6.129S4-Iqgap2tm1Vs)
|
increased hemangioma incidence
|
J:132670
|
| increased hepatocellular carcinoma incidence
|
J:132670
|
Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae)
|
increased hepatocellular carcinoma incidence
|
J:205882
|
Irf1tm1Mak/Irf1tm1Mak
(B6.129S2-Irf1tm1Mak/J)
|
increased incidence of tumors by chemical induction
|
J:91927
|
| increased lymphoma incidence
|
J:91927
|
Irf1tm1Mak/Irf1tm1Mak
Tg(HRAS)2Jic/?
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:55418
|
| increased tumor incidence
|
J:55418
|
Irf1tm1Mak/Irf1tm1Mak
Trp53tm1Sia/Trp53tm1Sia
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased hemangiosarcoma incidence
|
J:55418
|
| increased lymphoma incidence
|
J:55418
|
| increased teratoma incidence
|
J:55418
|
| increased tumor incidence
|
J:55418
|
Irf4tm1Mak/Irf4tm1Mak
(involves: 129P2/OlaHsd)
|
abnormal tumor susceptibility
|
J:42683
|
Irf8myls/Irf8myls
Slc11a1r/Slc11a1r
(BXH2/TyJ)
|
increased chronic myelocytic leukemia incidence
|
J:97931
|
Irf8myls/Irf8myls
Slc11a1r/Slc11a1r
(involves: A/J * BXH2/TyJ)
|
increased chronic myelocytic leukemia incidence
|
J:97931
|
Irf8tm1Hor/Irf8+
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
increased chronic myelocytic leukemia incidence
|
J:36038
|
Irf8tm1Hor/Irf8tm1Hor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
increased chronic myelocytic leukemia incidence
|
J:36038
|
| increased lymphoma incidence
|
J:36038
|
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
| increased leukemia incidence
|
J:156946
|
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:179879
|
| increased lymphoma incidence
|
J:179879
|
| increased small lymphocytic lymphoma incidence
|
J:179879
|
Is(14)1Rdf/Is(14)1Rdf
Is(14)5Rdf/Is(14)5Rdf
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:179879
|
| increased lymphoma incidence
|
J:179879
|
| increased small lymphocytic lymphoma incidence
|
J:179879
|
Itga6tm2Egl/Itga6tm2Egl
Tg(Tie1-cre)9Ref/0
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal tumor vascularization
|
J:156496
|
| increased tumor growth/size
|
J:156496
|
Itgaltm1Wpfl/Itgaltm1Wpfl
(involves: 129)
|
increased metastatic potential
|
J:37160
|
Itgavtm2Hyn/Itgavtm2.1Hyn
Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:125508
|
Itgb1tm1Mll/Itgb1tm1Mll
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)634Mul/0
(involves: 129X1/SvJ * FVB/N)
|
decreased mammary gland tumor incidence
|
J:92547
|
Itgb1tm1Ref/Itgb1tm1Ref
Tg(Ins2-cre)1Heed/?
Tg(RIP1-Tag)2Dh/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6J * CBA * DBA/2J)
|
abnormal tumor susceptibility
|
J:122649
|
| decreased metastatic potential
|
J:122649
|
Itgb1tm1Ref/Itgb1tm1Ref
Tg(RIP1-Tag)2Dh/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)
|
abnormal tumor morphology
|
J:122649
|
Itgb1tm4Ref/Itgb1tm4Ref
Tg(Ins2-cre)1Heed/?
Tg(RIP1-Tag)2Dh/?
(involves: C57BL/6 * C57BL/6J * CBA * DBA/2J)
|
abnormal tumor susceptibility
|
J:122649
|
Itgb1tm9.1Ref/Itgb1tm9.1Ref
(involves: 129S1/Sv * 129X1/SvJ)
|
neoplasm
|
J:176453
|
Itgb1tm9.1Ref/Itgb1tm10.1Ref
(involves: 129S1/Sv * 129X1/SvJ)
|
neoplasm
|
J:176453
|
Itgb1tm11.1Ref/Itgb1tm11.1Ref
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased incidence of tumors by chemical induction
|
J:176453
|
Itgb1tm11.1Ref/Itgb1tm11.1Ref
Tg(KRT5-SRC)CJdg/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
neoplasm
|
J:176453
|
Itgb3tm1Hyn/Itgb3tm1.1Wlbcr
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
abnormal tumor pathology
|
J:224675
|
| abnormal tumor susceptibility
|
J:224675
|
Itgb3tm1Hyn/Itgb3tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor vascularization
|
J:73752
|
| increased tumor growth/size
|
J:73752
|
Itgb3tm1Hyn/Itgb3tm1Hyn
Itgb5tm1Des/Itgb5tm1Des
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
abnormal tumor vascularization
|
J:73752
|
| increased tumor growth/size
|
J:73752
|
Itgb3bptm1.1Tfw/Itgb3bptm1.1Tfw
(involves: C57BL/6J)
|
abnormal incidence of induced tumors
|
J:271187
|
| abnormal tumor pathology
|
J:271187
|
| tumor regression
|
J:271187
|
Itih4tm1Mish/Itih4tm1Mish
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac * C57BL/6 * NIH Black Swiss)
|
decreased liver tumor incidence
|
J:132133
|
Jak2tm1(JAK2)Argr/Jak2+
Dppa3tm1(cre)Peli/Dppa3+
(involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:233169
|
Jak2tm1.2Ble/Jak2+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased hemolymphoid system tumor incidence
|
J:160883
|
Jam3tm1.1Chav/Jam3tm1.1Chav
Tg(Tal1-cre/ERT)1Jrg/?
(involves: 129 * C57BL/6)
|
decreased metastatic potential
|
J:173391
|
Jam3tm1.1Chav/Jam3tm1.2Chav
Tg(Cdh5-cre)7Mlia/?
(involves: 129 * C57BL/6 * FVB/N)
|
decreased metastatic potential
|
J:173391
|
Jam3tm1.2Chav/Jam3tm1.2Chav
(B6.129-Jam3tm1.2Chav)
|
decreased metastatic potential
|
J:173391
|
Jcadtm1Kih/Jcadtm1Kih
(involves: C57BL/6)
|
abnormal tumor vascularization
|
J:247469
|
| decreased tumor growth/size
|
J:247469
|
Junbtm3Wag/Junbtm3Wag
Meox2tm1(cre)Sor/Meox2+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:88126
|
Kars1Gt(AJ0130)Wtsi/Kars1+
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * FVB/N)
|
decreased metastatic potential
|
J:264950
|
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:125164
|
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
(involves: 129 * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:125164
|
Kat5tm1Jwl/Kat5+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased tumor incidence
|
J:125164
|
Kcmf1Gt(XE080)Byg/Kcmf1Gt(XE080)Byg
Tg(Mt1-Tgfa)149Bri/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)
|
decreased tumor incidence
|
J:162125
|
Kcne2tm1a(EUCOMM)Wtsi/Kcne2tm1a(EUCOMM)Wtsi
(C57BL/6N-Kcne2tm1a(EUCOMM)Wtsi)
|
increased adenoma incidence
|
J:230226
|
Kdm4cGt(897)Tgen/Kdm4c+
(B6.Cg-Kdm4cGt(897)Tgen)
|
decreased incidence of tumors by chemical induction
|
J:227280
|
Kdm5atm1.1Kael/Kdm5a+
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
| increased thyroid tumor incidence
|
J:175625
|
Kdm5atm1.1Kael/Kdm5atm1.1Kael
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
| increased thyroid tumor incidence
|
J:175625
|
Kdm5atm1Kael/Kdm5atm1Kael
Men1tm2.1Mmey/Men1tm2.1Mmey
Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
|
increased insulinoma incidence
|
J:175625
|
Kdm6atm1Cdcn/Y
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:263565
|
Kdm6atm1Cdcn/Y
Tg(CAG-cre/Esr1*)5Amc/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J * CBA * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:263565
|
Kdm6atm1Cdcn/Kdm6atm1Cdcn
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:263565
|
Khdrbs1tm1Rchd/Khdrbs1tm1Rchd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:115775
|
Kif15em1Lium/Kif15em1Lium
(C57BL/6-Kif15em1Lium)
|
decreased tumor growth/size
|
J:336767
|
Kifbptm1a(KOMP)Wtsi/Kifbptm1a(KOMP)Wtsi
(C57BL/6N-Kifbptm1a(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Kittm1Bpr/Kit+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased gastrointestinal stromal tumor incidence
|
J:100778
|
Kittm1Bpr/Kittm1Bpr
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased gastrointestinal stromal tumor incidence
|
J:100778
|
Kittm1Shta/Kit+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased gastrointestinal stromal tumor incidence
|
J:130890
|
Kittm1Shta/Kittm1Shta
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased gastrointestinal stromal tumor incidence
|
J:130890
|
Kittm2Bsm/Kit+
(involves: 129X1/SvJ * C57BL/6J)
|
increased gastrointestinal stromal tumor incidence
|
J:83616
|
Kittm4.1Bsm/Kit+
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
decreased tumor growth/size
|
J:188434
|
| increased gastrointestinal tumor incidence
|
J:188434
|
Kittm5.1Bsm/Kit+
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:188434
|
| increased tumor growth/size
|
J:188434
|
KitW-v/Kit+
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
decreased tumor incidence
|
J:88074
|
| increased melanoma incidence
|
J:88074
|
KitW-v/KitW-v
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
decreased tumor incidence
|
J:88074
|
| increased melanoma incidence
|
J:88074
|
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased ovary tumor incidence
|
J:236161
|
KitW/KitW-v
(involves: C57BL/6 * WB)
|
increased esophageal papilloma incidence
|
J:6393
|
| increased papilloma incidence
|
J:6393
|
KitlSl-17H/KitlSl-17H
(C3H/HeH-KitlSl-17H)
|
increased adenoma incidence
|
J:2880
|
KitlSl-d/KitlSl-d
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * DBA/2)
|
decreased tumor incidence
|
J:88074
|
| increased melanoma incidence
|
J:88074
|
KitlSl-J/Kitl+
(involves: 129)
|
increased testicular teratoma incidence
|
J:50508
|
KitlSl/Kitl+
(involves: 129/Sv * C3H)
|
increased testicular teratoma incidence
|
J:50508
|
| increased tumor incidence
|
J:50508
|
KitlSl/KitlSl-d
(involves: C57BL/6 * WC)
|
abnormal tumor incidence
|
J:5758
|
| increased leukemia incidence
|
J:5758
|
| increased papilloma incidence
|
J:2777
|
Klf4tm1Khk/Klf4tm1Khk
Tg(Foxa3-cre)1Khk/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
preneoplasia
|
J:97350
|
Klf4tm1Khk/Klf4tm1Khk
Tg(Klf4-cre/ERT)1Wai/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
increased incidence of tumors by chemical induction
|
J:189337
|
Klf5tm1.1Jtd/Klf5+
Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:206639
|
Klf5tm1.1Jtd/Klf5tm1.1Jtd
Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:206639
|
Klf10tm1Wkle/Klf10tm1Wkle
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased tumor latency
|
J:182595
|
| increased incidence of tumors by chemical induction
|
J:182595
|
| increased papilloma incidence
|
J:182595
|
| increased tumor growth/size
|
J:182595
|
Klf11tm1Czs/Klf11tm1Czs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:94499
|
Klf14em1Cgw/Klf14em1Cgw
(C57BL/6J-Klf14em1Cgw)
|
increased incidence of tumors by chemical induction
|
J:227200
|
| increased lung adenoma incidence
|
J:227200
|
| increased lymphoma incidence
|
J:227200
|
| increased tumor incidence
|
J:227200
|
Klhl22em1Cya/Klhl22em1Cya
(C57BL/6N-Klhl22em1Cya/Cya)
|
abnormal tumor pathology
|
J:297538
|
| increased tumor growth/size
|
J:297538
|
Klk6tm1Gsot/Klk6+
(involves: C57BL/6)
|
decreased incidence of induced tumors
|
J:270051
|
| decreased incidence of tumors by chemical induction
|
J:270051
|
Klk6tm1Gsot/Klk6tm1Gsot
(involves: C57BL/6)
|
decreased incidence of induced tumors
|
J:270051
|
| decreased incidence of tumors by chemical induction
|
J:270051
|
Klrb1btm1.1Apma/Klrb1btm1.1Apma
Tg(IghMyc)22Bri/0
(involves: BALB/c * C57BL * C57BL/6 * SJL)
|
decreased tumor latency
|
J:222057
|
Klrk1tm1Dhr/Klrk1tm1Dhr
Tg(IghMyc)22Bri/?
(involves: C57BL/6 * CD-1)
|
increased B cell derived lymphoma incidence
|
J:134509
|
Klrk1tm1Dhr/Klrk1tm1Dhr
Tg(TRAMP)8247Ng/?
(involves: C57BL/6 * CD-1)
|
increased prostate gland tumor incidence
|
J:134509
|
Kmt2atm1(AFF1)Ksy/Kmt2a+
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased B cell derived lymphoma incidence
|
J:110241
|
| increased leukemia incidence
|
J:110241
|
| increased malignant tumor incidence
|
J:110241
|
| increased spleen neoplasm incidence
|
J:110241
|
Kmt2atm1(MLL1/ERT)Divo/?
(involves: 129S4/SvJae * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:189329
|
Kmt2atm1.1(Sh3gl1)Lcc/Kmt2a+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased leukemia incidence
|
J:205605
|
Kmt2atm1Clgr/Kmt2a+
(B6.129-Kmt2atm1Clgr)
|
neoplasm
|
J:115001
|
Kmt2atm1Saam/Kmt2a+
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:140628
|
Kmt2atm1Thr/Kmt2a+
Mllt1tm1Thr/Mllt1+
Tg(Lck-cre)1Thr/?
(involves: 129S/SvEv)
|
neoplasm
|
J:100794
|
Kmt2atm1Thr/Kmt2a+
Mllt3tm2Thr/Mllt3+
Tg(Lck-cre)1Thr/?
(involves: 129S/SvEv)
|
increased hemolymphoid system tumor incidence
|
J:100794
|
| increased leukemia incidence
|
J:100794
|
| increased T cell derived lymphoma incidence
|
J:100794
|
Kmt2atm2(MLLT3)Thr/Kmt2a+
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:56340
|
Kmt2atm2(MLLT3)Thr/Kmt2atm2(MLLT3)Thr
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased B cell derived lymphoma incidence
|
J:110241
|
| increased hemolymphoid system tumor incidence
|
J:110241
|
| increased leukemia incidence
|
J:110241
|
Kmt2atm2Sjk/Kmt2a+
Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased incidence of induced tumors
|
J:95914
|
Kmt2dtm1.1Kaig/Kmt2d+
Ighg1tm1(cre)Cgn/Ighg1+
Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:228913
|
| increased follicular lymphoma incidence
|
J:228913
|
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig
Ighg1tm1(cre)Cgn/Ighg1+
Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:228913
|
| increased follicular lymphoma incidence
|
J:228913
|
Krasa/Krasa
(multiple strains)
|
increased lung adenoma incidence
|
J:17778,
J:17850
|
Krasb/Krasb
(multiple strains)
|
decreased lung tumor incidence
|
J:17778,
J:17850
|
Krastm1.1Hbji/Krastm1.1Hbji
Trp53tm5Tyj/Trp53tm5Tyj
(involves: 129S4/SvJae)
|
increased lung adenoma incidence
|
J:220921
|
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
neoplasm
|
J:276349
|
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
Map2k2tm1Chrn/Map2k2tm1Chrn
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL)
|
decreased classified tumor incidence
|
J:172200
|
Krastm1Bbd/Kras+
Map2k2tm1Chrn/Map2k2tm1Chrn
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ)
|
decreased classified tumor incidence
|
J:172200
|
Krastm1Bbd/Kras+
Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
abnormal tumor incidence
|
J:122397
|
| increased lung adenocarcinoma incidence
|
J:122397
|
| increased lung adenoma incidence
|
J:122397
|
| increased lung tumor incidence
|
J:122397
|
Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased hemolymphoid system tumor incidence
|
J:122397
|
| increased lung adenoma incidence
|
J:122397
|
| increased lung tumor incidence
|
J:122397
|
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased adenoma incidence
|
J:161780
|
| increased lung non-small cell carcinoma incidence
|
J:161780
|
Krastm1Bbd/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
decreased classified tumor incidence
|
J:172200
|
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:86101
|
| increased lung adenoma incidence
|
J:86101
|
| increased papilloma incidence
|
J:86101
|
| increased sarcoma incidence
|
J:86101
|
Krastm1Bbd/Kras+
Tg(CMV-cre/ERT)1Ipc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased lung adenocarcinoma incidence
|
J:86101
|
| increased lung adenoma incidence
|
J:86101
|
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034
|
| increased prostate intraepithelial neoplasia incidence
|
J:143034
|
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N)
|
increased metastatic potential
|
J:119988
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm1Bbd/Krastm1Bbd
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
| increased tumor latency
|
J:119988
|
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
| increased lung tumor incidence
|
J:161780
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:68981
|
| increased lung adenoma incidence
|
J:68981
|
| increased lung tumor incidence
|
J:68981
|
| increased skin papilloma incidence
|
J:68981
|
| increased T cell derived lymphoma incidence
|
J:68981
|
| increased tumor incidence
|
J:68981
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas)
|
increased carcinoma incidence
|
J:129627
|
| increased fibrosarcoma incidence
|
J:129627
|
| increased hemangiosarcoma incidence
|
J:129627
|
| increased lung adenocarcinoma incidence
|
J:136369
|
| increased lymphoma incidence
|
J:129627
|
| increased mesothelioma incidence
|
J:129627
|
| increased papilloma incidence
|
J:129627
|
| increased sarcoma incidence
|
J:129627
|
| increased skin papilloma incidence
|
J:68981
|
| increased squamous cell carcinoma incidence
|
J:129627
|
| increased T cell derived lymphoma incidence
|
J:68981
|
| increased tumor incidence
|
J:129627
|
Krastm2Tyj/Kras+
Trp53tm1Glo/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
abnormal tumor morphology
|
J:129627
|
| increased fibrosarcoma incidence
|
J:129627
|
| increased hemangiosarcoma incidence
|
J:129627
|
| increased lung adenoma incidence
|
J:129627
|
| increased lymphoma incidence
|
J:129627
|
| increased mesothelioma incidence
|
J:129627
|
| increased metastatic potential
|
J:129627
|
| increased papilloma incidence
|
J:129627
|
| increased squamous cell carcinoma incidence
|
J:129627
|
| increased tumor incidence
|
J:129627
|
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased fibrosarcoma incidence
|
J:68981
|
| increased hemangiosarcoma incidence
|
J:68981
|
| increased skin papilloma incidence
|
J:68981
|
| increased T cell derived lymphoma incidence
|
J:68981
|
| increased tumor incidence
|
J:68981
|
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased fibrosarcoma incidence
|
J:68981
|
| increased hemangiosarcoma incidence
|
J:68981
|
| increased skin papilloma incidence
|
J:68981
|
| increased T cell derived lymphoma incidence
|
J:68981
|
| increased tumor incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:68981
|
| increased lung adenoma incidence
|
J:68981
|
| increased lung tumor incidence
|
J:68981
|
| increased skin papilloma incidence
|
J:68981
|
| increased T cell derived lymphoma incidence
|
J:68981
|
| increased tumor incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:119477
|
| increased skin papilloma incidence
|
J:68981
|
| increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+
Mir21atm1.1Eno/Mir21atm1.1Eno
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
decreased lung tumor incidence
|
J:164198
|
| decreased tumor growth/size
|
J:164198
|
| decreased tumor incidence
|
J:164198
|
| increased lung adenoma incidence
|
J:164198
|
| increased T cell derived lymphoma incidence
|
J:164198
|
| neoplasm
|
J:164198
|
Krastm3Tyj/Kras+
Pik3catm1Jdo/Pik3catm1Jdo
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)
|
decreased incidence of induced tumors
|
J:122866
|
| decreased lung tumor incidence
|
J:122866
|
Krastm3Tyj/Kras+
Tg(CAG-Mir21,-EGFP)#Eno/0
(involves: 129S4/SvJae * C3H * C57BL/6)
|
decreased tumor incidence
|
J:164198
|
| increased lung non-small cell carcinoma incidence
|
J:164198
|
| increased lung tumor incidence
|
J:164198
|
| increased tumor growth/size
|
J:164198
|
Krastm3Tyj/Krastm3Tyj
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:237900
|
| increased skin papilloma incidence
|
J:237900
|
| increased T cell derived lymphoma incidence
|
J:237900
|
Krastm3Tyj/Krastm3Tyj
Mir301tm1Yoli/Mir301tm1Yoli
(involves: 129S4/SvJae * C57BL/6J)
|
decreased lung tumor incidence
|
J:237900
|
| decreased lymphoma incidence
|
J:237900
|
| decreased skin tumor incidence
|
J:237900
|
| decreased tumor growth/size
|
J:237900
|
| decreased tumor incidence
|
J:237900
|
Krastm4.1Tyj/Kras+
Spry2tm1Mrt/Spry2tm1Mrt
(involves: 129P2/OlaHsd)
|
increased lung tumor incidence
|
J:119477
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:207982,
J:333347
|
| increased lung adenoma incidence
|
J:207982,
J:333347
|
| increased lung tumor incidence
|
J:119477,
J:216266,
J:299900
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
abnormal tumor morphology
|
J:147590
|
| decreased tumor growth/size
|
J:147590
|
| increased lung adenocarcinoma incidence
|
J:147590
|
| increased lung adenoma incidence
|
J:158937
|
| increased lung carcinoma incidence
|
J:158937
|
| increased lung tumor incidence
|
J:158937,
J:147590
|
Krastm4Tyj/Kras+
(B6.129S4-Krastm4Tyj)
|
increased lung adenocarcinoma incidence
|
J:177379
|
| increased lung adenoma incidence
|
J:177379
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:203686
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Pdx1-cre)6Tuv/0
TgTn(sb-T2/Onc)#Dla/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased pancreas tumor incidence
|
J:186717
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:186717
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm3(CAG-luc)Tyj/Gt(ROSA)26Sor+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:141383
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Flt3-cre)#Ccb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:247853
|
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased lip tumor incidence
|
J:172048
|
| increased skin papilloma incidence
|
J:172048
|
| increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:254370
|
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung tumor incidence
|
J:158937
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
(B6.Cg-Krastm4Tyj Map2k7tm1.1Twad/Map2k7tm1.2Twad)
|
increased lung adenocarcinoma incidence
|
J:170904
|
| increased lung tumor incidence
|
J:170904
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Tg(Trp53)bSrn/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
neoplasm
|
J:170904
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:170904
|
| increased lung tumor incidence
|
J:170904
|
Krastm4Tyj/Kras+
Mapk8tm1Wag/Mapk8+
Mapk9tm1Mka/Mapk9tm1Mka
(involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:170904
|
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:203686
|
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:203686
|
Krastm4Tyj/Kras+
Myod1tm1.1(cre/ERT,TVA)Gcg/Myod1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:205518
|
| increased tumor incidence
|
J:205518
|
Krastm4Tyj/Kras+
Pax7tm2.1(cre/ERT2)Fan/Pax7+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129/Sv * 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:205518
|
| increased tumor incidence
|
J:205518
|
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae)
|
neoplasm
|
J:197054
|
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased lung non-small cell carcinoma incidence
|
J:197054
|
| neoplasm
|
J:197054
|
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1b+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:122107
|
| increased lung adenoma incidence
|
J:122107
|
| increased lung tumor incidence
|
J:122107
|
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased lung adenoma incidence
|
J:122107
|
| increased lung tumor incidence
|
J:122107
|
Krastm4Tyj/Kras+
Pik3r1tm1Lca/Pik3r1+
Pik3r2tm1Lca/Pik3r2tm1Lca
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased lung tumor incidence
|
J:142254
|
Krastm4Tyj/Kras+
Pik3r1tm1Lca/Pik3r1tm1Lca
Pik3r2tm1Lca/Pik3r2tm1Lca
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
decreased lung tumor incidence
|
J:142254
|
Krastm4Tyj/Kras+
Pik3r2tm1Lca/Pik3r2tm1Lca
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased lung tumor incidence
|
J:142254
|
Krastm4Tyj/Kras+
Plcl1tm1.1Matk/Plcl1tm1.1Matk
(involves: 129S4/SvJae * C57BL/6)
|
increased tumor incidence
|
J:207384
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Gfap-cre)77.6Mvs/0
(involves: 129S4/SvJae * BALB/c * C57BL/6NHsd)
|
increased classified tumor incidence
|
J:154673
|
| increased neurofibroma incidence
|
J:154673
|
| increased neurofibrosarcoma incidence
|
J:154673
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:184935
|
| increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased pancreas tumor incidence
|
J:164210
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:164210
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * FVB/N)
|
increased skin papilloma incidence
|
J:174242
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6J)
|
increased endometrial carcinoma incidence
|
J:96296
|
| increased metastatic potential
|
J:96296
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased ovary tumor incidence
|
J:161953
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased lung adenocarcinoma incidence
|
J:131721
|
| increased lung adenoma incidence
|
J:131721
|
| increased lung carcinoma incidence
|
J:131721
|
| increased lung tumor incidence
|
J:131721
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:184935
|
| increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:164210
|
Krastm4Tyj/Kras+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp)
|
increased metastatic potential
|
J:147732
|
| increased thyroid carcinoma incidence
|
J:147732
|
Krastm4Tyj/Kras+
Ptentm2Mak/Pten+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:254370
|
| increased hepatocellular carcinoma incidence
|
J:254370
|
| increased liver tumor incidence
|
J:254370
|
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:254370
|
| increased liver tumor incidence
|
J:254370
|
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
Ube2ftm1c(EUCOMM)Hmgu/Ube2ftm1c(EUCOMM)Hmgu
(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
|
decreased tumor incidence
|
J:348744
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:87973
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:262746
|
| increased tumor incidence
|
J:87973
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(B6.129(Cg)-Krastm4Tyj Ptf1atm1.1(cre)Cvw)
|
increased metastatic potential
|
J:138959
|
| increased pancreas tumor incidence
|
J:138959
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:138959
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(MUC1)79.24Gend/0
(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend)
|
decreased metastatic potential
|
J:138959
|
| increased pancreas tumor incidence
|
J:138959,
J:234412
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:138959,
J:234412
|
Krastm4Tyj/Kras+
Rab11fip1tm1.1Jicn/Rab11fip1tm1.1Jicn
Tg(Pdx1-cre)6Tuv/0
Trp53tm2.1Tyj/Trp53+
(involves: 129S4/SvJae * FVB/N)
|
decreased metastatic potential
|
J:244261
|
| neoplasm
|
J:244261
|
Krastm4Tyj/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+
Ralatm1.2Cjm/Ralatm1.2Cjm
Ralbtm1.1Cjm/Ralbtm1.2Cjm
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
decreased tumor growth/size
|
J:199742
|
Krastm4Tyj/Kras+
Rb1tm3Tyj/Rb1tm3Tyj
(involves: 129S4/SvJae)
|
abnormal tumor morphology
|
J:147590
|
| increased lung adenocarcinoma incidence
|
J:147590
|
| increased lung tumor incidence
|
J:147590
|
Krastm4Tyj/Kras+
Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129S4/SvJae)
|
abnormal tumor morphology
|
J:147590
|
| increased lung adenocarcinoma incidence
|
J:147590
|
| increased lung tumor incidence
|
J:147590
|
| increased tumor growth/size
|
J:147590
|
Krastm4Tyj/Kras+
Rnf7Gt(XE423)Byg/Rnf7+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:207982
|
| increased lung adenoma incidence
|
J:207982
|
Krastm4Tyj/Kras+
Rnf7Gt(XE423)Byg/Rnf7tm1.1Ysun
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
decreased lung tumor incidence
|
J:207982
|
Krastm4Tyj/Kras+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
|
increased adenocarcinoma incidence
|
J:182218
|
| increased lung adenoma incidence
|
J:182218
|
Krastm4Tyj/Kras+
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased lung adenoma incidence
|
J:131721
|
| increased lung tumor incidence
|
J:131721
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scrib+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:216266
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scrib+
Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
| increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scribtm1.1Phum
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:216266
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scribtm1.1Phum
Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased carcinoma incidence
|
J:178461
|
| increased prostate gland adenocarcinoma incidence
|
J:178461
|
| increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+
Sftpctm1(cre/ERT2)Blh/Sftpc+
Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
|
increased adenocarcinoma incidence
|
J:182218
|
| increased lung adenoma incidence
|
J:182218
|
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased lung adenoma incidence
|
J:195738
|
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased lung adenocarcinoma incidence
|
J:195738
|
| increased lung adenoma incidence
|
J:195738
|
Krastm4Tyj/Kras+
Siva1tm1.1Att/Siva1tm1.2Att
(involves: 129S4/SvJae * C57BL/6)
|
abnormal lung adenoma incidence
|
J:223572
|
| decreased lung tumor incidence
|
J:223572
|
Krastm4Tyj/Kras+
Siva1tm1.2Att/Siva1+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal lung adenoma incidence
|
J:223572
|
| decreased lung tumor incidence
|
J:223572
|
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
| increased tumor incidence
|
J:116130
|
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased stomach tumor incidence
|
J:116130
|
| increased tumor incidence
|
J:116130
|
Krastm4Tyj/Kras+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J)
|
increased adenoma incidence
|
J:203922
|
| increased metastatic potential
|
J:203922
|
| increased papilloma incidence
|
J:203922
|
| increased skin squamous cell carcinoma incidence
|
J:203922
|
| increased skin tumor incidence
|
J:203922
|
| increased trichoepithelioma incidence
|
J:203922
|
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
| increased liver tumor incidence
|
J:254370
|
Krastm4Tyj/Kras+
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
| increased lung large cell carcinoma incidence
|
J:124682
|
| increased lung squamous cell carcinoma incidence
|
J:124682
|
| increased lung tumor incidence
|
J:124682
|
| increased metastatic potential
|
J:124682
|
Krastm4Tyj/Kras+
Stk11tm1.1Rdp/Stk11tm1.2Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
| increased lung large cell carcinoma incidence
|
J:124682
|
| increased lung squamous cell carcinoma incidence
|
J:124682
|
| increased lung tumor incidence
|
J:124682
|
| increased metastatic potential
|
J:124682
|
Krastm4Tyj/Kras+
Tg(CAG-Bgeo,-tsA58T)T26Ichi/0
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:214846
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:214846
|
Krastm4Tyj/Kras+
Tg(CAG-HPV16E6E7,-luc)#Mspi/0
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N * FVB/NJ)
|
increased oral papilloma incidence
|
J:210533
|
Krastm4Tyj/Kras+
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased lung non-small cell carcinoma incidence
|
J:197054
|
| increased pancreas tumor incidence
|
J:197054
|
Krastm4Tyj/Kras+
Tg(Erbb2*)#Maed/0
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:262746
|
Krastm4Tyj/Kras+
Tg(Gfap-cre)77.6Mvs/0
(involves: 129 * BALB/c * C57BL/6NHsd)
|
neoplasm
|
J:154673
|
Krastm4Tyj/Kras+
Tg(IVL-cre/ERT2)1Blpn/0
(involves: 129S4/SvJae * C57BL/6)
|
increased facial tumor incidence
|
J:172048
|
| increased lip tumor incidence
|
J:172048
|
| increased skin papilloma incidence
|
J:172048
|
| increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased facial tumor incidence
|
J:172048
|
| increased lip tumor incidence
|
J:172048
|
| increased skin papilloma incidence
|
J:172048
|
| increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL/J)
|
increased papilloma incidence
|
J:203922
|
Krastm4Tyj/Kras+
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * C57BL/6 * FVB * ICR)
|
increased skin papilloma incidence
|
J:124222
|
Krastm4Tyj/Kras+
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased mouth tumor incidence
|
J:210533
|
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased esophageal papilloma incidence
|
J:88163
|
| increased lung adenoma incidence
|
J:88163
|
| increased lymphoblastic lymphoma incidence
|
J:88163
|
| increased oral papilloma incidence
|
J:88163
|
| increased papilloma incidence
|
J:88163
|
| increased skin papilloma incidence
|
J:88163
|
Krastm4Tyj/Kras+
Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/?
(involves: 129S4/SvJae * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:87973
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:276349,
J:214846,
J:98936
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:220300
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Y
(involves: 129S4/SvJae * FVB/N)
|
increased oral papilloma incidence
|
J:186717
|
| increased pancreas tumor incidence
|
J:186717
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
| increased skin papilloma incidence
|
J:186717
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Usp9x+
(involves: 129S4/SvJae * FVB/N)
|
increased oral papilloma incidence
|
J:186717
|
| increased pancreas tumor incidence
|
J:186717
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
| increased skin papilloma incidence
|
J:186717
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:164210
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:87196,
J:164210
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
Krastm4Tyj/Kras+
Tg(Scgb1a1-cre)1Kkw/?
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:107260
|
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129S4/SvJae * FVB)
|
increased melanoma incidence
|
J:164588
|
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * FVB/N)
|
neoplasm
|
J:234236,
J:174242
|
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:116129
|
| increased pancreas tumor incidence
|
J:116129
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
(B6.129-Krastm4Tyj Tgfbr2tm1.2Hlm)
|
increased lung adenocarcinoma incidence
|
J:177379
|
| increased metastatic potential
|
J:177379
|
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:116129
|
| increased pancreas tumor incidence
|
J:116129
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung adenoma incidence
|
J:103407
|
| increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
| increased hamartoma incidence
|
J:184949
|
| increased metastatic potential
|
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR)
|
increased carcinoma incidence
|
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased metastatic potential
|
J:108298
|
| increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
decreased incidence of induced tumors
|
J:154041
|
| increased adenocarcinoma incidence
|
J:103407
|
| increased lung adenocarcinoma incidence
|
J:195492,
J:154041,
J:103407
|
| increased lung adenoma incidence
|
J:203686,
J:103407
|
| increased lung tumor incidence
|
J:103407
|
| increased metastatic potential
|
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased metastatic potential
|
J:125101
|
| increased sarcoma incidence
|
J:155389,
J:125101
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
| increased metastatic potential
|
J:124682
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:172048
|
| increased gastrointestinal tumor incidence
|
J:172048
|
| increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
| increased hamartoma incidence
|
J:184949
|
| increased metastatic potential
|
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR)
|
decreased incidence of tumors by chemical induction
|
J:124222
|
| increased squamous cell carcinoma incidence
|
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased skin squamous cell carcinoma incidence
|
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129S4/SvJae)
|
abnormal tumor morphology
|
J:154041
|
| decreased incidence of induced tumors
|
J:154041
|
| decreased tumor growth/size
|
J:154041
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB)
|
increased melanoma incidence
|
J:164588
|
| increased spindle cell carcinoma incidence
|
J:164588
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased adenocarcinoma incidence
|
J:103407
|
| increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR)
|
increased carcinoma incidence
|
J:124222
|
| increased incidence of tumors by chemical induction
|
J:124222
|
| increased spindle cell carcinoma incidence
|
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:187012
|
| increased lung non-small cell carcinoma incidence
|
J:187012
|
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * FVB/N)
|
decreased tumor latency
|
J:177853
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:191425
|
| increased lung non-small cell carcinoma incidence
|
J:191425
|
| increased lung tumor incidence
|
J:191425,
J:103407
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased esophageal papilloma incidence
|
J:98936
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:98936
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:98936
|
| increased papilloma incidence
|
J:98936
|
| increased T cell derived lymphoma incidence
|
J:98936
|
| increased teratocarcinoma incidence
|
J:98936
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Zdhhc20em1Jdo/Zdhhc20em1Jdo
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
decreased metastatic potential
|
J:348743
|
Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * C57BL/6 * FVB * ICR)
|
abnormal tumor morphology
|
J:124222
|
| increased carcinoma incidence
|
J:124222
|
| increased incidence of tumors by chemical induction
|
J:124222
|
| increased metastatic potential
|
J:124222
|
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+
Trp53tm4Att/Trp53tm4Att
(involves: 129S4/SvJae)
|
increased organ/body region tumor incidence
|
J:173395
|
Krastm4Tyj/Kras+
Ube2cem1Gpt/Ube2cem1Gpt
(involves: 129S4/SvJae * C57BL/6J)
|
decreased lung tumor incidence
|
J:333347
|
Krastm4Tyj/Kras+
Ube2sem1Ysun/Ube2sem1Ysun
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:333347
|
Krastm4Tyj/Krastm4Tyj
Bhlha15tm3(cre/ERT2)Skz/Bhlha15+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142189
|
Krastm4Tyj/Krastm4Tyj
Mir182tm1.1Dgk/Mir182+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased metastatic potential
|
J:217635
|
Krastm4Tyj/Krastm4Tyj
Mir182tm1.1Dgk/Mir182tm1.1Dgk
Trp53tm1Brn/Trp53tm1Brn
(involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased metastatic potential
|
J:217635
|
Krastm4Tyj/Krastm4Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:162125
|
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT2)1Stof/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142189
|
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:151781
|
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
neoplasm
|
J:142189
|
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Krastm4Tyj/Krastm4Tyj
Trim33tm1Los/Trim33tm1Los
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:151781
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:151781
|
Krastm4Tyj/Krastm4Tyj
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:162628
|
Krastm5Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:172206
|
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53+
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:248550
|
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:248550
|
Krastm5Tyj/Kras+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:180576
|
| increased sarcoma incidence
|
J:180576
|
| increased tumor growth/size
|
J:180576
|
Krastm5Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:172206
|
Krit1tm1Kwhi/Krit1tm1.1Kwhi
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA)
|
increased retina hemangioma incidence
|
J:215458
|
Krt9tm1(KOMP)Vlcg/Krt9tm1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
|
increased skin papilloma incidence
|
J:206051
|
Krt10tm2Tmm/Krt10tm2Tmm
(involves: 129P2/OlaHsd * BALB/c)
|
decreased incidence of induced tumors
|
J:93045
|
Krt14tm1(cre)Wbm/Krt14+
Pard3tm1Shoh/Pard3tm1Shoh
(either: FVB.129-Pard3tm1Shoh Krt14tm1(cre)Wbm or (involves: 129P2/OlaHsd * 129S4/SvJae))
|
decreased incidence of tumors by chemical induction
|
J:192905
|
| decreased tumor growth/size
|
J:192905
|
| decreased tumor latency
|
J:192905
|
| increased incidence of tumors by chemical induction
|
J:192905
|
| increased metastatic potential
|
J:192905
|
| increased tumor growth/size
|
J:192905
|
| increased tumor latency
|
J:192905
|
| neoplasm
|
J:192905
|
Krt14tm1(cre)Wbm/Krt14+
Pard3tm1Shoh/Pard3tm1Shoh
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:240961
|
Krt14tm1(Krt10)Pko/Krt14tm1(Krt10)Pko
(B6.Cg-Krt14tm1(Krt10)Pko)
|
increased skin papilloma incidence
|
J:117347
|
Krt14tm1.1(cre)Wbm/Krt14+
Tg(KRT14-Snai1)1Efu/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * CD-1)
|
increased basal cell carcinoma incidence
|
J:229072
|
| increased sebaceous gland tumor incidence
|
J:229072
|
| increased skin squamous cell carcinoma incidence
|
J:229072
|
| increased skin tumor incidence
|
J:229072
|
Krt18tm1Tmm/Krt18+
(involves: 129P2/OlaHsd)
|
increased liver tumor incidence
|
J:309021
|
Krt18tm1Tmm/Krt18tm1Tmm
(involves: 129P2/OlaHsd)
|
increased hepatocellular carcinoma incidence
|
J:309021
|
| increased liver tumor incidence
|
J:309021
|
Ksr1tm1Kole/Ksr1tm1Kole
(involves: 129S1/Sv * C57BL/6)
|
neoplasm
|
J:84644
|
Ksr1tm1Kole/Ksr1tm1Kole
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:84644
|
Ksr1tm1Shaw/Ksr1tm1Shaw
Tg(MMTV-PyVT)634Mul/?
(involves: C57BL/6 * FVB/N)
|
increased tumor latency
|
J:75739
|
Lag3tm1Doi/Lag3tm1Doi
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor growth/size
|
J:269578
|
Lats1tm1Noj/Lats1tm1Noj
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor morphology
|
J:200232
|
| neoplasm
|
J:200232
|
Lats1tm1Tx/Lats1tm1Tx
(involves: 129S2/SvPas * C57BL/6J)
|
increased ovary tumor incidence
|
J:52536
|
| increased sarcoma incidence
|
J:52536
|
Laynem1Romd/Laynem1Romd
Tg(Cd8a-cre,-GFP)1Yzo/0
(involves: C57BL/6)
|
increased tumor growth/size
|
J:302853
|
Laynem2Romd/Laynem2Romd
(C57BL/6-Laynem2Romd)
|
increased tumor growth/size
|
J:302853
|
Ldahtm1Mrtn/Ldahtm1Mrtn
(CBACa.129S4(B6)-Ldahtm1Mrtn)
|
increased prostate intraepithelial neoplasia incidence
|
J:101977
|
Ldhaa-m1Neu/Ldhaa-m1Neu
Tg(IGL-MYC)3Hm/0
(involves: 101/El * C3H/El * C57BL/6N)
|
increased tumor growth/size
|
J:183477
|
Lect2tm1Ymg/Lect2tm1Ymg
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Lect2tm1Ymg Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
| increased malignant tumor incidence
|
J:184496
|
Lepob/Lepob
(B6.Cg-Lepob/J)
|
increased metastatic potential
|
J:117826
|
Leprdb/Leprdb
(B6.Cg-Dock7m +/+ Leprdb/J)
|
increased metastatic potential
|
J:117826
|
Lgals3tm1Ftl/Lgals3tm1Ftl
(involves: 129S2/SvPas * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:221030
|
Lgr5tm1(cre/ERT2)Cle/Lgr5+
Lrig1tm1.1(cre/ERT2)Rjc/Lrig1tm1.1(cre/ERT2)Rjc
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:186084
|
Lig1tm3Dwm/Lig1tm3Dwm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:77902
|
| increased lymphoma incidence
|
J:77902
|
| increased tumor incidence
|
J:77902
|
Lig4tm1Fwa/Lig4tm1Fwa
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:63078
|
Lig4tm1Icrf/Lig4tm1Icrf
Trp53tm1Tyj/Trp53+
(either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ))
|
decreased tumor incidence
|
J:111068
|
Lig4tm1Icrf/Lig4tm1Icrf
Trp53tm1Tyj/Trp53tm1Tyj
(either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ))
|
increased B cell derived lymphoma incidence
|
J:111068
|
| increased medulloblastoma incidence
|
J:111068
|
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53+
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
abnormal tumor morphology
|
J:144617
|
| increased medulloblastoma incidence
|
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
increased colon adenocarcinoma incidence
|
J:157574
|
| increased medulloblastoma incidence
|
J:157574
|
| increased T cell derived lymphoma incidence
|
J:157574
|
ll/ll
X/Yaa
(BXSB/MpJScr-ll)
|
increased lymphoma incidence
|
J:10973
|
| increased T cell derived lymphoma incidence
|
J:10973
|
llaSL/Kh/llaSL/Kh
(involves: AKR/JMs * SL/Kh)
|
increased lymphoma incidence
|
J:41197,
J:33016
|
Lmo2tm2(cre)Thr/Lmo2+
Kmt2atm1Thr/Kmt2a+
Mllt1tm1Thr/Mllt1+
(involves: 129S/SvEv)
|
increased hemolymphoid system tumor incidence
|
J:100794
|
| increased leukemia incidence
|
J:84518,
J:100794
|
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lonp1tm1Otin/Lonp1+
(Not Specified)
|
decreased incidence of tumors by chemical induction
|
J:221992
|
Loxtm1.1Khki/Loxtm1.1Khki
(involves: C57BL/6)
|
decreased tumor latency
|
J:264295
|
| increased incidence of tumors by chemical induction
|
J:264295
|
Loxl2tm1.2Acan/Loxl2tm1.2Acan
(Not Specified)
|
abnormal tumor pathology
|
J:220689
|
| decreased incidence of tumors by chemical induction
|
J:220689
|
| decreased tumor growth/size
|
J:220689
|
Lpar6tm1.1Bcz/Lpar6tm1.1Bcz
(involves: 129 * BALB/cJ * C57BL/6J * C57BL/6NCr)
|
increased incidence of tumors by chemical induction
|
J:350956
|
Lpoem1Zlu/Lpoem1Zlu
(involves: C57BL/6 * SJL)
|
increased histiocytic sarcoma incidence
|
J:307289
|
| increased lung carcinoma incidence
|
J:307289
|
| increased lymphoma incidence
|
J:307289
|
| increased sarcoma incidence
|
J:307289
|
| increased tumor incidence
|
J:307289
|
Lrg1tm1.1Tnaka/Lrg1tm1.1Tnaka
(involves: C57BL/6J * CBA)
|
increased tumor growth/size
|
J:263152
|
Lrig2tm1.1Hhed/Lrig2tm1.1Hhed
(involves: 129 * C57BL/6 * FVB/N)
|
decreased incidence of induced tumors
|
J:205929
|
Lrrc17tm1Nik/Lrrc17+
Srpk2tm1Nik/Srpk2+
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
|
neoplasm
|
J:161558
|
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(involves: 129S2/SvPas * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:85162
|
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(B6.129S2-Ltbp4Gt(U3Cre)1Vmel)
|
increased large intestine adenocarcinoma incidence
|
J:78819
|
Ltftm1.2Smoc/Ltftm1.2Smoc
(involves: 129 * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:219007
|
Ltsd1C57BL/10J/Ltsd1C57BL/10J
Ltsd2C57BL/10J/Ltsd2C57BL/10J
(involves: C57BL/10 * O20/A)
|
abnormal tumor morphology
|
J:81057
|
Ltsd1C57BL/10J/Ltsd1O20/A
Ltsd5C57BL/10J/Ltsd5O20/A
(involves: C57BL/10 * O20/A)
|
abnormal tumor morphology
|
J:81057
|
Ltsd1O20/A/Ltsd1O20/A
Ltsd7O20/A/Ltsd7O20/A
(involves: C57BL/10 * O20/A)
|
abnormal tumor morphology
|
J:81057
|
Ltsd3C57BL/10J/Ltsd3C57BL/10J
Ltsd4C57BL/10J/Ltsd4C57BL/10J
(involves: C57BL/10 * O20/A)
|
abnormal tumor morphology
|
J:81057
|
Ltsd3O20/A/Ltsd3O20/A
Ltsd6O20/A/Ltsd6O20/A
(involves: C57BL/10 * O20/A)
|
abnormal tumor morphology
|
J:81057
|
Ltsd8O20/A/Ltsd8O20/A
(involves: C57BL/10 * O20/A)
|
abnormal tumor morphology
|
J:81057
|
Ly6atm2(RUNX1)Grau/Ly6a+
(involves: 129X1/SvJ * C57BL/6J)
|
increased squamous cell carcinoma incidence
|
J:93408
|
LyarGt(RRG292)Byg/LyarGt(RRG292)Byg
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:263530
|
Lyg1tm1(KOMP)Vlcg/Lyg1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
increased tumor growth/size
|
J:256594
|
Lypd3tm1(KOMP)Vlcg/Lypd3tm1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
|
decreased incidence of tumors by chemical induction
|
J:235771
|
| neoplasm
|
J:235771
|
Lyr2SL/Ni/Lyr2SL/Ni
(involves: SL/Kh * SL/Ni)
|
decreased lymphoma incidence
|
J:32436
|
LyrBALB/cHeA/LyrBALB/cHeA
(involves: BALB/cHeA * STS/A)
|
increased incidence of tumors by ionizing radiation induction
|
J:10558
|
| increased lymphoma incidence
|
J:10558
|
LyrSTS/A/LyrSTS/A
(involves: BALB/cHeA * STS/A)
|
decreased lymphoma incidence
|
J:10558
|
Lystbg-2J/Lystbg-2J
(C3.Cg-Lystbg-2J/J)
|
abnormal metastatic potential
|
J:33522
|
| decreased metastatic potential
|
J:33522
|
Lystbg/Lystbg
(B6.C3Rl-Lystbg)
|
abnormal tumor susceptibility
|
J:6301
|
| increased incidence of induced tumors
|
J:6302
|
Lyz2tm1(cre)Ifo/0
Nup85tm1.1Yter/Nup85tm1.1Yter
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased tumor growth/size
|
J:292726
|
Lzts1tm1Cro/Lzts1+
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:119989
|
| increased gastric adenocarcinoma incidence
|
J:119989
|
| increased hepatocellular carcinoma incidence
|
J:119989
|
| increased lung adenoma incidence
|
J:119989
|
| increased lymphoma incidence
|
J:119989
|
| increased mammary gland tumor incidence
|
J:119989
|
| increased stomach tumor incidence
|
J:119989
|
| increased tumor incidence
|
J:119989
|
Lzts1tm1Cro/Lzts1tm1Cro
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:119989
|
| increased gastric adenocarcinoma incidence
|
J:119989
|
| increased hepatocellular carcinoma incidence
|
J:119989
|
| increased lung adenocarcinoma incidence
|
J:119989
|
| increased lymphoma incidence
|
J:119989
|
| increased mammary gland tumor incidence
|
J:119989
|
| increased sarcoma incidence
|
J:119989
|
| increased stomach tumor incidence
|
J:119989
|
| increased tumor incidence
|
J:119989
|
Lzts1tm1Kso/Lzts1tm1Kso
(B6J.B6NTac-Lzts1tm1Kso)
|
increased tumor incidence
|
J:226686
|
Mad1l1tm1.1Ktj/Mad1l1+
(involves: BALB/c * C57BL/6J)
|
increased carcinoma incidence
|
J:117337
|
| increased hemangiosarcoma incidence
|
J:117337
|
| increased hepatocellular carcinoma incidence
|
J:117337
|
| increased lung adenocarcinoma incidence
|
J:117337
|
| increased osteosarcoma incidence
|
J:117337
|
| increased rhabdomyosarcoma incidence
|
J:117337
|
| increased sarcoma incidence
|
J:117337
|
| increased tumor incidence
|
J:117337
|
Mad1l1tm1.1Ktj/Mad1l1+
Mad2l1tm1Sorg/Mad2l1+
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased tumor incidence
|
J:117337
|
Mad2l1tm1Sorg/Mad2l1+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:67456
|
Mad2l1tm1Sorg/Mad2l1+
(involves: 129S2/SvPas)
|
increased incidence of induced tumors
|
J:117337
|
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Tg(MMTV-cre)4Mam/0
Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:170904
|
| increased mammary gland tumor incidence
|
J:170904
|
Map3k1tm1Glj/Map3k1tm1Glj
Tg(MMTV-PyVT)634Mul/0
(involves: 129S/SvEv * FVB/N)
|
abnormal tumor morphology
|
J:112298
|
| decreased metastatic potential
|
J:112298
|
| increased mammary gland tumor incidence
|
J:112298
|
Map3k5tm1Hijo/Map3k5tm1Hijo
Map3k6tm1Hijo/Map3k6tm1Hijo
(B6.129-Map3k6tm1Hijo Map3k5tm1Hijo)
|
neoplasm
|
J:148044
|
Map3k6tm1Hijo/Map3k6+
(B6.129P2-Map3k6tm1Hijo)
|
increased incidence of tumors by chemical induction
|
J:148044
|
Map3k6tm1Hijo/Map3k6tm1Hijo
(B6.129P2-Map3k6tm1Hijo)
|
increased incidence of tumors by chemical induction
|
J:148044
|
| neoplasm
|
J:148044
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:160521
|
Map3k8tm1.1Gkl/Map3k8tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
(involves: C57BL/6 * FVB/N)
|
neoplasm
|
J:193546
|
Map3k8tm1.1Gkl/Map3k8tm1.1Gkl
Tg(Col6a1-cre)1Gkl/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:193546
|
| increased tumor growth/size
|
J:193546
|
Map3k8tm1.1Gkl/Map3k8tm1.1Gkl
Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * FVB/N * SJL)
|
neoplasm
|
J:193546
|
Map3k8tm1.2Gkl/Map3k8tm1.2Gkl
(involves: 129 * C57BL/6J * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:193546
|
| increased tumor growth/size
|
J:193546
|
Map9tm1.1Bcgen/Map9+
Tg(CDX2-cre/ERT2)752Erf/0
(involves: 129S4/SvJaeSor * C57BL/6J * SJL/J)
|
increased incidence of tumors by chemical induction
|
J:299895
|
Map9tm1.1Bcgen/Map9tm1.1Bcgen
Tg(CDX2-cre/ERT2)752Erf/0
(involves: 129S4/SvJaeSor * C57BL/6J * SJL/J)
|
increased colon tumor incidence
|
J:299895
|
| increased incidence of tumors by chemical induction
|
J:299895
|
Map9tm1.2Bcgen/Map9tm1.2Bcgen
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
|
neoplasm
|
J:299895
|
Mapk8tm1Flv/Mapk8tm1Flv
(involves: 129S1/Sv)
|
increased incidence of tumors by chemical induction
|
J:75228
|
Mapk14tm1.1Dvb/Mapk14+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
(involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL)
|
decreased tumor incidence
|
J:120284
|
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
abnormal tumor incidence
|
J:122397
|
| increased lung adenocarcinoma incidence
|
J:122397
|
| increased lung adenoma incidence
|
J:122397
|
| increased lung tumor incidence
|
J:122397
|
Mapkapk2tm1.1Gkl/Mapkapk2tm1.1Gkl
Tg(Tie1-cre)9Ref/0
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:262876
|
Mapkapk2tm1.1Gkl/Mapkapk2tm1.1Gkl
Twist2tm1.1(cre)Dor/Twist2+
(involves: 129X1/SvJ * BALB/cJ * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:262876
|
Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:262876
|
Mapkapk5tm1Pqs/Mapkapk5+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin papilloma incidence
|
J:117893
|
Mapkapk5tm1Pqs/Mapkapk5+
Tg(SV40-NRAS*G12D)1Sco/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:117893
|
Mapkapk5tm1Pqs/Mapkapk5tm1Pqs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin papilloma incidence
|
J:117893
|
Mapkapk5tm1Pqs/Mapkapk5tm1Pqs
Tg(SV40-NRAS*G12D)1Sco/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:117893
|
Mapttm1(EGFP)Klt/Mapttm1(EGFP)Klt
Tg(MAPT)8cPdav/?
(involves: 129S4/SvJae * C57BL/6 * Swiss Webster)
|
increased follicular lymphoma incidence
|
J:174270
|
| increased lymphoma incidence
|
J:174270
|
Mbd3tm2Bh/Mbd3tm2Bh
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased incidence of tumors by chemical induction
|
J:167984
|
| increased tumor growth/size
|
J:167984
|
Mc1re/Mc1re
Xpctm1Brd/Xpctm1Brd
Tg(KRT14-Kitl)1Takk/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased squamous cell carcinoma incidence
|
J:112959
|
| increased tumor incidence
|
J:112959
|
Mc4rtm1Lowl/Mc4rtm1Lowl
(involves: 129S4/SvJae * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:177386
|
Mcctm1.1Maija/Mcctm1.1Maija
Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased large intestine adenocarcinoma incidence
|
J:294342
|
MclrRF/J/MclrSWR/J
(involves: RF/J * SWR/J)
|
increased T cell derived lymphoma incidence
|
J:9614
|
MclrSWR/J/MclrSWR/J
(involves: RF/J * SWR/J)
|
increased T cell derived lymphoma incidence
|
J:9614
|
Mcm2Gt(AB0178)Wtsi/Mcm2+
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased tumor incidence
|
J:165667
|
Mcm2Gt(AB0178)Wtsi/Mcm2+
Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased leukemia incidence
|
J:165667
|
| increased T cell derived lymphoma incidence
|
J:165667
|
| increased tumor incidence
|
J:165667
|
Mcm2tm1(cre/ERT2)Scpr/Mcm2tm1(cre/ERT2)Scpr
(involves: 129S6/SvEvTac)
|
increased thymoma incidence
|
J:141493
|
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:165667
|
| neoplasm
|
J:165667
|
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4chaos3
Mcm6Gt(YHD248)Byg/Mcm6+
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased lymphoma incidence
|
J:165667
|
| increased tumor incidence
|
J:165667
|
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4Gt(RRE056)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased lymphoma incidence
|
J:165667
|
| increased mammary gland tumor incidence
|
J:165667
|
Mcm3tm1.1Geno/Mcm3+
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor latency
|
J:227638
|
| increased lymphoma incidence
|
J:227638
|
| increased metastatic potential
|
J:227638
|
| increased tumor incidence
|
J:227638
|
Mcm3tm1.2Geno/Mcm3+
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor latency
|
J:227638
|
| increased lymphoma incidence
|
J:227638
|
| increased metastatic potential
|
J:227638
|
| increased tumor incidence
|
J:227638
|
Mcm4chaos3/Mcm4chaos3
(involves: C57BL/6J)
|
increased lymphoma incidence
|
J:165667
|
| increased mammary gland tumor incidence
|
J:165667
|
| increased T cell derived lymphoma incidence
|
J:165667
|
Mcm4chaos3/Mcm4chaos3
(C3.B6-Mcm4chaos3)
|
increased hepatocellular carcinoma incidence
|
J:117494
|
| increased lung adenocarcinoma incidence
|
J:117494
|
| increased mammary adenocarcinoma incidence
|
J:117494
|
| increased mammary gland tumor incidence
|
J:117494
|
Mcm4Sdla/Mcm4+
(involves: C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:194117
|
| increased tumor incidence
|
J:194117
|
Mcm8tm1.1Geno/Mcm8tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J)
|
increased ovary adenoma incidence
|
J:187623
|
| increased ovary tumor incidence
|
J:187623
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(AW0655)Wtsi
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased adenoma incidence
|
J:177420
|
| increased hepatocellular carcinoma incidence
|
J:177420
|
| increased ovary tumor incidence
|
J:177420
|
| increased tumor incidence
|
J:177420
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
| increased ovary tumor incidence
|
J:177420
|
| increased tumor incidence
|
J:177420
|
Mcm9Gt(XG743)Byg/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
| increased ovary tumor incidence
|
J:177420
|
| increased tumor incidence
|
J:177420
|
Mdm2tm1.1Ypz/Mdm2tm1.1Ypz
Tg(IghMyc)22Bri/0
(B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri)
|
increased lymphoma incidence
|
J:164200
|
Mdm2tm2.1Snj/Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:189297
|
| increased T cell derived lymphoma incidence
|
J:189297
|
| increased tumor incidence
|
J:189297
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo
(B6.129S6-Mdm2tm3.1Glo)
|
increased lymphoma incidence
|
J:164201
|
| increased mammary adenocarcinoma incidence
|
J:164201
|
| increased tumor incidence
|
J:164201
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo
Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo)
|
increased adenocarcinoma incidence
|
J:164201
|
| increased carcinoma incidence
|
J:164201
|
| increased fibrosarcoma incidence
|
J:164201
|
| increased hemangiosarcoma incidence
|
J:164201
|
| increased histiocytic sarcoma incidence
|
J:164201
|
| increased leiomyosarcoma incidence
|
J:164201
|
| increased lipoma incidence
|
J:164201
|
| increased liver adenocarcinoma incidence
|
J:164201
|
| increased liver adenoma incidence
|
J:164201
|
| increased lung adenoma incidence
|
J:164201
|
| increased lymphoma incidence
|
J:164201
|
| increased mammary adenocarcinoma incidence
|
J:164201
|
| increased osteosarcoma incidence
|
J:164201
|
| increased papilloma incidence
|
J:164201
|
| increased sarcoma incidence
|
J:164201
|
| increased squamous cell carcinoma incidence
|
J:164201
|
| increased tumor incidence
|
J:164201
|
Mdm2tm3.1Snj/Mdm2tm3.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
increased salivary gland tumor incidence
|
J:189297
|
Mdm2tm4.1Glo/Mdm2tm4.1Glo
(B6.129S6-Mdm2tm4.1Glo)
|
increased sarcoma incidence
|
J:164201
|
Mdm2tm4.1Glo/Mdm2tm4.1Glo
Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm4.1Glo Trp53tm3.1Glo)
|
increased adenocarcinoma incidence
|
J:164201
|
| increased carcinoma incidence
|
J:164201
|
| increased fibrosarcoma incidence
|
J:164201
|
| increased histiocytic sarcoma incidence
|
J:164201
|
| increased liver adenocarcinoma incidence
|
J:164201
|
| increased lymphoma incidence
|
J:164201
|
| increased osteosarcoma incidence
|
J:164201
|
| increased sarcoma incidence
|
J:164201
|
| increased squamous cell carcinoma incidence
|
J:164201
|
Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6)
|
neoplasm
|
J:150341
|
Mdm4tm1Glo/Mdm4+
Tg(IghMyc)22Bri/0
(involves: 129S6/SvEvTac * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:123661
|
Mdm4tm2Glo/Mdm4tm2.1Glo
Tg(Myh6-cre)2182Mds/0
Trp53tm1Tyj/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S/Sv * C57BL/6J * FVB/N)
|
increased tumor incidence
|
J:137114
|
Mecomtm1Aspe/Mecomtm1Aspe
(involves: 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:178429
|
Mef2btm2Rdf/Mef2b+
Tg(BCL2/IGH)M23Tjd/0
Tg(Cr2-cre)3Cgn/0
(involves: C3H/He * C57BL/6)
|
increased follicular lymphoma incidence
|
J:265465
|
| increased lymphoma incidence
|
J:265465
|
Mef2btm2Rdf/Mef2b+
Tg(Cr2-cre)3Cgn/0
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:265465
|
Melm1BALB/cJ/Melm1BALB/cJ
(involves: BALB/cJ * C57BL/6J)
|
increased tumor latency
|
J:66211
|
Melm1C57BL/6J/Melm1C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased skin tumor incidence
|
J:66211
|
Melm2BALB/cJ/Melm2BALB/cJ
(involves: BALB/cJ * C57BL/6J)
|
increased tumor latency
|
J:66211
|
Melm2BALB/cJ/Melm2C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased tumor latency
|
J:66211
|
Melm2C57BL/6J/Melm2C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased skin tumor incidence
|
J:66211
|
Melm3BALB/cJ/Melm3BALB/cJ
(involves: BALB/cJ * C57BL/6J)
|
increased tumor latency
|
J:66211
|
Melm3BALB/cJ/Melm3C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased tumor latency
|
J:66211
|
Melm3C57BL/6J/Melm3C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased skin tumor incidence
|
J:66211
|
Men1tm1.1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased pancreas tumor incidence
|
J:67128
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * FVB/N)
|
increased adrenal gland tumor incidence
|
J:133299
|
| increased lung tumor incidence
|
J:133299
|
| increased pancreatic islet cell adenoma incidence
|
J:133299
|
| increased parathyroid adenoma incidence
|
J:133299
|
| increased pheochromocytoma incidence
|
J:133299
|
| increased pituitary adenohypophysis tumor incidence
|
J:133299
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
| increased gland tumor incidence
|
J:120835
|
| increased lung adenocarcinoma incidence
|
J:120835
|
| increased pancreas tumor incidence
|
J:120835
|
| increased parathyroid gland tumor incidence
|
J:120835
|
| increased pituitary gland tumor incidence
|
J:120835
|
| increased testis tumor incidence
|
J:120835
|
| increased thyroid tumor incidence
|
J:120835
|
Men1tm1.1Ctre/Men1+
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N)
|
increased adrenal gland tumor incidence
|
J:133299
|
| increased metastatic potential
|
J:133299
|
| increased pancreas tumor incidence
|
J:133299
|
| increased parathyroid gland tumor incidence
|
J:133299
|
| increased pheochromocytoma incidence
|
J:133299
|
| increased pituitary adenohypophysis tumor incidence
|
J:133299
|
| increased pituitary melanotroph tumor incidence
|
J:133299
|
| increased thyroid C-cell carcinoma incidence
|
J:133299
|
Men1tm1.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
|
increased adrenal gland adenoma incidence
|
J:116086
|
| increased glucagonoma incidence
|
J:116086
|
| increased insulinoma incidence
|
J:116086
|
| increased Leydig cell tumor incidence
|
J:116086
|
| increased ovary tumor incidence
|
J:116086
|
| increased pancreas adenoma incidence
|
J:116086
|
| increased parathyroid adenoma incidence
|
J:116086
|
| increased pituitary adenoma incidence
|
J:116086
|
| increased prolactinoma incidence
|
J:116086
|
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Zqw/Men1tm1.2Zqw
Tg(Ins2-cre)23Herr/0
(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
|
increased insulinoma incidence
|
J:85133
|
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased adrenal gland tumor incidence
|
J:67128
|
| increased carcinoma incidence
|
J:67128
|
| increased lung adenocarcinoma incidence
|
J:67128
|
| increased pancreas tumor incidence
|
J:67128
|
| increased parathyroid adenoma incidence
|
J:67128
|
| increased pheochromocytoma incidence
|
J:67128
|
| increased pituitary adenoma incidence
|
J:67128
|
| increased prolactinoma incidence
|
J:67128
|
| increased stomach tumor incidence
|
J:67128
|
| increased thyroid adenoma incidence
|
J:67128
|
Men1tm1Ctre/Men1tm1Ctre
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased insulinoma incidence
|
J:146440
|
Men1tm1Gfk/Men1tm1Gfk
Tg(Ins2-cre)25Mgn/0
(involves: 129T2/SvEms * C57BL/6 * C57BL/6J * DBA)
|
increased insulinoma incidence
|
J:89898
|
| increased pancreas tumor incidence
|
J:89898
|
| increased prolactinoma incidence
|
J:89898
|
Men1tm1Rvt/Men1+
(involves: 129 * C57BL/6)
|
increased adrenal cortical tumor incidence
|
J:191261
|
| increased ovary tumor incidence
|
J:191261
|
| increased pancreatic islet cell adenoma incidence
|
J:191261
|
| increased parathyroid adenoma incidence
|
J:191261
|
| increased parathyroid gland tumor incidence
|
J:191261
|
| increased pituitary adenohypophysis tumor incidence
|
J:191261
|
| increased pituitary gland tumor incidence
|
J:191261
|
| increased testis tumor incidence
|
J:191261
|
| increased thyroid tumor incidence
|
J:191261
|
| increased tumor incidence
|
J:191261
|
Men1tm1Zqw/Men1+
(involves: 129/Sv * 129P2/OlaHsd)
|
increased adrenal cortical tumor incidence
|
J:85302
|
| increased adrenal gland adenoma incidence
|
J:85302
|
| increased adrenal gland tumor incidence
|
J:85302
|
| increased adrenocortical adenoma incidence
|
J:85302
|
| increased gastrointestinal tumor incidence
|
J:85302
|
| increased gland tumor incidence
|
J:85302
|
| increased glucagonoma incidence
|
J:85302
|
| increased gonad tumor incidence
|
J:85302
|
| increased insulinoma incidence
|
J:85302
|
| increased intestinal adenoma incidence
|
J:85302
|
| increased Leydig cell tumor incidence
|
J:85302
|
| increased mammary gland tumor incidence
|
J:85302
|
| increased ovary tumor incidence
|
J:85302
|
| increased pancreas tumor incidence
|
J:85302
|
| increased pancreatic islet cell adenoma incidence
|
J:85302
|
| increased pancreatic islet cell carcinoma incidence
|
J:85302
|
| increased parathyroid adenoma incidence
|
J:85302
|
| increased pituitary adenohypophysis tumor incidence
|
J:85302
|
| increased prolactinoma incidence
|
J:85302
|
| increased stomach tumor incidence
|
J:85302
|
| increased testis tumor incidence
|
J:85302
|
| increased thyroid carcinoma incidence
|
J:85302
|
| increased thyroid tumor incidence
|
J:85302
|
Men1tm2.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
|
increased insulinoma incidence
|
J:116086
|
| increased Leydig cell tumor incidence
|
J:116086
|
| increased ovary tumor incidence
|
J:116086
|
| increased pancreas adenoma incidence
|
J:116086
|
| increased parathyroid adenoma incidence
|
J:116086
|
| increased pituitary adenoma incidence
|
J:116086
|
Men1tm2.1Mmey/Men1tm2.1Mmey
Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
|
increased insulinoma incidence
|
J:175625
|
Meox2tm1(cre)Sor/?
Nrastm1Zhng/Nrastm1Zhng
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:174880
|
MetPar4/Met+
(involves: BALB/cJ * SWR/J)
|
decreased lung tumor incidence
|
J:43176
|
Mettm1Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:94722
|
| increased histiocytic sarcoma incidence
|
J:94722
|
| increased lymphoma incidence
|
J:94722
|
| increased squamous cell carcinoma incidence
|
J:94722
|
| increased tumor incidence
|
J:94722
|
Mettm2Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:94722
|
| increased histiocytic sarcoma incidence
|
J:94722
|
| increased lymphoma incidence
|
J:94722
|
| increased tumor incidence
|
J:94722
|
Mettm3Gvw/Mettm3Gvw
(involves: 129 * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:94722
|
| increased tumor incidence
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased lymphoma incidence
|
J:94722
|
| increased sarcoma incidence
|
J:94722
|
| increased tumor incidence
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J * FVB/N)
|
increased hemangiosarcoma incidence
|
J:151890
|
| increased mammary adenocarcinoma incidence
|
J:151890
|
| increased mammary gland tumor incidence
|
J:151890
|
| increased myoepithelioma incidence
|
J:151890
|
| increased sarcoma incidence
|
J:151890
|
| increased squamous cell carcinoma incidence
|
J:151890
|
Mettm5Gvw/Met+
(involves: 129 * C57BL/6J)
|
neoplasm
|
J:94722
|
Mfge8tm1Mcu/Mfge8tm1Mcu
Tg(RIP1-Tag)2Dh/?
(involves: 129X1/SvJ * C57BL/6J * C57BL/6NCr * DBA/2J)
|
abnormal tumor morphology
|
J:123138
|
| decreased metastatic potential
|
J:123138
|
| decreased tumor growth/size
|
J:123138
|
| increased adenoma incidence
|
J:123138
|
| increased carcinoma incidence
|
J:123138
|
Mfsd1tm1a(KOMP)Wtsi/Mfsd1tm1a(KOMP)Wtsi
(involves: C57BL/6N)
|
increased liver tumor incidence
|
J:280713
|
Mgat3tm1Pst/Mgat3tm1Pst
(involves: 129/Sv * C57BL/6 * CD-1 * SJL)
|
decreased incidence of tumors by chemical induction
|
J:48441,
J:86643
|
Mgat5tm1Jwd/Mgat5tm1Jwd
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased metastatic potential
|
J:60960
|
| decreased tumor growth/size
|
J:60960
|
| increased tumor latency
|
J:60960
|
Mgmttm1Mse/Mgmttm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mgmttm1Mse/Mgmttm1Mse
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
|
increased lung adenoma incidence
|
J:47642
|
| increased T cell derived lymphoma incidence
|
J:47642
|
Miftm1Dvd/Miftm1Dvd
(B6.129S4-Miftm1Dvd)
|
decreased incidence of tumors by chemical induction
|
J:126543
|
Miftm1Gfr/Miftm1Gfr
(C57BL/6-Miftm1Gfr)
|
increased fibrosarcoma incidence
|
J:84791
|
| increased incidence of tumors by chemical induction
|
J:147772
|
Miftm2Gfr/Miftm2Gfr
(C57BL/6-Miftm2Gfr)
|
increased incidence of tumors by chemical induction
|
J:147772
|
Mir21atm1Yoli/Mir21atm1Yoli
(involves: 129S6/SvEvTac * C57BL/6N)
|
abnormal tumor pathology
|
J:173464
|
| decreased incidence of tumors by chemical induction
|
J:173464
|
Mir31em1Nju/Mir31em1Nju
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6J * FVB/N)
|
decreased mammary gland tumor incidence
|
J:271420
|
| decreased metastatic potential
|
J:271420
|
| decreased tumor growth/size
|
J:271420
|
Mir34atm1.1Pisc/Mir34atm1.1Pisc
Mirc21tm1.1Pisc/Mirc21tm1.1Pisc
Mirc34tm1.1Pisc/Mirc34tm1.1Pisc
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
neoplasm
|
J:256929
|
Mir34atm1.2Arte/Mir34a+
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N)
|
increased medulloblastoma incidence
|
J:221990
|
Mir34atm1.2Arte/Mir34atm1.2Arte
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N)
|
increased medulloblastoma incidence
|
J:221990
|
Mir34atm1Hher/Mir34atm1Hher
(involves: 129 * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:209587
|
Mir122tm1.1Apts/Mir122tm1.1Apts
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:190066
|
Mir122tm1.1Kgh/Mir122+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.1Kgh/Mir122tm1.1Kgh
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
| increased tumor growth/size
|
J:190067
|
Mir122tm1.2Kgh/Mir122+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.2Kgh/Mir122tm1.2Kgh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
| increased liver tumor incidence
|
J:190067
|
Mir139em1Jwli/Mir139em1Jwli
(C57BL/6J-Mir139em1Jwli)
|
increased incidence of tumors by chemical induction
|
J:280467,
J:248779
|
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173230
|
| increased follicular lymphoma incidence
|
J:173230
|
| increased myeloid sarcoma incidence
|
J:173230
|
| increased spleen neoplasm incidence
|
J:173230
|
| increased T cell derived lymphoma incidence
|
J:173230
|
Mir146tm2.1Bal/Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased follicular lymphoma incidence
|
J:173671
|
| increased hemolymphoid system tumor incidence
|
J:173671
|
| increased tumor incidence
|
J:173671
|
Mir203tm1.2Yir/Mir203tm1.2Yir
(B6(Cg)-Mir203tm1.2Yir)
|
decreased tumor latency
|
J:226044
|
| increased incidence of tumors by chemical induction
|
J:226044
|
Mir216aem1Uf/Mir216aem1Uf
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir216aem2Uf/Mir216aem2Uf
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir216bem1Uf/Mir216bem1Uf
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir217em1Uf/Mir217em1Uf
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir217em2Uf/Mir217em2Uf
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir301tm1Yoli/Mir301tm1Yoli
(involves: C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:237900
|
| decreased tumor incidence
|
J:237900
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(ARR2/Pbsn-MYC)7Key/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL/J)
|
decreased prostate gland tumor incidence
|
J:223213
|
| increased prostate gland adenocarcinoma incidence
|
J:223213
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(IghMyc)22Bri/?
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
|
increased B cell derived lymphoma incidence
|
J:223213
|
| increased tumor latency
|
J:223213
|
Mirc14tm1.2Czc/Mirc14tm1.2Czc
(either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))
|
increased tumor latency
|
J:188125
|
Mirc27em1Hhzg/Mirc27em1Hhzg
Tg(Vav1-cre)#Cgp/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)
|
neoplasm
|
J:320883
|
Mirc30em1Hhzg/Mirc30em1Hhzg
Tg(Vav1-cre)#Cgp/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)
|
increased chronic lymphocytic leukemia incidence
|
J:320883
|
Mirc30tm1.2Rdf/Mirc30tm1.2Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
| increased leukemia incidence
|
J:156946
|
Mki67em1Dfis/Mki67+
(involves: C57BL/6J)
|
increased tumor growth/size
|
J:304800
|
Mki67em1Dfis/Mki67em1Dfis
(involves: C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:304800
|
Mldhrtm1Zhgn/Mldhrtm1Zhgn
Tg(GFAP-cre)25Mes/0
(involves: FVB/N)
|
increased glioblastoma incidence
|
J:303725
|
Mleu1SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu2SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu3C57BL/6J/Mleu3SWR/J
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu4SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu5SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:34291
|
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
| increased intestinal adenoma incidence
|
J:75745
|
| increased lymphoma incidence
|
J:75745
|
| increased skin tumor incidence
|
J:75745
|
| increased uterus tumor incidence
|
J:75745
|
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
| increased tumor incidence
|
J:47642
|
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:53451
|
| increased carcinoma incidence
|
J:53451
|
| increased gastrointestinal tumor incidence
|
J:53451
|
| increased lung carcinoma incidence
|
J:53451
|
| increased lymphoma incidence
|
J:53451
|
| increased squamous cell carcinoma incidence
|
J:53451
|
| increased T cell derived lymphoma incidence
|
J:53451
|
| increased tumor incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenoma incidence
|
J:53451
|
| increased B cell derived lymphoma incidence
|
J:98929,
J:53451
|
| increased carcinoma incidence
|
J:53451
|
| increased gastrointestinal tumor incidence
|
J:53451
|
| increased lymphoma incidence
|
J:53451
|
| increased T cell derived lymphoma incidence
|
J:53451
|
| increased tumor incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd)
|
increased gastrointestinal tumor incidence
|
J:133352
|
| increased lymphoma incidence
|
J:133352
|
| increased skin tumor incidence
|
J:133352
|
| increased small intestine adenocarcinoma incidence
|
J:133352
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
| increased intestinal adenoma incidence
|
J:153684
|
| increased lymphoma incidence
|
J:153684
|
| increased T cell derived lymphoma incidence
|
J:153684
|
Mlh1tm1Wed/Mlh1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased basal cell carcinoma incidence
|
J:133352
|
| increased lymphoma incidence
|
J:133352
|
| increased tumor incidence
|
J:133352
|
Mmp1atm1Otin/Mmp1atm1Otin
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal tumor morphology
|
J:198586
|
| decreased incidence of tumors by chemical induction
|
J:198586
|
| decreased tumor growth/size
|
J:198586
|
Mmp2tm1Ito/Mmp2tm1Ito
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased tumor growth/size
|
J:46091
|
Mmp2tm1Ito/Mmp2tm1Ito
(B6.129P2-Mmp2tm1Ito)
|
neoplasm
|
J:105098
|
Mmp7tm1Lmm/Mmp7tm1Lmm
(B6.129-Mmp7tm1Lmm)
|
increased tumor incidence
|
J:105098
|
Mmp7tm1Lmm/Mmp7tm1Lmm
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp8tm1Otin/Mmp8tm1Otin
(involves: 129X1/SvJ * C57BL/6J)
|
increased fibrosarcoma incidence
|
J:86393
|
| increased papilloma incidence
|
J:86393
|
| increased tumor incidence
|
J:86393
|
Mmp9tm1Itoh/Mmp9tm1Itoh
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased metastatic potential
|
J:55823
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(B6.129S6-Mmp9tm1Tvu)
|
abnormal tumor morphology
|
J:105098
|
| decreased tumor incidence
|
J:105098
|
Mmp9tm1Tvu/Mmp9tm1Tvu
Rag2tm1Fwa/Rag2tm1Fwa
(B6.129S-Rag2tm1Fwa Mmp9tm1Tvu)
|
decreased tumor incidence
|
J:105098
|
Mmp9tm1Tvu/Mmp9tm1Tvu
Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:140033
|
| decreased metastatic potential
|
J:140033
|
| decreased tumor growth/size
|
J:140033
|
Mmp9tm1Tvu/Mmp9tm1Tvu
Tg(KRT14-HPV16)wt1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N)
|
decreased tumor incidence
|
J:65699
|
| increased skin squamous cell carcinoma incidence
|
J:65699
|
Mmp9tm1Tvu/Mmp9tm1Tvu
Tg(MMTV-PyVT)634Mul/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:140033
|
| decreased metastatic potential
|
J:140033
|
| decreased tumor growth/size
|
J:140033
|
| increased mammary gland tumor incidence
|
J:140033
|
Mmp9tm1Tvu/Mmp9tm1Tvu
Tg(MMTV-PyVT)634Mul/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp11tm1Mrio/Mmp11tm1Mrio
(either: (involves: 129S2/SvPas * 129X1/SvJ) or (involves: 129S2/SvPas * 129X1/SvJ * BALB/c) or (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J))
|
decreased incidence of tumors by chemical induction
|
J:79012
|
Mmp11tm1Mrio/Mmp11tm1Mrio
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
decreased tumor growth/size
|
J:86074
|
| increased carcinoma incidence
|
J:86074
|
| increased mammary gland tumor incidence
|
J:86074
|
| increased metastatic potential
|
J:86074
|
Mmp19tm1Amp/Mmp19tm1Amp
(Not Specified)
|
decreased incidence of tumors by chemical induction
|
J:90802
|
Mmrn2tm1Monm/Mmrn2tm1Monm
(involves: C57BL/6NCrl)
|
abnormal tumor vascularization
|
J:298039
|
Mmtp1I/LnJ/Mmtp1I/LnJ
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ)
|
abnormal tumor susceptibility
|
J:97671
|
| decreased tumor growth/size
|
J:97671
|
Mmtp2NZB/BlNJ/Mmtp2NZB/BlNJ
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ)
|
decreased tumor growth/size
|
J:97671
|
Mmtp3NZB/BlNJ/Mmtp3NZB/BlNJ
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ)
|
decreased tumor growth/size
|
J:97671
|
Mn1tm1Ecz/Mn1+
(FVB.129-Mn1tm1Ecz)
|
neoplasm
|
J:98889
|
Mnttm1Awb/Mnttm1.1Awb
Tg(MMTV-cre)4Mam/?
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:110115
|
Mnttm1Phu/Mnttm1Phu
Tg(MMTV-cre)4Mam/?
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:85481
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Albtm1(cre/ERT2)Mtz/Alb+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased hepatobiliary system tumor incidence
|
J:228499
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Mob1bGt(CC0690)Wtsi Mob1atm1.1Asuz Speer6-ps1Tg(Alb-cre)21Mgn)
|
increased cholangiocarcinoma incidence
|
J:228499
|
| increased hepatobiliary system tumor incidence
|
J:228499
|
| increased hepatocellular carcinoma incidence
|
J:228499
|
| increased liver adenoma incidence
|
J:228499
|
Mob1atm1.2Asuz/Mob1a+
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased fibrosarcoma incidence
|
J:193981
|
| increased integument system tumor incidence
|
J:193981
|
| increased mammary gland tumor incidence
|
J:193981
|
| increased osteosarcoma incidence
|
J:193981
|
| increased salivary gland tumor incidence
|
J:193981
|
| increased skin tumor incidence
|
J:193981
|
Mob1atm1.2Asuz/Mob1atm1.2Asuz
Mob1bGt(CC0690)Wtsi/Mob1b+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased fibrosarcoma incidence
|
J:193981
|
| increased integument system tumor incidence
|
J:193981
|
| increased liver tumor incidence
|
J:193981
|
| increased lung tumor incidence
|
J:193981
|
| increased mammary gland tumor incidence
|
J:193981
|
| increased osteosarcoma incidence
|
J:193981
|
| increased salivary gland tumor incidence
|
J:193981
|
| increased skin tumor incidence
|
J:193981
|
Modc1C3H/HeJ/Modc1C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
decreased tumor incidence
|
J:75743
|
Modc1C3H/HeJ/Modc1C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
decreased tumor incidence
|
J:75743
|
Modc2BALB/cJ/Modc2BALB/cJ
(involves: BALB/cJ * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:101472
|
Modc2BALB/cJ/Modc2C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:101472
|
Mom7AKR/Mom7AKR
(involves: AKR * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:123865
|
Mom21BTBR/Mom21BTBR
(involves: BTBR * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:123865
|
Morc2aem1(IMPC)Wtsi/Morc2aem1(IMPC)Wtsi
(C57BL/6N-Morc2aem1(IMPC)Wtsi/WtsiOulu)
|
increased trigeminal neuroma incidence
|
J:239583
|
Mostm1Sia/Mostm1Sia
(involves: C57BL/6 * CBA)
|
increased teratoma incidence
|
J:19086
|
Mp53d1BALB/c/Mp53d1MSM
(involves: BALB/c-Trp53tm1Brd * MSM)
|
decreased lymphoma incidence
|
J:81940
|
Mp53d2BALB/c/Mp53d2MSM
(involves: BALB/c-Trp53tm1Brd * MSM)
|
decreased lymphoma incidence
|
J:81940
|
Mp53d3BALB/c/Mp53d3MSM
(involves: BALB/c-Trp53tm1Brd * MSM)
|
decreased incidence of tumors by ionizing radiation induction
|
J:81940
|
| increased skin tumor incidence
|
J:81940
|
Mpgtm1Rhe/Mpgtm1Rhe
(B6.129P2-Mpgtm1Rhe)
|
decreased incidence of tumors by chemical induction
|
J:86644
|
Mre11atm1Jpt/Mre11a+
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Mre11atm1Jpt/Mre11atm1Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:87088
|
Mre11atm1Jpt/Mre11atm1Jpt
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Msh2tm1Htr/Msh2+
(involves: 129P2/OlaHsd)
|
increased hemangiosarcoma incidence
|
J:45433
|
| increased liver tumor incidence
|
J:45433
|
| increased lung tumor incidence
|
J:45433
|
| increased mammary gland tumor incidence
|
J:45433
|
| increased osteosarcoma incidence
|
J:45433
|
| increased skin tumor incidence
|
J:45433
|
| increased tumor incidence
|
J:45433
|
| increased uterus tumor incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
|
increased T cell derived lymphoma incidence
|
J:27469
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
increased brain tumor incidence
|
J:45433
|
| increased gastrointestinal tumor incidence
|
J:45433
|
| increased lymphoma incidence
|
J:45433
|
| increased skin tumor incidence
|
J:45433
|
| increased T cell derived lymphoma incidence
|
J:45433
|
| increased tumor incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * FVB)
|
increased gastrointestinal tumor incidence
|
J:45433
|
| increased incidence of tumors by chemical induction
|
J:45433
|
| increased lung tumor incidence
|
J:45433
|
| increased lymphoma incidence
|
J:45433
|
| increased mammary gland tumor incidence
|
J:45433
|
| increased skin tumor incidence
|
J:45433
|
| increased T cell derived lymphoma incidence
|
J:45433
|
| increased tumor incidence
|
J:45433
|
| increased uterus tumor incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased lymphoma incidence
|
J:197809
|
| increased tumor incidence
|
J:197809
|
Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased lymphoma incidence
|
J:197809
|
| increased tumor incidence
|
J:197809
|
Msh2tm1Htr/Msh2tm1Htr
Tap1tm1Hpl/Tap1tm1Hpl
(involves: 129P2/OlaHsd * FVB)
|
increased gastrointestinal tumor incidence
|
J:45433
|
| increased lung tumor incidence
|
J:45433
|
| increased mammary gland tumor incidence
|
J:45433
|
| increased skin tumor incidence
|
J:45433
|
| increased tumor incidence
|
J:45433
|
| increased uterus tumor incidence
|
J:45433
|
Msh2tm1Mak/Msh2+
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:89742
|
| increased lung adenoma incidence
|
J:89742
|
| increased lymphoma incidence
|
J:89742
|
| increased ovary tumor incidence
|
J:89742
|
| increased tumor incidence
|
J:89742
|
Msh2tm1Mak/Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lymphoma incidence
|
J:28397
|
Msh2tm1Mak/Msh2tm1Mak
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased lung adenoma incidence
|
J:89742
|
| increased lymphoma incidence
|
J:89742
|
| increased tumor incidence
|
J:89742
|
Msh2tm1Rak/Msh2+
(involves: 129P2/OlaHsd)
|
increased liver adenoma incidence
|
J:64667
|
| increased lymphoma incidence
|
J:64667
|
| increased tumor incidence
|
J:64667
|
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd)
|
increased gastrointestinal tumor incidence
|
J:64667
|
| increased lymphoma incidence
|
J:64667
|
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:98929
|
Msh2tm1Rak/Msh2tm2.1Rak
Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
|
abnormal tumor morphology
|
J:161577
|
| increased gastrointestinal tumor incidence
|
J:161577
|
| increased intestinal adenocarcinoma incidence
|
J:161577
|
| increased intestinal adenoma incidence
|
J:161577
|
Msh2tm1Wed/Msh2tm1Wed
(involves: C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:86278
|
| increased lymphoma incidence
|
J:86278
|
Msh2tm1Wed/Msh2tm1Wed
(involves: 129 * C57BL/6 * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:88092
|
| increased lymphoma incidence
|
J:88092
|
| increased tumor incidence
|
J:88092
|
| increased tumor latency
|
J:88092
|
Msh2tm1Whl/Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal tumor morphology
|
J:79016
|
| increased gastrointestinal tumor incidence
|
J:79016
|
| increased lymphoblastic lymphoma incidence
|
J:79016
|
| increased skin tumor incidence
|
J:79016
|
| increased squamous cell carcinoma incidence
|
J:79016
|
Msh2tm1Whl/Msh2tm1Whl
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
abnormal tumor morphology
|
J:79016
|
| increased gastrointestinal tumor incidence
|
J:79016
|
| increased lymphoblastic lymphoma incidence
|
J:79016
|
| increased pheochromocytoma incidence
|
J:79016
|
| increased pituitary adenohypophysis tumor incidence
|
J:79016
|
| increased pituitary melanotroph tumor incidence
|
J:79016
|
| increased skin tumor incidence
|
J:79016
|
| increased thyroid C-cell carcinoma incidence
|
J:79016
|
| increased tumor incidence
|
J:79016
|
Msh2tm2.1Rak/Msh2tm2.1Rak
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
|
neoplasm
|
J:161577
|
Msh2tm2.1Rak/Msh2tm2.1Rak
Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased gastrointestinal tumor incidence
|
J:161577
|
| increased intestinal adenoma incidence
|
J:161577
|
| increased lymphoma incidence
|
J:161577
|
| increased small intestine adenocarcinoma incidence
|
J:161577
|
Msh2tm2.1Rak/Msh2tm3.1Rak
Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
abnormal tumor morphology
|
J:161577
|
| increased gastrointestinal tumor incidence
|
J:161577
|
| increased intestinal adenocarcinoma incidence
|
J:161577
|
| increased intestinal adenoma incidence
|
J:161577
|
Msh2tm2.2Rak/Msh2tm2.2Rak
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased gastrointestinal tumor incidence
|
J:161577
|
| increased lymphoma incidence
|
J:161577
|
Msh3tm1Htr/Msh3tm1Htr
(involves: 129P2/OlaHsd * FVB/N)
|
neoplasm
|
J:59561
|
Msh3tm1Htr/Msh3tm1Htr
Msh6tm1Htr/Msh6tm1Htr
(involves: 129P2/OlaHsd * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:59561
|
| increased lymphoma incidence
|
J:59561
|
| increased skin tumor incidence
|
J:59561
|
Msh3tm1Rak/Msh3tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:60604
|
Msh3tm1Rak/Msh3tm1Rak
Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased gastrointestinal tumor incidence
|
J:60604
|
| increased intestinal adenocarcinoma incidence
|
J:60604
|
| increased lymphoma incidence
|
J:60604
|
Msh5tm1Htr/Msh5tm1Htr
(involves: 129P2/OlaHsd * FVB)
|
increased granulosa cell tumor incidence
|
J:180025
|
Msh6tm1Htr/Msh6tm1Htr
(involves: 129P2/OlaHsd * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:59561
|
| increased hemolymphoid system tumor incidence
|
J:59561
|
| increased lymphoma incidence
|
J:59561
|
| increased skin tumor incidence
|
J:59561
|
| increased uterus tumor incidence
|
J:59561
|
Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased gastrointestinal tumor incidence
|
J:44428
|
| increased lymphoma incidence
|
J:44428
|
| increased tumor incidence
|
J:44428
|
Msh6tm1Wed/Msh6+
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:92555
|
Msh6tm1Wed/Msh6tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased basal cell carcinoma incidence
|
J:92555
|
| increased intestinal adenoma incidence
|
J:92555
|
| increased lymphoma incidence
|
J:92555
|
| increased tumor incidence
|
J:92555
|
Msi2Gt(Ayu21-T2)Imeg/Msi2Gt(Ayu21-T2)Imeg
(involves: C57BL/6 * CBA/JNCrlj)
|
decreased tumor growth/size
|
J:162770
|
Msmbtm1Xuan/Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
|
increased metastatic potential
|
J:96884
|
| increased prostate gland adenocarcinoma incidence
|
J:96884
|
| increased prostate intraepithelial neoplasia incidence
|
J:96884
|
Msmr1MSM/Ms/Msmr1MSM/Ms
(involves: MSM/Ms * SL/Kh)
|
decreased lymphoma incidence
|
J:34941
|
Msmr1MSM/Ms/Msmr1SL/Kh
(involves: MSM/Ms * SL/Kh)
|
decreased lymphoma incidence
|
J:34941
|
Msmr1SL/Kh/Msmr1SL/Kh
(involves: MSM/Ms * SL/Kh)
|
increased lymphoma incidence
|
J:34941
|
Msmr1SL/Kh/Msmr1SL/Kh
Msmr2SL/Kh/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh)
|
increased B cell derived lymphoma incidence
|
J:34941
|
Msmr2MSM/Ms/Msmr2MSM/Ms
(involves: MSM/Ms * SL/Kh)
|
decreased lymphoma incidence
|
J:34941
|
Msmr2MSM/Ms/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh)
|
decreased lymphoma incidence
|
J:34941
|
Msmr2SL/Kh/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh)
|
increased lymphoma incidence
|
J:34941
|
Mt1tm1Bri/Mt1tm1Bri
Mt2tm1Bri/Mt2tm1Bri
(129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J)
|
increased incidence of tumors by chemical induction
|
J:56770
|
Mt1tm1Rch/Mt1tm1Rch
Mt2tm1Rch/Mt2tm1Rch
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:120459
|
| increased tumor incidence
|
J:84369
|
mt-Nd6m2Jiha
(involves: C3H/An * C57BL/6 * C57BL/6J * CBA)
|
neoplasm
|
J:164405
|
Mtbptm1Glo/Mtbp+
(involves: 129S7/SvEvBrd * C57BL/6J)
|
neoplasm
|
J:135509
|
Mtbptm1Glo/Mtbp+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased leukemia incidence
|
J:135509
|
| increased lymphoma incidence
|
J:135509
|
| increased metastatic potential
|
J:135509
|
| increased tumor incidence
|
J:135509
|
MtdhGt(XB780)Byg/Mtdh+
Tg(MMTV-PyVT)634Mul/0
(FVB.Cg-MtdhGt(XB780)Byg Tg(MMTV-PyVT)634Mul)
|
decreased mammary gland tumor incidence
|
J:214244
|
MtdhGt(XB780)Byg/Mtdh+
Tg(Wnt1)1Hev/0
(FVB.Cg-MtdhGt(XB780)Byg Tg(Wnt1)1Hev)
|
decreased mammary gland tumor incidence
|
J:214244
|
| increased tumor latency
|
J:214244
|
MtdhGt(XB780)Byg/MtdhGt(XB780)Byg
(FVB.129P2-MtdhGt(XB780)Byg)
|
decreased incidence of tumors by chemical induction
|
J:214244
|
MtdhGt(XB780)Byg/MtdhGt(XB780)Byg
Tg(MMTV-PyVT)634Mul/0
(FVB.Cg-MtdhGt(XB780)Byg Tg(MMTV-PyVT)634Mul)
|
abnormal tumor pathology
|
J:214244
|
| decreased mammary gland tumor incidence
|
J:214244
|
| decreased metastatic potential
|
J:214244
|
| increased tumor latency
|
J:214244
|
MtdhGt(XB780)Byg/MtdhGt(XB780)Byg
Tg(MMTVneu)202Mul/0
(FVB.Cg-MtdhGt(XB780)Byg Tg(MMTVneu)202Mul)
|
decreased mammary gland tumor incidence
|
J:214244
|
| decreased metastatic potential
|
J:214244
|
| increased tumor latency
|
J:214244
|
MtdhGt(XB780)Byg/MtdhGt(XB780)Byg
Tg(Wnt1)1Hev/0
(FVB.Cg-MtdhGt(XB780)Byg Tg(Wnt1)1Hev)
|
decreased mammary gland tumor incidence
|
J:214244
|
| increased tumor latency
|
J:214244
|
Mtdhtm1.2Dsar/Mtdhtm1.2Dsar
(either: B6.129(FVB)-Mtdhtm1.2Dsar or (129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N))
|
decreased cardiovascular system tumor incidence
|
J:216688
|
| decreased incidence of tumors by chemical induction
|
J:216688
|
| decreased liver tumor incidence
|
J:216688
|
| decreased lung tumor incidence
|
J:216688
|
| decreased organ/body region tumor incidence
|
J:216688
|
Mtes1AKR/J/?
(involves: AKR/J * DBA/2J)
|
increased mammary gland tumor incidence
|
J:73358
|
Mtes1NZB/BlNJ/Mtes1NZB/BlNJ
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/NJ * FVB/N-Tg(MMTV-PyVT)634Mul/J * I/LnJ)
|
decreased tumor growth/size
|
J:97671
|
Mtf1Thyls-BALB/c/Mtf1Thyls-BALB/c
(involves: BALB/c * MSM)
|
increased incidence of tumors by ionizing radiation induction
|
J:71358
|
| increased T cell derived lymphoma incidence
|
J:71358
|
Mtf1Thyls-BALB/c/Mtf1Thyls-MSM
(involves: BALB/c * MSM)
|
increased incidence of tumors by ionizing radiation induction
|
J:85264,
J:71358
|
| increased T cell derived lymphoma incidence
|
J:85264,
J:71358
|
Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg
(B6.129P2-Mtss1Gt(CSC156)Byg)
|
increased B cell derived lymphoma incidence
|
J:186118
|
Mtus1Gt(RRA048)Byg/Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:212144
|
Mtv2a/Mtv2a
(DDD.GR-Mtv2a)
|
increased mammary adenocarcinoma incidence
|
J:109201
|
Muc1tm1Gend/Muc1tm1Gend
(B6.129P2-Muc1tm1Gend)
|
decreased tumor growth/size
|
J:30128
|
Muc1tm1Gend/Muc1tm1Gend
Tg(WapTgfa)215Bri/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:123146
|
| neoplasm
|
J:123146
|
Muc1tm1Gend/Muc1tm1Gend
Tg(Wnt1)1Hev/?
(involves: FVB)
|
decreased tumor growth/size
|
J:82470
|
Muc2eey/Muc2eey
(C57BL/6-Muc2eey)
|
neoplasm
|
J:194148
|
Muc2tm1Avel/Muc2tm1Avel
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75047
|
Muc2wnn/Muc2wnn
(C57BL/6-Muc2wnn)
|
neoplasm
|
J:194148
|
Muc4tm1Skb/Muc4tm1Skb
(involves: 129 * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:234205
|
Mus81tm1Raz/Mus81+
(involves: 129P2/OlaHsd)
|
increased adenoma incidence
|
J:91570
|
| increased carcinoma incidence
|
J:91570
|
| increased lymphoma incidence
|
J:91570
|
Mus81tm1Raz/Mus81tm1Raz
(involves: 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:91570
|
| increased carcinoma incidence
|
J:91570
|
| increased lymphoma incidence
|
J:91570
|
Mutyhtm1Jhmi/Mutyhtm1Jhmi
(involves: 129X1/SvJ * C57BL/6J)
|
neoplasm
|
J:89742
|
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased hemangioma incidence
|
J:89742
|
| increased lung adenoma incidence
|
J:89742
|
| increased lung tumor incidence
|
J:89742
|
| increased lymphoma incidence
|
J:89742
|
| increased ovary tumor incidence
|
J:89742
|
| increased tumor incidence
|
J:89742
|
Mutyhtm1Yun/Mutyhtm1Yun
Nudt1tm1Tts/Nudt1tm1Tts
Ogg1tm1Yun/Ogg1tm1Yun
(B6JJcl.129-Mutyhtm1Yun Nudt1tm1Tts Ogg1tm1Yun)
|
increased tumor incidence
|
J:193978
|
Mxi1tm1Rdp/Mxi1tm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased incidence of tumors by chemical induction
|
J:48236
|
Mybl2tm1.1Jof/Mybl2+
Tg(Zp3-cre)3Mrt/0
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
increased leukemia incidence
|
J:196804
|
Myctm1Jlc/Myctm1Jlc
(involves: 129S7/SvEvBrd)
|
decreased tumor incidence
|
J:79427
|
Myctm1Lbox/Myc+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:97900
|
Myctm1Lbox/Myctm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:97900
|
Myctm2Fwa/Myc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:319454
|
Myct1em1Choi/Myct1em1Choi
(involves: C57BL/6)
|
abnormal tumor vascularization
|
J:303692
|
| decreased tumor growth/size
|
J:303692
|
Myct1em1Choi/Myct1em1Choi
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
abnormal tumor vascularization
|
J:303692
|
| decreased mammary gland tumor incidence
|
J:303692
|
Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd)
|
decreased liver tumor incidence
|
J:103464
|
Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:162097
|
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myh14tm2Rsad/Myh14+
(involves: 129S/SvEv * C57BL/6)
|
increased lymphoma incidence
|
J:171110
|
Myh14tm2Rsad/Myh14tm2Rsad
(involves: 129S/SvEv * C57BL/6)
|
increased lymphoma incidence
|
J:171110
|
Mzf1tm1Ppp/Mzf1tm1Ppp
(involves: 129)
|
increased hepatocellular carcinoma incidence
|
J:70407
|
| increased spleen neoplasm incidence
|
J:70407
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:195140
|
| increased hepatocellular carcinoma incidence
|
J:195140
|
| increased leukemia incidence
|
J:195140
|
| increased T cell derived lymphoma incidence
|
J:195140
|
| increased tumor incidence
|
J:195140
|
Nabp2tm1Schg/Nabp2tm1Schg
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:228558
|
Naipctm1.1Kmma/Naipctm1.1Kmma
(involves: BALB/cJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:222114
|
Naipctm1Kmma/Naipctm1Kmma
Lyz2tm1(cre)Ifo/Lyz2+
(B6.Cg-Lyz2tm1(cre)Ifo Naipctm1Kmma)
|
neoplasm
|
J:222114
|
Naipctm1Kmma/Naipctm1Kmma
Tg(Vil1-cre)997Gum/0
(B6.Cg-Naipctm1Kmma Tg(Vil1-cre)997Gum)
|
increased incidence of tumors by chemical induction
|
J:222114
|
Nbeal2tm1a(EUCOMM)Wtsi/Nbeal2tm1a(EUCOMM)Wtsi
(C57BL/6N-Nbeal2tm1a(EUCOMM)Wtsi/Wtsi)
|
decreased metastatic potential
|
J:220801
|
Nbnem3Jpt/Nbnem3Jpt
(Not Specified)
|
neoplasm
|
J:251434
|
Nbnem3Jpt/Nbnem3Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
decreased tumor latency
|
J:251434
|
| increased hemangiosarcoma incidence
|
J:251434
|
| increased histiocytic sarcoma incidence
|
J:251434
|
| increased leiomyosarcoma incidence
|
J:251434
|
| increased rhabdomyosarcoma incidence
|
J:251434
|
| increased squamous cell carcinoma incidence
|
J:251434
|
Nbnem4Jpt/Nbnem4Jpt
(Not Specified)
|
neoplasm
|
J:251434
|
Nbnem4Jpt/Nbnem4Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
decreased tumor latency
|
J:251434
|
| increased hemangiosarcoma incidence
|
J:251434
|
| increased histiocytic sarcoma incidence
|
J:251434
|
| increased leiomyosarcoma incidence
|
J:251434
|
| increased rhabdomyosarcoma incidence
|
J:251434
|
| increased squamous cell carcinoma incidence
|
J:251434
|
Nbnem7Jpt/Nbntm2Zqw
Tg(VAV1-cre)1Graf/0
(involves: 129P2/OlaHsd)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:277750
|
| increased T cell derived lymphoma incidence
|
J:277750
|
Nbntm1Jpt/Nbntm1Jpt
(involves: 129S7/SvEvBrd)
|
neoplasm
|
J:75956
|
Nbntm1Jpt/Nbntm1Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
decreased tumor latency
|
J:75956
|
| increased lymphoma incidence
|
J:75956
|
| increased teratoma incidence
|
J:75956
|
Nbntm1Nus/Nbn+
(involves: 129 * C57BL/6)
|
neoplasm
|
J:68993
|
Nbntm1Xu/Nbntm1Xu
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:75272
|
Nbntm1Zqw/Nbn+
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor latency
|
J:86563
|
| increased B cell derived lymphoma incidence
|
J:86563
|
| increased gonad tumor incidence
|
J:86563
|
| increased incidence of tumors by ionizing radiation induction
|
J:86563
|
| increased Leydig cell tumor incidence
|
J:86563
|
| increased liver adenocarcinoma incidence
|
J:86563
|
| increased liver adenoma incidence
|
J:86563
|
| increased lung adenocarcinoma incidence
|
J:86563
|
| increased lymphoma incidence
|
J:86563
|
| increased mammary adenocarcinoma incidence
|
J:86563
|
| increased prostate intraepithelial neoplasia incidence
|
J:86563
|
| increased T cell derived lymphoma incidence
|
J:86563
|
| increased thyroid adenoma incidence
|
J:86563
|
| increased tumor incidence
|
J:86563
|
Nbntm2Zqw/Nbntm2Zqw
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Wme/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:98316
|
| increased sarcoma incidence
|
J:98316
|
| increased tumor incidence
|
J:98316
|
Ncapd2em1Cya/Ncapd2+
(C57BL/6N-Ncapd2em1Cya)
|
decreased incidence of tumors by chemical induction
|
J:310248
|
NciltC57BL/10J/NciltC57BL/10J
(involves: B10.O20 * O20/A)
|
neoplasm
|
J:68464
|
Ncoa3tm1.1Bwo/Ncoa3tm1.1Bwo
(involves: 129S/SvEv * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:161276
|
Ncoa3tm1Jxu/Ncoa3+
Tg(MMTV-vHaras)SH1Led/0
(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:88789
|
| increased mammary gland tumor incidence
|
J:88789
|
Ncoa3tm1Jxu/Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:109522
|
| increased lymphoma incidence
|
J:109522
|
Ncoa3tm1Jxu/Ncoa3tm1Jxu
Tg(MMTV-vHaras)SH1Led/0
(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
|
decreased incidence of induced tumors
|
J:88789
|
| decreased mammary gland tumor incidence
|
J:88789
|
| decreased metastatic potential
|
J:88789
|
| decreased tumor growth/size
|
J:88789
|
Ncoa5tm1Hxia/Ncoa5+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Ncoa5tm1Hxia/Ncoa5+
(C.129(B6)-Ncoa5tm1Hxia)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Ncstntm1.1Akli/Ncstntm1.1Akli
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
(involves: 129S/SvEv * C57BL/6)
|
abnormal tumor pathology
|
J:196407
|
| increased leukemia incidence
|
J:196407
|
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * CBA * SJL)
|
increased leukemia incidence
|
J:172442
|
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(Upk2-cre,-EGFP)#Akli/0
(involves: 129)
|
increased urinary bladder carcinoma incidence
|
J:227748
|
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(VAV1-cre)1Graf/0
(involves: 129 * C57BL/6 * SJL)
|
increased leukemia incidence
|
J:172442
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rpl11tm1.1Srn/Rpl11+
(involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1)
|
increased incidence of tumors by ionizing radiation induction
|
J:292575
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rragatm2Dmsa/Rragatm2Dmsa
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
increased lymphoma incidence
|
J:213516
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Stag2tm1.1Alos/Y
(involves: 129S6/SvEvTac * C57BL/6NCrl)
|
neoplasm
|
J:298088
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Stag2tm1.1Alos/Stag2tm1.1Alos
(involves: 129S6/SvEvTac * C57BL/6NCrl)
|
neoplasm
|
J:298088
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
tumor regression
|
J:223417
|
Ndrg1em1Lxli/Ndrg1em1Lxli
(C57BL/6N-Ndrg1em1Lxli)
|
neoplasm
|
J:330126
|
Ndrg2tm1Kmori/Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased brain tumor incidence
|
J:210264
|
| increased gastrointestinal tumor incidence
|
J:210264
|
| increased hepatocellular carcinoma incidence
|
J:210264
|
| increased lung carcinoma incidence
|
J:210264
|
| increased pancreas tumor incidence
|
J:210264
|
| increased skin tumor incidence
|
J:210264
|
| increased T cell derived lymphoma incidence
|
J:210264
|
| increased testis tumor incidence
|
J:210264
|
| increased tumor incidence
|
J:210264
|
Ndrg2tm1Kmori/Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased hepatocellular carcinoma incidence
|
J:210264
|
| increased lung carcinoma incidence
|
J:210264
|
| increased T cell derived lymphoma incidence
|
J:210264
|
| increased tumor incidence
|
J:210264
|
Neil1tm1Rsld/Neil1tm1Rsld
(involves: 129S1/Sv * C57BL/6)
|
increased tumor incidence
|
J:106077
|
Nell1tm1Kuv/Nell1tm1Kuv
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
(involves: 129 * FVB/NJ)
|
abnormal tumor morphology
|
J:326989
|
| abnormal tumor vascular morphology
|
J:326989
|
| decreased osteosarcoma incidence
|
J:326989
|
Neu3tm1Yamk/Neu3tm1Yamk
(B6.129-Neu3tm1Yamk)
|
decreased incidence of tumors by chemical induction
|
J:189604
|
| neoplasm
|
J:189604
|
Neurl1atm1Led/Neurl1atm1Led
(involves: 129S6/SvEvTac)
|
neoplasm
|
J:72105
|
Nf1tm1.1Kest/Nf1tm1c(KOMP)Wtsi
Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)
|
increased neurofibroma incidence
|
J:234172
|
Nf1tm1c(KOMP)Wtsi/Nf1tm1c(KOMP)Wtsi
Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N)
|
increased neurofibroma incidence
|
J:234172
|
Nf1tm1Cbr/Nf1+
(involves: 129S1/Sv * C57BL/6)
|
neoplasm
|
J:68489
|
Nf1tm1Cbr/Nf1tm1Cbr
(involves: 129S1/Sv * C57BL/6)
|
neoplasm
|
J:68489
|
Nf1tm1Fcr/Nf1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(B6.Cg-Tg(Mx1-cre)1Cgn Nf1tm1Fcr Ptentm1Hwu)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:232645
|
| increased tumor incidence
|
J:232645
|
Nf1tm1Fcr/Nf1+
Tg(Cnp-EGFR)10Nrat/0
(involves: 129S/SvEv * C57BL/6 * SJL)
|
decreased tumor incidence
|
J:95933
|
Nf1tm1Fcr/Nf1+
Tg(GFAP-cre)#Gtm/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA)
|
increased glioma incidence
|
J:176586
|
Nf1tm1Fcr/Nf1+
Trp53tm1Brd/Trp53+
(B6.129-Trp53tm1Brd Nf1tm1Fcr)
|
increased brain tumor incidence
|
J:95933
|
| increased malignant tumor incidence
|
J:95933
|
| increased sarcoma incidence
|
J:95933
|
Nf1tm1Fcr/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased carcinoma incidence
|
J:58877
|
| increased fibrohistocytoma incidence
|
J:58877
|
| increased leiomyosarcoma incidence
|
J:58877
|
| increased lymphoma incidence
|
J:58877
|
| increased malignant triton tumor incidence
|
J:58877
|
| increased neuroblastoma incidence
|
J:58877
|
| increased neurofibrosarcoma incidence
|
J:58877
|
| increased rhabdomyosarcoma incidence
|
J:58877
|
| increased sarcoma incidence
|
J:58877
|
Nf1tm1Fcr/Nf1+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:58877
|
Nf1tm1Fcr/Nf1+
Tsc1tm1Djk/Tsc1tm1Djk
Tg(GFAP-cre)#Gtm/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA)
|
neoplasm
|
J:176586
|
Nf1tm1Fcr/Nf1tm1Fcr
Trp53tm1Elee/Trp53tm1Elee
Tg(GFAP-cre)25Mes/0
(involves: 129S/SvEv * 129S4/SvJae * FVB/N)
|
decreased tumor latency
|
J:149662
|
| increased glioma incidence
|
J:149662
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Tg(Gfap-cre)77.6Mvs/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6NHsd)
|
neoplasm
|
J:154673
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Trp53tm1Elee/Trp53+
Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
| increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Trp53tm1Tyj/Trp53+
Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
| increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1+
Trp53tm1Elee/Trp53+
Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
| increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1+
Trp53tm1Tyj/Trp53+
Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
| increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1tm1Fcr
Tg(GFAP-cre)#Gtm/0
(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased glioma incidence
|
J:165209
|
Nf1tm1Par/Nf1tm1Par
H2az2Tg(Wnt1-cre)11Rth/H2az2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased ganglioneuroma incidence
|
J:80323
|
| increased gangliosarcoma incidence
|
J:80323
|
| increased pheochromocytoma incidence
|
J:80323
|
| increased tumor incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par
Tg(Gfap-cre)77.6Mvs/0
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6NHsd)
|
neoplasm
|
J:154673
|
Nf1tm1Par/Nf1tm1Par
Tg(Mpz-cre)94Imeg/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased ganglioneuroma incidence
|
J:80323
|
| increased gangliosarcoma incidence
|
J:80323
|
| increased pheochromocytoma incidence
|
J:80323
|
| increased tumor incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par
Tg(Pax3-cre)1Joe/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased ganglioneuroma incidence
|
J:80323
|
| increased gangliosarcoma incidence
|
J:80323
|
| increased pheochromocytoma incidence
|
J:80323
|
| increased tumor incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par
Tg(Syn1-cre)671Jxm/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
neoplasm
|
J:68558
|
Nf1tm1Par/Nf1tm1Tyj
Tg(Mpz-cre)1Brn/0
(involves: 129/Sv * FVB/N)
|
increased neurofibroma incidence
|
J:131914
|
Nf1tm1Par/Nf1tm1Tyj
Tg(Postn-cre)1Sjc/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
neoplasm
|
J:131914
|
Nf1tm1Tyj/?
Nstr1A/J/?
Trp53tm1Tyj/?
(involves: 129S2/SvPas * A/J * C57BL/6J)
|
decreased tumor incidence
|
J:105038
|
Nf1tm1Tyj/?
Nstr1C57BL/6J/Nstr1C57BL/6J
Trp53tm1Tyj/?
(involves: 129S2/SvPas * A/J * C57BL/6J)
|
increased neurofibrosarcoma incidence
|
J:105038
|
Nf1tm1Tyj/?
Nstr2A/J/?
Trp53tm1Tyj/?
(involves: 129S2/SvPas * A/J * C57BL/6J)
|
decreased tumor incidence
|
J:105038
|
Nf1tm1Tyj/?
Trp53tm1Tyj/?
Mastr129S4/SvJae/?
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
decreased tumor incidence
|
J:92444
|
Nf1tm1Tyj/?
Trp53tm1Tyj/?
MastrC57BL/6J/?
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
increased astrocytoma incidence
|
J:92444
|
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:18542
|
| increased fibrosarcoma incidence
|
J:18542
|
| increased hepatoma incidence
|
J:18542
|
| increased leukemia incidence
|
J:18542
|
| increased lung adenocarcinoma incidence
|
J:18542
|
| increased lymphoma incidence
|
J:18542
|
| increased neurofibrosarcoma incidence
|
J:18542
|
| increased pheochromocytoma incidence
|
J:18542
|
| increased tumor incidence
|
J:18542
|
Nf1tm1Tyj/Nf1+
Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:217077
|
| increased histiocytic sarcoma incidence
|
J:217077
|
| increased intestinal adenoma incidence
|
J:217077
|
| increased lymphoma incidence
|
J:217077
|
| increased neurofibroma incidence
|
J:217077
|
| increased neurofibrosarcoma incidence
|
J:217077
|
| increased Schwannoma incidence
|
J:217077
|
| increased tumor incidence
|
J:217077
|
Nf1tm1Tyj/Nf1+
Suz12Gt(Betageo)1Khe/Suz12+
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased glioma incidence
|
J:217077
|
| increased hemangiosarcoma incidence
|
J:217077
|
| increased histiocytic sarcoma incidence
|
J:217077
|
| increased lymphoma incidence
|
J:217077
|
| increased neurofibrosarcoma incidence
|
J:217077
|
| increased tumor incidence
|
J:217077
|
Nf1tm1Tyj/Nf1+
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129/Sv * C57BL/6)
|
increased neurofibrosarcoma incidence
|
J:58876
|
| increased sarcoma incidence
|
J:58876
|
| increased tumor incidence
|
J:58876
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)
|
increased astrocytoma incidence
|
J:64364
|
| increased brain tumor incidence
|
J:64364
|
| increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((C3H/HeJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased astrocytoma incidence
|
J:64364
|
| increased brain tumor incidence
|
J:64364
|
| increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((CAST/EiJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased astrocytoma incidence
|
J:64364
|
| increased brain tumor incidence
|
J:64364
|
| increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((CBA/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased brain tumor incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((SJL/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased astrocytoma incidence
|
J:64364
|
| increased brain tumor incidence
|
J:64364
|
| increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased glioma incidence
|
J:217077
|
| increased histiocytic sarcoma incidence
|
J:217077
|
| increased lymphoma incidence
|
J:228258,
J:217077
|
| increased metastatic potential
|
J:228258
|
| increased neuroblastoma incidence
|
J:217077
|
| increased neurofibrosarcoma incidence
|
J:217077
|
| increased sarcoma incidence
|
J:228258
|
| increased tumor incidence
|
J:217077
|
Nf1tm1Tyj/Nf1tm2Tyj
(chimera involves: 129S2/SvPas)
|
increased neurofibroma incidence
|
J:58876
|
Nf2tm1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
| increased lung adenocarcinoma incidence
|
J:63264
|
| increased mesothelioma incidence
|
J:63264
|
| increased neurofibroma incidence
|
J:63264
|
| increased neurofibrosarcoma incidence
|
J:63264
|
| increased osteoma incidence
|
J:63264
|
| increased osteosarcoma incidence
|
J:63264
|
| increased renal carcinoma incidence
|
J:63264
|
| increased sarcoma incidence
|
J:63264
|
| neoplasm
|
J:63264
|
| osseous metaplasia
|
J:63264
|
Nf2tm1Gth/Nf2tm2Gth
Tg(Mpz-cre)1Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased hamartoma incidence
|
J:63264
|
Nf2tm1Gth/Nf2tm2Gth
Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mesothelioma incidence
|
J:63264
|
| increased neurofibrosarcoma incidence
|
J:63264
|
| increased odontoma incidence
|
J:63264
|
| increased odontosarcoma incidence
|
J:63264
|
| increased Schwannoma incidence
|
J:63264
|
| osseous metaplasia
|
J:63264
|
Nf2tm1Tyj/Nf2+
(either: (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) or (involves: 129S2/SvPas * C57BL/6J))
|
increased carcinoma incidence
|
J:47282
|
| increased fibrosarcoma incidence
|
J:47282
|
| increased lung adenocarcinoma incidence
|
J:47282
|
| increased lymphoma incidence
|
J:47282
|
| increased malignant tumor incidence
|
J:47282
|
| increased osteosarcoma incidence
|
J:47282
|
| increased sarcoma incidence
|
J:47282
|
| neoplasm
|
J:47282
|
Nf2tm2.1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibrosarcoma incidence
|
J:63264
|
| increased lung adenocarcinoma incidence
|
J:63264
|
| increased osteoma incidence
|
J:63264
|
| increased osteosarcoma incidence
|
J:63264
|
| neoplasm
|
J:63264
|
Nf2tm2Gth/Nf2+
Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
| increased lung adenocarcinoma incidence
|
J:63264
|
| increased osteoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2+
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
| increased osteoma incidence
|
J:92413
|
| increased osteosarcoma incidence
|
J:92413
|
| increased skeletal tumor incidence
|
J:92413
|
Nf2tm2Gth/Nf2+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:132943
|
| increased mesothelioma incidence
|
J:132943
|
| increased Schwannoma incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
| increased uterus leiomyoma incidence
|
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd)
|
increased tumor incidence
|
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd * FVB/N)
|
increased meningioma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
(involves: 129P2/OlaHsd * FVB/N)
|
increased meningioma incidence
|
J:173718
|
| increased osteoma incidence
|
J:173718
|
| increased pituitary adenoma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased nervous system tumor incidence
|
J:173718
|
| increased osteosarcoma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatobiliary system tumor incidence
|
J:162628
|
| increased hepatocellular carcinoma incidence
|
J:162628
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)1Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased tumor incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased extremity angiosarcoma incidence
|
J:92413
|
| increased lung adenocarcinoma incidence
|
J:92413
|
| increased neurofibrosarcoma incidence
|
J:92413
|
| increased renal carcinoma incidence
|
J:92413
|
| increased Schwannoma incidence
|
J:63264,
J:92413
|
| osseous metaplasia
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
| increased lung adenocarcinoma incidence
|
J:63264
|
| increased neurofibrosarcoma incidence
|
J:63264
|
| increased odontoma incidence
|
J:63264
|
| increased osteoma incidence
|
J:63264
|
| increased osteosarcoma incidence
|
J:63264
|
| increased renal carcinoma incidence
|
J:63264
|
| increased sarcoma incidence
|
J:63264
|
| increased Schwannoma incidence
|
J:63264,
J:92413
|
| osseous metaplasia
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)4Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased Schwannoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:63264
|
| increased odontoma incidence
|
J:63264
|
| increased odontosarcoma incidence
|
J:63264
|
| increased osteoma incidence
|
J:63264
|
| increased osteosarcoma incidence
|
J:63264
|
| increased renal carcinoma incidence
|
J:63264
|
| osseous metaplasia
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased renal carcinoma incidence
|
J:150071
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Postn-cre)1Sjc/0
(involves: 129P2/OlaHsd * FVB/NTac)
|
increased neurofibrosarcoma incidence
|
J:216420
|
| increased Schwannoma incidence
|
J:216420
|
Nf2tm2Gth/Nf2tm2Gth
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * FVB/NCr)
|
neoplasm
|
J:231492
|
Nf2tm2Gth/Nf2tm2Gth
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased renal carcinoma incidence
|
J:150071
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased leiomyosarcoma incidence
|
J:92413
|
| increased nervous system tumor incidence
|
J:92413
|
| increased neurofibroma incidence
|
J:92413
|
| increased neurofibrosarcoma incidence
|
J:92413
|
| increased sarcoma incidence
|
J:92413
|
| increased Schwannoma incidence
|
J:92413
|
| osseous metaplasia
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53tm1Brd
Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased extremity angiosarcoma incidence
|
J:92413
|
| increased neurofibrosarcoma incidence
|
J:92413
|
| increased osteoma incidence
|
J:92413
|
| increased osteosarcoma incidence
|
J:92413
|
| increased rhabdomyosarcoma incidence
|
J:92413
|
| increased sarcoma incidence
|
J:92413
|
| increased tumor incidence
|
J:92413
|
| osseous metaplasia
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:132943
|
| increased mesothelioma incidence
|
J:132943
|
| increased Schwannoma incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
| increased uterus leiomyoma incidence
|
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:132943
|
| increased mesothelioma incidence
|
J:132943
|
| increased rhabdomyosarcoma incidence
|
J:132943
|
| increased Schwannoma incidence
|
J:132943
|
| increased T cell derived lymphoma incidence
|
J:132943
|
| increased tumor incidence
|
J:132943
|
| increased uterus leiomyoma incidence
|
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
Yap1tm1.1Dupa/Yap1+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
neoplasm
|
J:162628
|
Nf2tm2Gth/Nf2tm2Gth
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
neoplasm
|
J:162628
|
Nf2tm2Gth/Nf2tm2Gth
Yap1tm2.1Dupa/Yap1tm2.1Dupa
(involves: 129P2/OlaHsd)
|
increased hamartoma incidence
|
J:223215
|
Nfe2tm1.1Hlpa/?
(involves: 129 * C57BL/6)
|
increased acute myeloid leukemia incidence
|
J:275444
|
| increased myeloid sarcoma incidence
|
J:275444
|
Nfe2tm1Sho/Nfe2+
(C.129S4-Nfe2tm1Sho)
|
increased incidence of induced tumors
|
J:125982
|
Nfe2l1tm1Jefc/Nfe2l1tm1Ywk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:97188
|
| increased liver adenoma incidence
|
J:97188
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * ICR)
|
increased incidence of tumors by chemical induction
|
J:68072
|
| increased stomach tumor incidence
|
J:68072
|
Nhej1tm1Fwa/Nhej1tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129)
|
increased B cell derived lymphoma incidence
|
J:138774
|
| increased medulloblastoma incidence
|
J:138774
|
| increased T cell derived lymphoma incidence
|
J:138774
|
Nit1tm1.1Hbn/Nit1tm1.1Hbn
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:115052
|
Nit1tm1Hbn/Nit1tm1.1Hbn
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:115052
|
Nkx2-1tm2Shk/Nkx2-1tm2Shk
Tg(TPO-cre)1Shk/0
(involves: 129X1/SvJ * FVB/NCr)
|
increased adenoma incidence
|
J:111027
|
Nkx2-9tm1Jlck/Nkx2-9tm1Jlck
(involves: 129/Sv * C57BL/6 * SJL)
|
increased lung adenoma incidence
|
J:115581
|
| increased lung tumor incidence
|
J:115581
|
| increased squamous cell carcinoma incidence
|
J:115581
|
Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa
(involves: C57BL/6)
|
preneoplasia
|
J:74350,
J:89571
|
Nkx3-1tm1Mms/Nkx3-1+
(either: (involves: 129S1/Sv * 129S1/SvImJ) or (involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J))
|
preneoplasia
|
J:54465
|
Nkx3-1tm1Mms/Nkx3-1+
Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:75085
|
| increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms
(either: (involves: 129S1/Sv * 129S1/SvImJ) or (involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J))
|
preneoplasia
|
J:54465
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms
(involves: 129S1/Sv)
|
increased prostate intraepithelial neoplasia incidence
|
J:131932
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms
Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:75085
|
| increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Nkx3-1tm1Saa/Nkx3-1tm1Saa
Tg(KLK3-cre)13Saa/?
(involves: C57BL/6)
|
increased prostate intraepithelial neoplasia incidence
|
J:74350
|
| preneoplasia
|
J:74350
|
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:153425
|
| increased prostate intraepithelial neoplasia incidence
|
J:191327,
J:153425
|
Nlrp6tm1Macha/Nlrp6tm1Macha
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:173352
|
| increased incidence of tumors by chemical induction
|
J:173352
|
Nlrp12tm1Tdk/Nlrp12tm1Tdk
(B6.Cg-Nlrp12tm1Tdk)
|
increased incidence of tumors by chemical induction
|
J:178951
|
Nme1tm1Jyd/Nme1tm1Jyd
(involves: 129/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:109190
|
Nmitm1.1Geno/Nmitm1.1Geno
Tg(KRT14-cre)1Amc/0
(B6.Cg-Nmitm1.1Geno Tg(KRT14-cre)1Amc)
|
increased incidence of tumors by chemical induction
|
J:261035
|
| increased metastatic potential
|
J:261035
|
Nmitm1.1Geno/Nmitm1.1Geno
Tg(KRT14-cre)1Amc/0
Tg(MMTVneu)202Mul/0
(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:261035
|
| increased metastatic potential
|
J:261035
|
Nmral1Gt(S8-10A1)Sor/Nmral1Gt(S8-10A1)Sor
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-Nmral1Gt(S8-10A1)Sor Tg(MMTV-PyVT)634Mul)
|
decreased mammary gland tumor incidence
|
J:282813
|
| decreased tumor growth/size
|
J:282813
|
| increased tumor latency
|
J:282813
|
Nop53tm1Asuz/Nop53+
(B6.129P2-Nop53tm1Asuz)
|
decreased papilloma incidence
|
J:241062
|
Nos2tm1Lau/Nos2tm1Lau
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal tumor susceptibility
|
J:93780
|
Nos2tm1Lau/Nos2tm1Lau
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-Nos2tm1Lau Tg(MMTV-PyVT)634Mul)
|
abnormal tumor morphology
|
J:121391
|
| decreased tumor incidence
|
J:121391
|
| increased tumor latency
|
J:84218,
J:121391
|
Nos2tm1Lau/Nos2tm1Lau
Tg(MMTV-PyVT)634Mul/0
(FVB.Cg-Nos2tm1Lau Tg(MMTV-PyVT)634Mul)
|
decreased tumor latency
|
J:121391
|
| increased tumor growth/size
|
J:121391
|
| increased tumor incidence
|
J:121391
|
Notch1tm2Rko/Notch1tm2Rko
Notch2tm1Rko/Notch2tm1Rko
Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:172442
|
Notch1tm2Rko/Notch1tm3(cre)Rko
(involves: 129X1/SvJ * C57BL/6)
|
increased hemangioma incidence
|
J:171829
|
Npm1tm1Gsva/Npm1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute promyelocytic leukemia incidence
|
J:172071
|
| increased B cell derived lymphoma incidence
|
J:172071
|
Npm1tm1Hft/Npm1+
(involves: 129)
|
neoplasm
|
J:194999
|
Npm1tm1Ppp/Npm1+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
abnormal tumor morphology
|
J:101494
|
| increased B cell derived lymphoma incidence
|
J:101494
|
Npr1tm1.1Kkan/Npr1tm1.1Kkan
Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * SJL)
|
increased metastatic potential
|
J:220676
|
Nqo1tm1Akj/Nqo1tm1Akj
(Not Specified)
|
increased skin tumor incidence
|
J:66196
|
Nqo2tm1Akj/Nqo2tm1Akj
(Not Specified)
|
increased skin tumor incidence
|
J:92400
|
Nr0b1tm1.1Lja/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
increased testis tumor incidence
|
J:71710
|
Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr
Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung squamous cell carcinoma incidence
|
J:234268
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:121075
|
| increased liver adenoma incidence
|
J:121075
|
| increased liver tumor incidence
|
J:121075
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:118204
|
| increased liver adenoma incidence
|
J:118204
|
| increased liver tumor incidence
|
J:118204
|
Nr4a1tm1Jmi/Nr4a1tm1Jmi
(involves: 129S2/SvPas * C57BL/6)
|
increased tumor growth/size
|
J:239509
|
Nr4a1tm1Jmi/Nr4a1tm1Jmi
Nr4a3tm1Omc/Nr4a3tm1Omc
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased leukemia incidence
|
J:121903
|
Nrastm1Tyj/Nrastm1Tyj
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:204263
|
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre)1Lru/0
(involves: C57BL/6 * DBA/2)
|
increased melanoma incidence
|
J:198244
|
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)1Lru/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:198244
|
Nrbp1tm1.1Dja/Nrbp1tm1.1Dja
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:184685
|
| increased leukemia incidence
|
J:184685
|
| increased lung carcinoma incidence
|
J:184685
|
| increased lymphoma incidence
|
J:184685
|
| increased tumor incidence
|
J:184685
|
Nrbp1tm1.1Dja/Nrbp1tm1.2Dja
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:184685
|
| increased leukemia incidence
|
J:184685
|
| increased lung carcinoma incidence
|
J:184685
|
| increased lymphoma incidence
|
J:184685
|
| increased tumor incidence
|
J:184685
|
Nrp1tm1.1Izac/Nrp1tm1.1Izac
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor growth/size
|
J:208348
|
Nsmce2Gt(AA0032)Wtsi/Nsmce2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased cardiovascular system tumor incidence
|
J:227197
|
| increased histiocytic sarcoma incidence
|
J:227197
|
| increased liver tumor incidence
|
J:227197
|
| increased lymphoma incidence
|
J:227197
|
| increased pancreas tumor incidence
|
J:227197
|
| increased tumor incidence
|
J:227197
|
Nsun2tm1a(EUCOMM)Wtsi/Nsun2tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Nsun2tm1a(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Nthl1tm1Tbor/Nthl1tm1Tbor
(involves: 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:78429
|
Nuak2tm1Esu/Nuak2+
(B6.129S4-Nuak2tm1Esu)
|
increased intestinal adenoma incidence
|
J:139603
|
Nudt1tm1Tts/Nudt1tm1Tts
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased liver tumor incidence
|
J:71836
|
| increased lung adenocarcinoma incidence
|
J:71836
|
| increased lung adenoma incidence
|
J:71836
|
| increased stomach tumor incidence
|
J:71836
|
Nudt1tm1Tts/Nudt1tm1Tts
Ogg1tm1Yun/Ogg1tm1Yun
(involves: 129S/SvEv * C57BL/6J)
|
neoplasm
|
J:82287
|
Nufip1em1Cya/Nufip1em1Cya
S100a4em1(cre)Zhyg/S100a4+
(involves: C57BL/6J)
|
decreased tumor growth/size
|
J:330821
|
| neoplasm
|
J:330821
|
Nup85tm1.1Yter/Nup85tm1.1Yter
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * CBA)
|
decreased tumor growth/size
|
J:292726
|
Ogg1tm1Yun/Ogg1tm1Yun
(involves: 129S/SvEv * C57BL/6J)
|
increased lung adenoma incidence
|
J:82287
|
| increased lung carcinoma incidence
|
J:82287
|
Ossc1C3H/HeJ/?
Ossc2102/El/?
(involves: 102/El * C3H/HeJ)
|
increased sarcoma incidence
|
J:75213
|
Ossc3BALB/c/Ossc3CBA/Ca
(involves: BALB/c * CBA/Ca)
|
increased osteosarcoma incidence
|
J:107725
|
Otub2tm1.1Gpt/Otub2+
(involves: C57BL/6JGpt)
|
increased incidence of tumors by chemical induction
|
J:330595
|
Otub2tm1.1Gpt/Otub2tm1.1Gpt
(involves: C57BL/6JGpt)
|
increased incidence of tumors by chemical induction
|
J:330595
|
Otulinem1Gvl/Otulintm1c(EUCOMM)Hmgu
Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)
|
increased squamous cell carcinoma incidence
|
J:312394
|
Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu
Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
increased skin squamous cell carcinoma incidence
|
J:312394
|
Pak1em1Yuwa/Pak1+
(FVB/N-Pak1em1Yuwa)
|
decreased papilloma incidence
|
J:323200
|
Pak1em1Yuwa/Pak1em1Yuwa
(FVB/N-Pak1em1Yuwa)
|
decreased papilloma incidence
|
J:323200
|
Pak1em2Yuwa/Pak1+
(FVB/N-Pak1em2Yuwa)
|
neoplasm
|
J:323200
|
Pak1em2Yuwa/Pak1em2Yuwa
(FVB/N-Pak1em2Yuwa)
|
neoplasm
|
J:323200
|
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
|
decreased tumor latency
|
J:197442
|
| increased mammary gland tumor incidence
|
J:197442
|
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
|
abnormal tumor morphology
|
J:197442
|
| decreased tumor latency
|
J:197442
|
| increased mammary gland tumor incidence
|
J:197442
|
| increased mouth tumor incidence
|
J:197442
|
| increased skin tumor incidence
|
J:197442
|
Papg1BALB/cJ/Papg1BALB/cJ
(involves: BALB/cJ * SWR/J)
|
increased tumor incidence
|
J:43176
|
Paqr3tm1Ychn/Paqr3+
(involves: 129 * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:139058
|
| increased skin papilloma incidence
|
J:139058
|
Paqr3tm1Ychn/Paqr3tm1Ychn
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:139058
|
| increased incidence of tumors by chemical induction
|
J:139058
|
| increased skin papilloma incidence
|
J:139058
|
| increased tumor growth/size
|
J:139058
|
Par1M. spretus/Par1M. spretus
(involves: A/J * M. spretus)
|
decreased incidence of tumors by chemical induction
|
J:120319
|
Par2A/J/?
Politm1.1Lgh/Poli+
(involves: A/J * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:212610
|
Par2A/JSlc/Par2BALB/cByJJcl
(involves: BALB/cByJJcl * A/JSlc)
|
increased lung adenoma incidence
|
J:70565
|
Par2BALB/c/?
(involves: A/J * BALB/c)
|
decreased incidence of tumors by chemical induction
|
J:36219
|
Par2BALB/cByJJcl/Par2BALB/cByJJcl
(involves: BALB/cByJJcl * A/JSlc)
|
increased lung adenoma incidence
|
J:70565
|
Par3A/J/Par3SM/J
(involves: A/J * SM/J)
|
decreased incidence of tumors by chemical induction
|
J:67468
|
Par3SM/J/Par3SM/J
(involves: A/J * SM/J)
|
decreased incidence of tumors by chemical induction
|
J:67468
|
Par5BALB/cJ/?
(involves: BALB/cJ * SWR/J)
|
decreased lung tumor incidence
|
J:43176
|
Parms1BALB/cByJ/Parms1C57BL/6NCrl
Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl)
|
increased rhabdomyosarcoma incidence
|
J:93364
|
Parms1C57BL/6NCrl/Parms1C57BL/6NCrl
Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl)
|
increased rhabdomyosarcoma incidence
|
J:93364
|
Parp2tm1Jmdm/Parp2tm1Jmdm
(involves: 129S2/SvPas * C57BL/6)
|
neoplasm
|
J:83371
|
Pas1cBALB/cOlaHsd/Pas1cBALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of tumors by chemical induction
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas5bA/JOlaHsd/Pas5bA/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of tumors by chemical induction
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas5bA/JOlaHsd/Pas5bBALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
abnormal tumor susceptibility
|
J:50533
|
Pas7A/JOlaHsd/Pas7A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of tumors by chemical induction
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas8A/JOlaHsd/Pas8A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of tumors by chemical induction
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas8A/JOlaHsd/Pas8BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of tumors by chemical induction
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas9A/JOlaHsd/Pas9A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
decreased incidence of tumors by chemical induction
|
J:50533
|
Pas9A/JOlaHsd/Pas9BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of induced tumors
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas9BALB/cOlaHsd/Pas9BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased incidence of induced tumors
|
J:50533
|
| increased lung adenoma incidence
|
J:50533
|
Pas14A/J/?
(involves: A/J * C57BL/6J * M. spretus)
|
decreased lung tumor incidence
|
J:29218
|
Pas14A/J/?
(involves: A/J * C57BL/6J)
|
decreased lung tumor incidence
|
J:86399
|
Pas14A/J/Pas14A/J
(involves: A/J * C57BL/6J)
|
increased lung adenoma incidence
|
J:21801
|
Pas17C57BL/6JBy/Pas17C57BL/6JBy
Politm1.1Lgh/Poli+
(involves: C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:212610
|
Pas17C57BL/6JBy/Pas17C57BL/6JBy
Politm1.1Lgh/Politm1.1Lgh
(involves: C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:212610
|
Pas17M. spretus/?
(involves: A/J * C57BL/6J * M. spretus)
|
decreased lung tumor incidence
|
J:29218
|
Pas19A/J/Pas19A/J
(involves: A/J * C57BL/6J)
|
increased lung adenoma incidence
|
J:21801
|
Pax3tm1(FOXO1A)Gcg/Pax3+
(either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * NMRI))
|
neoplasm
|
J:79365
|
Pax3tm1Mrc/Pax3+
Pax7tm1(cre)Mrc/Pax7+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:93443
|
Pax5tm3Mbu/Pax5+
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Pax6Sey-4H/Pax6+
(involves: 101/H * C3H/HeCrj * C3H/HeH)
|
increased alimentary system tumor incidence
|
J:124276
|
| increased intestinal adenoma incidence
|
J:124276
|
| increased stomach tumor incidence
|
J:124276
|
| increased tumor incidence
|
J:124276
|
Pax6Sey-Dey/Pax6+
(C3H/HeJ-Pax6Sey-Dey)
|
neoplasm
|
J:10820
|
Paxxem1Spj/Paxxem1Spj
(C57BL/6NTac-Paxxem1Spj)
|
neoplasm
|
J:236776
|
Pcbp4Gt(D136D11)Wrst/Pcbp4+
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:231514
|
| increased kidney tumor incidence
|
J:231514
|
| increased lung adenocarcinoma incidence
|
J:231514
|
Pcbp4Gt(D136D11)Wrst/Pcbp4Gt(D136D11)Wrst
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:231514
|
| increased kidney tumor incidence
|
J:231514
|
| increased lung adenocarcinoma incidence
|
J:231514
|
Pcsk2tm1Dfs/Pcsk2tm1Dfs
(B6;129-Pcsk2tm1Dfs/J)
|
increased glucagonoma incidence
|
J:236511
|
| increased pancreas tumor incidence
|
J:236905
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:236905
|
| increased pancreatic islet cell adenoma incidence
|
J:236905
|
Pcsk6tm1Rob/Pcsk6tm1Rob
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased tumor latency
|
J:180839
|
| increased ovary tumor incidence
|
J:180839
|
| increased reproductive system tumor incidence
|
J:180839
|
PctmBALB/cAnPt/PctmBALB/cAnPt
(involves: BALB/cAnPt * DBA/2N)
|
decreased incidence of tumors by chemical induction
|
J:15235
|
PctmBALB/cAnPt/PctmDBA/2N
(involves: BALB/cAnPt * DBA/2N)
|
increased incidence of tumors by chemical induction
|
J:15235
|
| increased plasmacytoma incidence
|
J:15235
|
Pctr2DBA/2N/?
(involves: BALB/cAnPt * DBA/2N)
|
decreased tumor incidence
|
J:16958
|
PctsBALB/cAnPt/PctsBALB/cAnPt
(involves: BALB/cAnPt * DBA/2N)
|
increased incidence of tumors by chemical induction
|
J:15235
|
| increased plasmacytoma incidence
|
J:15235
|
Pcyt1btm1Mkar/Pcyt1btm1Mkar
(involves: 129S1/Sv * C57BL/6J)
|
increased tumor incidence
|
J:90150
|
Pcyts1BALB/c/Pcyts1BALB/c
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts1BALB/c/Pcyts1C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts2BALB/c/Pcyts2BALB/c
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts2BALB/c/Pcyts2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts3BALB/c/Pcyts3BALB/c
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts3BALB/c/Pcyts3C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts4BALB/c/Pcyts4BALB/c
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts4BALB/c/Pcyts4C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts5BALB/c/Pcyts5BALB/c
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts5BALB/c/Pcyts5C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts6BALB/c/Pcyts6C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pcyts6C57BL/6J/Pcyts6C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased plasmacytoma incidence
|
J:78523
|
Pdcd1tm1.1Liux/Pdcd1tm1.1Liux
(involves: C57BL/6)
|
decreased tumor growth/size
|
J:190150
|
Pdcd1tm1.1Liux/Pdcd1tm1.1Liux
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
decreased tumor growth/size
|
J:190150
|
| increased tumor latency
|
J:190150
|
Pdcd1lg2tm1Dmp/Pdcd1lg2tm1Dmp
(C.129-Pdcd1lg2tm1Dmp)
|
increased tumor growth/size
|
J:99212
|
Pdcd4tm1.1Tosc/Pdcd4tm1.1Tosc
(involves: 129 * C57BL/6 * CD-1)
|
increased papilloma incidence
|
J:132696
|
Pdcd4tm1Yhcn/Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn)
|
increased B cell derived lymphoma incidence
|
J:120583
|
| preneoplasia
|
J:120583
|
Pdcd10tm1Wami/Pdcd10tm1Wami
Emx1tm1(cre)Krj/Emx1+
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased hemangioma incidence
|
J:170480
|
Pdcd10tm1Wami/Pdcd10tm1Wami
Tg(GFAP-cre)25Mes/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased hemangioma incidence
|
J:170480
|
Peak1tm1.2Itl/Peak1tm1.2Itl
(involves: C57BL/6NTac * FVB/N)
|
abnormal tumor vascularization
|
J:278882
|
Per2tm1Brd/Per2tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased incidence of tumors by ionizing radiation induction
|
J:79456
|
| increased lymphoma incidence
|
J:79456
|
Per2tm1Ccl/Per2tm1Ccl
(involves: 129 * C57BL/6)
|
increased salivary gland tumor incidence
|
J:79456
|
Perptm2Att/Perptm2Att
Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S4/SvJae)
|
decreased tumor latency
|
J:167545
|
| increased skin squamous cell carcinoma incidence
|
J:167545
|
Pex1tm1.1Hrw/Pex1tm1.1Hrw
(involves: C57BL/6NTac)
|
increased liver adenoma incidence
|
J:278655
|
Pex5tm1Pec/Pex5tm1Pec
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased liver tumor incidence
|
J:112503
|
Pgbd5tm1.1Aken/Pgbd5tm1.2Aken
Ptch1tm1Bjw/Ptch1tm1Bjw
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * C57BL/6J * C57BL/6NTac * FVB/N * SW)
|
increased medulloblastoma incidence
|
J:346387
|
Pgbd5tm1.2Aken/Pgbd5tm1.2Aken
Ptch1tm1Bjw/Ptch1tm1Bjw
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * C57BL/6J * C57BL/6NTac * FVB/N * SW)
|
decreased classified tumor incidence
|
J:346387
|
Pgcem1Hcz/Pgcem1Hcz
(Not Specified)
|
decreased incidence of tumors by chemical induction
|
J:338079
|
Pgct1129S1/SvImJ/?
(involves: 129S1/SvImJ * C57BL/6J)
|
increased testis tumor incidence
|
J:63413
|
Pgdtm1.1Pse/Pgdtm1.1Pse
Foxp3tm9(EGFP/cre/ERT2)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased tumor growth/size
|
J:313817
|
Pgftm1Pec/Pgftm1Pec
(either: (involves: 129X1/SvJ * C57BL/6J) or (involves: 129X1/SvJ * Swiss))
|
decreased tumor growth/size
|
J:77481
|
Pgftm1Pec/Pgftm1Pec
(involves: 129)
|
decreased tumor growth/size
|
J:77481
|
Pgrtm1Bwo/Pgrtm1Bwo
(involves: 129S7/SvEvBrd)
|
decreased incidence of induced tumors
|
J:87522
|
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:139053
|
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:162027,
J:218222
|
| increased papilloma incidence
|
J:218222
|
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:139053
|
Phf6tm1.1Avo/Y
Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * SJL)
|
increased leukemia incidence
|
J:276228
|
Phf6tm1.2Avo/Phf6+
(involves: BALB/cJ * C57BL/6)
|
increased leukemia incidence
|
J:276228
|
Pigatm1Bsl/Y
Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * C57BL/6 * CBA/Ca)
|
increased B cell derived lymphoma incidence
|
J:71354
|
| increased hemangioma incidence
|
J:71354
|
Pigatm1Bsl/Piga+
Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * C57BL/6 * CBA/Ca)
|
increased B cell derived lymphoma incidence
|
J:71354
|
| increased hemangioma incidence
|
J:71354
|
Pik3catm1.1Waph/Pik3ca+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6)
|
increased adenocarcinoma incidence
|
J:184382
|
| increased granulosa cell tumor incidence
|
J:184382
|
| increased ovary tumor incidence
|
J:184382
|
Pik3catm1.1Waph/Pik3ca+
Tg(MMTV-cre)#Mam/0
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased fibroadenoma incidence
|
J:187299
|
| increased mammary adenoacanthoma incidence
|
J:187299
|
| increased mammary gland tumor incidence
|
J:187299
|
| increased osteosarcoma incidence
|
J:187299
|
| increased sarcoma incidence
|
J:187299
|
Pik3catm1Gilb/Pik3ca+
(Not Specified)
|
neoplasm
|
J:186709
|
Pik3catm1Gne/Pik3ca+
Tg(MMTV-cre)1Mam/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:193377
|
| neoplasm
|
J:193377
|
Pik3catm1Jdo/Pik3catm1Jdo
(B6.129S7(Cg)-Pik3catm1Jdo)
|
decreased incidence of tumors by chemical induction
|
J:122866
|
Pik3catm1Jjz/Pik3catm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(FVB.Cg-Pik3catm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr)
|
increased skin hamartoma incidence
|
J:199362
|
Pik3catm1Jjz/Pik3catm1Jjz
Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:138565
|
Pik3cbtm1.1Ehi/Pik3cbtm1.1Ehi
Tg(MMTVneu)202Mul/0
(involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6J * FVB/N)
|
decreased mammary gland tumor incidence
|
J:152332
|
| decreased tumor growth/size
|
J:152332
|
Pik3cbtm1Jjz/Pik3cbtm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(FVB.Cg-Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr)
|
increased skin hamartoma incidence
|
J:199362
|
Pik3cbtm1Jjz/Pik3cbtm1Jjz
Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
neoplasm
|
J:138565
|
Pinx1tm1.1Kplu/Pinx1+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:171997
|
| increased gastrointestinal tumor incidence
|
J:171997
|
| increased Harderian gland adenoma incidence
|
J:171997
|
| increased hemangiosarcoma incidence
|
J:171997
|
| increased hibernoma incidence
|
J:171997
|
| increased histiocytic sarcoma incidence
|
J:171997
|
| increased liver tumor incidence
|
J:171997
|
| increased lung tumor incidence
|
J:171997
|
| increased lymphoma incidence
|
J:171997
|
| increased mammary gland tumor incidence
|
J:171997
|
| increased sarcoma incidence
|
J:171997
|
| increased tumor incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:171997
|
| increased hepatocellular carcinoma incidence
|
J:171997
|
| increased liver tumor incidence
|
J:171997
|
| increased lung carcinoma incidence
|
J:171997
|
| increased lung tumor incidence
|
J:171997
|
| increased lymphoma incidence
|
J:171997
|
| increased mammary gland tumor incidence
|
J:171997
|
| increased ovary tumor incidence
|
J:171997
|
| increased tumor incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:171997
|
| increased gastrointestinal tumor incidence
|
J:171997
|
| increased hepatocellular carcinoma incidence
|
J:171997
|
| increased liver tumor incidence
|
J:171997
|
| increased lung carcinoma incidence
|
J:171997
|
| increased lymphoma incidence
|
J:171997
|
| increased mammary gland tumor incidence
|
J:171997
|
Pip4k2atm1.2Lca/Pip4k2atm1.2Lca
Pip4k2bGt(Betageo)1Lca/Pip4k2b+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * 129S5/SvEvBrd)
|
decreased tumor incidence
|
J:205288
|
Pkd1tm1.1Pcha/Pkd1tm1.1Pcha
(involves: 129S1/Sv * C57BL/6)
|
increased renal hamartoma incidence
|
J:193544
|
Pkn3tm1.1Mrl/Pkn3+
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J)
|
increased acute lymphoblastic leukemia incidence
|
J:216983
|
| increased hemolymphoid system tumor incidence
|
J:216983
|
Pkn3tm1.1Mrl/Pkn3tm1.1Mrl
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J)
|
increased acute lymphoblastic leukemia incidence
|
J:216983
|
| increased hemolymphoid system tumor incidence
|
J:216983
|
Pknox1tm1Ngc/Pknox1+
Tg(IghMyc)22Bri/0
(involves: C57BL * SJL)
|
increased B cell derived lymphoma incidence
|
J:192251
|
Pla2g4atm1Jvb/Pla2g4atm1Jvb
(involves: 129S4/SvJae * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:91526
|
Pla2r1tm1Itoh/Pla2r1tm1Itoh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased tumor incidence
|
J:313998
|
Plautm1Mlg/Plautm1Mlg
(B6.Cg-Plautm1Mlg)
|
abnormal tumor morphology
|
J:65383
|
| decreased metastatic potential
|
J:65383
|
| decreased tumor growth/size
|
J:65383
|
Plautm1Mlg/Plautm1Mlg
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6)
|
increased carcinoma incidence
|
J:65019
|
Plbcq6FVB/NJ/?
(involves: FVB/NJ * M16i)
|
decreased mammary gland tumor incidence
|
J:136011
|
Plbcq6M16i/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Plcd1tm1Tta/Plcd1tm1Tta
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased skin tumor incidence
|
J:83948
|
Plce1tm1Tkat/Plce1+
(involves: 129/Sv * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:94952
|
Plce1tm1Tkat/Plce1tm1Tkat
(involves: 129/Sv * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:94952
|
Plcg2tm1Jni/Plcg2tm1Jni
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:117023
|
| increased lymphoma incidence
|
J:117023
|
Plcl1tm1.1Matk/Plcl1tm1.1Matk
(FVB.Cg-Plcl1tm1.1Matk)
|
increased incidence of tumors by chemical induction
|
J:207384
|
| increased tumor growth/size
|
J:207384
|
Plcl1tm1.1Matk/Plcl1tm1.1Matk
(involves: C57BL/6 * FVB)
|
increased incidence of tumors by chemical induction
|
J:207384
|
Plcl1tm2.1Matk/Plcl1tm2.1Matk
(FVB.Cg-Plcl1tm2.1Matk)
|
increased incidence of tumors by chemical induction
|
J:207384
|
Pld1tm1.1Mafr/Pld1tm1.1Mafr
(B6.Cg-Pld1tm1.1Mafr)
|
abnormal tumor vascularization
|
J:193451
|
| decreased metastatic potential
|
J:193451
|
| decreased tumor growth/size
|
J:193451
|
Pld2tm1.1Gdp/Pld2tm1.1Gdp
(involves: 129/SvJ * C57BL/6)
|
neoplasm
|
J:193451
|
Pldmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
|
decreased mammary gland tumor incidence
|
J:136011
|
| increased mammary gland tumor incidence
|
J:136011
|
| increased metastatic potential
|
J:136011
|
Pldmq2FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased metastatic potential
|
J:136011
|
Pldmq2M16i/?
(involves: FVB/NJ * M16i)
|
increased metastatic potential
|
J:136011
|
Pldmq3FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
| increased metastatic potential
|
J:136011
|
Pldmq4FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq5FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Plet1em1Yhh/Plet1em1Yhh
(Not Specified)
|
abnormal tumor susceptibility
|
J:251136
|
Plgtm1Jld/Plgtm1Jld
(B6.129P2-Plgtm1Jld)
|
decreased tumor growth/size
|
J:44314
|
Plgtm1Jld/Plgtm1Jld
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
|
decreased metastatic potential
|
J:48285
|
| increased mammary adenocarcinoma incidence
|
J:48285
|
Plk1Gt(RRR358)Byg/Plk1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung carcinoma incidence
|
J:142593
|
| increased lymphoma incidence
|
J:142593
|
| increased sarcoma incidence
|
J:142593
|
| increased squamous cell carcinoma incidence
|
J:142593
|
| increased tumor incidence
|
J:142593
|
Plk3tm1Dai/Plk3tm1Dai
(involves: 129S4/SvJae * C57BL/6)
|
abnormal tumor morphology
|
J:136425
|
| increased leiomyosarcoma incidence
|
J:136425
|
| increased liver tumor incidence
|
J:136425
|
| increased lung adenocarcinoma incidence
|
J:136425
|
| increased lung tumor incidence
|
J:136425
|
| increased tumor growth/size
|
J:136425
|
| increased tumor incidence
|
J:136425
|
Plk3tm1Pjs/Plk3tm1Pjs
(involves: 129S6/SvEvTac * Black Swiss)
|
neoplasm
|
J:175096
|
Pmaip1tm1Ttg/Pmaip1tm1Ttg
(B6.129P2-Pmaip1tm1Ttg)
|
neoplasm
|
J:85569
|
Pmltm1(PML/RARA)Ley/Pml+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased leukemia incidence
|
J:172024
|
Pmltm1.1Ews/Pmltm1.1Ews
(involves: 129 * 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:262172
|
| increased T cell derived lymphoma incidence
|
J:262172
|
Pmltm1.1Ews/Pmltm1.1Ews
(FVB.129P2-Pmltm1.1Ews)
|
neoplasm
|
J:262172
|
Pmltm1.1Ews/Pmltm1.1Ews
Tg(PML-RARA)556Kog/0
(FVB.Cg-Pmltm1.1Ews Tg(PML-RARA)556Kog)
|
increased acute promyelocytic leukemia incidence
|
J:262172
|
Pmltm1Ppp/Pml+
Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased B cell derived lymphoma incidence
|
J:317504
|
| increased carcinoma incidence
|
J:317504
|
| increased lymphoma incidence
|
J:317504
|
| increased osteosarcoma incidence
|
J:317504
|
| increased sarcoma incidence
|
J:317504
|
| increased T cell derived lymphoma incidence
|
J:317504
|
Pmltm1Ppp/Pmltm1Ppp
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:46381
|
| increased tumor incidence
|
J:46381
|
Pmltm1Ppp/Pmltm1Ppp
Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased B cell derived lymphoma incidence
|
J:317504
|
| increased carcinoma incidence
|
J:317504
|
| increased lymphoma incidence
|
J:317504
|
| increased osteosarcoma incidence
|
J:317504
|
| increased sarcoma incidence
|
J:317504
|
| increased T cell derived lymphoma incidence
|
J:317504
|
Pms1tm1Lisk/Pms1tm1Lisk
(involves: 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:46382
|
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
|
increased adenocarcinoma incidence
|
J:162378
|
| increased B cell derived lymphoma incidence
|
J:162378
|
| increased hemangioma incidence
|
J:162378
|
| increased liver adenoma incidence
|
J:162378
|
| increased lymphoma incidence
|
J:162378
|
| increased sarcoma incidence
|
J:162378
|
| increased T cell derived lymphoma incidence
|
J:162378
|
Pms2tm1Lisk/Pms2+
(involves: 129S2/SvPas)
|
increased incidence of tumors by chemical induction
|
J:61787
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:27389
|
| increased sarcoma incidence
|
J:27389
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas)
|
increased B cell derived lymphoma incidence
|
J:162378
|
| increased carcinoma incidence
|
J:125218
|
| increased lymphoma incidence
|
J:125218
|
| increased sarcoma incidence
|
J:125218
|
Pms2tm1Lisk/Pms2tm1Lisk
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL)
|
increased carcinoma incidence
|
J:125218
|
| increased lymphoma incidence
|
J:125218
|
| increased sarcoma incidence
|
J:125218
|
Poats1C57BL/6JCrl/Poats1C57BL/6JCrl
(involves: C57BL/6JCrl * DBA/2JCrl)
|
increased adrenal gland tumor incidence
|
J:131752
|
Polbtm1a(KOMP)Wtsi/Polbtm1a(KOMP)Wtsi
(C57BL/6N-Polbtm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp)
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
| increased intestinal adenoma incidence
|
J:153684
|
| increased lung tumor incidence
|
J:153684
|
| increased lymphoma incidence
|
J:153684
|
| increased skin tumor incidence
|
J:153684
|
| increased T cell derived lymphoma incidence
|
J:153684
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp
Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp Pold1tm1.1Bdp)
|
increased skin tumor incidence
|
J:153684
|
| increased T cell derived lymphoma incidence
|
J:153684
|
Pold1tm1.1Uchi/Pold1tm1.1Uchi
(C57BL/6-Pold1tm1.1Uchi)
|
increased tumor incidence
|
J:144992
|
Pold1tm1Bdp/Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:100685
|
| increased lymphoma incidence
|
J:80306,
J:100685
|
| increased sarcoma incidence
|
J:100685
|
| increased skin tumor incidence
|
J:80306
|
| increased squamous cell carcinoma incidence
|
J:100685
|
| increased T cell derived lymphoma incidence
|
J:100685
|
| increased tumor incidence
|
J:80306,
J:100685
|
Pold1tm1Uchi/Pold1tm1.1Uchi
(C57BL/6-Pold1tm1Uchi/Pold1tm1.1Uchi)
|
increased tumor incidence
|
J:144992
|
Pold1tm2Loeb/Pold1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased tumor incidence
|
J:129046
|
Pold4em1Zzho/Pold4em1Zzho
(C57BL/6-Pold4em1Zzho)
|
decreased liver tumor incidence
|
J:331883
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)
|
increased lymphoma incidence
|
J:261973
|
| increased T cell derived lymphoma incidence
|
J:261973
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
Trp53tm1Brd/Trp53+
(involves: C57BL/6J * C57BL/6NTac)
|
decreased tumor latency
|
J:261973
|
| increased T cell derived lymphoma incidence
|
J:261973
|
Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp)
|
increased adenoma incidence
|
J:153684
|
| increased colon adenocarcinoma incidence
|
J:153684
|
| increased histiocytic sarcoma incidence
|
J:153684
|
| increased intestinal adenocarcinoma incidence
|
J:153684
|
| increased intestinal adenoma incidence
|
J:153684
|
| increased lung tumor incidence
|
J:153684
|
| increased lymphoma incidence
|
J:153684
|
| increased small intestine adenocarcinoma incidence
|
J:153684
|
Poletm1.1Bdp/Poletm1.1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased tumor incidence
|
J:153684
|
Polgtm1Jiha/Polg+
(involves: C57BL/6JJcl)
|
increased B cell derived lymphoma incidence
|
J:199416
|
| increased incidence of induced tumors
|
J:199416
|
Polhtm1.1Rak/Polh+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased incidence of tumors by UV-induction
|
J:105034
|
| increased skin tumor incidence
|
J:105034
|
Polhtm1.1Rak/Polhtm1.1Rak
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased skin tumor incidence
|
J:105034
|
| increased squamous cell carcinoma incidence
|
J:105034
|
Polhtm2Fmh/Polh+
(B6.129-Polhtm2Fmh)
|
increased incidence of tumors by UV-induction
|
J:115000
|
Polhtm2Fmh/Polhtm2Fmh
(B6.129-Polhtm2Fmh)
|
increased incidence of tumors by UV-induction
|
J:115000
|
Polhtm2Fmh/Polhtm2Fmh
Polid/Poli+
(B6.129-Polhtm2Fmh Polid)
|
increased incidence of induced tumors
|
J:115000
|
Polhtm2Fmh/Polhtm2Fmh
Polid/Polid
(B6.129-Polhtm2Fmh Polid)
|
increased incidence of induced tumors
|
J:115000
|
Polid/Polid
(B6.129-Polid)
|
neoplasm
|
J:115000
|
Politm1.1Lgh/Politm1.1Lgh
Tg(gptdelta)1Nmi/0
(involves: C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:212610
|
| neoplasm
|
J:212610
|
Pomctm1Low/Pomc+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomc+
Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomctm1Low
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomctm1Low
Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
|
increased pituitary adenoma incidence
|
J:119240
|
Postntm1Kudo/Postntm1Kudo
(B6.Cg-Postntm1Kudo)
|
increased tumor growth/size
|
J:131295
|
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
|
increased incidence of tumors by chemical induction
|
J:90337,
J:90217
|
| increased intestinal adenocarcinoma incidence
|
J:90217
|
| increased sebaceous gland adenoma incidence
|
J:90337
|
| increased skin papilloma incidence
|
J:90337
|
| increased skin tumor incidence
|
J:90337
|
| increased tumor incidence
|
J:90337
|
Ppargtm1Tka/Pparg+
(involves: C57BL/6 * CBA)
|
increased incidence of tumors by chemical induction
|
J:98823
|
Ppargc1atm1.1Amos/Ppargc1atm1.1Amos
(involves: C57BL/6JOlaHsd)
|
increased incidence of tumors by chemical induction
|
J:171361
|
| increased tumor growth/size
|
J:171361
|
Ppm1dtm1Lad/Ppm1d+
Tg(IghMyc)22Bri/0
(involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL)
|
decreased tumor incidence
|
J:120284
|
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
(involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL)
|
decreased tumor incidence
|
J:120284
|
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
Trp53tm1Brd/Trp53+
(involves: 129 * C57BL * FVB/N * SJL)
|
increased tumor incidence
|
J:120284
|
Ppp2r1atm1.2Wltr/Ppp2r1a+
(FVB.129S1-Ppp2r1atm1.2Wltr)
|
increased incidence of tumors by chemical induction
|
J:175748
|
| increased lung tumor incidence
|
J:175748
|
Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr
(FVB.129-Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr)
|
increased incidence of tumors by chemical induction
|
J:175748
|
| increased lung adenocarcinoma incidence
|
J:175748
|
| increased lung adenoma incidence
|
J:175748
|
| increased lung tumor incidence
|
J:175748
|
Ppp2r1atm2.1Wltr/Ppp2r1a+
(FVB.129-Ppp2r1atm2.1Wltr)
|
increased incidence of tumors by chemical induction
|
J:175748
|
| increased lung tumor incidence
|
J:175748
|
Ppp2r5aGt(IST13127C10)Tigm/Ppp2r5aGt(IST13127C10)Tigm
(involves: C57BL/6N * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:254808
|
Ppp5ctm1a(EUCOMM)Wtsi/Ppp5ctm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased lymphoma incidence
|
J:213427
|
Ppp6ctm1Shma/Ppp6ctm1Shma
Tg(KRT14-cre/ERT)20Efu/0
(involves: C57BL/6 * CBA * CD-1)
|
increased incidence of tumors by chemical induction
|
J:231809
|
Prdm2tm1Shg/Prdm2+
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:71406
|
| increased hemangiosarcoma incidence
|
J:71406
|
| increased lung adenocarcinoma incidence
|
J:71406
|
| increased lymphoma incidence
|
J:71406
|
| increased pituitary adenoma incidence
|
J:71406
|
| increased tumor incidence
|
J:71406
|
Prdm2tm1Shg/Prdm2tm1Shg
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:71406
|
| increased hemangiosarcoma incidence
|
J:71406
|
| increased lung adenocarcinoma incidence
|
J:71406
|
| increased lymphoma incidence
|
J:71406
|
| increased pituitary adenoma incidence
|
J:71406
|
| increased tumor incidence
|
J:71406
|
Prdm2tm1Shg/Prdm2tm1Shg
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased tumor incidence
|
J:71406
|
Prdm11tm1.1Ahl/Prdm11tm1.1Ahl
Tg(IghMyc)22Bri/0
(B6.Cg-Prdm11tm1.1Ahl Tg(IghMyc)22Bri)
|
increased B cell derived lymphoma incidence
|
J:221379
|
Prdx1tm1Rave/Prdx1+
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal tumor morphology
|
J:84677
|
| increased fibrosarcoma incidence
|
J:84677
|
| increased hemangiosarcoma incidence
|
J:84677
|
| increased hepatocellular carcinoma incidence
|
J:84677
|
| increased histiocytic sarcoma incidence
|
J:84677
|
| increased lung adenocarcinoma incidence
|
J:84677
|
| increased lymphoma incidence
|
J:84677
|
| increased malignant tumor incidence
|
J:84677
|
| increased mammary adenocarcinoma incidence
|
J:84677
|
| increased osteosarcoma incidence
|
J:84677
|
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
|
increased adenoma incidence
|
J:84677
|
| increased B cell derived lymphoma incidence
|
J:84677
|
| increased carcinoma incidence
|
J:84677
|
| increased fibrosarcoma incidence
|
J:84677
|
| increased hemangiosarcoma incidence
|
J:84677
|
| increased hepatocellular carcinoma incidence
|
J:84677
|
| increased histiocytic sarcoma incidence
|
J:84677
|
| increased lung adenocarcinoma incidence
|
J:84677
|
| increased lymphoma incidence
|
J:84677
|
| increased mammary adenocarcinoma incidence
|
J:84677
|
| increased pancreatic islet cell adenoma incidence
|
J:84677
|
| increased sarcoma incidence
|
J:84677
|
| increased T cell derived lymphoma incidence
|
J:84677
|
| increased tumor incidence
|
J:84677
|
Prdx1tm1Yu/Prdx1tm1Yu
(Not Specified)
|
decreased incidence of tumors by chemical induction
|
J:306075
|
Prf1tm1Sdz/Prf1+
(A.B6-Prf1tm1Sdz)
|
increased incidence of induced tumors
|
J:211842
|
Prf1tm1Sdz/Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz)
|
decreased tumor latency
|
J:77491
|
| increased B cell derived lymphoma incidence
|
J:77491
|
| increased lymphoma incidence
|
J:77491
|
Prf1tm1Sdz/Prf1tm1Sdz
(C.B6-Prf1tm1Sdz)
|
abnormal tumor morphology
|
J:77491
|
| increased lung adenocarcinoma incidence
|
J:77491
|
| increased lymphoma incidence
|
J:77491
|
| increased sarcoma incidence
|
J:77491
|
| increased T cell derived lymphoma incidence
|
J:77491
|
| increased tumor latency
|
J:77491
|
Prf1tm1Sdz/Prf1tm1Sdz
(A.B6-Prf1tm1Sdz)
|
increased incidence of induced tumors
|
J:211842
|
Prf1tm1Tsc/Prf1tm1Tsc
(129X1.129S2-Prf1tm1Tsc)
|
increased tumor growth/size
|
J:126114
|
Prkacatm1Gsm/Prkaca+
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteochondroma incidence
|
J:160299
|
| increased osteosarcoma incidence
|
J:160299
|
| increased skeletal tumor incidence
|
J:160299,
J:166728
|
| neoplasm
|
J:160299
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased thyroid tumor incidence
|
J:98799
|
| increased tumor incidence
|
J:98799
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:160299
|
| increased Schwannoma incidence
|
J:160299
|
| increased skeletal tumor incidence
|
J:160299
|
| increased thyroid tumor incidence
|
J:160299
|
Prkar1atm1.2Lsk/Prkar1a+
Ptentm1.1Mwst/Pten+
Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
neoplasm
|
J:225245
|
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+
Tg(Bglap2-TAg)1Rkho/0
Tg(Col1a1-cre)1Kry/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:165282
|
Prkar1atm1.2Lsk/Prkar1a+
Tg(Col1a1-cre)1Kry/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased skeletal tumor incidence
|
J:165282
|
Prkar1atm1.2Lsk/Prkar1a+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased metastatic potential
|
J:225245
|
| increased thyroid carcinoma incidence
|
J:225245
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Tg(Ghrhr-cre)3242Lsk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pituitary gland tumor incidence
|
J:130264
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245,
J:241066
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Tg(Tyr-cre)3Gfk/0
(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
increased facial tumor incidence
|
J:98799
|
| increased Schwannoma incidence
|
J:98799
|
Prkar1atm1Gsm/Prkar1a+
(involves: 129X1/SvJ)
|
increased fibrosarcoma incidence
|
J:93393
|
| increased hemangiosarcoma incidence
|
J:93393
|
| increased hepatocellular carcinoma incidence
|
J:93393
|
| increased sarcoma incidence
|
J:93393
|
| increased tumor incidence
|
J:93393
|
Prkcatm1Cda/Prkcatm1Cda
(involves: 129S/SvEv * C57BL/6)
|
increased skin papilloma incidence
|
J:100793
|
Prkchtm1Cda/Prkchtm1Cda
(involves: 129S/SvEv * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:83498
|
| increased skin papilloma incidence
|
J:83498
|
Prkcqtm1Litt/Prkcqtm1Litt
Tg(Lck-Notch3)#Issc/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased lymphoma incidence
|
J:96010
|
Prkdcscid/Prkdc+
Tg(LPV-TAg1135)11Tvd/0
(involves: C57BL/6J * DBA/2J)
|
increased thymoma incidence
|
J:47667
|
Prkdcscid/Prkdc+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
increased thymoma incidence
|
J:47667
|
Prkdcscid/Prkdcscid
(C.BKa-Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:6958
|
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:109833,
J:22026
|
Prkdcscid/Prkdcscid
Gnrh1hpg/Gnrh1hpg
(STOCK Prkdcscid Gnrh1hpg/Bm)
|
decreased tumor incidence
|
J:14443,
J:138840
|
Prkdcscid/Prkdcscid
Tg(LPV-TAg1135)11Tvd/0
(involves: C57BL/6J * DBA/2J)
|
increased thymoma incidence
|
J:47667
|
Prkdcscid/Prkdcscid
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
decreased tumor incidence
|
J:47667
|
Prkdctm1Gcl/Prkdctm1Gcl
(involves: 129S1/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53765
|
| preneoplasia
|
J:53765
|
Prltm1Hmn/Prltm1Hmn
(involves: 129S2/SvPas)
|
increased pituitary adenoma incidence
|
J:79661
|
Prlrtm1Cnp/Prlrtm1Cnp
(involves: 129/Sv * 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:101609
|
Prlrtm1Cnp/Prlrtm1Cnp
Tg(C3-1-TAg)cJeg/0
(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:84352
|
Prmt1tm1a(EUCOMM)Wtsi/Prmt1tm1a(EUCOMM)Wtsi
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:245660
|
| increased tumor latency
|
J:245660
|
Prmt1tm1c(EUCOMM)Wtsi/Prmt1+
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:245660
|
Prmt7tm1a(EUCOMM)Wtsi/Prmt7tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Prmt7tm1a(EUCOMM)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Prps2tm1a(KOMP)Wtsi/Y
Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL)
|
increased tumor latency
|
J:214383
|
Pscatm1Witt/Psca+
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
| increased prostate gland tumor incidence
|
J:133908
|
| increased prostate intraepithelial neoplasia incidence
|
J:133908
|
Pscatm1Witt/Pscatm1Witt
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
| increased prostate gland tumor incidence
|
J:133908
|
| increased prostate intraepithelial neoplasia incidence
|
J:133908
|
Psl1DBA/2/?
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:44548
|
Psl2C57BL/6/Psl2DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl2DBA/2/Psl2DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl3C57BL/6/Psl3C57BL/6
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl3C57BL/6/Psl3DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl4DBA/2/Psl4DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psmb8tm1Hjf/Psmb8tm1Hjf
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal tumor susceptibility
|
J:108550
|
Psmb9tm1Stl/Psmb9tm1Stl
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:73945
|
| increased leiomyosarcoma incidence
|
J:73945
|
| increased lung tumor incidence
|
J:73945
|
Psmb9tm1Stl/Psmb9tm1Stl
Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:67509
|
| increased sarcoma incidence
|
J:67509
|
| increased tumor incidence
|
J:67509
|
Psme1/Psme2tm1Tchi/Psme1/Psme2tm1Tchi
(involves: C57BL/6 * CBA)
|
abnormal tumor susceptibility
|
J:108550
|
Psme1/Psme2tm1Tchi/Psme1/Psme2tm1Tchi
(involves: C57BL/6 * CBA)
|
abnormal tumor susceptibility
|
J:108550
|
Psphtm1a(EUCOMM)Hmgu/Psphtm1a(EUCOMM)Hmgu
(C57BL/6N-Psphtm1a(EUCOMM)Hmgu/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Ptch1tm1.1Hahn/Ptch1+
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:149148
|
| increased rhabdomyosarcoma incidence
|
J:149148
|
| increased tumor incidence
|
J:149148
|
Ptch1tm1Bjw/Ptch1tm1Bjw
Tcf21tm1(cre)Seq/Tcf21+
(involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ)
|
increased tumor incidence
|
J:189643
|
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(Atoh1-cre)1Bfri/0
(involves: 129T2/SvEms * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129T2/SvEms * FVB/N)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(GFAP-cre)25Mes/0
(involves: 129T2/SvEms * FVB/N)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(KRT14-cre)8Brn/0
(involves: 129T2/SvEms * FVB/N)
|
increased basal cell carcinoma incidence
|
J:231264
|
Ptch1tm1Cklr/Ptch1+
Pax7tm1(cre)Mrc/Pax7+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:159972
|
Ptch1tm1Cklr/Ptch1+
Trp53tm1Brn/?
Pax7tm1(cre)Mrc/Pax7+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:159972
|
Ptch1tm1Cklr/Ptch1tm1Cklr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
neoplasm
|
J:159972
|
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased fibroma incidence
|
J:149148
|
| increased tumor incidence
|
J:149148
|
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:149148
|
| increased tumor incidence
|
J:149148
|
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
decreased tumor growth/size
|
J:158915
|
| increased basal cell carcinoma incidence
|
J:158915
|
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:149148
|
| increased tumor incidence
|
J:149148
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:205254
|
| increased hemangiosarcoma incidence
|
J:205254
|
| increased lymphoma incidence
|
J:205254
|
| increased medulloblastoma incidence
|
J:205254
|
| increased rhabdomyosarcoma incidence
|
J:205254
|
| increased tumor incidence
|
J:205254
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:42441
|
| increased tumor incidence
|
J:42441
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:144811,
J:114992,
J:102702
|
| increased rhabdomyosarcoma incidence
|
J:114992
|
| increased skin tumor incidence
|
J:82653
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2J)
|
increased basal cell carcinoma incidence
|
J:58328
|
| increased incidence of tumors by ionizing radiation induction
|
J:58328
|
| increased incidence of tumors by UV-induction
|
J:58328
|
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased tumor latency
|
J:112118
|
| increased basal cell carcinoma incidence
|
J:112118
|
| increased rhabdomyosarcoma incidence
|
J:112118
|
| increased testicular teratoma incidence
|
J:112118
|
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:112118
|
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2tm1Pmc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased tumor latency
|
J:112118
|
| increased basal cell carcinoma incidence
|
J:112118
|
| increased medulloblastoma incidence
|
J:112118
|
| increased rhabdomyosarcoma incidence
|
J:112118
|
| increased tumor incidence
|
J:112118
|
Ptch1tm1Mps/Ptch1+
Tg(Atoh1-GFP)1Jejo/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:144811
|
Ptch1tm1Mps/Ptch1+
Tg(Atoh1-sb11)1Mtay/0
TgTn(sb-T2/Onc3)12740Njen/0
(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J * ICR)
|
increased medulloblastoma incidence
|
J:181542
|
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:125534
|
| increased rhabdomyosarcoma incidence
|
J:125534
|
Ptch1tm1Yy/Ptch1+
Tg(BGLAP-cre)1Clem/0
(involves: 129 * C57BL/6 * FVB/NJ)
|
neoplasm
|
J:214349
|
Ptch1tm1Yy/Ptch1+
Trp53tm1Brd/Trp53+
Tg(BGLAP-cre)1Clem/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/NJ)
|
increased metastatic potential
|
J:214349
|
| increased osteosarcoma incidence
|
J:214349
|
Ptch1tm1Zim/Ptch1+
(either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1))
|
increased incidence of tumors by ionizing radiation induction
|
J:47421
|
| increased medulloblastoma incidence
|
J:47421
|
| increased rhabdomyosarcoma incidence
|
J:47421
|
Ptch1tm1Zim/Ptch1+
(involves: 129 * CD-1)
|
increased incidence of tumors by ionizing radiation induction
|
J:79666,
J:165388
|
| increased medulloblastoma incidence
|
J:79666,
J:165388
|
Ptch2tm1Pmc/Ptch2tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
neoplasm
|
J:112118
|
Ptentm1.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
| increased lymphoma incidence
|
J:158751
|
| increased mammary gland tumor incidence
|
J:158751
|
| increased prostate gland tumor incidence
|
J:158751
|
| increased stomach tumor incidence
|
J:158751
|
| increased T cell derived lymphoma incidence
|
J:158751
|
| increased thyroid tumor incidence
|
J:158751
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
|
abnormal metastatic potential
|
J:110567
|
| abnormal tumor incidence
|
J:110567
|
| increased hemangioma incidence
|
J:110567
|
| increased mammary adenocarcinoma incidence
|
J:110567
|
| increased prostate gland tumor incidence
|
J:110567
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
abnormal tumor incidence
|
J:110567
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
|
increased lymphoma incidence
|
J:170965
|
| increased thyroid adenoma incidence
|
J:170965
|
Ptentm1.1Hwu/Pten+
Tmprss2tm1.1(ERG)Sho/Tmprss2tm1.1(ERG)Sho
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Ptentm1.1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Ptentm1.1Mro/Pten+
(Not Specified)
|
increased metastatic potential
|
J:236514
|
| increased pheochromocytoma incidence
|
J:236514
|
Ptentm1.1Mro/Pten+
Sdhbtm1.2Ics/Sdhb+
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
increased metastatic potential
|
J:236514
|
| increased pheochromocytoma incidence
|
J:236514
|
Ptentm1.1Mro/Ptentm1.1Mro
(involves: BALB/cJ)
|
increased tumor incidence
|
J:77123
|
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(MMTVneu)202Mul/0
Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153747
|
| increased mammary gland tumor incidence
|
J:153747
|
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:153747
|
Ptentm1.2Mwst/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
| increased gastrointestinal tumor incidence
|
J:158751
|
| increased lymphoma incidence
|
J:158751
|
| increased mammary adenoacanthoma incidence
|
J:158751
|
| increased mammary gland tumor incidence
|
J:158751
|
| increased prostate gland tumor incidence
|
J:158751
|
| increased stomach tumor incidence
|
J:158751
|
| increased T cell derived lymphoma incidence
|
J:158751
|
| increased thyroid tumor incidence
|
J:158751
|
| increased uterus carcinoma incidence
|
J:158751
|
Ptentm1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
|
abnormal tumor incidence
|
J:110567
|
Ptentm1Hwu/Pten+
Tg(ARR2/Pbsn-FGF8)3Prb/0
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:106650
|
| increased prostate gland adenocarcinoma incidence
|
J:106650
|
| increased prostate intraepithelial neoplasia incidence
|
J:106650
|
Ptentm1Hwu/Pten+
Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
| increased mammary gland tumor incidence
|
J:138927
|
Ptentm1Hwu/Pten+
Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
|
increased thyroid tumor incidence
|
J:197590
|
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:93902
|
Ptentm1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased prostate gland adenocarcinoma incidence
|
J:144810
|
| increased prostate intraepithelial neoplasia incidence
|
J:144810
|
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:142150,
J:222579
|
| increased metastatic potential
|
J:142150
|
Ptentm1Hwu/Ptentm1Hwu
Cop1tm2.1Vmd/Cop1tm2.1Vmd
Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
| increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Ptentm1Hwu/Ptentm1Hwu
Ptpn1tm1Bpk/Ptpn1tm1Bpk
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:231906
|
| increased prostate intraepithelial neoplasia incidence
|
J:231906
|
Ptentm1Hwu/Ptentm1Hwu
Rictortm1.1Mgn/Rictortm1.1Mgn
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
decreased tumor incidence
|
J:144810
|
Ptentm1Hwu/Ptentm1Hwu
Rps6kb1tm1Gtho/Rps6kb1tm1Gtho
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:169097
|
Ptentm1Hwu/Ptentm1Hwu
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased cholangiocarcinoma incidence
|
J:111718
|
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:218587
|
| increased hepatocellular carcinoma incidence
|
J:218587
|
| increased liver tumor incidence
|
J:218587
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJae * C57BL/6J * FVB/NJ)
|
neoplasm
|
J:237232
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * FVB/N)
|
increased cholangiocarcinoma incidence
|
J:111718
|
| increased hepatocellular carcinoma incidence
|
J:111718
|
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
Tg(TPO-cre)1Shk/0
(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
|
increased thyroid carcinoma incidence
|
J:177181
|
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:261540
|
| increased prostate intraepithelial neoplasia incidence
|
J:261540
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh5-cre)7Mlia/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N)
|
increased acute lymphoblastic leukemia incidence
|
J:135172
|
| increased acute promyelocytic leukemia incidence
|
J:135172
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR)
|
neoplasm
|
J:137442
|
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae)
|
neoplasm
|
J:138315
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * FVB/N)
|
increased carcinoma incidence
|
J:106662
|
| increased colon adenocarcinoma incidence
|
J:106662
|
| increased metastatic potential
|
J:106662
|
| increased prostate gland tumor incidence
|
J:106662
|
| increased renal carcinoma incidence
|
J:106662
|
| increased squamous cell carcinoma incidence
|
J:106662
|
| increased urethra carcinoma incidence
|
J:106662
|
| increased urinary bladder carcinoma incidence
|
J:106662
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Gfap-cre)77.6Mvs/0
(involves: 129S4/SvJae * BALB/c * C57BL/6NHsd)
|
neoplasm
|
J:146630,
J:154673
|
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
| increased mammary gland tumor incidence
|
J:138927
|
| increased skin papilloma incidence
|
J:138927
|
| increased skin tumor incidence
|
J:138927
|
| increased thyroid tumor incidence
|
J:138927
|
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(FVB.Cg-Ptentm1Hwu Tg(KRT14-cre)#Smr)
|
increased skin hamartoma incidence
|
J:199362
|
| increased skin papilloma incidence
|
J:199362
|
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)7Mul/0
(involves: 129S4/SvJae * FVB/N)
|
neoplasm
|
J:133305
|
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)#Tfln/0
(involves: 129S4/SvJae)
|
increased fibroadenoma incidence
|
J:78415
|
| increased mammary adenocarcinoma incidence
|
J:78415
|
| increased mammary gland tumor incidence
|
J:78415
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:169097
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(BKS.Cg-Ptprcb Thy1a Tg(Mx1-cre)1Cgn Ptentm1Hwu)
|
increased acute lymphoblastic leukemia incidence
|
J:109085
|
| increased acute promyelocytic leukemia incidence
|
J:109085
|
| increased leukemia incidence
|
J:109085
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(B6.Cg-Tg(Mx1-cre)1Cgn Ptentm1Hwu)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:232645
|
| increased tumor incidence
|
J:232645
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
|
increased thyroid adenoma incidence
|
J:197590
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
| increased prostate gland tumor incidence
|
J:142106
|
| increased prostate intraepithelial neoplasia incidence
|
J:138565
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased carcinoma incidence
|
J:268934
|
| increased metastatic potential
|
J:268934
|
| increased prostate gland adenocarcinoma incidence
|
J:268934,
J:184935,
J:212219
|
| increased prostate gland tumor incidence
|
J:268934,
J:172730,
J:170965
|
| increased prostate intraepithelial neoplasia incidence
|
J:268934,
J:131932,
J:212219
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
decreased tumor incidence
|
J:124208
|
| increased prostate gland adenocarcinoma incidence
|
J:93902,
J:124208
|
| increased prostate gland tumor incidence
|
J:124208
|
| increased prostate intraepithelial neoplasia incidence
|
J:93902,
J:106650
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
| increased prostate intraepithelial neoplasia incidence
|
J:238768
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased malignant tumor incidence
|
J:102226
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic acinar cell carcinoma incidence
|
J:102226
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pgc-cre,-secNluc)#Hcz/0
(involves: 129S4/SvJae)
|
increased mammary adenocarcinoma incidence
|
J:338079
|
Ptentm1Hwu/Ptentm1Hwu
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129S4/SvJae * C57BL/6 * FVB/N)
|
neoplasm
|
J:146355
|
Ptentm1Hwu/Ptentm1Hwu
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased oral papilloma incidence
|
J:194652
|
| increased organ/body region tumor incidence
|
J:209026
|
| increased papilloma incidence
|
J:194652
|
| increased squamous cell carcinoma incidence
|
J:209026,
J:194652
|
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased carcinoma incidence
|
J:146760
|
| increased urinary bladder carcinoma incidence
|
J:146760
|
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:222579
|
| increased metastatic potential
|
J:222579
|
| increased ovarian carcinoma incidence
|
J:222579
|
Ptentm1Hwu/Ptentm1Hwu
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR)
|
increased adenoma incidence
|
J:137442
|
| increased epididymal cystadenoma incidence
|
J:137442
|
| increased tumor incidence
|
J:137442
|
Ptentm1Hwu/Ptentm1Hwu
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J * ICR)
|
neoplasm
|
J:137073
|
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased adrenal gland tumor incidence
|
J:63478
|
| increased carcinoma incidence
|
J:50437
|
| increased endometrial carcinoma incidence
|
J:63478
|
| increased fibroadenoma incidence
|
J:63478
|
| increased hamartoma incidence
|
J:63478
|
| increased incidence of tumors by ionizing radiation induction
|
J:50437
|
| increased leukemia incidence
|
J:50437
|
| increased lymphoma incidence
|
J:63478
|
| increased mammary adenocarcinoma incidence
|
J:63478
|
| increased mammary gland tumor incidence
|
J:63478
|
| increased prostate gland tumor incidence
|
J:63478
|
| increased T cell derived lymphoma incidence
|
J:50437
|
| increased tumor incidence
|
J:50437
|
Ptentm1Mak/Pten+
(B6.129P2-Ptentm1Mak)
|
increased adrenal gland tumor incidence
|
J:93530
|
| increased endometrial carcinoma incidence
|
J:93530
|
| increased lymphoma incidence
|
J:93530
|
| increased tumor incidence
|
J:93530
|
Ptentm1Mro/Pten+
Sdhbtm1.1Ics/Sdhb+
Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Pten+
Tg(KLK3-cre)D4Trp/0
(involves: 129P2/OlaHsd * FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:99524
|
| increased prostate gland tumor incidence
|
J:99524
|
| increased prostate intraepithelial neoplasia incidence
|
J:99524
|
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Ptentm1Mro/Ptentm1Mro
Sdhbtm1.1Ics/Sdhb+
Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Ptentm1Mro
Sdhbtm1.1Ics/Sdhbtm1.2Ics
Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * BALB/c * C57BL/6 * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Ptentm1Mro
Tg(En2-cre)22Alj/0
(Not Specified)
|
neoplasm
|
J:77123
|
Ptentm1Mro/Ptentm1Mro
Tg(KRT14-cre)8Brn/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
increased carcinoma incidence
|
J:144831
|
Ptentm1Ppp/Pten+
(involves: 129S1/Sv * C57BL/6J)
|
increased malignant tumor incidence
|
J:49532
|
Ptentm1Ppp/Pten+
Tg(Pbsn-TAg)15Tvd/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
| increased prostate gland tumor incidence
|
J:103408
|
| increased prostate intraepithelial neoplasia incidence
|
J:103408
|
Ptentm1Ppp/Ptentm2Ppp
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:86212
|
Ptentm1Rdp/Pten+
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased astrocytoma incidence
|
J:140704
|
| increased glioblastoma incidence
|
J:140704
|
| increased glioma incidence
|
J:140704
|
Ptentm1Rdp/Ptentm1Rdp
Smad4tm1Rdp/Smad4tm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:186105
|
| increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Tert+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
| increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Terttm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
decreased tumor growth/size
|
J:186105
|
| increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm3Rdp/Terttm3Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:186105
|
| increased prostate gland adenocarcinoma incidence
|
J:186105
|
| increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
| increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * C57BL/6J)
|
increased leukemia incidence
|
J:53065
|
| increased liver adenoma incidence
|
J:53065
|
| increased lymphoma incidence
|
J:53065
|
| increased prostate intraepithelial neoplasia incidence
|
J:53065
|
| increased teratoma incidence
|
J:53065
|
| increased thyroid carcinoma incidence
|
J:53065
|
| increased tumor incidence
|
J:53065
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Ptentm1Rps/Pten+
RictorGt(RRR347)Byg/Rictor+
(involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6)
|
decreased tumor incidence
|
J:144810
|
Ptentm1Rps/Pten+
Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased adenocarcinoma incidence
|
J:67497
|
| increased mammary adenocarcinoma incidence
|
J:67497
|
| increased mammary gland ductal carcinoma incidence
|
J:67497
|
| increased metastatic potential
|
J:67497
|
| increased salivary adenocarcinoma incidence
|
J:67497
|
Ptentm2.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
| increased lymphoma incidence
|
J:158751
|
| increased mammary adenoacanthoma incidence
|
J:158751
|
| increased mammary gland tumor incidence
|
J:158751
|
| increased prostate gland tumor incidence
|
J:158751
|
| increased T cell derived lymphoma incidence
|
J:158751
|
| increased thyroid tumor incidence
|
J:158751
|
Ptentm2.1Ppp/Pten+
Spry1tm1Jdli/Spry1tm1.1Jdli
Spry2tm1Mrt/Spry2tm1.1Mrt
Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased prostate gland tumor incidence
|
J:192348
|
| increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Pten+
Tg(Cnp-EGFR)10Nrat/0
Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:307910
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(CAG-Bgeo,-Spry2,-ALPP)1Mrt/0
Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Cnp-EGFR)10Nrat/0
Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(GFAP-TAg121)1Tvd/0
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2 * FVB/N)
|
increased astrocytoma incidence
|
J:99385
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:163589,
J:100683
|
| increased prostate gland tumor incidence
|
J:86212,
J:100683
|
| increased prostate intraepithelial neoplasia incidence
|
J:239660,
J:163589,
J:100683,
J:200002
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)8113ANg/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:86212
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk)
|
increased thyroid adenoma incidence
|
J:165293
|
| increased thyroid carcinoma incidence
|
J:165293
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0
(129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp)
|
increased metastatic potential
|
J:211100
|
| increased thyroid carcinoma incidence
|
J:211100
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased carcinoma incidence
|
J:100683
|
| increased prostate gland tumor incidence
|
J:100683
|
Ptentm2Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
|
abnormal tumor incidence
|
J:110567
|
Ptentm2Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal tumor incidence
|
J:110567
|
Ptentm2Mak/Ptentm2Mak
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(KRT5-cre)1Xya/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
decreased tumor latency
|
J:101602
|
| increased carcinoma incidence
|
J:101602
|
| increased skin papilloma incidence
|
J:101602
|
| increased skin tumor incidence
|
J:101602
|
| increased stomach tumor incidence
|
J:101602
|
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:138099
|
| increased liver adenoma incidence
|
J:138099
|
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * DBA)
|
increased hepatocellular carcinoma incidence
|
J:90905
|
| increased liver adenoma incidence
|
J:90905
|
| increased metastatic potential
|
J:90905
|
Ptentm2Mak/Ptentm2Mak
Stk11tm1Keis/Stk11tm1Keis
Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
|
increased urinary bladder carcinoma incidence
|
J:169565
|
Ptentm2Mak/Ptentm2Mak
Tg(Col2a1-cre)1Xya/?
(involves: 129P2/OlaHsd)
|
abnormal tumor susceptibility
|
J:143447
|
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:143082
|
| increased lymphoma incidence
|
J:143082
|
Ptentm2Mak/Ptentm2Mak
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased incidence of tumors by chemical induction
|
J:113388
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:113388
|
Ptentm2Mak/Ptentm2Mak
Tg(Gfap-cre)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased hamartoma incidence
|
J:75500
|
Ptentm2Mak/Ptentm2Mak
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/NJ)
|
increased glioblastoma incidence
|
J:290447
|
Ptentm2Mak/Ptentm2Mak
Tg(KLK3-cre)13Saa/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased metastatic potential
|
J:214242
|
| increased prostate gland adenocarcinoma incidence
|
J:214242
|
| increased prostate gland tumor incidence
|
J:214242
|
| increased prostate intraepithelial neoplasia incidence
|
J:214242
|
Ptentm2Mak/Ptentm2Mak
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
| increased mammary gland tumor incidence
|
J:224955
|
| increased mammary gland tumor incidence in breeding females
|
J:224955
|
| increased myoepithelioma incidence
|
J:224955
|
| increased spindle cell carcinoma incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
neoplasm
|
J:237990
|
Ptentm2Mak/Ptentm2Mak
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:127405
|
| increased lung adenocarcinoma incidence
|
J:127405
|
| increased lung squamous cell carcinoma incidence
|
J:127405
|
Ptentm2Mak/Ptentm2Mak
Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
| increased mammary gland tumor incidence
|
J:224955
|
| increased mammary gland tumor incidence in breeding females
|
J:224955
|
| increased myoepithelioma incidence
|
J:224955
|
| increased spindle cell carcinoma incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
| increased mammary gland tumor incidence
|
J:224955
|
| increased myoepithelioma incidence
|
J:224955
|
| increased spindle cell carcinoma incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased glioma incidence
|
J:237990
|
| increased medulloblastoma incidence
|
J:237990
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
| increased mammary gland tumor incidence
|
J:224955
|
| increased myoepithelioma incidence
|
J:224955
|
| increased spindle cell carcinoma incidence
|
J:224955
|
Ptger1tm1Sna/Ptger1tm1Sna
(involves: 129P2/OlaHsd * C57BL/6Cr)
|
decreased incidence of tumors by chemical induction
|
J:95533
|
| decreased tumor growth/size
|
J:95533
|
Ptger2tm1Brey/Ptger2tm1Brey
(involves: 129S6/SvEvTac)
|
decreased incidence of tumors by chemical induction
|
J:116015
|
| decreased tumor growth/size
|
J:116015
|
Ptger4tm1Sna/Ptger4tm1Sna
(involves: 129P2/OlaHsd * C57BL/6Cr)
|
decreased incidence of tumors by chemical induction
|
J:73944
|
| preneoplasia
|
J:73944
|
Ptgirtm1Sna/Ptgirtm1Sna
(involves: 129P2/OlaHsd * C57BL/6Cr)
|
neoplasm
|
J:73944
|
Ptgs1tm1Unc/Ptgs1tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:158426
|
Ptgs2tm1Jed/Ptgs2tm1Jed
Stk11tm1Tpm/Stk11+
(involves: 129S7/SvEvBrd * C57BL/6 * CD-1)
|
decreased tumor incidence
|
J:93361
|
Ptgs2tm1Unc/Ptgs2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:158426
|
| increased incidence of induced tumors
|
J:158426
|
Ptgs2tm1Unc/Ptgs2tm2.1Hahe
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:158426
|
Pth1rtm1a(EUCOMM)Hmgu/Pth1rtm1a(EUCOMM)Hmgu
(C57BL/6N-Pth1rtm1a(EUCOMM)Hmgu/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Pthlhtm1a(KOMP)Wtsi/Pthlhtm1a(KOMP)Wtsi
(C57BL/6N-Pthlhtm1a(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
Ptk2tm1Gwm/Ptk2tm1Gwm
Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129P2/OlaHsd * FVB)
|
decreased incidence of tumors by chemical induction
|
J:94680
|
| decreased tumor growth/size
|
J:94680
|
Ptk2tm3.1Guan/Ptk2tm3.1Guan
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
abnormal tumor morphology
|
J:195658
|
| decreased metastatic potential
|
J:195658
|
| decreased tumor growth/size
|
J:195658
|
Ptp4a3tm1.1Geh/Ptp4a3tm1.1Geh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:194458
|
| decreased tumor growth/size
|
J:194458
|
Ptpn11tm1Ckq/Ptpn11+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
increased acute promyelocytic leukemia incidence
|
J:177285
|
Ptpn11tm1Ckq/Ptpn11+
Tg(Lck-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:177285
|
| increased lymphoblastic lymphoma incidence
|
J:177285
|
Ptpn11tm1Ckq/Ptpn11+
Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:177285
|
| increased acute promyelocytic leukemia incidence
|
J:177285
|
| increased B cell derived lymphoma incidence
|
J:177285
|
| increased leukemia incidence
|
J:177285
|
| increased lymphoblastic lymphoma incidence
|
J:177285
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased incidence of tumors by chemical induction
|
J:172422
|
| increased liver adenoma incidence
|
J:172422
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Stat3tm1Vpo/Stat3tm1Vpo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased incidence of tumors by chemical induction
|
J:172422
|
Ptprctm1Holm/Ptprctm1Holm
Tg(Lck*F505)2964Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:64671
|
Ptprctm1Holm/Ptprctm1Holm
Tg(Lck*F505)3073Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:64671
|
PtprjScc1-r/PtprjScc1-r
(involves: BALB/cHeA * STS/A)
|
decreased incidence of tumors by chemical induction
|
J:31355
|
PtprjScc1-s/?
(involves: BALB/cJ * STS/A)
|
increased tumor incidence
|
J:44
|
PtprjScc1-s/?
(involves: BALB/cHeA * STS/A)
|
increased tumor incidence
|
J:36996,
J:31355
|
Ptprjtm1Fus/Ptprjtm1Fus
(involves: 129X1/SvJ * C57BL/6J)
|
neoplasm
|
J:112807
|
Ptprttm1Sata/Ptprttm1Sata
(B6.129P2-Ptprttm1Sata)
|
increased colon adenoma incidence
|
J:157542
|
| increased incidence of tumors by chemical induction
|
J:157542
|
Ptprz1tm1Schl/Ptprz1+
Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
(involves: 129)
|
increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
abnormal tumor pathology
|
J:243104
|
| increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
neoplasm
|
J:243104
|
Puf60tm1.1Kmtsu/Puf60+
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)
|
increased metastatic potential
|
J:233347
|
| increased T cell derived lymphoma incidence
|
J:233347
|
Pvrtm1Hfuk/Pvr+
(involves: 129X1/SvJ * C57BL/6 * DBA)
|
decreased incidence of tumors by chemical induction
|
J:143250
|
Pvrtm1Hfuk/Pvrtm1Hfuk
(involves: 129X1/SvJ * C57BL/6 * DBA)
|
decreased incidence of tumors by chemical induction
|
J:143250
|
Pycardtm1Ayaz/Pycardtm1Ayaz
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:191239
|
Pycardtm1Ayaz/Pycardtm1Ayaz
Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
neoplasm
|
J:191239
|
Pycardtm1Vmd/Pycardtm1Vmd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:191239
|
Pzptm1Vln/Pzptm1Vln
(involves: 129P2/OlaHsd * C57BL)
|
neoplasm
|
J:28328
|
Qpctltm1.1Gne/Qpctltm1.1Gne
(C57BL/6N-Qpctltm1.1Gne)
|
decreased tumor growth/size
|
J:324112
|
Rab11atm1.1Ngao/Rab11atm1.1Ngao
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL)
|
increased incidence of tumors by chemical induction
|
J:278932
|
| increased intestinal adenoma incidence
|
J:278932
|
Rab25tm1Jrgo/Rab25tm1Jrgo
Smad3tm1Par/Smad3+
(129-Rab25tm1Jrgo Smad3tm1Par)
|
increased colon adenocarcinoma incidence
|
J:158733
|
Rac3tm1Hkp/Rac3tm1Hkp
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased leukemia incidence
|
J:99168
|
Rad9atm2Lieb/Rad9a+
Tg(KRT5-cre)1Xya/?
(involves: 129S/SvEv * C57BL/6)
|
increased skin papilloma incidence
|
J:138845
|
Rad9atm2Lieb/Rad9atm2Lieb
Tg(KRT5-cre)1Xya/?
(involves: 129S/SvEv * C57BL/6)
|
increased skin papilloma incidence
|
J:138845
|
Rad50tm1Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Rad50tm2Jpt/Rad50tm2Jpt
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
|
increased leukemia incidence
|
J:78820
|
| increased T cell derived lymphoma incidence
|
J:78820
|
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Rad50tm2Jpt/Rad50tm2Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:78820
|
Rad50tm4.1Jpt/Rad50+
(involves: 129/Sv * C57BL/6)
|
increased hepatoblastoma incidence
|
J:209141
|
| increased liver adenoma incidence
|
J:209141
|
| increased liver tumor incidence
|
J:209141
|
Rad50tm4Jpt/Rad50+
(involves: 129/Sv * C57BL/6)
|
increased liver adenoma incidence
|
J:209141
|
| increased liver tumor incidence
|
J:209141
|
Rae1tm1Jvd/Rae1+
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:81546
|
Rag1tm1Jsek/Rag1tm1Jsek
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:146912
|
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom
Prf1tm1Sdz/Prf1tm1Sdz
(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz)
|
increased T cell derived lymphoma incidence
|
J:109843
|
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL)
|
increased hemangiosarcoma incidence
|
J:141515
|
| increased hepatocellular carcinoma incidence
|
J:141515
|
| increased medulloblastoma incidence
|
J:141515
|
| increased pituitary adenoma incidence
|
J:141515
|
| increased sarcoma incidence
|
J:141515
|
| increased T cell derived lymphoma incidence
|
J:141515
|
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased medulloblastoma incidence
|
J:141515
|
| increased sarcoma incidence
|
J:141515
|
| increased stomach tumor incidence
|
J:141515
|
| increased T cell derived lymphoma incidence
|
J:141515
|
Rag1tm1Mom/Rag1tm1Mom
Tyrp1B-w/Tyrp1B-w
X/Tg(Tcra,Tcrb)9Rest
(involves: 101/Rl * 129S7/SvEvBrd * C3H/Rl * C57BL/6)
|
abnormal tumor susceptibility
|
J:138466
|
Rag1tm1Mom/Rag1tm1Mom
Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
neoplasm
|
J:141515
|
Rag2tm1.1Desi/Rag2tm1.1Desi
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:168974
|
| increased T cell derived lymphoma incidence
|
J:168974
|
Rag2tm1.1Mss/Rag2tm1.1Mss
(involves: 129S6/SvEvTac)
|
neoplasm
|
J:170462
|
Rag2tm1.1Mss/Rag2tm1.1Mss
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:170462
|
| increased T cell derived lymphoma incidence
|
J:170462
|
Rag2tm1Fwa/Rag2+
Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa
Stat1tm1Rds/Stat1tm1Rds
(involves: 129S/SvEv * 129S6/SvEvTac)
|
increased gastrointestinal tumor incidence
|
J:216040
|
| increased mammary adenocarcinoma incidence
|
J:216040
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
|
increased T cell derived lymphoma incidence
|
J:235890
|
| increased thymus tumor incidence
|
J:235890
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
|
increased gastrointestinal stromal tumor incidence
|
J:235890
|
| increased hepatocellular carcinoma incidence
|
J:235890
|
| increased sarcoma incidence
|
J:235890
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm2.1Desi/Rag2tm2.1Desi
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:168974
|
Ralatm1.2Cjm/Ralatm1.2Cjm
Tg(KRT14-cre)8Brn/0
(involves: C57BL/6 * C57BL/6J * FVB/N)
|
neoplasm
|
J:199742
|
Ralatm1a(EUCOMM)Wtsi/Ralatm1a(EUCOMM)Wtsi
(C57BL/6N-Ralatm1a(EUCOMM)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Ralgapa2tm1Hhor/Ralgapa2tm1Hhor
(C57BL/6J-Ralgapa2tm1Hhor)
|
increased incidence of tumors by chemical induction
|
J:193368
|
| increased urinary system tumor incidence
|
J:193368
|
Ralgdstm1Cjm/Ralgdstm1Cjm
(involves: 129X1/SvJ * MF1)
|
decreased incidence of tumors by chemical induction
|
J:96936
|
| decreased tumor growth/size
|
J:96936
|
RalyGt(RST374)Byg/Raly+
(129-RalyGt(RST374)Byg Chr 19MOLF/Ei)
|
neoplasm
|
J:146879
|
Ramls1CBA/H/Ramls1CBA/H
(involves: C57BL/6 * CBA/H)
|
increased incidence of tumors by ionizing radiation induction
|
J:82643
|
Ramls2C57BL/6/Ramls2CBA/H
(involves: C57BL/6 * CBA/H)
|
increased incidence of tumors by ionizing radiation induction
|
J:82643
|
Ranbp2tm1Jvd/Ranbp2tm1.1Jvd
(involves: 129/Sv * C57BL/6)
|
decreased tumor latency
|
J:137482
|
| increased hepatocellular carcinoma incidence
|
J:137482
|
| increased incidence of tumors by chemical induction
|
J:137482
|
| increased lung carcinoma incidence
|
J:137482
|
| increased sarcoma incidence
|
J:137482
|
| increased tumor incidence
|
J:137482
|
Ranbp2tm1Jvd/Ranbp2tm1Jvd
(involves: 129/Sv * C57BL/6)
|
decreased tumor latency
|
J:137482
|
| increased hepatocellular carcinoma incidence
|
J:137482
|
| increased incidence of tumors by chemical induction
|
J:137482
|
| increased lung carcinoma incidence
|
J:137482
|
| increased sarcoma incidence
|
J:137482
|
| increased tumor incidence
|
J:137482
|
Raph1tm1.2Fbg/Raph1tm1.2Fbg
(involves: 129S4/SvJae * C57BL/6)
|
increased carcinoma incidence
|
J:238262
|
Raratm3.1Ipc/Rara+
Trim24tm1.1Los/Trim24tm1.1Los
(involves: 129/Sv * C57BL/6 * SJL)
|
neoplasm
|
J:130210
|
Rarres1tm1.2Mhl/Rarres1+
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)
|
increased follicular lymphoma incidence
|
J:324270
|
Rarres1tm1.2Mhl/Rarres1tm1.2Mhl
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)
|
increased follicular lymphoma incidence
|
J:324270
|
Rarres1tm1d(KOMP)Wtsi/Rarres1+
(involves: C57BL/6N)
|
increased follicular lymphoma incidence
|
J:324270
|
Rasal2Gt(463C12)Cmhd/Rasal2+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl)
|
increased metastatic potential
|
J:202603
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl)
|
decreased tumor latency
|
J:202603
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
Tg(MMTVneu)202Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:202603
|
| increased metastatic potential
|
J:202603
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl)
|
increased colon adenoma incidence
|
J:202603
|
| increased hepatocellular carcinoma incidence
|
J:202603
|
| increased liver tumor incidence
|
J:202603
|
| increased lymphoma incidence
|
J:202603
|
| increased metastatic potential
|
J:202603
|
| increased mouth tumor incidence
|
J:202603
|
| increased stomach tumor incidence
|
J:202603
|
Rassf1tm1.2Brd/Rassf1tm1.2Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenoma incidence
|
J:101369
|
| increased incidence of tumors by ionizing radiation induction
|
J:101369
|
| increased intestinal adenocarcinoma incidence
|
J:101369
|
| increased lymphoma incidence
|
J:101369
|
Rassf1tm1Gpp/Rassf1+
(involves: 129S1/SvImJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:95683
|
| increased lung adenoma incidence
|
J:95683
|
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:95683
|
| increased incidence of tumors by chemical induction
|
J:95683
|
| increased lung adenoma incidence
|
J:95683
|
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ)
|
increased hepatocellular carcinoma incidence
|
J:231761
|
| increased liver adenoma incidence
|
J:231761
|
| increased liver tumor incidence
|
J:231761
|
Rassf1tm1Gpp/Rassf1tm1Gpp
Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv * 129S1/SvImJ)
|
increased hepatoblastoma incidence
|
J:231761
|
| increased hepatocellular carcinoma incidence
|
J:231761
|
| increased liver adenoma incidence
|
J:231761
|
| increased liver tumor incidence
|
J:231761
|
Rassf5tm1Kina/Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
|
increased B cell derived lymphoma incidence
|
J:168749
|
| increased hepatocellular carcinoma incidence
|
J:168749
|
| increased lung adenocarcinoma incidence
|
J:168749
|
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
neoplasm
|
J:102483
|
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased colon adenoma incidence
|
J:102483
|
| increased intestinal adenocarcinoma incidence
|
J:102483
|
| increased lymphoma incidence
|
J:102483
|
| increased teratoma incidence
|
J:102483
|
| increased testicular teratoma incidence
|
J:102483
|
Rb1tm1.2Gfk/Rb1+
(involves: 129T2/SvEms * C57BL/6 * SJL)
|
increased tumor incidence
|
J:108628
|
Rb1tm1Brd/Rb1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased brain tumor incidence
|
J:2516
|
| increased metastatic potential
|
J:17434
|
| increased pituitary adenoma incidence
|
J:17434
|
| neoplasm
|
J:2516,
J:79648
|
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:79016
|
| increased pituitary adenohypophysis tumor incidence
|
J:79016
|
| increased pituitary melanotroph tumor incidence
|
J:79016
|
| increased thyroid C-cell carcinoma incidence
|
J:79016
|
Rb1tm1Brn/Rb1+
Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Brn/Rb1tm1Brn
Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Brn/Rb1tm1Brn
X/Tg(Pomc-FLP)1bBrn
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
|
increased pituitary melanotroph tumor incidence
|
J:20542
|
| neoplasm
|
J:20542,
J:2498
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:81082,
J:2511
|
| increased thyroid tumor incidence
|
J:81082
|
| neoplasm
|
J:2511
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased lung tumor incidence
|
J:133299
|
| increased metastatic potential
|
J:133299
|
| increased pheochromocytoma incidence
|
J:133299
|
| increased pituitary adenohypophysis tumor incidence
|
J:133299
|
| increased pituitary melanotroph tumor incidence
|
J:133299
|
| increased thyroid C-cell carcinoma incidence
|
J:133299
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
| increased thyroid tumor incidence
|
J:175625
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas)
|
increased pituitary gland tumor incidence
|
J:215358
|
Rb1tm1Tyj/Rb1+
Rbl1tm1Tyj/Rbl1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:34058
|
Rb1tm1Tyj/Rb1+
Rbl1tm1Tyj/Rbl1tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:34058
|
Rb1tm1Tyj/Rb1+
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased pituitary gland tumor incidence
|
J:132091
|
Rb1tm1Tyj/Rb1+
Tg(S100b-v-erbB)4496Waw/0
(involves: 129S2/SvPas * C57BL/6J * DBA/2J * FVB/N)
|
increased glioma incidence
|
J:82649
|
Rb1tm1Tyj/Rb1+
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Rb1tm1Tyj/Rb1+
Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:189317
|
| increased thyroid tumor incidence
|
J:189317
|
| increased tumor incidence
|
J:189317
|
Rb1tm1Tyj/Rb1+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor morphology
|
J:19542
|
| increased leiomyosarcoma incidence
|
J:19542
|
| increased pancreatic islet cell carcinoma incidence
|
J:19542
|
| increased pituitary melanotroph tumor incidence
|
J:19542
|
| increased sarcoma incidence
|
J:19542
|
| increased thyroid tumor incidence
|
J:19542
|
| increased tumor incidence
|
J:19542
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Tyj
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Tyj
(chimera involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:59268
|
| preneoplasia
|
J:59268
|
Rb1tm2.1Fad/Rb1tm2.1Fad
(involves: 129 * C57BL/6)
|
neoplasm
|
J:215358
|
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
abnormal tumor pathology
|
J:86077
|
| increased lung adenocarcinoma incidence
|
J:86077
|
| increased lung small cell carcinoma incidence
|
J:86077
|
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Rb1tm2Brn/Rb1tm2Brn
(involves: 129)
|
neoplasm
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129 * 129S2/SvPas * 129S4/SvJae)
|
increased urinary bladder carcinoma incidence
|
J:217195
|
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0
(involves: 129 * FVB/N)
|
increased carcinoma incidence
|
J:187257
|
| increased pituitary gland tumor incidence
|
J:187257
|
| neoplasm
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn
Tg(KRT14-cre)8Brn/0
Tg(KRT5-Akt1*)Jmpa/0
(involves: 129 * C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
increased tumor incidence
|
J:144831
|
Rb1tm2Brn/Rb1tm2Brn
Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Rb1tm2Brn Tg(MMTV-cre)105Ayn)
|
neoplasm
|
J:165292
|
Rb1tm2Brn/Rb1tm2Brn
Tg(Rbp3-cre)1Brn/0
(involves: 129 * FVB/N)
|
increased pituitary adenohypophysis tumor incidence
|
J:77982
|
| increased pituitary melanotroph tumor incidence
|
J:77982
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53+
Tg(Rbp3-cre)1Brn/0
(involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
abnormal tumor morphology
|
J:77982
|
| increased tumor incidence
|
J:77982
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53tm1Brd
Tg(Gfap-cre)2Brn/0
(involves: 129 * 129S7/SvEvBrd * FVB/N)
|
increased medulloblastoma incidence
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
| increased lung small cell carcinoma incidence
|
J:86077,
J:157319
|
| increased lung tumor incidence
|
J:157319
|
| increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
abnormal tumor pathology
|
J:86077
|
| increased lung carcinoma incidence
|
J:86077
|
| increased lung small cell carcinoma incidence
|
J:86077,
J:157319
|
| increased lung tumor incidence
|
J:157319
|
| increased metastatic potential
|
J:84345
|
| increased ovarian carcinoma incidence
|
J:84345
|
| increased ovary tumor incidence
|
J:84345
|
| increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
(involves: 129 * 129P2/OlaHsd * FVB/NJ)
|
increased osteosarcoma incidence
|
J:326989
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased medulloblastoma incidence
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased carcinoma incidence
|
J:187257
|
| increased medulloblastoma incidence
|
J:187257
|
| increased papilloma incidence
|
J:187257
|
| increased pituitary gland tumor incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn)
|
increased carcinoma incidence
|
J:165292
|
| increased lung tumor incidence
|
J:165292
|
| increased mammary gland tumor incidence
|
J:165292
|
| increased squamous cell carcinoma incidence
|
J:165292
|
| increased tumor growth/size
|
J:165292
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Ren-cre)#Kwg/0
(involves: 129 * 129P2/OlaHsd)
|
increased glucagonoma incidence
|
J:216559
|
| increased metastatic potential
|
J:216559
|
| increased pancreatic islet cell carcinoma incidence
|
J:216559
|
| increased sarcoma incidence
|
J:216559
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129)
|
increased lung small cell carcinoma incidence
|
J:187012
|
Rb1tm2Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
|
increased pituitary melanotroph tumor incidence
|
J:20542
|
| neoplasm
|
J:20542,
J:2498
|
Rb1tm3Fad/Rb1tm3Fad
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lymphoma incidence
|
J:249124
|
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:318885
|
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2tm4.1Skn
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:318885
|
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased metastatic potential
|
J:136693
|
| increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased metastatic potential
|
J:136693
|
| increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:318885
|
Rb1tm3Tyj/Rb1tm3Tyj
(involves: 129S4/SvJae)
|
neoplasm
|
J:172430
|
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:177573
|
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased retinoblastoma incidence
|
J:119919
|
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm1Tyj/Rbl2tm1Tyj
Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased retinoblastoma incidence
|
J:91406
|
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased retinoblastoma incidence
|
J:119919
|
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung small cell carcinoma incidence
|
J:160148
|
| increased lung tumor incidence
|
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj
Tg(Nes-cre)1Atp/0
(involves: 129S4/SvJae * FVB/N)
|
increased pituitary gland tumor incidence
|
J:91406
|
Rb1tm3Tyj/Rb1tm3Tyj
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129S4/SvJae * C57BL/6J * CD-1)
|
neoplasm
|
J:136693
|
Rb1tm3Tyj/Rb1tm3Tyj
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: 129S4/SvJae * C57BL/6 * CD-1)
|
increased metastatic potential
|
J:199542
|
| increased osteosarcoma incidence
|
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:172430
|
| increased liver tumor incidence
|
J:172430
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased metastatic potential
|
J:136693
|
| increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung small cell carcinoma incidence
|
J:160148
|
| increased lung tumor incidence
|
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased metastatic potential
|
J:318035
|
| increased osteosarcoma incidence
|
J:136693,
J:318035
|
| increased tumor incidence
|
J:136693
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
increased hibernoma incidence
|
J:199542
|
| increased metastatic potential
|
J:199542
|
| increased osteosarcoma incidence
|
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased pituitary gland tumor incidence
|
J:91406
|
Rbbp8tm1Whl/Rbbp8+
(Not Specified)
|
increased lymphoma incidence
|
J:97648
|
Rbbp8tm2.1Thl/Rbbp8tm2.1Thl
(involves: 129)
|
neoplasm
|
J:197743
|
Rbbp8tm2Thl/Rbbp8tm2Thl
(involves: 129)
|
neoplasm
|
J:197743
|
Rbm15tm1.1(MAL)Dgg/Rbm15tm1.1(MAL)Dgg
(B6.129-Rbm15tm1.1(MAL)Dgg)
|
increased leukemia incidence
|
J:149622
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
(involves: C57BL/6 * FVB/N)
|
increased hemangiosarcoma incidence
|
J:216929
|
| increased hepatoma incidence
|
J:216929
|
| increased lymphoma incidence
|
J:216929
|
| increased tumor incidence
|
J:216929
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
abnormal tumor susceptibility
|
J:216929
|
| decreased tumor incidence
|
J:216929
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
abnormal tumor susceptibility
|
J:216929
|
| decreased sarcoma incidence
|
J:216929
|
| decreased tumor incidence
|
J:216929
|
| decreased tumor latency
|
J:216929
|
| increased lymphoma incidence
|
J:216929
|
Rbpjtm1Hon/Rbpjtm1Hon
Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)
|
decreased tumor growth/size
|
J:162770
|
Rc3h1san/Rc3h1+
(involves: C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Rcan1tm1Fmc/Rcan1+
Ts(1716)65Dn/0
(involves: 129S4/SvJae * C3H/HeSn * C57BL/6 * C57BL/6Ei * DBA/2J)
|
decreased tumor growth/size
|
J:150286
|
Rcbtb2tm1.1Xyw/Rcbtb2+
(involves: C57BL/6 * CBA)
|
increased gastrointestinal tumor incidence
|
J:282928
|
| increased histiocytic sarcoma incidence
|
J:282928
|
| increased liver tumor incidence
|
J:282928
|
| increased lymphoma incidence
|
J:282928
|
| increased tumor incidence
|
J:282928
|
Rcbtb2tm1.1Xyw/Rcbtb2tm1.1Xyw
(involves: C57BL/6 * CBA)
|
increased gastrointestinal tumor incidence
|
J:282928
|
| increased histiocytic sarcoma incidence
|
J:282928
|
| increased liver tumor incidence
|
J:282928
|
| increased lymphoma incidence
|
J:282928
|
| increased tumor incidence
|
J:282928
|
Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased lymphoma incidence
|
J:97101
|
| increased sarcoma incidence
|
J:97101
|
Relttm1Hlee/Relttm1Hlee
(Not Specified)
|
abnormal tumor susceptibility
|
J:266480
|
Rettm1Cos/Rettm2.1Cos
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J * FVB/N * MF1)
|
neoplasm
|
J:60659
|
Rettm1Giro/Ret+
(129.129P2-Rettm1Giro)
|
increased thyroid adenoma incidence
|
J:141658
|
Rettm2.1Cos/?
Tg(Th-MYCN)41Waw/0
(involves: 129S1/Sv * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033
|
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
increased ganglioneuroma incidence
|
J:60659
|
| increased pheochromocytoma incidence
|
J:60659
|
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:148708
|
Retnlbtm1Lex/Retnlbtm1Lex
(FVB.129S5-Retnlbtm1Lex)
|
increased incidence of tumors by chemical induction
|
J:235058
|
Retnlbtm1Lex/Retnlbtm1Lex
(B6.129S5-Retnlbtm1Lex)
|
decreased incidence of tumors by chemical induction
|
J:235058
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased carcinoma incidence
|
J:158922
|
| increased mammary gland tumor incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:158922
|
| increased mammary gland tumor incidence
|
J:158922
|
| increased osteosarcoma incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53tm1Brd
Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:158922
|
Rgs5tm1.1Rgan/Rgs5tm1.1Rgan
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
|
abnormal tumor morphology
|
J:136259
|
| increased insulinoma incidence
|
J:136259
|
| increased tumor growth/size
|
J:136259
|
| preneoplasia
|
J:136259
|
Rgsc142/Rgsc142+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased leukemia incidence
|
J:133634
|
| increased T cell derived lymphoma incidence
|
J:133634
|
Rgsc682/Rgsc682+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased squamous cell carcinoma incidence
|
J:133634
|
Rgsc814/Rgsc814+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased squamous cell carcinoma incidence
|
J:133634
|
Rgsc1033/Rgsc1033+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pituitary adenoma incidence
|
J:133634
|
| increased thyroid carcinoma incidence
|
J:133634
|
Rgsc1049/Rgsc1049+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased squamous cell carcinoma incidence
|
J:133634
|
Rgsc1050/Rgsc1050+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased renal carcinoma incidence
|
J:133634
|
Rgsc1324/Rgsc1324+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pheochromocytoma incidence
|
J:133634
|
Rgsc1328/Rgsc1328+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pheochromocytoma incidence
|
J:133634
|
Rgv1C57BL/6/Rgv1C57BL/6
(involves: C3Hf/Bi * C57BL/6)
|
decreased incidence of induced tumors
|
J:5011
|
| increased leukemia incidence
|
J:5011
|
Rhobtm1Gcp/Rhobtm1Gcp
(involves: 129)
|
increased incidence of induced tumors
|
J:71577
|
| increased incidence of tumors by chemical induction
|
J:71577
|
Rhoctm1Mak/Rhoctm1Mak
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * FVB/N)
|
decreased metastatic potential
|
J:100482
|
| increased mammary adenocarcinoma incidence
|
J:100482
|
Rhojtm1.1Auem/Rhojtm1.1Auem
Tg(Cdh5-cre/ERT2)1Rha/0
(involves: C57BL/6 * CBA/JNCrlj)
|
abnormal tumor morphology
|
J:208154
|
| abnormal tumor vascularization
|
J:208154
|
| decreased tumor growth/size
|
J:208154
|
Rhojtm1.2Auem/Rhojtm1.2Auem
(B6.Cg-Rhojtm1.2Auem)
|
abnormal tumor morphology
|
J:208154
|
| abnormal tumor vascularization
|
J:208154
|
| decreased metastatic potential
|
J:208154
|
| decreased tumor growth/size
|
J:208154
|
Rhojtm1.2Auem/Rhojtm1.2Auem
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * CBA/JNCrlj * FVB/N)
|
abnormal tumor vascularization
|
J:208154
|
| decreased mammary gland tumor incidence
|
J:208154
|
| decreased metastatic potential
|
J:208154
|
| decreased tumor growth/size
|
J:208154
|
Rigitm1Zgwg/Rigitm1Zgwg
(involves: 129S1/Sv)
|
increased chronic myelocytic leukemia incidence
|
J:139016
|
Ril1A/J/Ril1A/J
(involves: A/J * C57BL/10ScSn)
|
decreased incidence of tumors by ionizing radiation induction
|
J:6610
|
| increased leukemia incidence
|
J:6610
|
Ril1A/J/Ril1C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
decreased incidence of tumors by ionizing radiation induction
|
J:6610
|
| increased leukemia incidence
|
J:6610
|
Ril2A/J/Ril2C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
decreased incidence of induced tumors
|
J:6610
|
| increased leukemia incidence
|
J:6610
|
Ril2C57BL/10ScSn/Ril2C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
decreased incidence of tumors by ionizing radiation induction
|
J:6610
|
| increased leukemia incidence
|
J:6610
|
Ril3A/J/Ril3C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
decreased incidence of tumors by ionizing radiation induction
|
J:6610
|
| increased leukemia incidence
|
J:6610
|
Ril3C57BL/10ScSn/Ril3C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
decreased incidence of tumors by ionizing radiation induction
|
J:6610
|
| increased leukemia incidence
|
J:6610
|
Ril4BALB/c/Ril4BALB/c
(B6.C-H30c/(HW105)ByJ)
|
increased leukemia incidence
|
J:7027
|
Rint1tm1Whl/Rint1+
(Not Specified)
|
increased cystadenoma incidence
|
J:122805
|
| increased hemangioma incidence
|
J:122805
|
| increased hepatocellular carcinoma incidence
|
J:122805
|
| increased keratoacanthoma incidence
|
J:122805
|
| increased lung adenocarcinoma incidence
|
J:122805
|
| increased lymphoma incidence
|
J:122805
|
| increased mammary adenocarcinoma incidence
|
J:122805
|
| increased mammary gland tumor incidence
|
J:122805
|
| increased mesothelioma incidence
|
J:122805
|
| increased ovary tumor incidence
|
J:122805
|
| increased papilloma incidence
|
J:122805
|
| increased pituitary adenoma incidence
|
J:122805
|
| increased skin squamous cell carcinoma incidence
|
J:122805
|
| increased tumor incidence
|
J:122805
|
| increased uterus leiomyoma incidence
|
J:122805
|
Rnf8Gt(AS0574)Wtsi/Rnf8+
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:161240
|
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:161240
|
| increased mammary adenocarcinoma incidence
|
J:161240
|
| increased sarcoma incidence
|
J:161240
|
| increased skin tumor incidence
|
J:161240
|
| increased T cell derived lymphoma incidence
|
J:161240
|
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:161240
|
| increased mammary adenocarcinoma incidence
|
J:161240
|
| increased sarcoma incidence
|
J:161240
|
| increased skin tumor incidence
|
J:161240
|
| increased T cell derived lymphoma incidence
|
J:161240
|
Rnf19btm1Jkorn/Rnf19btm1Jkorn
(B6.129S-Rnf19btm1Jkorn)
|
increased metastatic potential
|
J:157393
|
| increased tumor growth/size
|
J:157393
|
Rnf20Gt(RRJ249)Byg/Rnf20+
(involves: 129P2/OlaHsd)
|
increased colon adenocarcinoma incidence
|
J:268221
|
| increased incidence of tumors by chemical induction
|
J:268221
|
| increased large intestine adenocarcinoma incidence
|
J:268221
|
Rnf43tm1Cle/Rnf43tm1Cle
Znrf3tm1Cle/Znrf3tm1Cle
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd)
|
increased intestinal adenoma incidence
|
J:186765
|
Rnf43tm1Cle/Rnf43tm1Cle
Znrf3tm1Cle/Znrf3tm1Cle
Tg(Vil1-cre/ERT2)23Syr/0
(involves: C57BL/6 * DBA/2)
|
increased intestinal adenoma incidence
|
J:186765
|
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:198260
|
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:198260
|
| increased hemangiosarcoma incidence
|
J:198260
|
| increased sarcoma incidence
|
J:198260
|
| increased thymoma incidence
|
J:198260
|
| increased tumor incidence
|
J:198260
|
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:198260
|
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:198260
|
| increased hemangiosarcoma incidence
|
J:198260
|
| increased sarcoma incidence
|
J:198260
|
| increased thymoma incidence
|
J:198260
|
| increased tumor incidence
|
J:198260
|
Robo1tm1Phr/Robo1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased carcinoma incidence
|
J:93666
|
| increased lung adenocarcinoma incidence
|
J:93666
|
| increased lymphoma incidence
|
J:93666
|
Rpa1tm1Wed/Rpa1+
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:99303
|
Rpl27aSfa/Rpl27a+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J)
|
abnormal tumor incidence
|
J:174216
|
| decreased lymphoma incidence
|
J:174216
|
| increased metastatic potential
|
J:174216
|
| increased tumor latency
|
J:174216
|
Rps6kb1tm1Gtho/Rps6kb1tm1Gtho
Rps6kb2tm1Gtho/Rps6kb2tm1Gtho
Tg(Ins2-Akt1*)3Mbb/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
neoplasm
|
J:144599
|
Rps6kb2tm1Gtho/Rps6kb2tm1Gtho
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb)
|
increased insulinoma incidence
|
J:144599
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N)
|
increased B cell derived lymphoma incidence
|
J:223276
|
| increased T cell derived lymphoma incidence
|
J:223276
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N)
|
increased lymphoma incidence
|
J:223276
|
Rr28tm1Tilg/Rr28+
Tg(CRP-TAg)60-3Urt/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
increased liver tumor incidence
|
J:138826
|
Rr39em1Ched/Rr39em1Ched
(C57BL/6-Rr39em1Ched)
|
increased tumor growth/size
|
J:239509
|
Rr420em1Itok/Rr420em1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:319454
|
Rr420tm1.1Itok/Rr420tm1.1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:319454
|
Rr149356tm1Che/Rr149356tm1Che
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:106246
|
Rr149356tm1Che/Rr149356tm1Che
Tcrdtm1Mom/Tcrdtm1Mom
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:106246
|
Rr149356tm1Che/Rr149356tm1Che
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
decreased metastatic potential
|
J:106246
|
| increased T cell derived lymphoma incidence
|
J:106246
|
Rragcem1Efe/Rragc+
Tg(Vav-BCL2)69Jad/0
(Not Specified)
|
increased tumor latency
|
J:320567
|
RrasGt(OST24882)Lex/RrasGt(OST24882)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal tumor vascularization
|
J:104130
|
Rrastm1Itl/Rras+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased tumor growth/size
|
J:181730
|
Rrastm1Itl/Rrastm1Itl
(involves: 129S6/SvEvTac * C57BL/6)
|
increased tumor growth/size
|
J:181730
|
RrsvA/WySnJ/RrsvA/WySnJ
(involves: A/WySnJ * SW)
|
increased incidence of induced tumors
|
J:6009
|
| increased sarcoma incidence
|
J:6009
|
RrsvCBA/J/RrsvCBA/J
(involves: CBA/J * SW)
|
increased incidence of induced tumors
|
J:6009
|
| increased sarcoma incidence
|
J:6009
|
RrsvSW/RrsvSW
(involves: A/WySnJ * SW)
|
decreased incidence of induced tumors
|
J:6009
|
RrsvSW/RrsvSW
(involves: CBA/J * SW)
|
decreased incidence of induced tumors
|
J:6009
|
Rtel1tm2.1Hdin/Rtel1tm2.1Hdin
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
decreased tumor latency
|
J:202812
|
| increased lymphoma incidence
|
J:202812
|
| increased medulloblastoma incidence
|
J:202812
|
| increased sarcoma incidence
|
J:202812
|
| increased teratoma incidence
|
J:202812
|
Rundc1tm1b(EUCOMM)Wtsi/Rundc1tm1b(EUCOMM)Wtsi
(C57BL/6N-Rundc1tm1b(EUCOMM)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Runx1tm1(RUNX1)Gcg/Runx1tm1(RUNX1)Gcg
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased metastatic potential
|
J:106800
|
| increased T cell derived lymphoma incidence
|
J:106800
|
Runx1tm1Spe/Runx1+
(either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))
|
increased T cell derived lymphoma incidence
|
J:80829
|
Runx1tm1Spe/Runx1+
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
|
neoplasm
|
J:80829
|
Runx1tm2Buch/Runx1tm2Buch
Tg(Mx1-cre)1Cgn/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:105709
|
| increased T cell derived lymphoma incidence
|
J:105709
|
Runx1tm3Dow/Runx1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute promyelocytic leukemia incidence
|
J:77129
|
| increased sarcoma incidence
|
J:77129
|
| increased T cell derived lymphoma incidence
|
J:77129
|
| increased tumor incidence
|
J:77129
|
Runx1tm3Spe/Runx1tm3Spe
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased incidence of tumors by chemical induction
|
J:267082
|
Runx1tm3Spe/Runx1tm3Spe
U2af1tm1.1Hev/U2af1+
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * 129S6/SvEvTac * BALB/c * C57BL/6 * CBA/J)
|
increased incidence of tumors by chemical induction
|
J:267082
|
Runx3tm1.1Itok/Runx3tm1.1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:319454
|
Runx3tm1Itan/Runx3+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
decreased osteosarcoma incidence
|
J:319454
|
Rv2BALB/cJ/Rv2BALB/cJ
(B6.C-H7b/By)
|
increased leukemia incidence
|
J:7613
|
Rv2BALB/cJ/Rv2BALB/cJ
(B10.C-H7b/(47N)SnJ)
|
increased leukemia incidence
|
J:7613
|
Rv3C57BL/6J/Rv3C57BL/6J
(involves: C57BL/6J * CBA/Lac)
|
increased leukemia incidence
|
J:7613
|
Rv3C57BL/6J/Rv3CBA/Lac
(involves: C57BL/6J * CBA/Lac)
|
increased leukemia incidence
|
J:7613
|
Rv3CBA/Lac/Rv3CBA/Lac
(involves: C57BL/6J * CBA/Lac)
|
increased leukemia incidence
|
J:7613
|
Rvil1CE/J/Rvil1CE/J
(B10.CE-H3bb/(30NX)SnDcr)
|
increased leukemia incidence
|
J:7027
|
Rxratm1Krc/Rxra+
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:78553
|
Rxratm1Krc/Rxratm1Krc
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:78553
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
Trp53tm1Sia/Trp53+
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased rhabdomyosarcoma incidence
|
J:117828
|
| increased tumor incidence
|
J:117828
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
Trp53tm1Sia/Trp53tm1Sia
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased rhabdomyosarcoma incidence
|
J:117828
|
| increased tumor incidence
|
J:117828
|
S1pr2tm1Ajml/S1pr2tm1Ajml
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:154439
|
| increased lung tumor incidence
|
J:154439
|
S1pr2tm1Ajml/S1pr2tm1Ajml
(129S5/SvEvBrd-S1pr2tm1Ajml)
|
increased B cell derived lymphoma incidence
|
J:154439
|
S1pr2tm1Ytak/S1pr2tm1Ytak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal tumor morphology
|
J:168060
|
| abnormal tumor vascularization
|
J:168060
|
| increased tumor growth/size
|
J:168060
|
S100a4tm1Amba/S100a4tm1Amba
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
|
increased fibrosarcoma incidence
|
J:89563
|
| increased hepatocellular carcinoma incidence
|
J:89563
|
| increased lung carcinoma incidence
|
J:89563
|
| increased lymphoma incidence
|
J:89563
|
| increased mammary adenocarcinoma incidence
|
J:89563
|
| increased tumor incidence
|
J:89563
|
Samd9ltm1Homy/Samd9l+
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:180923,
J:202604
|
| increased tumor incidence following infection
|
J:202604
|
Samd9ltm1Homy/Samd9ltm1Homy
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:180923,
J:202604
|
| increased tumor incidence following infection
|
J:202604
|
Samd9ltm1Homy/Samd9ltm1Homy
(B6N.129P2-Samd9ltm1Homy)
|
increased leukemia incidence
|
J:225110
|
Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv)
|
increased hepatocellular carcinoma incidence
|
J:231761
|
| increased liver adenoma incidence
|
J:231761
|
| increased liver tumor incidence
|
J:231761
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL)
|
increased carcinoma incidence
|
J:156531
|
| increased hepatocellular carcinoma incidence
|
J:156531
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo
Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * CD-1 * SJL)
|
increased liver tumor incidence
|
J:156531
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo
Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased liver tumor incidence
|
J:156531
|
Sav1tm1Dlim/Sav1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatoma incidence
|
J:160325
|
| increased liver tumor incidence
|
J:160325
|
| increased lymphoma incidence
|
J:160325
|
| increased osteosarcoma incidence
|
J:160325
|
| increased ovary tumor incidence
|
J:160325
|
Sav1tm1Dlim/Sav1tm1Dlim
(involves: 129S1/Sv * 129X1/SvJ)
|
increased liver tumor incidence
|
J:160325
|
Sav1tm2.1Dlim/Sav1tm2.1Dlim
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:238319
|
| increased hepatoma incidence
|
J:160325
|
Scc2STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased tumor incidence
|
J:36996,
J:31355
|
Scc4BALB/cHeA/?
Scc5STS/A/Scc5STS/A
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:36996
|
Scc4STS/A/Scc4STS/A
Scc5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:36996
|
Scc6STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:57235
|
Scc7STS/A/?
Scc8STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:57235
|
Scc8STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:57235
|
Scc9STS/A/?
(involves: BALB/cHeA * CcS-5)
|
increased colon adenoma incidence
|
J:57235
|
Scc11BALB/cHeA/Scc11BALB/cHeA
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Scc11BALB/cHeA/Scc11STS/A
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Scc11STS/A/Scc11STS/A
Scc3STS/A/Scc3STS/A
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Scc12BALB/cHeA/Scc12STS/A
Scc5STS/A/Scc5STS/A
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Scc13BALB/cHeA/Scc13STS/A
Scc14STS/A/Scc14STS/A
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Scc15BALB/cHeA/Scc15STS/A
Scc5BALB/cHeA/Scc5STS/A
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Scc15BALB/cHeA/Scc15STS/A
Scc5STS/A/Scc5STS/A
(involves: BALB/cHeA * Ccs-19/Dem)
|
increased tumor incidence
|
J:86054
|
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)68Dla/0
(FVB/N-TgTn(sb-T2/Onc)68Dla Sclt1Tg(CAG-sb10)1Dla)
|
neoplasm
|
J:99991
|
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)76Dla/0
(FVB/N-TgTn(sb-T2/Onc)76Dla Sclt1Tg(CAG-sb10)1Dla)
|
neoplasm
|
J:99991
|
Scribtm1.1Phum/Scribtm1.1Phum
Tg(Pbsn-cre)20Fwan/0
(involves: FVB/NCrl)
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Scribtm1.2Phum/Scrib+
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:178461
|
| increased lung adenoma incidence
|
J:216266
|
| increased lung non-small cell carcinoma incidence
|
J:216266
|
Sdc1tm1Cma/Sdc1+
Tg(Wnt1)1Hev/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
decreased tumor incidence
|
J:63122
|
Sdc1tm1Cma/Sdc1tm1Cma
Tg(Wnt1)1Hev/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
decreased tumor incidence
|
J:63122
|
Sdhctm1c(EUCOMM)Wtsi/Sdhctm1c(EUCOMM)Wtsi
Gt(ROSA)26Sortm1.1(rtTA,tetO-cre)Bkmn/Gt(ROSA)26Sor+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
|
neoplasm
|
J:284745
|
Sdhdtm1Jlob/Sdhd+
(involves: 129X1/SvJ)
|
neoplasm
|
J:95252
|
Sdhdtm1Jlob/Sdhdtm2Jlob
Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
neoplasm
|
J:186713
|
Sdhdtm1Jlob/Sdhdtm2Jlob
Thtm1(cre)Te/Th+
(involves: 129S1/Sv * 129X1/SvJ)
|
neoplasm
|
J:186713
|
seb/seb
(Him:OF1)
|
decreased tumor incidence
|
J:20987
|
| increased skin tumor incidence
|
J:20987
|
Selltm1Tft/Selltm1Tft
(B6.129P2-Selltm1Tft)
|
increased tumor growth/size
|
J:108135
|
Selltm2Hyn/Selltm2Hyn
(involves: 129S2/SvPas * C57BL/6)
|
decreased metastatic potential
|
J:106671
|
| decreased tumor incidence
|
J:106671
|
Serpine1tm1Mlg/Serpine1tm1Mlg
(involves: 129S2/SvPas * C57BL/6)
|
neoplasm
|
J:33232
|
Sertad1tm1Srn/Sertad1tm1Srn
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
|
neoplasm
|
J:157231
|
Setd2tm1c(NCOM)Mfgc/Setd2tm1c(NCOM)Mfgc
Tg(Lck-cre)#Zhu/0
(involves: C57BL/6 * SJL/J)
|
neoplasm
|
J:243973
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6N)
|
abnormal tumor pathology
|
J:297725
|
| decreased tumor growth/size
|
J:297725
|
| increased metastatic potential
|
J:297725
|
| increased tumor latency
|
J:297725
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Trp53tm1Brn/Trp53+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N)
|
abnormal tumor latency
|
J:297725
|
| neoplasm
|
J:297725
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N)
|
abnormal tumor latency
|
J:297725
|
| decreased metastatic potential
|
J:297725
|
| decreased tumor latency
|
J:297725
|
| increased tumor growth/size
|
J:297725
|
Sf1Gt(pU17)1Teya/Sf1+
(involves: C57BL/6 * CBA)
|
abnormal tumor morphology
|
J:141491
|
| increased incidence of tumors by chemical induction
|
J:141491
|
Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:164224
|
SfnEr/Sfn+
(involves: 129/Sv * C57BL/6)
|
increased skin papilloma incidence
|
J:12025
|
| increased squamous cell carcinoma incidence
|
J:12025
|
Sgo1Gt(neo-btk)1Dai/Sgo1+
(involves: 129S4/SvJae * C57BL/6)
|
increased colon tumor incidence
|
J:204809
|
Shc1tm5Paw/Shc1+
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased metastatic potential
|
J:133325
|
| increased mammary gland tumor incidence
|
J:133325
|
| increased tumor latency
|
J:133325
|
Shc1tm5Paw/Shc1tm5Paw
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased metastatic potential
|
J:133325
|
| increased mammary gland tumor incidence
|
J:133325
|
| increased tumor latency
|
J:133325
|
Shc1tm6Paw/Shc1+
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased metastatic potential
|
J:133325
|
| increased mammary gland tumor incidence
|
J:133325
|
| increased tumor latency
|
J:133325
|
Shc1tm6Paw/Shc1tm6Paw
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased metastatic potential
|
J:133325
|
| increased mammary gland tumor incidence
|
J:133325
|
| increased tumor latency
|
J:133325
|
Shc1tm7Paw/Shc1+
Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased metastatic potential
|
J:133325
|
| increased mammary gland tumor incidence
|
J:133325
|
| increased tumor latency
|
J:133325
|
Shc1tm9Paw/Shc1tm9Paw
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
neoplasm
|
J:133325
|
Shmt1Gt(AD0236)Wtsi/Shmt1Gt(AD0236)Wtsi
Tg(IGL-MYC)3Hm/0
(B6.Cg-Shmt1Gt(AD0236)Wtsi Tg(IGL-MYC)3Hm)
|
increased tumor growth/size
|
J:183477
|
Shmt1Gt(AD0236)Wtsi/Shmt1Gt(AD0236)Wtsi
Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:183477
|
Sin3atm1.1Rdp/Sin3a+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * FVB)
|
neoplasm
|
J:117829
|
Sipa1tm1Nm/Sipa1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:97239
|
Sipa1tm1Nm/Sipa1tm1Nm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:97239
|
Sirt1tm1.1Cxd/Sirt1+
Trp53tm1Brd/Trp53+
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N))
|
abnormal tumor morphology
|
J:140089
|
| increased carcinoma incidence
|
J:140089
|
| increased lymphoma incidence
|
J:140089
|
| increased sarcoma incidence
|
J:140089
|
| increased teratoma incidence
|
J:140089
|
| increased tumor incidence
|
J:140089
|
Sirt2tm1.1Cxd/Sirt2tm1.1Cxd
(either: (involves: C57BL/6 * FVB/N) or (involves: FVB/N * NIH Black Swiss))
|
increased B cell derived lymphoma incidence
|
J:177486
|
| increased gastrointestinal tumor incidence
|
J:177486
|
| increased hepatocellular carcinoma incidence
|
J:177486
|
| increased lung tumor incidence
|
J:177486
|
| increased mammary gland tumor incidence
|
J:177486
|
| increased pancreas tumor incidence
|
J:177486
|
| increased prostate gland tumor incidence
|
J:177486
|
| increased stomach tumor incidence
|
J:177486
|
| increased tumor incidence
|
J:177486
|
Sirt2tm1.1Fwa/Sirt2tm1.1Fwa
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal tumor susceptibility
|
J:195041
|
Skitm1Cco/Ski+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:73349
|
| increased lymphoma incidence
|
J:73349
|
Skiltm1.1Kluo/Skiltm1.1Kluo
(B6.129P2-Skiltm1.1Kluo)
|
decreased incidence of tumors by chemical induction
|
J:154718
|
| decreased tumor growth/size
|
J:154718
|
Skiltm1Sis/Skil+
(involves: C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:62174
|
| increased incidence of tumors by chemical induction
|
J:62174
|
| increased T cell derived lymphoma incidence
|
J:62174
|
Skiltm1Spw/Skiltm1Spw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
neoplasm
|
J:84554
|
Skiltm2Spw/Skiltm2Spw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
neoplasm
|
J:84554
|
Skts1M. spretus/?
(involves: M. spretus * NIH)
|
decreased tumor incidence
|
J:27733
|
| increased skin tumor incidence
|
J:27733
|
Skts2M. spretus/?
(involves: M. spretus * NIH)
|
increased skin tumor incidence
|
J:27733
|
Skts4SENCARA/Pt/?
(involves: BALB/cAnPt * SENCARA/Pt)
|
increased skin tumor incidence
|
J:48305
|
Skts5NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts6NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts7NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts8NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts9NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts10M. spretus/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts11M. spretus/Skts11M. spretus
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts12M. spretus/Skts12M. spretus
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:27733
|
Skts12M. spretus/Skts12NIH/Ola
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:27733
|
Skts13M. spretus/?
(involves: M. spretus * NIH/Ola)
|
increased skin papilloma incidence
|
J:84842
|
Skts16Car-R/Skts16Car-R
(involves: Car-R * Car-S)
|
decreased tumor incidence
|
J:68404
|
Skts16Car-R/Skts16Car-S
(involves: Car-R * Car-S)
|
decreased tumor incidence
|
J:68404
|
Skts16Car-S/Skts16Car-S
(involves: Car-R * Car-S)
|
increased skin tumor incidence
|
J:68404
|
Skts-fp2FVB/NTac/Skts-fp2FVB/NTac
Skts-fp3FVB/NTac/Skts-fp3FVB/NTac
(involves: FVB/NTac * PWK/Rbrc)
|
increased skin papilloma incidence
|
J:125337
|
Slc3a2tm1.1Merl/Slc3a2+
Tg(Vil1-cre)997Gum/0
(B6.Cg-Slc3a2tm1.1Merl Tg(Vil1-cre)997Gum)
|
decreased incidence of tumors by chemical induction
|
J:173946
|
| decreased tumor growth/size
|
J:173946
|
Slc5a8tm1.1Boet/Slc5a8tm1.1Boet
(involves: C57BL/6)
|
neoplasm
|
J:139883
|
Slc6a14tm1Gana/Slc6a14tm1Gana
Tg(MMTV-PyVT)634Mul/0
(Not Specified)
|
decreased metastatic potential
|
J:226105
|
| decreased tumor growth/size
|
J:226105
|
| increased tumor latency
|
J:226105
|
Slc6a14tm1Gana/Slc6a14tm1Gana
Tg(MMTVneu)202Mul/0
(involves: FVB/N)
|
decreased mammary gland tumor incidence
|
J:226105
|
| decreased tumor growth/size
|
J:226105
|
| increased tumor latency
|
J:226105
|
Slc7a11m1Mtka/Slc7a11m1Mtka
(C57BL/6-Slc7a11m1Mtka)
|
increased incidence of tumors by chemical induction
|
J:159323
|
Slc20a2tm1a(EUCOMM)Wtsi/Slc20a2tm1a(EUCOMM)Wtsi
(C57BL/6N-Slc20a2tm1a(EUCOMM)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased hemangioma incidence
|
J:239583
|
Slc25a11em1Syki/Slc25a11+
Krastm3Tyj/Kras+
(involves: 129S * C57BL/6)
|
decreased lung tumor incidence
|
J:294965
|
Slc29a3tm1Lex/Slc29a3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:179286
|
Slc33a1tm1.1Lpu/Slc33a1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lung adenoma incidence
|
J:211266
|
| increased lymphoma incidence
|
J:211266
|
| increased sarcoma incidence
|
J:211266
|
| increased tumor incidence
|
J:211266
|
| neoplasm
|
J:211266
|
Sluc1O20/A/Sluc1O20/A
Sluc20O20/A/Sluc20O20/A
(involves: C57BL/10 * O20/A)
|
increased tumor growth/size
|
J:71973
|
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem
Sluc25B10.O20/Dem/Sluc25B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem
Sluc25B10.O20/Dem/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem
Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem
Sluc26O20/A/Sluc26O20/A
(involves: B10.O20/Dem * O20/A)
|
increased tumor growth/size
|
J:71973
|
Sluc10O20/A/Sluc10O20/A
Sluc25B10.O20/Dem/Sluc25B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc10O20/A/Sluc10O20/A
Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc12B10.O20/Dem/Sluc12B10.O20/Dem
Sluc22O20/A/Sluc22O20/A
(involves: C57BL/10 * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc12O20/A/Sluc12O20/A
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: C57BL/10 * O20/A)
|
increased tumor growth/size
|
J:71973
|
Sluc15B10.O20/Dem/Sluc15B10.O20/Dem
Sluc23O20/A/Sluc23O20/A
(involves: C57BL/10 * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc16B10.O20/Dem/Sluc16O20/A
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc17B10.O20/Dem/Sluc17B10.O20/Dem
Sluc20O20/A/Sluc20O20/A
(involves: C57BL/10 * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc18B10.O20/Dem/Sluc18B10.O20/Dem
Sluc26B10.O20/Dem/Sluc26B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc19B10.O20/Dem/Sluc19B10.O20/Dem
Sluc27O20/A/Sluc27O20/A
(involves: C57BL/10 * O20/A)
|
increased tumor growth/size
|
J:71973
|
Sluc21B10.O20/Dem/Sluc21B10.O20/Dem
Sluc28O20/A/Sluc28O20/A
(involves: C57BL/10 * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc21O20/A/Sluc21O20/A
Sluc28B10.O20/Dem/Sluc28B10.O20/Dem
(involves: C57BL/10 * O20/A)
|
increased tumor growth/size
|
J:71973
|
Sluc23B10.O20/Dem/Sluc23O20/A
Sluc30O20/A/Sluc30O20/A
(involves: B10.O20/Dem * O20/A)
|
increased tumor growth/size
|
J:71973
|
Sluc24O20/A/Sluc24O20/A
Sluc5O20/A/Sluc5O20/A
(involves: C57BL/10 * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc25B10.O20/Dem/Sluc25B10.O20/Dem
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc25B10.O20/Dem/Sluc25B10.O20/Dem
Sluc5B10.O20/Dem/Sluc5O20/A
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc25B10.O20/Dem/Sluc25B10.O20/Dem
Sluc9O20/A/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc25B10.O20/Dem/Sluc25O20/A
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc25O20/A/Sluc25O20/A
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A
Sluc9B10.O20/Dem/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A
Sluc9O20/A/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc26O20/A/Sluc26O20/A
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
decreased tumor growth/size
|
J:71973
|
Sluc29B10.O20/Dem/Sluc29B10.O20/Dem
Sluc9B10.O20/Dem/Sluc9B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased tumor growth/size
|
J:71973
|
Smad3tm1Cxd/Smad3tm1Cxd
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased intestinal adenocarcinoma incidence
|
J:53510
|
Smad3tm1Par/Smad3tm1Par
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
increased intestinal adenocarcinoma incidence
|
J:49839
|
| increased metastatic potential
|
J:49839
|
Smad3tm1Par/Smad3tm1Par
(129-Smad3tm1Par/J)
|
increased intestinal adenocarcinoma incidence
|
J:106572
|
Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:81488
|
| increased stomach tumor incidence
|
J:81488
|
Smad4m4Mag/Smad4+
(involves: 129S/Sv * Black Swiss * C57BL/6)
|
increased lung tumor incidence
|
J:106440
|
| increased ovary tumor incidence
|
J:106440
|
| increased stomach tumor incidence
|
J:106440
|
| increased tumor incidence
|
J:106440
|
Smad4tm1.1Gsu/Smad4tm1.1Gsu
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(MtTGFA)Lmb/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:229184
|
Smad4tm1.1Rob/Smad4+
(involves: 129S/SvEv * CD-1)
|
increased stomach tumor incidence
|
J:92066
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J)
|
neoplasm
|
J:203922
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(KRT5-cre)1Xya/0
(involves: 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:101602
|
| increased skin papilloma incidence
|
J:101602
|
| increased skin tumor incidence
|
J:101602
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
| increased metastatic potential
|
J:212549
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
neoplasm
|
J:212549
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased intestinal adenocarcinoma incidence
|
J:212549
|
Smad9tm3Jfm/Smad9tm3Jfm
(involves: 129S4/SvJaeSor)
|
increased lung adenoma incidence
|
J:150213
|
Smap1tm1.1Sata/Smap1tm1.1Sata
(B6.Cg-Smap1tm1.1Sata)
|
increased leukemia incidence
|
J:196385
|
Smarca2tm1Mya/Smarca2tm1Mya
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased hemangiosarcoma incidence
|
J:132091
|
| increased mammary gland tumor incidence
|
J:132091
|
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * CD-1)
|
increased tumor incidence
|
J:66861
|
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:132091
|
| increased osteosarcoma incidence
|
J:132091
|
Smarca5tm1Ais/Smarca5+
(involves: 129/Sv * C57BL/6 * SJL)
|
neoplasm
|
J:86695
|
Smarcb1em1Koke/Smarcb1em1Koke
(C57BL/6-Smarcb1em1Koke)
|
neoplasm
|
J:337790
|
Smarcb1Gt(OST32815)Lex/Smarcb1+
(either: (involves: 129 * 129S5/SvEvBrd) or (involves: 129S5/SvEvBrd * C57BL/6))
|
increased tumor incidence
|
J:69009,
J:87955
|
Smarcb1tm1Gvk/Smarcb1+
(involves: 129/Sv * C57BL/6J * SJL/J)
|
increased blastoma incidence
|
J:101185
|
| increased brain tumor incidence
|
J:101185
|
| increased facial tumor incidence
|
J:101185
|
| increased tumor incidence
|
J:101185
|
Smarcb1tm1Mya/Smarcb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased sarcoma incidence
|
J:68501
|
Smarcb1tm1Sho/Smarcb1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased tumor incidence
|
J:66417
|
Smarcb1tm1Sho/Smarcb1+
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J)
|
increased malignant tumor incidence
|
J:120820
|
Smarcb1tm1Sho/Smarcb1+
Tg(LPV-TAg121)2Tvd/0
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J)
|
increased carcinoma incidence
|
J:120820
|
| increased malignant tumor incidence
|
J:120820
|
Smarcb1tm1Sho/Smarcb1tm3Sho
Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:80224
|
| increased rhabdomyoma incidence
|
J:80224
|
| increased T cell derived lymphoma incidence
|
J:80224
|
| increased tumor incidence
|
J:80224
|
Smarcb1tm2Sho/Smarcb1tm2Sho
Tg(GFAP-cre)#Gtm/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
neoplasm
|
J:226786
|
Smarcb1tm2Sho/Smarcb1tm2Sho
Trp53tm1Brn/Trp53+
Tg(GFAP-cre)#Gtm/0
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA)
|
neoplasm
|
J:226786
|
Smarcb1tm2Sho/Smarcb1tm2Sho
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)#Gtm/0
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA)
|
increased brain tumor incidence
|
J:226786
|
Smg1Gt(AG0297)Wtsi/Smg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:193626
|
| increased lung adenocarcinoma incidence
|
J:193626
|
| increased lymphoma incidence
|
J:193626
|
| increased tumor incidence
|
J:193626
|
Smurf2Gt(RRA098)Byg/Smurf2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:189320
|
| increased tumor incidence
|
J:189320
|
Smurf2Gt(RRA098)Byg/Smurf2Gt(RRA098)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:189320,
J:245679
|
| increased hepatocellular carcinoma incidence
|
J:189320
|
| increased lymphoma incidence
|
J:189320
|
| increased sarcoma incidence
|
J:189320
|
| increased small intestine adenocarcinoma incidence
|
J:189320
|
| increased tumor incidence
|
J:189320
|
Snord50a/Snord50btm1.1Soen/Snord50a/Snord50btm1.1Soen
(B6.129P2-Snord50a/Snord50btm1.1Soen)
|
neoplasm
|
J:206419
|
Snord50a/Snord50btm1.1Soen/Snord50a/Snord50btm1.1Soen
(B6.129P2-Snord50a/Snord50btm1.1Soen)
|
neoplasm
|
J:206419
|
Soat1ald/Soat1ald
(AKR/O)
|
increased leukemia incidence
|
J:12157
|
Socs1tm1Jni/Socs1+
(Not Specified)
|
increased hepatoma incidence
|
J:91651
|
Sod1m1H/Sod1m1H
(involves: C3H/HeH * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:219360
|
| increased liver tumor incidence
|
J:219360
|
Sod2tm1Cje/Sod2+
(B6.Cg-Sod2tm1Cje/Mmmh)
|
increased lymphoma incidence
|
J:87514
|
| increased tumor incidence
|
J:87514
|
Sox9em1(cre/ERT2)Tchn/Sox9+
Stk26tm2.1Zzh/Stk26tm2.1Zzh
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:322311
|
Sox9em1(cre/ERT2)Tchn/Sox9+
Stk26tm2.1Zzh/Stk26tm2.1Zzh
(involves: C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:322311
|
Sparctm1Hwe/Sparctm1Hwe
(involves: 129S/SvEv * C57BL/6J)
|
increased tumor growth/size
|
J:81896
|
Sparttm1.1Xen/Sparttm1.1Xen
(involves: C57BL/6J)
|
increased tumor incidence
|
J:185987
|
Spi1tm1.1Dgt/Spi1tm1.1Dgt
(involves: 129S1/Sv * 129X1/SvJ)
|
increased leukemia incidence
|
J:90331
|
| increased T cell derived lymphoma incidence
|
J:90331
|
| increased tumor incidence
|
J:90331
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased leukemia incidence
|
J:106040
|
| increased T cell derived lymphoma incidence
|
J:106040
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129 * BALB/c * C57BL/6)
|
increased leukemia incidence
|
J:90331
|
| increased T cell derived lymphoma incidence
|
J:90331
|
Spntm1Bam/Spntm1Bam
(B6;129S4-Spntm1Bam/J)
|
decreased tumor incidence
|
J:88253
|
Spp1tm1Blh/Spp1tm1Blh
(129S6/SvEvTac-Spp1tm1Blh)
|
decreased incidence of tumors by chemical induction
|
J:112122
|
Spry1tm1Jdli/Spry1tm1.1Jdli
Spry2tm1Mrt/Spry2tm1.1Mrt
Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Spry2tm1.1Mrt/Spry2+
Spry4tm1.2Mrt/Spry4tm1.2Mrt
(involves: 129P2/OlaHsd)
|
increased enchondroma incidence
|
J:315670
|
| increased osteochondroma incidence
|
J:315670
|
Spry2tm1.1Mrt/Spry2tm1.1Mrt
Spry4tm1.2Mrt/Spry4+
(involves: 129P2/OlaHsd)
|
increased enchondroma incidence
|
J:315670
|
| increased osteochondroma incidence
|
J:315670
|
Spry2tm1Mrt/Spry2tm1Mrt
(involves: 129P2/OlaHsd)
|
increased lung tumor incidence
|
J:119477
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:132133
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac)
|
increased adenoma incidence
|
J:166879
|
| increased adrenal cortical tumor incidence
|
J:166879
|
| increased carcinoma incidence
|
J:166879
|
| increased glioma incidence
|
J:166879
|
| increased hepatocellular carcinoma incidence
|
J:166879
|
| increased liver tumor incidence
|
J:166879
|
| increased lung adenocarcinoma incidence
|
J:166879
|
| increased lymphoma incidence
|
J:166879
|
| increased ovary tumor incidence
|
J:166879
|
| increased renal carcinoma incidence
|
J:166879
|
| increased sarcoma incidence
|
J:166879
|
| increased testis tumor incidence
|
J:166879
|
| increased thyroid carcinoma incidence
|
J:166879
|
Srctm1Mul/Src+
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:181822
|
Srctm1Mul/Srctm1Mul
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:181822
|
Srctm1Mul/Srctm1Mul
Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased tumor growth/size
|
J:181822
|
Srcr/Srcr+
(BALB/c-Srcr/Cui)
|
decreased tumor incidence
|
J:83618
|
Srcr/Srcr+
(B6.C-Srcr/Cui)
|
decreased tumor incidence
|
J:83618
|
Srcr/Srcr+
(CAST.C-Srcr/Cui)
|
decreased tumor incidence
|
J:83618
|
Srpxtm1Hzi/Srpx+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:119999
|
Srpxtm1Hzi/Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased hepatoma incidence
|
J:119999
|
| increased lung adenocarcinoma incidence
|
J:119999
|
| increased lymphoma incidence
|
J:119999
|
| increased sarcoma incidence
|
J:119999
|
| increased T cell derived lymphoma incidence
|
J:119999
|
| increased tumor incidence
|
J:119999
|
Ssbp2tm1Lana/Ssbp2tm1Lana
(involves: 129S/SvEv * C57BL/6)
|
increased adenoma incidence
|
J:162035
|
| increased B cell derived lymphoma incidence
|
J:162035
|
| increased carcinoma incidence
|
J:162035
|
| increased jejunum adenocarcinoma incidence
|
J:162035
|
| increased lung adenoma incidence
|
J:162035
|
| increased lymphoma incidence
|
J:162035
|
| increased malignant tumor incidence
|
J:162035
|
| increased sarcoma incidence
|
J:162035
|
| increased squamous cell carcinoma incidence
|
J:162035
|
Ssbp2tm1Lana/Ssbp2tm1Lana
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:162035
|
Ssic1C57BL/10J/Ssic1C57BL/10J
(involves: C57BL/10 * O20/A)
|
increased small intestine adenocarcinoma incidence
|
J:26873
|
Ssr2tm1b(EUCOMM)Wtsi/Ssr2tm1b(EUCOMM)Wtsi
(C57BL/6N-Ssr2tm1b(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Ssu72tm1Cwl/Ssu72tm1Cwl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Ssu72tm1Cwl Speer6-ps1Tg(Alb-cre)21Mgn)
|
neoplasm
|
J:309624
|
Stab2tm1Ami/Stab2tm1Ami
(B6.Cg-Stab2tm1Ami)
|
decreased metastatic potential
|
J:182239
|
Stag1Gt(P099A04)Wrst/Stag1+
(involves: 129S2/SvPas)
|
decreased incidence of tumors by chemical induction
|
J:184720
|
| decreased tumor growth/size
|
J:184720
|
| increased carcinoma incidence
|
J:184720
|
| increased hepatocellular carcinoma incidence
|
J:184720
|
| increased histiocytic sarcoma incidence
|
J:184720
|
| increased lymphoma incidence
|
J:184720
|
| increased papilloma incidence
|
J:184720
|
| increased tumor incidence
|
J:184720
|
Stard13tm1a(KOMP)Wtsi/Stard13tm1a(KOMP)Wtsi
(C57BL/6-Stard13tm1a(KOMP)Wtsi)
|
abnormal tumor vascularization
|
J:168264
|
| increased tumor growth/size
|
J:168264
|
Stard13tm1Ioln/Stard13tm1Ioln
(B6.129S7-Stard13tm1Ioln)
|
neoplasm
|
J:152475
|
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat1tm1Mam/Stat1tm1Mam
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S/SvEv * FVB)
|
decreased tumor latency
|
J:169262
|
Stat1tm1Rds/Stat1tm1Rds
(C3.129-Stat1tm1Rds)
|
tumor regression
|
J:108303
|
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat1tm1Rds/Stat1tm1Rds
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
neoplasm
|
J:94092
|
Stat3tm1Dlv/Stat3tm1Dlv
Tg(Csf1r-icre)1Jwp/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased carcinoma incidence
|
J:156593
|
| increased gastrointestinal tumor incidence
|
J:156593
|
Stat3tm1Vpo/Stat3tm1Vpo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased incidence of tumors by chemical induction
|
J:172422
|
Stat3tm2Aki/Stat3tm2Aki
Tg(KRT5-cre/ERT2)AJdg/0
(involves: 129P2/OlaHsd * FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:138529
|
Stat3tm4Vpo/Stat3tm4Vpo
Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:157976
|
| increased mammary gland tumor incidence
|
J:157976
|
| increased metastatic potential
|
J:157976
|
| increased tumor growth/size
|
J:157976
|
Stat6tm1Gru/Stat6tm1Gru
(C.129S2-Stat6tm1Gru)
|
abnormal tumor susceptibility
|
J:65894
|
| decreased metastatic potential
|
J:65894
|
Stk3tm1.1Jav/Stk3+
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1.1Jav
(involves: 129 * C57BL/6)
|
increased mammary gland tumor incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1.1Jav
Stk4Gt(AJ0315)Wtsi/Stk4+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Rjo/Stk3tm1.1Rjo
Stk4tm1.1Rjo/Stk4tm1.1Rjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL)
|
increased hepatocellular carcinoma incidence
|
J:156531
|
| increased liver tumor incidence
|
J:156531
|
Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
(involves: C57BL/6 * CBA)
|
increased liver tumor incidence
|
J:156541
|
Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * CBA)
|
increased carcinoma incidence
|
J:156541
|
| increased hepatocellular carcinoma incidence
|
J:156541
|
| increased liver tumor incidence
|
J:156541
|
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:238319
|
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153945
|
Stk11tm1.1Jish/Stk11+
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased adenoma incidence
|
J:77213
|
| increased intestinal adenoma incidence
|
J:77213
|
Stk11tm1.1Mlfr/Stk11+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased hamartoma incidence
|
J:104347
|
Stk11tm1.1Mlfr/Stk11+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased hamartoma incidence
|
J:104347
|
| increased lymphoma incidence
|
J:104347
|
| increased osteosarcoma incidence
|
J:104347
|
| increased sarcoma incidence
|
J:104347
|
Stk11tm1.1Mlfr/Stk11+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased hamartoma incidence
|
J:104347
|
Stk11tm1.1Rdp/Stk11+
Taglntm1(cre/ERT2)Feil/Tagln+
(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased gastrointestinal tumor incidence
|
J:134476
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:131865
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
neoplasm
|
J:124682
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Isl1tm1(cre)Tmj/Isl1+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased gastrointestinal tumor incidence
|
J:201695
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Taglntm1(cre/ERT2)Feil/Tagln+
(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased gastrointestinal tumor incidence
|
J:134476
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(KRT14-cre)1Ipc/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased squamous cell carcinoma incidence
|
J:131037
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Sprr2f-cre)1Dcas/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:158190
|
| increased metastatic potential
|
J:158190
|
Stk11tm1.1Rdp/Stk11tm1.2Rdp
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
neoplasm
|
J:124682
|
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:131865
|
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased hamartoma incidence
|
J:78818
|
| increased incidence of tumors by chemical induction
|
J:131037
|
| increased tumor incidence
|
J:131037,
J:78818
|
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased gastrointestinal tumor incidence
|
J:134476
|
Stk11tm1Mmt/Stk11+
(involves: 129X1/SvJ)
|
increased hamartoma incidence
|
J:76202,
J:107275
|
| increased hepatocellular carcinoma incidence
|
J:76202
|
| increased tumor incidence
|
J:76202
|
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * 129X1/SvJ)
|
increased hamartoma incidence
|
J:107275
|
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ)
|
increased hamartoma incidence
|
J:107275
|
| increased hepatocellular carcinoma incidence
|
J:107275
|
| increased liver tumor incidence
|
J:107275
|
| increased ovary tumor incidence
|
J:107275
|
| increased tumor incidence
|
J:107275
|
Stk11tm1Rdp/Stk11tm1Rdp
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased tumor latency
|
J:198481
|
| increased mammary gland tumor incidence
|
J:198481
|
Stk11tm1Tpm/Stk11+
(Not Specified)
|
increased endometrial carcinoma incidence
|
J:79074
|
| increased hemangioma incidence
|
J:79074
|
| increased hepatocellular carcinoma incidence
|
J:79074
|
| increased liver adenoma incidence
|
J:79074
|
Stk11tm1Tpm/Stk11+
(involves: 129S7/SvEvBrd * C57BL/6 * CD-1)
|
decreased tumor incidence
|
J:93361
|
Stk26tm1.1Zzh/Stk26+
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:289548
|
Stk26tm1.1Zzh/Stk26tm1.1Zzh
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:289548
|
Stk38tm1Hem/Stk38+
(involves: 129P2/Ola * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:185408
|
| increased T cell derived lymphoma incidence
|
J:185408
|
Stk38tm1Hem/Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:185408
|
| increased T cell derived lymphoma incidence
|
J:185408
|
Strapem1Pkda/Strap+
(involves: C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:245661
|
Suds3tm1.1Rdp/Suds3+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * FVB)
|
decreased tumor incidence
|
J:117829
|
Suds3tm1.1Rdp/Suds3+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * FVB)
|
decreased tumor latency
|
J:117829
|
| increased tumor incidence
|
J:117829
|
SufuGt(XB699)Byg/Sufu+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:125534
|
| increased medulloblastoma incidence
|
J:125534
|
| increased rhabdomyosarcoma incidence
|
J:125534
|
Suprmam1BALB/cMed/Suprmam1BALB/cMed
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/cMed * C57BL/6 * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:122161
|
Suv39h1tm1Jnw/Suv39h1+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1+
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1+
Suv39h2tm1Jnw/Suv39h2tm1Jnw
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1tm1Jnw
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1tm1Jnw
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h2tm1Jnw/Suv39h2tm1Jnw
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd)
|
increased histiocytic sarcoma incidence
|
J:217077
|
T(9;17)138Ca/T(9;17)138Ca
(Not Specified)
|
increased adenocarcinoma incidence
|
J:189952
|
| increased mammary gland tumor incidence
|
J:169366
|
Tacc2tm1Jni/Tacc2tm1Jni
(Not Specified)
|
neoplasm
|
J:91577
|
Tacstd2tm1Lsm/Tacstd2tm1Lsm
(involves: C57BL/6)
|
neoplasm
|
J:182647
|
Taf4tm1Idvd/Taf4tm1Idvd
Tg(KRT14-cre/ERT2)1Ipc/0
(involves: C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:124111
|
| increased malignant tumor incidence
|
J:124111
|
| increased squamous cell carcinoma incidence
|
J:124111
|
Tbrg1tm1a(KOMP)Wtsi/Tbrg1tm1a(KOMP)Wtsi
(C57BL/6N-Tbrg1tm1a(KOMP)Wtsi)
|
increased B cell derived lymphoma incidence
|
J:225146
|
| increased Harderian gland adenoma incidence
|
J:225146
|
| increased hemangioma incidence
|
J:225146
|
| increased lung adenoma incidence
|
J:225146
|
| increased tumor incidence
|
J:225146
|
Tbx21tm1Glm/Tbx21tm1Glm
Tg(TRAMP)8247Ng/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased metastatic potential
|
J:88093
|
| increased prostate gland adenocarcinoma incidence
|
J:88093
|
| increased prostate gland tumor incidence
|
J:88093
|
| increased prostate intraepithelial neoplasia incidence
|
J:88093
|
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Tcf3tm1(PBX1)Mlc/Tcf3+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * CBA/J)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Tcf3tm1(TCF3/HLF)Homy/Tcf3+
Tg(Emu-Zfp521)1Homy/0
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:160392
|
Tcf3tm1(TCF3/HLF)Homy/Tcf3+
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased incidence of induced tumors
|
J:160392
|
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44278
|
Tcf3tm2Wein/Tcf3tm2Wein
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:47671
|
Tcf3tm4Zhu/Tcf3tm4Zhu
Tg(Lck-cre)#Zhu/0
Tg(TcrAND)53Hed/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
neoplasm
|
J:75746
|
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd)
|
increased intestinal adenoma incidence
|
J:57721
|
| increased mammary adenoacanthoma incidence
|
J:57721
|
Tcf7l2tm1(EGFP/cre)Mrc/Tcf7l2tm2.1Mrc
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NCrl)
|
neoplasm
|
J:170088
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
| increased malignant tumor incidence
|
J:184496
|
| increased metastatic potential
|
J:184496
|
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
decreased incidence of induced tumors
|
J:74001
|
| decreased incidence of tumors by chemical induction
|
J:96945
|
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:125218
|
Terctm1Rdp/Terctm1Rdp
Tg(KRT5-Tert)8043Blas/0
(involves: 129/Sv * C57BL/6 * C57BL/6J * DBA/2 * SJL)
|
decreased incidence of tumors by chemical induction
|
J:96945
|
Terctm1Rdp/Terctm1Rdp
Wrntm1Lgu/Wrntm1Lgu
(involves: 129/Sv * BALB/c * C57BL/6 * SLJ)
|
increased osteosarcoma incidence
|
J:91715
|
| increased sarcoma incidence
|
J:91715
|
Terf1tm1.1Blas/Terf1tm1.1Blas
Tg(KRT5-cre)1Tak/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * C3H * C57BL/6 * SJL)
|
increased skin squamous cell carcinoma incidence
|
J:152077
|
Terttm1Rdp/Terttm1Rdp
(B6.Cg-Terttm1Rdp)
|
decreased incidence of tumors by chemical induction
|
J:108914
|
| decreased liver tumor incidence
|
J:108914
|
Terttm1Rdp/Terttm1Rdp
Trp53tm1Tyj/Trp53+
(B6.Cg-Trp53tm1Tyj Terttm1Rdp)
|
increased incidence of tumors by chemical induction
|
J:108914
|
Testm1Cro/Tes+
(involves: 129X1/SvJ * C57BL/6J)
|
increased carcinoma incidence
|
J:100181
|
| increased stomach tumor incidence
|
J:100181
|
Testm1Cro/Testm1Cro
(involves: 129X1/SvJ * C57BL/6J)
|
increased carcinoma incidence
|
J:100181
|
| increased stomach tumor incidence
|
J:100181
|
Tet1tuft/Tet1tuft
(3H1/Lznf-Tet1tuft)
|
increased lipoma incidence
|
J:242827
|
Tet1tuft/Tet1tuft
(involves: 3H1/Lznf * BALB/c)
|
increased lipoma incidence
|
J:242827
|
Tet1tuft/Tet1tuft
(involves: 3H1/Lznf * M. m. castaneus)
|
increased lipoma incidence
|
J:242827
|
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
(involves: 129S/SvEv * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:174053
|
Tet2tm1.1Mjxu/Tet2+
(involves: 129 * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:178415
|
| increased leukemia incidence
|
J:178415
|
Tet2tm1.1Mjxu/Tet2tm1.1Mjxu
(involves: 129 * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:178415
|
| increased leukemia incidence
|
J:178415
|
Tfdp1tm1Lili/Tfdp1+
(involves: 129S2/SvPas * C57BL/6)
|
neoplasm
|
J:81580
|
Tff1tm1Mrio/Tff1tm1Mrio
(involves: 129S2/SvPas * 129X1/SvJ)
|
increased adenoma incidence
|
J:35923
|
| increased carcinoma incidence
|
J:35923
|
Tff1tm1Mrio/Tff1tm1Mrio
(involves: 129S2/SvPas)
|
increased stomach tumor incidence
|
J:84201
|
Tg(Acta2-RAC1*G12V)33Pjgc/0
(involves: C57BL/6 * FVB/N)
|
increased sarcoma incidence
|
J:150015
|
Tg(Acta2-RAC1*G12V)33Pjgc/Tg(Acta2-RAC1*G12V)33Pjgc
(involves: C57BL/6 * FVB/N)
|
increased sarcoma incidence
|
J:150015
|
Tg(ACTB-A)1Jahe/0
(129/Sv-Tg(ACTB-A)1Jahe Chr 19MOLF/Ei)
|
neoplasm
|
J:146879
|
Tg(ACTB-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
|
increased adrenal gland tumor incidence
|
J:90843
|
Tg(ACTB-Eif4e)#Ppp/?
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:89878
|
| increased liver adenoma incidence
|
J:89878
|
| increased lung adenocarcinoma incidence
|
J:89878
|
| increased sarcoma incidence
|
J:89878
|
| increased tumor incidence
|
J:89878
|
Tg(ACTB-Eif4e)#Ppp/0
Tg(IghMyc)22Bri/0
(involves: C57BL * SJL)
|
increased lymphoma incidence
|
J:89878
|
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:199528
|
| increased lung adenoma incidence
|
J:199528
|
| increased lung tumor incidence
|
J:199528
|
Tg(Alb1-Myc)#Sst/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
| increased liver adenoma incidence
|
J:34434
|
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
| increased liver adenoma incidence
|
J:34434
|
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:176432
|
Tg(Alb1HBV)43Bri/0
(involves: C57BL/6J)
|
increased liver tumor incidence
|
J:86165
|
Tg(Alb1HBV)44Bri/0
(involves: C57BL/6J * SJL/J)
|
increased hepatocellular carcinoma incidence
|
J:86165
|
| increased liver adenoma incidence
|
J:86165
|
| increased liver tumor incidence
|
J:86165
|
Tg(Alb1HBV)44Bri/0
(C57BL/6J-Tg(Alb1HBV)44Bri/J)
|
increased hepatocellular carcinoma incidence
|
J:223921
|
| increased incidence of tumors by chemical induction
|
J:223921
|
| increased liver adenoma incidence
|
J:223921
|
| increased liver tumor incidence
|
J:223921
|
Tg(Alb1HBV)141Bri/0
(involves: C57BL/6J)
|
neoplasm
|
J:86165
|
Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6J * CBA/J)
|
increased hepatocellular carcinoma incidence
|
J:65354,
J:101128
|
| increased liver adenoma incidence
|
J:65354
|
| increased liver tumor incidence
|
J:65354,
J:101128
|
Tg(Alb-HBx)A112Tfts/0
(involves: C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:104728
|
Tg(Alb-HRAS*G12V)28Yu/0
(involves: C57BL/6J * CBA/J)
|
increased hepatocellular carcinoma incidence
|
J:107083,
J:238319
|
| increased liver adenoma incidence
|
J:107083,
J:238319
|
| increased liver tumor incidence
|
J:107083,
J:238319
|
Tg(Alb-PDGFC)#Jcam/0
(involves: C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:96979,
J:211984
|
Tg(Alb-SND1)3aDsar/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:242582
|
| increased incidence of tumors by chemical induction
|
J:242582
|
Tg(Alb-TAg)1Gjh/0
(C3.Cg-Tg(Alb-TAg)1Gjh)
|
increased hepatocellular carcinoma incidence
|
J:105110
|
Tg(Alb-TAg)#Arnd/0
(C3Fe.Cg-Tg(Alb-TAg)#Arnd)
|
increased hepatocellular carcinoma incidence
|
J:171880
|
Tg(AMH-Fshr)27Hht/0
(involves: FVB/N)
|
increased ovarian teratoma incidence
|
J:160015
|
Tg(AMH-Fshr*D580H)#Hht/0
(involves: FVB/N)
|
increased ovarian carcinoma incidence
|
J:160015
|
| increased ovarian teratoma incidence
|
J:160015
|
| increased prolactinoma incidence
|
J:160015
|
Tg(AMH-Fshr*D580Y)#Hht/0
(involves: FVB/N)
|
increased ovarian teratoma incidence
|
J:160015
|
Tg(Amh-SMAD2*)#Jebu/0
(FVB/N-Tg(Amh-SMAD2*)#Jebu)
|
increased ovarian teratoma incidence
|
J:200783
|
| increased ovary tumor incidence
|
J:200783
|
Tg(Amh-SMAD2*)#Jebu/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased ovarian teratoma incidence
|
J:200783
|
Tg(Amhr2-Pik3ca*,-GFP)#Lzh/0
(involves: C3H * C57BL/6)
|
neoplasm
|
J:144834
|
Tg(Amhr2-SV40TAg)1Dcco/0
((C57BL/6 x C3H)F1)
|
increased ovarian carcinoma incidence
|
J:82550
|
| increased ovary tumor incidence
|
J:82550
|
| increased testis tumor incidence
|
J:82550
|
Tg(Amy1TAg)354Knw/0
(C57BL/6J-Tg(Amy1TAg)354Knw)
|
increased hepatoma incidence
|
J:90326
|
| increased hibernoma incidence
|
J:90326
|
| increased tumor incidence
|
J:90326
|
Tg(Amy1TAg)501Knw/?
(C57BL/6-Tg(Amy1TAg)501Knw)
|
increased metastatic potential
|
J:90730
|
| increased osteosarcoma incidence
|
J:90730
|
Tg(APOE-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
|
increased adrenal gland tumor incidence
|
J:90843
|
Tg(ARR2/Pbsn-FGF8)3Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:106650,
J:78918
|
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0
Tg(Pbsn-FGFR2_iiib*)#Ng/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(ARR2/Pbsn-MYC)7Key/?
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:223213,
J:85480
|
| increased prostate gland tumor incidence
|
J:85480
|
| increased prostate intraepithelial neoplasia incidence
|
J:223213,
J:85480
|
Tg(Atoh1-sb11)1Mtay/0
TgTn(sb-T2/Onc3)12740Njen/0
(involves: C3H * C57BL/6J * ICR)
|
neoplasm
|
J:181542
|
Tg(Atoh1-sb11)1Mtay/0
TgTn(sb-T2/Onc3)12740Njen/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C3H * C57BL/6J * ICR)
|
increased medulloblastoma incidence
|
J:181542
|
Tg(Atp4b-TAg)#Jig/0
(involves: FVB/N)
|
increased carcinoma incidence
|
J:89240
|
| increased stomach tumor incidence
|
J:89240
|
Tg(BCL2)22Wehi/0
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)
|
increased lymphoma incidence
|
J:69571
|
Tg(BCL2)25Wehi/0
Tg(Igkv3-5*-MYC)#Plbe/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/JWehi)
|
increased plasmacytoma incidence
|
J:131912
|
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased T cell derived lymphoma incidence
|
J:93111
|
Tg(BCL2/IGH)#Jcre/0
Tg(H2-K/Igh-Traf2*)#Ywc/0
(involves: BALB/c * C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J)
|
increased chronic lymphocytic leukemia incidence
|
J:94116
|
| increased small lymphocytic lymphoma incidence
|
J:94116
|
Tg(BCL2OVARY)1Ah/0
(involves: FVB)
|
increased ovarian teratoma incidence
|
J:55158
|
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:160846
|
| increased B cell derived lymphoma incidence
|
J:89786
|
| increased leukemia incidence
|
J:89786
|
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased leukemia incidence
|
J:99168
|
Tg(BCR/ABL)623Hkp/?
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:76680
|
| increased leukemia incidence
|
J:76680
|
Tg(Bglap2-TAg)1Rkho/0
(FVB/N-Tg(Bglap2-TAg)1Rkho)
|
increased metastatic potential
|
J:165282
|
| increased osteosarcoma incidence
|
J:165282
|
| increased skeletal tumor incidence
|
J:165282
|
Tg(Bglap2-TAg)1Rkho/0
(involves: FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0
Tg(Col1a1-cre)1Kry/0
Tnfrsf11atm1.1Pngr/Tnfrsf11atm1.1Pngr
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0
Tnfsf11tm1Pngr/Tnfsf11+
(involves: 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0
Tnfsf11tm1Pngr/Tnfsf11tm1Pngr
(involves: 129P2/OlaHsd * FVB/N)
|
decreased osteosarcoma incidence
|
J:234128
|
Tg(BLG-STAT5A)6Itb/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:80588
|
Tg(BLG-STAT5A)15Itb/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:80588
|
Tg(C3-1-TAg)cJeg/0
(involves: FVB/N)
|
increased bulbourethral gland adenocarcinoma incidence
|
J:46513
|
| increased mammary adenocarcinoma incidence
|
J:52786,
J:46513
|
| increased prostate gland adenocarcinoma incidence
|
J:52786,
J:46513,
J:72324
|
| increased prostate intraepithelial neoplasia incidence
|
J:46513,
J:72324
|
| increased tumor incidence
|
J:46513
|
| increased urethral gland adenocarcinoma incidence
|
J:46513
|
Tg(C3-1-TAg)cJeg/0
(FVB/N-Tg(C3-1-TAg)cJeg)
|
increased prostate gland tumor incidence
|
J:84352
|
| increased prostate intraepithelial neoplasia incidence
|
J:84352
|
Tg(CAG-Aes,-ALPP)1Lbe/0
Tg(CAG-Tle1,-ALPP)1Lbe/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal tumor susceptibility
|
J:106684
|
| decreased lung tumor incidence
|
J:106684
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0
Tg(Dbh-icre)1Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased metastatic potential
|
J:186696
|
| increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0
Tg(Dbh-icre)1Gsc/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0
Thtm1(cre)Te/Th+
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased metastatic potential
|
J:186696
|
| increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Bgeo,-Tle1,-ALPP)1Lbe/0
Tg(CAG-cre)1Nagy/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased lung adenocarcinoma incidence
|
J:106684
|
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased metastatic potential
|
J:197052
|
| increased pancreas tumor incidence
|
J:197052
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
| increased pancreatic intraepithelial neoplasia incidence
|
J:197052
|
Tg(CAG-cat,-ALOX15)1868Klv/0
Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:114903
|
Tg(CAG-cat,-ALOX15)1868Klv/Tg(CAG-cat,-ALOX15)1868Klv
Tg(Pbsn-cre)4Prb/?
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:114903
|
Tg(CAG-cre/Esr1*)5Amc/?
(involves: C57BL/6 * CBA)
|
neoplasm
|
J:114992
|
Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
Tg(TPO-cre)1Shk/0
(involves: FVB/NCr * FVB/NJ)
|
neoplasm
|
J:177181
|
Tg(CAG-Has2)99Nita/0
Tg(MMTV-cre)4Mam/0
Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531,
J:164205
|
| increased mammary gland tumor incidence
|
J:164205
|
Tg(CAG-Has2)99Nita/0
Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531
|
Tg(CAG-lacZ,-SV40)#Bcv/0
(involves: FVB/N)
|
abnormal tumor incidence
|
J:158388
|
| abnormal tumor morphology
|
J:158388
|
| abnormal tumor susceptibility
|
J:158388
|
| decreased tumor incidence
|
J:158388
|
| increased liver tumor incidence
|
J:158388
|
| increased metastatic potential
|
J:158388
|
| increased ovarian carcinoma incidence
|
J:158388
|
| increased ovary tumor incidence
|
J:158388
|
| increased pancreas tumor incidence
|
J:158388
|
| increased spleen neoplasm incidence
|
J:158388
|
Tg(CAG-Mir21,-EGFP)#Eno/0
(involves: C3H * C57BL/6)
|
neoplasm
|
J:164198
|
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * C57BL/6J * DBA/2)
|
neoplasm
|
J:261540
|
Tg(CAG-Pgam2)#Hiko/0
(involves: C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:306793
|
Tg(CAG-Ptafr)1Tksh/0
(B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)
|
increased cutaneous melanoma incidence
|
J:38639
|
Tg(CAG-SAC/EGFP)35Rang/0
(involves: C3H * C57BL/6)
|
decreased liver tumor incidence
|
J:125633
|
| decreased lymphoma incidence
|
J:125633
|
| decreased tumor incidence
|
J:125633
|
Tg(CAG-SAC/EGFP)35Rang/0
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6)
|
decreased tumor incidence
|
J:125633
|
Tg(CAG-Tle1,-ALPP)1Lbe/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased lung adenocarcinoma incidence
|
J:106684
|
Tg(CAG-TRIM29)ADims/0
(FVB/NJ-Tg(CAG-TRIM29)ADims)
|
increased urinary bladder carcinoma incidence
|
J:226764
|
Tg(CD2-Fos)#Liux/0
(Not Specified)
|
increased tumor growth/size
|
J:190150
|
Tg(CD2-Lmo2)#Thr/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:102058
|
Tg(CD2-NPM/ALK)4Sudt/0
(involves: C57BL/6J * CBA)
|
increased B cell derived lymphoma incidence
|
J:181238
|
| increased hemolymphoid system tumor incidence
|
J:181238
|
| increased liver tumor incidence
|
J:181238
|
Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
|
increased leukemia incidence
|
J:93665
|
| increased T cell derived lymphoma incidence
|
J:93665
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))
|
increased hemolymphoid system tumor incidence
|
J:82127
|
| increased lymphoblastic lymphoma incidence
|
J:82127
|
| increased myeloma incidence
|
J:82127
|
| increased plasmacytoma incidence
|
J:82127
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: C57BL/6 * Swiss Webster)
|
increased thymus tumor incidence
|
J:235890
|
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * Swiss Webster)
|
increased gastrointestinal stromal tumor incidence
|
J:235890
|
| increased hepatocellular carcinoma incidence
|
J:235890
|
| increased sarcoma incidence
|
J:235890
|
| increased T cell derived lymphoma incidence
|
J:235890
|
Tg(Cd79b-TCL1A)BKTeit/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:79703
|
Tg(Cdh16-cre)91Igr/0
Tg(EIF1AX-Lin28a)#Gqda/0
(involves: 129S4/SvJae * C57BL/6 * ICR)
|
neoplasm
|
J:211179
|
Tg(CDX2-cre/ERT2)752Erf/0
Zfp82tm1.1Cya/Zfp82tm1.1Cya
(involves: 129S4/SvJaeSor * C57BL/6J * C57BL/6NTac)
|
increased incidence of induced tumors
|
J:316087
|
Tg(CEACAM5-Tag)L5496Wzm/0
(involves: C57BL/6 * CBA)
|
increased gastric adenocarcinoma incidence
|
J:62581
|
Tg(Cebpb-tTA)5Bjd/0
Tg(tetO-MYC,-OVAL)#Gtgm/0
(B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)
|
increased hepatocellular carcinoma incidence
|
J:186226
|
Tg(Cela1-luc,Cela1-TAg)#Nzh/0
(involves: FVB/N)
|
increased metastatic potential
|
J:207960
|
| increased ovary tumor incidence
|
J:207960
|
| increased pancreatic acinar cell carcinoma incidence
|
J:207960
|
Tg(Cga-LHB/CGB)94Jhn/?
(involves: C57BL/6 * SJL)
|
increased ovary tumor incidence
|
J:55157
|
Tg(Cma1-cre)ARoer/0
Tg(Kit*D814V)1Roer/0
(involves: C57BL/6)
|
increased skin tumor incidence
|
J:169611
|
Tg(Cma1-cre)ARoer/0
Tg(Kit*D814V)3Roer/0
(involves: C57BL/6)
|
increased skin tumor incidence
|
J:169611
|
Tg(CMV-SALL4_iB)#Chai/?
(Not Specified)
|
increased leukemia incidence
|
J:115037
|
Tg(CMV-Serpine1)1Dgi/0
(involves: C57BL/6J * SJL/J)
|
neoplasm
|
J:33232
|
Tg(CMV-Tsc2*)1Arbi/0
(involves: C57BL/6)
|
increased hamartoma incidence
|
J:96943
|
| increased skin hamartoma incidence
|
J:96943
|
Tg(CMV-tTA)3Bjd/0
Tg(tetO-Prkar1a*x2as)1Stra/0
(involves: C57BL/6 * NMRI * SJL)
|
increased histiocytic sarcoma incidence
|
J:94953
|
| increased liver adenoma incidence
|
J:94953
|
| increased liver tumor incidence
|
J:94953
|
| increased lymphoma incidence
|
J:94953
|
| increased metastatic potential
|
J:94953
|
| increased papilloma incidence
|
J:94953
|
| increased Schwannoma incidence
|
J:95465
|
| increased skin papilloma incidence
|
J:95465
|
| increased spindle cell carcinoma incidence
|
J:94953
|
| increased thyroid adenoma incidence
|
J:95465,
J:94953
|
Tg(Cnp-EGFR)10Nrat/0
(involves: C57BL/6 * SJL)
|
increased malignant triton tumor incidence
|
J:95933
|
| increased neurofibroma incidence
|
J:95933
|
| increased rhabdomyosarcoma incidence
|
J:95933
|
Tg(Cryaa-TAg)7488Lmgd/?
(Not Specified)
|
abnormal tumor incidence
|
J:127709
|
| increased eye tumor incidence
|
J:127709
|
Tg(CSTG-NPM1/RARA)#Sjch/0
(involves: C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:55196
|
| increased chronic myelocytic leukemia incidence
|
J:55196
|
| increased leukemia incidence
|
J:55196
|
Tg(CTNNB1)1Efu/0
(involves: CD-1)
|
increased pilomatricoma incidence
|
J:51296
|
| increased trichofolliculoma incidence
|
J:51296
|
Tg(CTSG-NUMA1/RARA)#Skr/0
(involves: C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:88103
|
Tg(CTSG-PML/RARA)135Ley/?
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:77881
|
Tg(CTSG-PML/RARA)135Ley/?
(involves: C3H * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:59080
|
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)2544Ley/0
(involves: C3H * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:59080
|
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)#Ley/0
(involves: C3H * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:59080
|
Tg(CTSG-PML/RARA)6179Ppp/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:40373
|
| increased leukemia incidence
|
J:40373
|
Tg(CTSG-PML/RARA)#Ppp/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:78201,
J:40373
|
| increased leukemia incidence
|
J:78201,
J:40373
|
Tg(CTSG-RARA/PML)2544Ley/0
(involves: C3H * C57BL/6)
|
neoplasm
|
J:59080
|
Tg(CTSG-RARA/PML)#Ley/0
(involves: C3H * C57BL/6)
|
neoplasm
|
J:59080
|
Tg(CTSG-RARA/ZBTB16)#Ppp/0
(Not Specified)
|
neoplasm
|
J:65878
|
Tg(CTSG-RARA/ZBTB16)#Ppp/0
Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:65878
|
| increased leukemia incidence
|
J:65878
|
Tg(CTSG-RARA/ZBTB16)#Sjch/0
Tg(CTSG-ZBTB16/RARA)#Sjch/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:194312
|
Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified)
|
increased chronic myelocytic leukemia incidence
|
J:65878,
J:78201
|
| increased leukemia incidence
|
J:78201
|
Tg(CTSG-ZBTB16/RARA)#Ppp/0
Zbtb16tm1Ppp/Zbtb16tm1Ppp
(involves: 129S1/Sv)
|
increased acute promyelocytic leukemia incidence
|
J:65878
|
Tg(CTSG-ZBTB16/RARA)#Sjch/0
(involves: C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:55196
|
| increased leukemia incidence
|
J:55196
|
Tg(Cyp19)C2-3Rrte/0
(involves: BALB/c * C57BL/6)
|
increased fibroadenoma incidence
|
J:34063
|
| increased incidence of tumors by chemical induction
|
J:69745
|
| increased mammary gland tumor incidence
|
J:78693
|
Tg(Dct-Birc5)21Gros/0
(involves: C57BL/6 * CBA)
|
neoplasm
|
J:122181
|
Tg(Dct-Birc5)21Gros/0
Tg(Mt1-Hgf)19Lmb/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased incidence of tumors by UV-induction
|
J:122181
|
| increased melanoma incidence
|
J:122181
|
| increased metastatic potential
|
J:122181
|
| increased skin tumor incidence
|
J:122181
|
Tg(Dct-Grm1)ESzc/0
(involves: C57BL/6J)
|
increased cutaneous melanoma incidence
|
J:83183
|
Tg(Dct-Grm1)ESzc/0
(C57BL/6J-Tg(Dct-Grm1)ESzc)
|
increased intraocular melanoma incidence
|
J:230115
|
Tg(Ddx4-cre)1Dcas/0
Tg(EIF1AX-Lin28a)#Gqda/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased kidney tumor incidence
|
J:211179
|
Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw)
|
increased adenocarcinoma incidence
|
J:180282
|
| increased incidence of tumors by chemical induction
|
J:180282
|
Tg(EIF1AX-Lin28a)#Gqda/0
Foxd1tm1(GFP/cre)Amc/Foxd1+
(involves: 129S4/SvJae * C57BL/6)
|
neoplasm
|
J:211179
|
Tg(EIF1AX-Lin28a)#Gqda/0
Tg(Six2-EGFP/cre)1Amc/0
(involves: 129S4/SvJae * C57BL/6 * CD-1)
|
neoplasm
|
J:211179
|
Tg(Ela1-Myc)158Bri/0
(involves: C57BL/6 * SJL)
|
increased metastatic potential
|
J:76992
|
| increased pancreas tumor incidence
|
J:76992
|
| increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)159Bri/0
(involves: C57BL/6 * SJL)
|
increased metastatic potential
|
J:76992
|
| increased pancreas tumor incidence
|
J:76992
|
| increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)160Bri/0
(involves: C57BL/6 * SJL)
|
increased metastatic potential
|
J:76992
|
| increased pancreas tumor incidence
|
J:76992
|
| increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
|
increased insulinoma incidence
|
J:76995
|
| increased pancreas tumor incidence
|
J:76995
|
| increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
| increased pancreatic islet cell adenoma incidence
|
J:76995
|
Tg(Ela1-TAg)19Bri/0
(involves: C57BL/6 * SJL)
|
increased insulinoma incidence
|
J:76995
|
| increased pancreas tumor incidence
|
J:76995
|
| increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
Tg(Ela1-TAg*)79Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased metastatic potential
|
J:78026
|
| increased pancreas adenoma incidence
|
J:78026
|
| increased pancreas tumor incidence
|
J:78026
|
| increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-TAg*)79Mjt/0
Tg(MUC1)79.24Gend/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:64570
|
| increased pancreas tumor incidence
|
J:64570
|
| increased pancreatic acinar cell carcinoma incidence
|
J:64570
|
Tg(Ela1-TAg*)289Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:78026
|
| increased pancreas tumor incidence
|
J:78026
|
| increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-Tgfa)150Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:52757,
J:67389
|
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:67389
|
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased malignant tumor incidence
|
J:67389
|
| increased pancreas tumor incidence
|
J:67389
|
| increased pancreatic ductal adenocarcinoma incidence
|
J:67389
|
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0
Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0
Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0
Tgfbr1tm1Bopa/Tgfbr1+
Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: 129S1/SvImJ * C57BL/6 * FVB)
|
decreased gland tumor incidence
|
J:231759
|
Tg(Emu-Pim1)64aBrn/0
(involves: C57BL/6LiA * CBA)
|
increased incidence of induced tumors
|
J:79624
|
| increased lymphoma incidence
|
J:79624
|
| increased T cell derived lymphoma incidence
|
J:79624
|
Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr)
|
increased B cell derived lymphoma incidence
|
J:117018
|
Tg(Emu-Zfp521)1Homy/0
(Not Specified)
|
neoplasm
|
J:160392
|
Tg(EmuSR-HDAC9)1468Kpet/0
(involves: C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:237420
|
| increased histiocytic sarcoma incidence
|
J:237420
|
| increased leukemia incidence
|
J:237420
|
| increased splenic marginal zone lymphoma incidence
|
J:237420
|
Tg(EmuSR-tTa)83Bop/0
Tg(IghMyc)22Bri/0
Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL * C57BL/6 * FVB/N * SJL)
|
increased lymphoma incidence
|
J:123006
|
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop
Tg(tetO-NPM1/ALK,-luc)2Gde/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:160236
|
| increased leukemia incidence
|
J:160236
|
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop
Tg(tetO-TPM3/ALK,-luc)2Gde/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:160236
|
| increased leukemia incidence
|
J:160236
|
Tg(Erbb2)1Jek/0
(involves: C57BL/6 * SJL)
|
increased papilloma incidence
|
J:47225
|
| preneoplasia
|
J:47225
|
Tg(Erbb2*)#Maed/0
Tg(Foxa3-cre)1Khk/0
(involves: C57BL/6 * C57BL/6J * DBA)
|
increased pancreas tumor incidence
|
J:262746
|
Tg(Erbb2-Erbb2)NN60Led/0
(involves: FVB/N)
|
increased keratoacanthoma incidence
|
J:62441
|
Tg(Erbb2-Erbb2*V664E)#Led/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62441
|
| increased mammary gland tumor incidence in breeding females
|
J:62441
|
Tg(Fabp1-Ccnd1)2Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)2Rdb)
|
increased liver adenoma incidence
|
J:70394
|
Tg(Fabp1-Ccnd1)4Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)4Rdb/J)
|
increased hepatocellular carcinoma incidence
|
J:70394
|
| increased liver adenoma incidence
|
J:70394
|
Tg(Fabp4-Il22)#Ychn/0
(involves: ICR)
|
increased liposarcoma incidence
|
J:176141
|
Tg(Fabp4-Phb*Y114F)#Smis/0
(Not Specified)
|
increased tumor incidence
|
J:227976
|
Tg(GAS)2Tcw/0
(involves: FVB/N)
|
increased incidence of tumors by chemical induction
|
J:63579
|
Tg(Gcg-TAg)25Ddr/?
(involves: CD-1)
|
increased colon tumor incidence
|
J:101537
|
| increased large intestine adenocarcinoma incidence
|
J:91490,
J:101537
|
| increased metastatic potential
|
J:91490,
J:101537
|
| increased pancreas tumor incidence
|
J:91490,
J:101537
|
Tg(GFAP-Hras1)2Agu/0
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
increased astrocytoma incidence
|
J:69129
|
Tg(GFAP-Hras1)2Agu/Tg(GFAP-Hras1)2Agu
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
increased astrocytoma incidence
|
J:69129
|
Tg(GFAP-SRC)1Aag/0
(involves: C3H * C57BL/6)
|
increased astrocytoma incidence
|
J:40335
|
Tg(GFAP-SRC)2Aag/0
(involves: C3H * C57BL/6)
|
increased astrocytoma incidence
|
J:40335
|
| increased Schwannoma incidence
|
J:40335
|
Tg(GFAP-TAg121)1Tvd/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased astrocytoma incidence
|
J:77132
|
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
(B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop)
|
increased medulloblastoma incidence
|
J:94092
|
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:94092
|
Tg(GFAP-TVA)5Hev/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Tg(GFAP-TVA)10Ech/0
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
neoplasm
|
J:52161
|
Tg(Ggamma-T)15Cps/0
(involves: C57BL/6J * CBA/J)
|
increased adrenal gland tumor incidence
|
J:38778
|
| increased hibernoma incidence
|
J:38778
|
| increased prostate gland tumor incidence
|
J:38778
|
| increased prostate intraepithelial neoplasia incidence
|
J:38778
|
| increased testis tumor incidence
|
J:38778
|
Tg(Ggamma-T)15Cps/Tg(Ggamma-T)15Cps
(involves: C57BL/6J * CBA/J)
|
increased adrenal gland tumor incidence
|
J:38778
|
| increased hibernoma incidence
|
J:38778
|
| increased prostate gland tumor incidence
|
J:38778
|
| increased prostate intraepithelial neoplasia incidence
|
J:38778
|
| increased testis tumor incidence
|
J:38778
|
Tg(Ggt1-Hif1a*)43Log/0
(involves: C57BL/6)
|
increased renal carcinoma incidence
|
J:177381
|
Tg(Ggt1-tTA)#Agoc/0
Tg(tetO-MYC)36aBop/0
(involves: FVB/N)
|
increased renal carcinoma incidence
|
J:222943
|
Tg(Gh-Gal)4599Vron/?
(involves: C57BL/6 * CD-1 * SJL)
|
increased pituitary adenoma incidence
|
J:86486
|
Tg(GHRL-TAg)1-5Hiwa/0
(C57BL/6-Tg(GHRL-TAg)1-5Hiwa)
|
increased pancreas tumor incidence
|
J:152492
|
| increased stomach tumor incidence
|
J:152492
|
| increased thyroid tumor incidence
|
J:152492
|
| increased tumor incidence
|
J:152492
|
Tg(GHRL-TAg)3-1Hiwa/0
(C57BL/6-Tg(GHRL-TAg)3-1Hiwa)
|
increased stomach tumor incidence
|
J:152492
|
Tg(GHRL-TAg)4-3Hiwa/0
(C57BL/6-Tg(GHRL-TAg)4-3Hiwa)
|
increased tumor latency
|
J:152492
|
Tg(GZMB-Tax)#Lera/0
(involves: C57BL/6)
|
increased skeletal tumor incidence
|
J:147601
|
Tg(H2-D-Il15)3304Clgr/?
(FVB/N-Tg(H2-D-Il15)3304Clgr)
|
increased leukemia incidence
|
J:97873,
J:67478
|
Tg(H2-K-BCL2)1Josd/0
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Tg(H2-K-Fosl1)1Wag/0
(involves: C57BL/6 * CBA)
|
increased tumor incidence
|
J:64494
|
Tg(H2-K-Fosl2,-EGFP)13Wag/0
(either: 129.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag or B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)
|
increased fibrosarcoma incidence
|
J:139032
|
Tg(H2-K-Hmga1)#Lmsr/0
(involves: C57BL/6 * SJL)
|
increased leukemia incidence
|
J:121308
|
| increased lymphoma incidence
|
J:90252,
J:121308
|
| increased T cell acute lymphoblastic leukemia incidence
|
J:90252
|
| increased uterus leiomyoma incidence
|
J:121308
|
| increased uterus tumor incidence
|
J:121308
|
Tg(H2-L-IL6)1Kish/Tg(H2-L-IL6)1Kish
(C57BL/6-Tg(H2-L-IL6)1Kish)
|
increased plasmacytoma incidence
|
J:138762
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C57BL/6-Tg(H2-L-IL6)46Kish)
|
increased plasmacytoma incidence
|
J:40405
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(involves: BALB/c * C57BL/6)
|
increased plasmacytoma incidence
|
J:40405
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C.B6-Tg(H2-L-IL6)46Kish)
|
increased B cell derived lymphoma incidence
|
J:74377
|
| increased follicular lymphoma incidence
|
J:74377
|
| increased plasmacytoma incidence
|
J:74377
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727,
J:184212
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
| increased spindle cell carcinoma incidence
|
J:206727
|
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: 129 * FVB/N * Black Swiss)
|
increased incidence of induced tumors
|
J:79056
|
| increased papilloma incidence
|
J:79056
|
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: FVB/N)
|
increased incidence of induced tumors
|
J:79056
|
| increased papilloma incidence
|
J:79056
|
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
Tg(KRT5-cre)1Tak/Tg(KRT5-cre)1Tak
(involves: C3H * C57BL/6 * FVB/NTac)
|
increased incidence of tumors by chemical induction
|
J:120797
|
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
Wrntm1Led/Wrntm1Led
(involves: 129 * FVB/N * Black Swiss)
|
increased incidence of tumors by chemical induction
|
J:79056
|
| increased papilloma incidence
|
J:79056
|
Tg(HBB-Myc)#Cos/0
(involves: C57BL/6J * CBA/J)
|
increased adenoma incidence
|
J:276641
|
Tg(HBV-HCV)21Kko/0
(C57BL/6N-Tg(HBV-HCV)21Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
| increased liver adenoma incidence
|
J:52686
|
Tg(HBV-HCV)49Kko/0
(C57BL/6N-Tg(HBV-HCV)49Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
| increased liver adenoma incidence
|
J:52686
|
Tg(HBV-HCV)Kko/0
(C57BL/6N-Tg(HBV-HCV)Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
| increased liver adenoma incidence
|
J:52686
|
Tg(HBVX*,-Myc)#Skp/0
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:81098
|
Tg(HBVX*,-Myc)#Skp/Tg(HBVX*,-Myc)#Skp
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:81098
|
Tg(HBx)3Yu/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:56196
|
Tg(HIV)26Aln/0
(involves: FVB/N)
|
increased skin papilloma incidence
|
J:90297
|
Tg(Hnf1a-RB1*)XMiu/?
(Not Specified)
|
increased liver adenoma incidence
|
J:180294
|
Tg(HRAS)2Jic/?
(involves: BALB/c * C57BL/6)
|
abnormal tumor morphology
|
J:64968
|
| increased adenocarcinoma incidence
|
J:64968
|
| increased classified tumor incidence
|
J:64968
|
| increased incidence of tumors by chemical induction
|
J:101590,
J:73016
|
| increased lung adenocarcinoma incidence
|
J:64968
|
| increased lymphoma incidence
|
J:64968
|
| increased sarcoma incidence
|
J:64968
|
| increased skin papilloma incidence
|
J:64968
|
| increased tumor incidence
|
J:64968
|
| neoplasm
|
J:64968
|
Tg(HRAS)7Mok/?
(involves: C57BL/6)
|
increased adenocarcinoma incidence
|
J:64968
|
| increased lung adenocarcinoma incidence
|
J:64968
|
| increased lymphoma incidence
|
J:64968
|
| increased sarcoma incidence
|
J:64968
|
| increased tumor incidence
|
J:64968
|
| neoplasm
|
J:64968
|
Tg(IGF1)1Jdg/0
(involves: FVB * ICR)
|
increased incidence of tumors by chemical induction
|
J:39752
|
| increased skin papilloma incidence
|
J:39752
|
Tg(Igh*-Mir125b-1)5Toki/0
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:178816
|
| increased lymphoma incidence
|
J:178816
|
Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:178816
|
| increased lymphoma incidence
|
J:178816
|
| increased T cell derived lymphoma incidence
|
J:178816
|
Tg(Igh-Abl1)40Sco/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased plasmacytoma incidence
|
J:78204
|
Tg(Igh-Abl1)40Sco/0
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)
|
increased plasmacytoma incidence
|
J:78204
|
Tg(Igh-HMGA2)#Cro/0
(FVB/N-Tg(Igh-HMGA2)#Cro)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:233225
|
Tg(Igh-HOX11)11Idd/0
(CD-1)
|
increased B cell derived lymphoma incidence
|
J:52782
|
Tg(Igh-Maf)68Staka/0
(C57BL/6-Tg(Igh-Maf)68Staka)
|
increased lymphoma incidence
|
J:168074
|
Tg(Igh-Maf)524Staka/0
(involves: C57BL/6 * C57BL/6J * DBA/2)
|
increased lymphoma incidence
|
J:168074
|
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
(FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro)
|
increased chronic lymphocytic leukemia incidence
|
J:162077
|
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6 * FVB/N)
|
increased chronic lymphocytic leukemia incidence
|
J:162077
|
Tg(Igh-Mir155)8Cro/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:109591
|
| increased lymphoblastic lymphoma incidence
|
J:109591
|
Tg(Igh-Pim1)1Brn/0
(involves: C57BL/6LiA * CBA)
|
increased incidence of induced tumors
|
J:79624
|
| increased lymphoma incidence
|
J:79624
|
| increased T cell derived lymphoma incidence
|
J:79624
|
Tg(Igh-ROR1)1Kip/0
(C57BL/6-Tg(Igh-ROR1)1Kip)
|
increased chronic lymphocytic leukemia incidence
|
J:206368
|
Tg(Igh-ROR1)1Kip/0
Tg(Igh-V186.2-TCL1A)3Cro/0
(B6.Cg-Tg(Igh-ROR1)1Kip Tg(Igh-V186.2-TCL1A)3Cro)
|
increased chronic lymphocytic leukemia incidence
|
J:206368
|
Tg(Igh-TCL1A)1Ypek/0
(FVB/N-Tg(Igh-TCL1A)1Ypek)
|
increased chronic lymphocytic leukemia incidence
|
J:160184
|
Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6)
|
increased leukemia incidence
|
J:76574
|
Tg(Igh-V186.2-TCL1A)3Cro/0
(B6.Cg-Tg(Igh-V186.2-TCL1A)3Cro)
|
increased chronic lymphocytic leukemia incidence
|
J:206368
|
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:121564
|
| increased metastatic potential
|
J:121564
|
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117,
J:78177
|
| increased leukemia incidence
|
J:78177
|
| increased lymphoma incidence
|
J:78177,
J:223213
|
| increased sarcoma incidence
|
J:78177
|
| increased tumor incidence
|
J:78177
|
Tg(IghMyc)22Bri/0
(B6.Cg-Tg(IghMyc)22Bri/J)
|
increased lymphoma incidence
|
J:164200
|
Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:117023
|
Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL)
|
increased lymphoma incidence
|
J:214383
|
Tg(IghMyc)22Bri/0
Tg(Igk-V21-Bax)1967Bvn/0
(involves: C57BL/6 * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:89049
|
| increased plasmacytoma incidence
|
J:89049
|
Tg(IghMyc)22Bri/0
Tg(Lck/Emu-Eif4e)#Ppp/0
(involves: C57BL * SJL)
|
increased lymphoma incidence
|
J:89878
|
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
(involves: 129/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:125164
|
Tg(IghMyc)186Brn/0
Rpl24Bst/Rpl24+
(involves: C57BL/LiA * C57BLKS * CBA/BrA)
|
neoplasm
|
J:142390
|
Tg(IghMyc)186Brn/0
Rpl38tm1Rugg/Rpl38+
(involves: C57BL/LiA * CBA/BrA)
|
neoplasm
|
J:142390
|
Tg(Igkv3-5*-MYC)24Plbe/0
(C57BL/6J-Tg(Igkv3-5*-MYC)DLoxP4Plbe/PlbeMmmh)
|
increased B cell derived lymphoma incidence
|
J:131912
|
| increased myeloma incidence
|
J:131912
|
| increased plasmacytoma incidence
|
J:131912
|
Tg(Igkv3-5-MYC)#Plbe/0
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:131912
|
Tg(IGL-MYC)3Hm/0
(C57BL/6N-Tg(IGL-MYC)3Hm/Nci)
|
increased B cell derived lymphoma incidence
|
J:65245
|
Tg(Ins1-GAS)1Sbr/0
(involves: FVB/NTac)
|
increased carcinoma incidence
|
J:59575
|
| increased incidence of tumors by chemical induction
|
J:63579
|
| increased tumor incidence following infection
|
J:59575
|
Tg(Ins1-Tag,-luc)1Gcr/0
(FVB/N-Tg(Ins1-Tag,-luc)1Gcr)
|
increased insulinoma incidence
|
J:162648
|
Tg(Ins1-Tag,-luc)1Gcr/0
(involves: C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:162648
|
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Tg(Ins2-Akt1*)3Mbb)
|
increased insulinoma incidence
|
J:144599
|
| increased pancreas tumor incidence
|
J:144599
|
| increased pancreatic islet cell carcinoma incidence
|
J:144599
|
Tg(Ins2-IGF1R)1Dh/0
Tg(RIP1-Tag)2Dh/0
(involves: C3H * C57BL/6 * C57BL/6J * DBA/2J)
|
increased insulinoma incidence
|
J:205389
|
| increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(Ins2-rtTA)2Efr/0
Tg(tetO-TAg)1Efr/0
(involves: C3HeB/FeJ * C57BL/6 * CBA)
|
increased insulinoma incidence
|
J:130049
|
Tg(Ins2-TAg)1Lt/0
(NOD/ShiLt-Tg(Ins2-TAg)1Lt)
|
increased insulinoma incidence
|
J:92449
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(involves: C57BL/6J)
|
increased insulinoma incidence
|
J:187012
|
| increased pancreas tumor incidence
|
J:187012
|
| increased pancreatic islet cell carcinoma incidence
|
J:187012
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(Not Specified)
|
increased pancreatic islet cell carcinoma incidence
|
J:188693
|
Tg(IRS1)1Mhep/0
Tg(SERPINA1-HBVX)1655Jtsb/0
(involves: C3H * C57BL/6 * FVB * ICR)
|
increased hepatocellular carcinoma incidence
|
J:227278
|
Tg(K5-Ptgs2)19Kmd/0
(involves: NMRI)
|
increased incidence of tumors by chemical induction
|
J:79071
|
| increased sebaceous gland adenoma incidence
|
J:79071
|
| increased skin papilloma incidence
|
J:79071
|
| increased squamous cell carcinoma incidence
|
J:79071
|
Tg(K5-Ptgs2)667Kmd/0
(involves: NMRI)
|
increased incidence of tumors by chemical induction
|
J:79071
|
| increased sebaceous gland adenoma incidence
|
J:79071
|
| increased skin papilloma incidence
|
J:79071
|
| increased squamous cell carcinoma incidence
|
J:79071
|
Tg(K6ODCtr)55Tgo/0
(involves: C3H * C57BL/6)
|
increased keratoacanthoma incidence
|
J:29098
|
| increased skin papilloma incidence
|
J:29098
|
| increased skin tumor incidence
|
J:29098
|
Tg(Kit*D814V)1Roer/0
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:169611
|
| increased leukemia incidence
|
J:169611
|
| increased skin tumor incidence
|
J:169611
|
Tg(Kit*D814V)2Roer/0
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased skin tumor incidence
|
J:169611
|
Tg(Kit*D814V)3Roer/0
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased leukemia incidence
|
J:169611
|
| increased skin tumor incidence
|
J:169611
|
Tg(Krt1-14-GLI)1Oro/0
(involves: C57BL/6 * CBA)
|
increased trichofolliculoma incidence
|
J:82653
|
| increased tumor incidence
|
J:82653
|
Tg(KRT5-Akt1*)Jmpa/0
(involves: C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
abnormal tumor morphology
|
J:144831
|
| increased adenocarcinoma incidence
|
J:144831
|
| increased carcinoma incidence
|
J:144831
|
| increased squamous cell carcinoma incidence
|
J:144831
|
| increased trichoepithelioma incidence
|
J:144831
|
Tg(KRT5-rtTA)#Glk/0
Tg(tetO/CMV-Dek,-luc)317Siwe/0
(involves: FVB/N)
|
increased incidence of tumors by chemical induction
|
J:261249
|
| increased squamous cell carcinoma incidence
|
J:261249
|
Tg(KRT5-Terf2)PMBlas/Y
(involves: C57BL/6 * CBA)
|
increased incidence of tumors by UV-induction
|
J:102653
|
| increased keratoacanthoma incidence
|
J:102653
|
| increased skin squamous cell carcinoma incidence
|
J:102653
|
| increased skin tumor incidence
|
J:102653
|
Tg(KRT5-Terf2)PNBlas/0
(involves: C57BL/6 * CBA)
|
neoplasm
|
J:102653
|
Tg(KRT5-Terf2)POBlas/0
(involves: C57BL/6 * CBA)
|
increased incidence of tumors by UV-induction
|
J:102653
|
| increased keratoacanthoma incidence
|
J:102653
|
| increased skin squamous cell carcinoma incidence
|
J:102653
|
| increased skin tumor incidence
|
J:102653
|
Tg(KRT5-Tert)8043Blas/0
(involves: C57BL/6 * DBA/2)
|
increased incidence of tumors by chemical induction
|
J:69757,
J:96945
|
Tg(KRT14-Birc5)19Gros/0
(involves: C3H * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:81530
|
Tg(KRT14-Birc5)19Gros/0
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C3H * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:81530
|
Tg(KRT14-cre)8Brn/0
Tg(KRT5-Akt1*)Jmpa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
abnormal tumor morphology
|
J:144831
|
| increased carcinoma incidence
|
J:144831
|
| increased squamous cell carcinoma incidence
|
J:144831
|
Tg(Krt14-dnLef1)LFmw/?
(involves: C57BL/6 * CBA)
|
increased skin tumor incidence
|
J:73649
|
Tg(KRT14-Edn3)1Takk/?
(B6.Cg-Tg(KRT14-Edn3)1Takk)
|
increased thyroid tumor incidence
|
J:104881
|
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:155536
|
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:155536
|
Tg(KRT14-HPV8)9Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)9Vuc)
|
increased skin papilloma incidence
|
J:96784
|
| increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV8)9Vuc/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased skin papilloma incidence
|
J:96784
|
Tg(KRT14-HPV8)61Vuc/0
(involves: C57BL/6 * DBA)
|
increased skin papilloma incidence
|
J:96784
|
Tg(KRT14-HPV8)85Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)85Vuc)
|
increased skin papilloma incidence
|
J:96784
|
| increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV8)85Vuc/0
(B6.Cg-Tg(KRT14-HPV8)85Vuc)
|
increased skin papilloma incidence
|
J:96784
|
Tg(KRT14-HPV8)#Vuc/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased skin papilloma incidence
|
J:96784
|
| increased skin squamous cell carcinoma incidence
|
J:96784
|
| increased skin tumor incidence
|
J:96784
|
Tg(KRT14-HPV16)wt1Dh/0
(FVB.Cg-Tg(KRT14-HPV16)wt1Dh/Nci)
|
increased skin squamous cell carcinoma incidence
|
J:65699
|
Tg(KRT14-HPV16)wt1Dh/0
(either: FVB.Cg-Tg(KRT14-HPV16)wt1Dh or (involves: C57BL/6 * DBA/2 * FVB/N))
|
increased skin squamous cell carcinoma incidence
|
J:20130
|
| increased spindle cell carcinoma incidence
|
J:20130
|
Tg(KRT14-HPV16)wt1Dh/0
(either: (involves: C57BL/6 * DBA/2) or (involves: C57BL/6 * DBA/2 * SENCAR * SSIN))
|
neoplasm
|
J:20130
|
Tg(KRT14-HPV16)wt1Dh/0
(C.Cg-Tg(KRT14-HPV16)wt1Dh)
|
neoplasm
|
J:20130
|
Tg(KRT14-HPV16E7)2304Plam/0
(involves: FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:86018
|
Tg(KRT14-HPV16E7)2326Plam/0
(involves: FVB/N)
|
increased sebaceous gland tumor incidence
|
J:86018
|
| increased skin squamous cell carcinoma incidence
|
J:86018
|
Tg(KRT14-Shh)#Cobm/0
(involves: C57BL/6 * CBA)
|
increased basal cell carcinoma incidence
|
J:150375
|
Tg(KRT14-Snai1)1Efu/0
(involves: CD-1)
|
increased basal cell carcinoma incidence
|
J:229072
|
| increased metastatic potential
|
J:229072
|
| increased sebaceous gland tumor incidence
|
J:229072
|
| increased skin squamous cell carcinoma incidence
|
J:229072
|
| increased skin tumor incidence
|
J:229072
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
(involves: C57BL/6 * DBA/2)
|
increased ovarian carcinoma incidence
|
J:189304
|
| increased ovary tumor incidence
|
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0
Tg(Krt19-Wnt1)2Maos/0
(involves: C3H * C57BL/6)
|
increased gastric adenocarcinoma incidence
|
J:116782
|
| increased stomach tumor incidence
|
J:116782,
J:153058
|
Tg(KRT19-TAg)7Eps/0
(involves: FVB/N)
|
increased adrenal gland tumor incidence
|
J:64395
|
| increased mesothelioma incidence
|
J:64395
|
| increased metastatic potential
|
J:64395
|
| increased prostate gland tumor incidence
|
J:64395
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:64395
|
Tg(LANA,vFLIP,vCYC)801Dtmr/?
(involves: C57BL/6)
|
increased lymphoma incidence
|
J:196403
|
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Tg(Lck*F505)2964Rmp/?
(involves: C57BL/6J * DBA/2)
|
neoplasm
|
J:88309
|
Tg(Lck*F505)3073Rmp/?
(involves: C57BL/6J * DBA/2)
|
neoplasm
|
J:88309
|
Tg(Lck-Akt1*)M-1Pnt/0
(involves: C3H/He * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73487
|
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: C3H/He * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73487
|
Tg(Lck-Akt1*E40K)E-3Pnt/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:144975
|
Tg(Lck-Akt2*)#Test/0
(Not Specified)
|
increased lymphoma incidence
|
J:154583
|
| increased T cell derived lymphoma incidence
|
J:153923
|
Tg(Lck-Id1)28Xhsu/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:58607
|
Tg(Lck-LMO1)11Sjk/0
(involves: C3H * C57BL/6)
|
neoplasm
|
J:40868
|
Tg(Lck-LMO1)11Sjk/0
Tg(STIL-TAL1)A5(3)Alpa/0
(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)
|
increased leukemia incidence
|
J:40868
|
| increased T cell derived lymphoma incidence
|
J:40868
|
Tg(Lck-Map3k8)3456Ngc/?
(involves: C3H/HeJ * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:39450
|
Tg(Lck-Notch3)#Issc/0
(involves: C57BL/6 * DBA/2)
|
increased acute lymphoblastic leukemia incidence
|
J:63300
|
| increased lymphoblastic lymphoma incidence
|
J:63300
|
| increased T cell derived lymphoma incidence
|
J:96010
|
Tg(Lck-Tal1)4709Led/0
(FVB/N-Tg(Lck-Tal1)4709Led)
|
increased leukemia incidence
|
J:36076
|
| increased lymphoblastic lymphoma incidence
|
J:36076
|
Tg(Lck-Tax)53Hall/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:129531
|
| increased T cell derived lymphoma incidence
|
J:129531
|
Tg(Lck-TNFSF13)3919Mhah/0
(B6.Cg-Tg(Lck-TNFSF13)3919Mhah)
|
increased chronic lymphocytic leukemia incidence
|
J:94628
|
Tg(LckNotch1)9Erob/?
(involves: C57BL/6 * CBA/J)
|
increased T cell derived lymphoma incidence
|
J:93005
|
Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:28635
|
Tg(LPV-TAg121)2Tvd/0
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J)
|
increased carcinoma incidence
|
J:120820
|
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:144382
|
| increased hepatoma incidence
|
J:144382
|
| increased lung adenocarcinoma incidence
|
J:144382
|
| increased osteosarcoma incidence
|
J:144382
|
| increased testis tumor incidence
|
J:144382
|
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
|
increased leukemia incidence
|
J:144382
|
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:144382
|
| increased hepatoma incidence
|
J:144382
|
| increased lung adenocarcinoma incidence
|
J:144382
|
| increased osteosarcoma incidence
|
J:144382
|
| increased testis tumor incidence
|
J:144382
|
Tg(Ly6a-SET/NUP214)2969Gcg/0
(involves: FVB/NJ)
|
neoplasm
|
J:142938
|
Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:144382
|
Tg(Ly6e-MALT1)#Isg/0
(involves: C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:185590
|
Tg(LYZ-rtTA2S*M2,tetO-ELAVL1)632Dkon/0
(B6.Cg-Tg(LYZ-rtTA2S*M2,tetO-ELAVL1)632Dkon)
|
decreased incidence of tumors by chemical induction
|
J:184388
|
| decreased tumor growth/size
|
J:184388
|
Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL)
|
increased follicular lymphoma incidence
|
J:69755
|
| increased lymphoma incidence
|
J:69755
|
| increased T cell derived lymphoma incidence
|
J:69755
|
Tg(Mdm2)1Snj/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:51661
|
| increased hemangiosarcoma incidence
|
J:51661
|
| increased lymphoma incidence
|
J:51661
|
| increased pituitary adenoma incidence
|
J:51661
|
| increased rhabdomyosarcoma incidence
|
J:51661
|
| increased sarcoma incidence
|
J:51661
|
| increased tumor incidence
|
J:51661
|
Tg(Mdm2)1Snj/0
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:51661
|
| increased lymphoma incidence
|
J:51661
|
| increased medulloblastoma incidence
|
J:51661
|
| increased osteosarcoma incidence
|
J:51661
|
| increased squamous cell carcinoma incidence
|
J:51661
|
Tg(Mdm2)1Snj/Tg(Mdm2)1Snj
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased tumor incidence
|
J:51661
|
Tg(MGMT)3Bec/Tg(MGMT)3Bec
(involves: NMRI)
|
decreased incidence of tumors by chemical induction
|
J:92925
|
| increased incidence of tumors by chemical induction
|
J:92925
|
| increased skin papilloma incidence
|
J:92925
|
Tg(MMTV-AURKA)#Cxd/?
(involves: FVB/N)
|
increased kidney tumor incidence
|
J:145680
|
| increased mammary adenocarcinoma incidence
|
J:145680
|
| increased ovary tumor incidence
|
J:145680
|
Tg(MMTV-AURKA)#Cxd/?
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:145680
|
Tg(MMTV-CCND1)1Esmp/0
(Not Specified)
|
increased mammary adenoacanthoma incidence
|
J:70571
|
| increased mammary adenocarcinoma incidence
|
J:70571
|
| increased mammary gland tumor incidence
|
J:70571
|
| increased sarcoma incidence
|
J:70571
|
| increased testis tumor incidence
|
J:70571
|
| increased tumor incidence
|
J:70571
|
Tg(MMTV-CCND1)1Esmp/0
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62465
|
| increased mammary gland tumor incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased lymphoma incidence
|
J:62465
|
| increased mammary adenoacanthoma incidence
|
J:62465
|
| increased mammary adenocarcinoma incidence
|
J:62465
|
| increased tumor incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0
Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6 * CD-1 * DBA/2 * FVB/N)
|
increased Leydig cell tumor incidence
|
J:62465
|
| increased lymphoma incidence
|
J:62465
|
| increased mammary adenocarcinoma incidence
|
J:62465
|
| increased mammary gland tumor incidence
|
J:62465
|
| increased salivary adenocarcinoma incidence
|
J:62465
|
| increased tumor incidence
|
J:62465
|
Tg(MMTV-Cdc37)2Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased lymphoma incidence
|
J:62465
|
| increased mammary adenoacanthoma incidence
|
J:62465
|
| increased sarcoma incidence
|
J:62465
|
| increased tumor incidence
|
J:62465
|
Tg(MMTV-DMTF1_i2)7Kai/0
(FVB/NJ-Tg(MMTV-DMTF1_i2)7Kai)
|
increased mammary gland tumor incidence in breeding females
|
J:220608
|
Tg(MMTV-ENPP2)20Gbm/0
(FVB/N-Tg(MMTV-ENPP2)20Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-ENPP2)21Gbm/0
(FVB/N-Tg(MMTV-ENPP2)21Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-Erbb2)1Pv/0
(involves: BALB/c * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:234420
|
Tg(MMTV-ERBB2)5Erick/?
(FVB/N-Tg(MMTV-ERBB2)5Erick)
|
increased Harderian gland adenoma incidence
|
J:90202
|
| increased mammary adenocarcinoma incidence
|
J:90202
|
| increased mammary gland tumor incidence
|
J:90202
|
| increased metastatic potential
|
J:90202
|
Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased Harderian gland tumor incidence
|
J:72129
|
| increased mammary adenocarcinoma incidence
|
J:72129
|
| increased salivary gland tumor incidence
|
J:72129
|
Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
| increased salivary gland tumor incidence
|
J:72129
|
Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)NA1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NF1Mul)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:76653
|
| increased tumor latency
|
J:76653
|
Tg(MMTV-Erbb2)NK1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NK1Mul)
|
increased mammary gland tumor incidence
|
J:67457
|
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: C57BL/6)
|
increased mammary gland tumor incidence
|
J:189292
|
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: FVB)
|
decreased tumor latency
|
J:198481
|
| increased mammary gland tumor incidence
|
J:198481
|
Tg(MMTV-ERBB2*,-luc)6157Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6157Aami)
|
increased mammary adenocarcinoma incidence
|
J:172352
|
| increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB2*,-luc)6177Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6177Aami)
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB2*,-luc)6180Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6180Aami)
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB3)1Slg/0
(involves: FVB)
|
increased incidence of tumors by chemical induction
|
J:80974
|
| increased lung adenocarcinoma incidence
|
J:80974
|
Tg(MMTV-ERBB3)1Slg/0
Tg(MMTVneu)202Mul/0
(involves: FVB)
|
increased incidence of tumors by chemical induction
|
J:80974
|
| increased lung adenocarcinoma incidence
|
J:80974
|
| increased mammary gland tumor incidence
|
J:80974
|
Tg(MMTV-Espl1)1Pati/0
(involves: C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:216267
|
| increased mammary gland tumor incidence in breeding females
|
J:216267
|
Tg(MMTV-KLF4)1Rup/0
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6NTac * FVB/NJ * SJL)
|
increased sarcoma incidence
|
J:96886
|
Tg(MMTV-KRAS*G12V)3025Mrl/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary adenocarcinoma incidence
|
J:77272
|
| increased metastatic potential
|
J:77272
|
Tg(MMTV-KRAS*G12V)3025Mrl/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-MYC)1Lach/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)27Gbm/Tg(MMTV-LPAR1)27Gbm
(FVB/N-Tg(MMTV-LPAR1)27Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
| increased metastatic potential
|
J:149661
|
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
| increased metastatic potential
|
J:149661
|
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)22Gbm/Tg(MMTV-LPAR3)22Gbm
(FVB/N-Tg(MMTV-LPAR3)22Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
| increased mammary gland tumor incidence in breeding females
|
J:149661
|
| increased metastatic potential
|
J:149661
|
Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6J * CD-1)
|
increased B cell derived lymphoma incidence
|
J:62465
|
| increased tumor incidence
|
J:62465
|
Tg(MMTV-Myc)141-3Led/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0
(involves: C57BL/6J * CD-1 * FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-Myc)WT13Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
| increased mammary gland tumor incidence
|
J:153233,
J:193362
|
| increased metastatic potential
|
J:153233
|
Tg(MMTV-Myc)WT21Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
| increased mammary gland tumor incidence
|
J:153233,
J:193362
|
| increased metastatic potential
|
J:153233
|
Tg(MMTV-Myc*T58A)TA14Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
| increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc*T58A)TA39Jrn/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:193362
|
Tg(MMTV-Myc*T58A)TA41Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
| increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-NCOA3)#Mybr/0
(FVB/N-Tg(MMTV-NCOA3)#Mybr)
|
increased leiomyosarcoma incidence
|
J:93548
|
| increased lung adenocarcinoma incidence
|
J:93548
|
| increased mammary adenocarcinoma incidence
|
J:93548
|
| increased mammary gland tumor incidence
|
J:93548
|
| increased metastatic potential
|
J:93548
|
| increased pituitary adenoma incidence
|
J:93548
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
(involves: C57BL/6)
|
increased lung tumor incidence
|
J:122846
|
| increased mammary gland tumor incidence
|
J:122846
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
Tg(Trp53R172H)8512Jmr/?
(involves: C57BL/6 * FVB)
|
increased mammary adenocarcinoma incidence
|
J:122846
|
Tg(MMTV-Notch4)3Rnc/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:11644
|
| increased metastatic potential
|
J:11644
|
| increased salivary adenocarcinoma incidence
|
J:11644
|
Tg(MMTV-PTGS2)#Thla/0
(involves: CD-1)
|
increased adenocarcinoma incidence
|
J:68565
|
| increased mammary adenocarcinoma incidence
|
J:68565
|
| increased mammary gland ductal carcinoma incidence
|
J:68565
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/Nci)
|
increased mammary adenocarcinoma incidence
|
J:46460,
J:51424,
J:87544,
J:48285
|
| increased metastatic potential
|
J:46460,
J:48285
|
Tg(MMTV-PyVT)634Mul/0
(multiple strains)
|
decreased mammary gland tumor incidence
|
J:48854
|
| decreased metastatic potential
|
J:48854
|
| increased mammary adenocarcinoma incidence
|
J:48854
|
| increased metastatic potential
|
J:48854
|
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/J)
|
abnormal tumor morphology
|
J:140033
|
| increased mammary gland tumor incidence
|
J:140033,
J:147458
|
| increased tumor growth/size
|
J:140033
|
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:147458
|
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133325,
J:236031
|
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:147923
|
| increased metastatic potential
|
J:147923
|
Tg(MMTV-PyVT*Y250F)250-2Mul/?
(FVB/N-Tg(MMTV-PyVT*Y250F)250-2Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(FVB/N-Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-rtTA)1Lach/0
Tg(TetO-Erbb2)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:81083
|
| increased metastatic potential
|
J:81083
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-ERBB2)#Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:231766
|
| increased metastatic potential
|
J:231766
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
(involves: FVB/N)
|
increased mammary gland ductal carcinoma incidence
|
J:96383
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-IGF1R)1Ramo/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:121069
|
| increased mammary gland tumor incidence
|
J:121069
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0
Tg(tetO-MYC)1Lach/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-MYC)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:67498
|
| increased mammary gland tumor incidence
|
J:133578,
J:67498
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:175839
|
| increased mammary gland tumor incidence
|
J:175839
|
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PyVT,-cre)1Mul/0
(FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:231983
|
| increased mammary gland tumor incidence in virgin females
|
J:231983
|
| increased metastatic potential
|
J:231983
|
Tg(MMTV-TGFBR2)7Hlm/?
Tg(MMTVTGFA)29Rjc/?
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-TGFBR2)7Hlm/Tg(MMTV-TGFBR2)7Hlm
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-vHaras)SH1Led/0
(involves: C57BL/6J * CD-1)
|
increased mammary gland tumor incidence
|
J:88789
|
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased carcinoma incidence
|
J:86074
|
| increased mammary adenocarcinoma incidence
|
J:86074
|
| increased metastatic potential
|
J:86074
|
Tg(MMTVneu)202Mul/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:35344,
J:80974
|
Tg(MMTVneu)202Mul/0
(FVB/N-Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:56332
|
| increased metastatic potential
|
J:56332
|
Tg(MMTVneu)202Mul/0
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary gland tumor incidence
|
J:35344
|
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0
(C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr)
|
increased lung tumor incidence
|
J:115041
|
| increased mammary adenocarcinoma incidence
|
J:115041
|
| increased parotid gland tumor incidence
|
J:115041
|
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:40336
|
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085,
J:72080,
J:28453,
J:71696
|
| increased mammary gland tumor incidence
|
J:28453,
J:71696
|
| increased squamous cell carcinoma incidence
|
J:72080
|
Tg(MMTVTGFA)29Rjc/0
Tg(MMTVTGFB1)46Hlm/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:71696
|
Tg(MMTVTGFA)64Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary gland tumor incidence
|
J:72085
|
Tg(MMTVTGFA)254Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085
|
Tg(MMTVTGFB1)46Hlm/0
(involves: C57BL/6 * DBA/2)
|
decreased incidence of tumors by chemical induction
|
J:71696
|
| neoplasm
|
J:72128
|
Tg(Msmb-TAg)183-2Xuan/0
(either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * CD-1))
|
increased carcinoma incidence
|
J:96884
|
| increased tumor latency
|
J:96884
|
Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA)
|
increased metastatic potential
|
J:80313
|
| increased prostate gland adenocarcinoma incidence
|
J:80313
|
| increased prostate intraepithelial neoplasia incidence
|
J:80313
|
Tg(Msmb-TAg)186-3Xuan/0
(either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * CD-1))
|
increased carcinoma incidence
|
J:96884
|
| increased tumor latency
|
J:96884
|
Tg(Msmb-TAg)186-3Xuan/0
(involves: C57BL/6 * CBA)
|
increased carcinoma incidence
|
J:80313
|
| increased tumor incidence
|
J:80313
|
Tg(Mt1-Hgf)19Lmb/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased skin tumor incidence
|
J:122181
|
| neoplasm
|
J:122181
|
Tg(Mt1-Hgf)19Lmb/0
(involves: FVB/N)
|
increased cutaneous melanoma incidence
|
J:50947
|
| increased melanoma incidence
|
J:50947
|
| increased metastatic potential
|
J:50947
|
Tg(Mt1-RET)304Ina/0
(B6.C-Tg(Mt1-RET)304Ina)
|
increased cutaneous melanoma incidence
|
J:50392
|
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
increased cutaneous melanoma incidence
|
J:88074,
J:155735
|
| increased melanoma incidence
|
J:155735
|
| increased metastatic potential
|
J:155735
|
Tg(Mt1-Tgfa)147Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
| increased mammary gland tumor incidence
|
J:56318
|
Tg(Mt1-Tgfa)149Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:162125
|
Tg(MT2A-TGFBR2)4Rser/0
(involves: C57BL/6 * DBA)
|
increased tumor incidence
|
J:44579
|
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CD-1)
|
increased liver tumor incidence
|
J:2578
|
Tg(MtTGFA)42Lmb/0
(involves: CD-1 * FVB/N)
|
increased liver tumor incidence
|
J:2578
|
Tg(MtTGFA)42Lmb/Tg(MtTGFA)42Lmb
(involves: CD-1)
|
increased hepatocellular carcinoma incidence
|
J:28452
|
Tg(MtTGFA)100Lmb/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:72083
|
| increased mammary gland tumor incidence
|
J:72083
|
Tg(MtTGFA)Lmb/0
(involves: CD-1)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:229184
|
Tg(MtTPRMET)243Lng/0
(FVB/N-Tg(MtTPRMET)243Lng)
|
increased lymphoma incidence
|
J:71573
|
| increased mammary gland tumor incidence
|
J:71573
|
| increased osteosarcoma incidence
|
J:71573
|
| increased sarcoma incidence
|
J:71573
|
Tg(MtTPRMET)773Lng/0
(FVB/N-Tg(MtTPRMET)773Lng)
|
increased mammary gland tumor incidence
|
J:71573
|
| increased sarcoma incidence
|
J:71573
|
Tg(MUC1)79.24Gend/0
(involves: C57BL/6)
|
increased tumor incidence
|
J:128899
|
Tg(Mup3-Plau)350-2Eps/0
(involves: C57BL/6)
|
increased liver tumor incidence
|
J:66132
|
Tg(Mup3-Plau)350-2Eps/?
(C57BL/6-Tg(Mup3-Plau)350-2Eps)
|
increased hepatocellular carcinoma incidence
|
J:233146
|
| increased liver adenoma incidence
|
J:233146
|
| increased liver tumor incidence
|
J:233146
|
Tg(Mx1-cre)1Cgn/0
Tg(Tal1-tTA)19Dgt/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
(involves: C57BL/6 * CBA/J * DBA/2 * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:227558
|
Tg(Mx1-cre)1Cgn/0
U2af1tm1.1Hev/U2af1+
(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6J * CBA/J)
|
neoplasm
|
J:267082
|
Tg(Mx1-cre)1Cgn/0
Zmiz1tm1c(EUCOMM)Hmgu/Zmiz1tm1c(EUCOMM)Hmgu
(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA/J)
|
decreased incidence of induced tumors
|
J:234445
|
Tg(Myl2-FGF19)1Dfre/?
(involves: FVB)
|
increased hepatocellular carcinoma incidence
|
J:187236,
J:77160
|
| increased incidence of tumors by chemical induction
|
J:187236
|
| increased liver tumor incidence
|
J:77160
|
Tg(NES-TVA)J12Ech/0
(involves: 129 * C57BL/6 * FVB/N)
|
neoplasm
|
J:52161
|
Tg(NES-TVA)J12Ech/0
(involves: FVB/N)
|
increased glioma incidence
|
J:125535
|
| increased oligodendroglioma incidence
|
J:125535
|
Tg(NES-TVA)J12Ech/0
Trp53tm1Brd/Trp53+
(involves: 129 * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:52161
|
Tg(Neurod2-Smo*A1)199Jols/0
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols)
|
increased medulloblastoma incidence
|
J:93861
|
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6)
|
increased medulloblastoma incidence
|
J:221990
|
Tg(Neurod2-Smo*A1)199Jols/Tg(Neurod2-Smo*A1)199Jols
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols)
|
increased medulloblastoma incidence
|
J:133312,
J:189258
|
Tg(Neurod2-Smo*A2)#Jols/0
(C57BL/6-Tg(Neurod2-Smo*A2)#Jols)
|
increased medulloblastoma incidence
|
J:189258
|
| neoplasm
|
J:93861
|
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
|
increased adrenal gland tumor incidence
|
J:54269
|
| increased metastatic potential
|
J:54269
|
| increased neuroblastoma incidence
|
J:54269
|
Tg(Pax6-TAg)1796Hur/0
(involves: FVB)
|
increased eye tumor incidence
|
J:196814
|
| increased retinoblastoma incidence
|
J:196814
|
Tg(Pax8-rtTA2S*M2)1Koes/0
Tg(tetO-MYC)36aBop/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased adenoma incidence
|
J:140925
|
| increased renal carcinoma incidence
|
J:140925
|
Tg(Pbsn-Ar*E231G)7353Ng/0
(involves: FVB/N)
|
increased metastatic potential
|
J:96117
|
| increased prostate gland adenocarcinoma incidence
|
J:96117
|
| increased prostate gland tumor incidence
|
J:96117
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129/Sv * C57BL/6J * CBA)
|
increased prostate intraepithelial neoplasia incidence
|
J:131932
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129S1/SvImJ * C57BL/6J * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
| increased prostate gland tumor incidence
|
J:222916
|
Tg(Pbsn-FGF7)3293Ng/0
(Not Specified)
|
increased prostate intraepithelial neoplasia incidence
|
J:80821
|
Tg(Pbsn-FGFR1*K656E)#Wmck/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87519
|
Tg(Pbsn-FGFR1*K656E)#Wmck/0
Tg(Pbsn-FGFR2_iiib*)#Ng/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(FVB-Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp)
|
increased metastatic potential
|
J:130340
|
| increased prostate gland adenocarcinoma incidence
|
J:130340
|
| increased prostate gland tumor incidence
|
J:130340
|
| increased prostate intraepithelial neoplasia incidence
|
J:130340,
J:87092
|
| increased sarcoma incidence
|
J:130340
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
Tg(Pbsn-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
Tg(Pbsn-Hpn,-GFP)DVv/0
Tg(Pbsn-Tag)12T7fRjm/0
(involves: C57BL/6J * CBA * CD-1)
|
increased metastatic potential
|
J:92562
|
| increased prostate gland adenocarcinoma incidence
|
J:92562
|
| increased prostate intraepithelial neoplasia incidence
|
J:92562
|
Tg(Pbsn-IGF1*)5305Ng/0
(involves: FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:144539
|
| neoplasm
|
J:144539
|
Tg(Pbsn-IGF1*)5305Ng/0
Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * FVB/N)
|
abnormal metastatic potential
|
J:144539
|
| decreased tumor incidence
|
J:144539
|
| increased prostate gland tumor incidence
|
J:144539
|
Tg(Pbsn-MYC)6Key/?
(involves: FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:85480
|
| increased prostate gland tumor incidence
|
J:85480
|
| increased prostate intraepithelial neoplasia incidence
|
J:85480
|
Tg(Pbsn-MYC)#Tt/?
(involves: C57BL/6J)
|
increased prostate gland adenocarcinoma incidence
|
J:205395
|
| increased prostate intraepithelial neoplasia incidence
|
J:205395
|
Tg(Pbsn-Tag)12T7fRjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:48623
|
| increased prostate gland tumor incidence
|
J:48623
|
| increased prostate intraepithelial neoplasia incidence
|
J:92562,
J:48623
|
Tg(Pbsn-Tag)12T10Rjm/0
(involves: CD-1)
|
increased metastatic potential
|
J:68483
|
| increased prostate gland adenocarcinoma incidence
|
J:68483,
J:48623
|
| increased prostate gland tumor incidence
|
J:48623
|
| increased prostate intraepithelial neoplasia incidence
|
J:68483
|
Tg(Pbsn-TAg)15Tvd/0
(involves: C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
| increased prostate intraepithelial neoplasia incidence
|
J:103408
|
Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N)
|
increased incidence of tumors by chemical induction
|
J:17848
|
| increased T cell derived lymphoma incidence
|
J:17848
|
Tg(Pklr-HRAS*G12V)23Ak/0
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:44803
|
| increased hepatoma incidence
|
J:44803
|
| increased kidney tumor incidence
|
J:44803
|
Tg(Pklr-Myc)73Ak/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:185488
|
| increased hepatoma incidence
|
J:185488
|
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
Tg(Pklr-SV40)1Ak/0
(involves: C57BL/6 * DBA)
|
increased adenocarcinoma incidence
|
J:185488
|
| increased hepatocellular carcinoma incidence
|
J:185488
|
| increased hepatoma incidence
|
J:185488
|
| increased insulinoma incidence
|
J:185488
|
| increased osteosarcoma incidence
|
J:185488
|
| increased pancreas tumor incidence
|
J:185488
|
Tg(Pklr-SV40)1Ak/Tg(Pklr-SV40)1Ak
(involves: C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:185488
|
Tg(PML-RARA)556Kog/?
(involves: FVB/N)
|
increased acute promyelocytic leukemia incidence
|
J:39327
|
| increased skin papilloma incidence
|
J:39327
|
Tg(PML-RARA)556Kog/0
(FVB/N-Tg(PML-RARA)556Kog)
|
increased acute promyelocytic leukemia incidence
|
J:262172
|
Tg(Prl-EGFR)#Sme/0
(Not Specified)
|
increased prolactinoma incidence
|
J:219654
|
Tg(Pten)1Srn/0
(involves: C57BL/6 * CBA)
|
decreased incidence of tumors by chemical induction
|
J:182671
|
Tg(PTH-CCND1)PC2Anar/0
(FVB/N-Tg(PTH-CCND1)PC2Anar)
|
increased parathyroid adenoma incidence
|
J:69423
|
Tg(PyLT)1Vb/0
(Not Specified)
|
increased pituitary adenoma incidence
|
J:55528
|
| increased pituitary gland tumor incidence
|
J:55528
|
Tg(RasE)290Biat/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:226601
|
Tg(RasE)290Biat/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:226601
|
Tg(Rbp3-SV40)IT-2Jjw/?
(involves: BALB/c * C57BL/6)
|
increased pineal gland tumor incidence
|
J:60231
|
| increased retinoblastoma incidence
|
J:60231
|
Tg(RBP3-TAg)#Ove/0
(involves: C57BL/6 * FVB/N)
|
increased brain tumor incidence
|
J:59267
|
| increased retina tumor incidence
|
J:59267
|
| increased tumor incidence
|
J:59267
|
Tg(Ren2-TAg)4Kwg/?
(involves: C3H/HeRos * C57BL/10Ros)
|
increased sarcoma incidence
|
J:36423
|
| increased tumor incidence
|
J:36423
|
| preneoplasia
|
J:36423
|
Tg(RIP1-Tag)2Dh/?
(C3.Cg-Tg(RIP1-Tag)2Dh/Nci)
|
increased insulinoma incidence
|
J:80168
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6)
|
increased insulinoma incidence
|
J:162648
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased insulinoma incidence
|
J:205389
|
| increased pancreas tumor incidence
|
J:50695
|
| increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:80168
|
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:136259
|
| preneoplasia
|
J:136259
|
Tg(RIR-Tag)87Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased pancreas tumor incidence
|
J:50695
|
Tg(rTH-Tag)20Dmc/0
(involves: C57BL/6NTac * DBA/2NTac)
|
increased adrenal gland tumor incidence
|
J:90323
|
| increased brain tumor incidence
|
J:90323
|
| increased neuroblastoma incidence
|
J:90323
|
Tg(S100b-v-erbB)4496Waw/0
(involves: C57BL/6J * DBA/2J * FVB/N)
|
increased oligodendroglioma incidence
|
J:82649
|
Tg(S100b-v-erbB)4496Waw/0
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6J * DBA/2J * FVB/N)
|
increased glioma incidence
|
J:82649
|
| increased oligodendroglioma incidence
|
J:82649
|
Tg(S100b-v-erbB)4496Waw/0
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J * DBA/2J)
|
increased glioma incidence
|
J:225862
|
| increased oligodendroglioma incidence
|
J:225862
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*)#Kkw/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:156440,
J:235747
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*delta19)11Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)56Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)57Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)#Hev/0
(involves: 129 * C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:128700,
J:213447
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M)8Paow/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:128700
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)19Kkw/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122849
|
| increased lung carcinoma incidence
|
J:122849
|
| increased lung tumor incidence
|
J:122849,
J:156440,
J:235747
|
| increased metastatic potential
|
J:122849
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)51Paow/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:128700
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-ERBB2*)5BKkw/0
(involves: FVB/N)
|
increased lung carcinoma incidence
|
J:143874
|
| increased lung non-small cell carcinoma incidence
|
J:143874
|
| increased lung tumor incidence
|
J:143874
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-ERBB2*)26Kkw/0
(involves: FVB/N)
|
increased lung carcinoma incidence
|
J:143874
|
| increased lung non-small cell carcinoma incidence
|
J:143874
|
| increased lung tumor incidence
|
J:143874
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-IGF1R)1Ramo/0
(involves: 129 * C57BL/6 * FVB)
|
increased lung adenoma incidence
|
J:271820
|
| increased lung tumor incidence
|
J:271820
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:73468
|
| increased lung adenoma incidence
|
J:73468
|
| increased lung tumor incidence
|
J:73468
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:73468
|
| increased lung tumor incidence
|
J:73468
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-MYC)36Bop/0
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:169920
|
| increased lung adenoma incidence
|
J:169920
|
| increased lung tumor incidence
|
J:169920
|
| increased metastatic potential
|
J:169920
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PIK3CA*H1047R)13Lca/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:142254
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PTPN11*E76K)#Jiwu/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenoma incidence
|
J:212505
|
| increased lung non-small cell carcinoma incidence
|
J:212505
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:102839
|
| increased lung adenoma incidence
|
J:102839
|
| increased tumor incidence
|
J:102839
|
Tg(SERPINA1-TAg)1812Jtsb/0
(involves: C3H * C57BL/6 * ICR)
|
increased hepatocellular carcinoma incidence
|
J:101633
|
Tg(SERPINC1-SV40)A1Pbr/0
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:101541
|
| increased metastatic potential
|
J:101541
|
Tg(SERPINC1-SV40)A1Pbr/Tg(SERPINC1-SV40)A1Pbr
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:101541
|
X/Tg(SERPINC1-SV40)BPbr
(involves: C57BL/6 * DBA/2)
|
abnormal tumor vascularization
|
J:84204
|
| increased hepatocellular carcinoma incidence
|
J:84204,
J:101541
|
| increased liver adenoma incidence
|
J:84204
|
Tg(SFTPC-CCNE1)1Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
| increased metastatic potential
|
J:122698
|
Tg(SFTPC-CCNE1*T62A*T380A)3Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
| increased metastatic potential
|
J:122698
|
Tg(SFTPC-CCNE1*T62A*T380A)4Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
| increased metastatic potential
|
J:122698
|
Tg(SFTPC-CD74/ROS1)125Tno/0
(C57BL/6J-Tg(SFTPC-CD74/ROS1)125Tno)
|
increased lung adenocarcinoma incidence
|
J:231770
|
| increased lung adenoma incidence
|
J:231770
|
| increased lung non-small cell carcinoma incidence
|
J:231770
|
| increased lung tumor incidence
|
J:231770
|
Tg(SFTPC-EGFR*L858R)4-3Kkiu/0
(involves: C57BL/6Cr)
|
increased lung adenocarcinoma incidence
|
J:152157
|
| increased lung carcinoma incidence
|
J:152157
|
| increased lung tumor incidence
|
J:152157
|
Tg(SFTPC-EML4/ALK)502-4Hima/0
(involves: C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:142679
|
Tg(SFTPC-env)1Yhch/0
(FVB/N-Tg(SFTPC-env)1Yhch)
|
increased lung adenocarcinoma incidence
|
J:153538,
J:247986
|
| increased lung tumor incidence
|
J:153538
|
| increased metastatic potential
|
J:247986
|
Tg(SFTPC-EZR/ROS1)AShiba/0
(C57BL/6-Tg(SFTPC-EZR/ROS1)AShiba)
|
increased lung adenocarcinoma incidence
|
J:199415
|
Tg(SFTPC-KIF5B/RET)1Tkoh/0
(involves: C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:215989
|
| increased lung adenoma incidence
|
J:215989
|
| increased lung tumor incidence
|
J:215989
|
Tg(SFTPC-MST1R)71Mhw/0
(involves: C3H * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:79080
|
| increased lung adenoma incidence
|
J:79080
|
Tg(SFTPC-RAF1)87Urr/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:80895
|
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:80895
|
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-Fgf9,-EGFP)#Dor/0
(involves: FVB)
|
increased blastoma incidence
|
J:224791
|
| increased lung adenocarcinoma incidence
|
J:204282
|
| increased lung adenoma incidence
|
J:204282
|
| increased lung tumor incidence
|
J:204282
|
| increased malignant tumor incidence
|
J:204282
|
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-IGF1R)1Ramo/0
(involves: FVB)
|
increased lung adenoma incidence
|
J:271820
|
| increased lung tumor incidence
|
J:271820
|
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-MYC)36Bop/0
(Not Specified)
|
decreased tumor incidence
|
J:169920
|
| increased lung adenocarcinoma incidence
|
J:169920
|
| increased lung adenoma incidence
|
J:169920
|
| increased lung tumor incidence
|
J:169920
|
| increased metastatic potential
|
J:169920
|
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N)
|
increased lung adenoma incidence
|
J:102839
|
| increased tumor incidence
|
J:102839
|
Tg(Sftpc-rtTA,Nudt18-tetO-cre)1Ptch/0
Tg(tetO-EGFR*L858R)56Hev/0
(involves: C57BL/6 * CBA * CD-1)
|
increased tumor incidence
|
J:195738
|
Tg(SFTPC-SDC4/ROS1)141Tno/0
(C57BL/6J-Tg(SFTPC-SDC4/ROS1)141Tno)
|
increased lung adenocarcinoma incidence
|
J:231770
|
| increased lung adenoma incidence
|
J:231770
|
| increased lung non-small cell carcinoma incidence
|
J:231770
|
| increased lung tumor incidence
|
J:231770
|
Tg(Slc1a2-tTA)#Waw/0
Tg(tetO-MYCN,-luc)#Waw/0
(involves: FVB/NJ)
|
increased malignant tumor incidence
|
J:160518
|
| increased medulloblastoma incidence
|
J:160518
|
| increased metastatic potential
|
J:160518
|
Tg(Slc1a2-tTA)#Waw/0
Tg(tetO-MYCN,-luc)#Waw/Tg(tetO-MYCN,-luc)#Waw
(involves: FVB/NJ)
|
increased malignant tumor incidence
|
J:160518
|
| increased medulloblastoma incidence
|
J:160518
|
| increased metastatic potential
|
J:160518
|
Tg(Smgb-TAg)8Mir/Tg(Smgb-TAg)8Mir
(involves: BALB/cJ * C57BL/6J)
|
increased salivary adenocarcinoma incidence
|
J:66189
|
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL/6 * CD-1)
|
increased metastatic potential
|
J:199542
|
| increased osteosarcoma incidence
|
J:199542
|
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N)
|
increased metastatic potential
|
J:136693
|
| increased osteosarcoma incidence
|
J:136693
|
Tg(STIL-TAL1)A5(3)Alpa/0
(involves: C3H/HeRos * C57BL/10Ros)
|
neoplasm
|
J:40868
|
Tg(SV40-Ahr)1Poe/0
(involves: C57BL/6 * CBA)
|
increased stomach tumor incidence
|
J:77977
|
Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified)
|
increased sarcoma incidence
|
J:125150
|
| increased T cell derived lymphoma incidence
|
J:125150
|
Tg(SV)7Bri/0
(C57BL/6J-Tg(SV)7Bri/J)
|
increased brain tumor incidence
|
J:94307
|
Tg(SV)419Bri/Tg(SV)419Bri
(C57BL/6J-Tg(SV)419Bri)
|
increased brain tumor incidence
|
J:147031
|
| increased kidney tumor incidence
|
J:147031
|
| increased T cell derived lymphoma incidence
|
J:147031
|
| neoplasm
|
J:79096
|
Tg(SV)427Bri/0
(C57BL/6J-Tg(SV)427Bri)
|
increased brain tumor incidence
|
J:79096,
J:147031
|
Tg(TagRb)1Plm/?
(involves: BALB/cJ * C57BL/6J)
|
increased retinoblastoma incidence
|
J:10320
|
Tg(Tal1-cre/ERT)1Jrg/0
Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129S4/SvJae * C57BL/6)
|
increased extremity angiosarcoma incidence
|
J:231316
|
| increased hemangiosarcoma incidence
|
J:231316
|
| increased liver tumor incidence
|
J:231316
|
| increased metastatic potential
|
J:231316
|
Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:55022
|
| increased T cell derived lymphoma incidence
|
J:55022
|
Tg(Tcra2B4)1Mmd/?
(involves: C3H/HeJ * C57BL/6)
|
increased lymphoma incidence
|
J:92992
|
Tg(Tcra,Tcrb)HRVAll/0
Tg(TRAMP)8247Ng/0
(B6.Cg-Tg(TRAMP)8247Ng Tg(Tcra,Tcrb)HRVAll)
|
increased prostate gland tumor incidence
|
J:131347
|
| increased tumor incidence
|
J:131347
|
Tg(TcraCl1,TcrbCl1)1Shrm/0
(B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm)
|
increased tumor incidence
|
J:106230
|
Tg(TcraTcrb)8Rest/?
(C57BL/6-Tg(TcraTcrb)8Rest)
|
abnormal tumor susceptibility
|
J:85058
|
Tg(TcraTcrb)1100Mjb/?
(either: C57BL/6 or (involves: C57BL/6 * SJL))
|
increased tumor latency
|
J:134776
|
Tg(Tcrb-TCF3/PBX1)19Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:95693
|
| increased leukemia incidence
|
J:95693
|
Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:95693
|
| increased leukemia incidence
|
J:95693
|
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
Tg(Tek-Npr1)#Kkan/0
(involves: C57BL/6)
|
decreased metastatic potential
|
J:220676
|
Tg(tetO-BCR/ABL1)2Dgt/0
Tg(MMTVtTA)1Mam/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased leukemia incidence
|
J:72377
|
Tg(tetO-BCR/ABL1)2Dgt/0
Tg(Tal1-tTA)19Dgt/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased lymphoma incidence
|
J:96511
|
| increased sarcoma incidence
|
J:96511
|
Tg(tetO-BCR/ABL1)27Dgt/0
Tg(MMTVtTA)1Mam/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased leukemia incidence
|
J:72377
|
Tg(tetO-BRAF*V600E)26Jaf/0
Tg(TG-rtTA)30Jaf/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:184420
|
| increased thyroid tumor incidence
|
J:184420
|
Tg(tetO-Kras2)12Hev/0
(involves: FVB/N)
|
neoplasm
|
J:73468
|
Tg(tetO-MET)23Rwng/0
Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:69731
|
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
decreased tumor growth/size
|
J:190067
|
| increased hepatoblastoma incidence
|
J:93899
|
| increased hepatocellular carcinoma incidence
|
J:172430,
J:186226,
J:190067,
J:93899
|
| increased liver tumor incidence
|
J:172430,
J:93899
|
Tg(tetO-TAg)2-5Hiwa/0
(involves: C57BL/6)
|
increased adrenal gland tumor incidence
|
J:175962
|
| increased neuroblastoma incidence
|
J:156984,
J:175962
|
Tg(tetO-TAg,CMV-rtTA)123Yihu/0
(involves: FVB/N)
|
increased medulloblastoma incidence
|
J:141623
|
Tg(TetOp-Polb/tTA)2Sbl/0
(B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)
|
increased intestinal adenoma incidence
|
J:152481
|
| increased osteoma incidence
|
J:152481
|
| increased osteosarcoma incidence
|
J:152481
|
| increased skeletal tumor incidence
|
J:152481
|
| neoplasm
|
J:152481
|
Tg(Tff3-Tmem207)1Tamo/0
(C57BL/6-Tg(Tff3-Tmem207)1Tamo)
|
increased carcinoma incidence
|
J:217436
|
| increased skin tumor incidence
|
J:217436
|
| increased trichoepithelioma incidence
|
J:217436
|
Tg(TG-BRAF*V600E)2Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)2Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
| increased thyroid tumor incidence
|
J:98550
|
Tg(TG-BRAF*V600E)3Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)3Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
Tg(TG-NRAS*Q61K)#Msnt/0
(Not Specified)
|
increased metastatic potential
|
J:210016
|
| increased thyroid adenoma incidence
|
J:210016
|
| increased thyroid carcinoma incidence
|
J:210016
|
Tg(TG-RET/CCDC6)1Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/CCDC6)42Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/NCOA4)3209Rstn/0
(involves: C57BL/6)
|
increased metastatic potential
|
J:51366
|
| increased thyroid carcinoma incidence
|
J:51366
|
Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J)
|
increased metastatic potential
|
J:209788
|
| increased thyroid carcinoma incidence
|
J:209788
|
Tg(TG-TPR/NTRK1)5215Rstn/0
(involves: C3H * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:67120
|
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Tg(Tgfa)1Efu/0
(Not Specified)
|
increased skin papilloma incidence
|
J:65045
|
Tg(Th-ALK*F1174L)2Loch/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J * CBA)
|
increased neuroblastoma incidence
|
J:191012
|
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:172448
|
Tg(Th-MYCN)41Waw/0
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/Tg(Th-MYCN)41Waw
(involves: BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-TAg)17Dmc/0
((C57BL/6NTac x DBA/2NTac)F2)
|
increased adrenal gland tumor incidence
|
J:90323
|
Tg(Thy1-cmyc)6Kio/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:129440
|
Tg(Thy1-cmyc)6LKio/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:129440
|
Tg(Thy1/THY1)hT10Gsv/0
(involves: C57BL/10 * CBA)
|
increased kidney tumor incidence
|
J:133943
|
Tg(Thy1/THY1)hT13Gsv/0
(involves: C57BL/10 * CBA)
|
increased kidney tumor incidence
|
J:133943
|
| increased papilloma incidence
|
J:133943
|
Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased submandibular gland tumor incidence
|
J:73711
|
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Tg(TRAMP)8247Ng/0
(involves: C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:217920,
J:65303
|
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:125633
|
| increased prostate gland tumor incidence
|
J:125633
|
| increased prostate intraepithelial neoplasia incidence
|
J:125633
|
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
| increased prostate gland tumor incidence
|
J:133908
|
| increased prostate intraepithelial neoplasia incidence
|
J:133908,
J:131932
|
Tg(TRAMP)8247Ng/0
Tmprss2tm1Psn/Tmprss2tm1Psn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased metastatic potential
|
J:217920
|
| increased tumor growth/size
|
J:217920
|
Tg(TRAMP)8247Ng/0
Usp11tm1Tac/Y
(involves: 129 * C57BL/6)
|
increased metastatic potential
|
J:270214
|
| increased prostate gland adenocarcinoma incidence
|
J:270214
|
| increased prostate intraepithelial neoplasia incidence
|
J:270214
|
| increased tumor growth/size
|
J:270214
|
Tg(Trp53)1Srn/0
(involves: C57BL/6 * CBA)
|
decreased incidence of tumors by chemical induction
|
J:80311
|
| decreased tumor incidence
|
J:80311
|
Tg(TRP53)4Dgj/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB)
|
decreased lymphoma incidence
|
J:162466
|
| increased osteosarcoma incidence
|
J:162466
|
Tg(TRP53*R72P)7Dgj/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB)
|
decreased lymphoma incidence
|
J:162466
|
| increased hemangiosarcoma incidence
|
J:162466
|
Tg(Trp53A135V)L3Ber/0
(involves: C57BL/6 * CD-1)
|
decreased tumor incidence
|
J:73757
|
| increased lung adenocarcinoma incidence
|
J:73757
|
Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased incidence of tumors by chemical induction
|
J:46426
|
| increased mammary adenocarcinoma incidence
|
J:46426
|
Tg(Trp53R172L)4491Jmr/0
(FVB/N-Tg(Trp53R172L)4491Jmr)
|
neoplasm
|
J:56433
|
Tg(Trp53R172L)4491Jmr/0
(involves: FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:101547
|
Tg(Tyr-BRAF*V600E)470Fgh/0
(involves: C57BL/6J * CBA)
|
increased malignant tumor incidence
|
J:151455
|
Tg(Tyr-BRAF*V600E)476Fgh/0
(involves: C57BL/6J * CBA)
|
increased malignant tumor incidence
|
J:151455
|
Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0
(involves: FVB/N)
|
increased tumor incidence
|
J:107175
|
Tg(Tyr-HRAS*G12V)#Acc/0
(involves: C3H/HeN * C57BL/6 * SJL)
|
neoplasm
|
J:90877
|
Tg(Tyr-TAg)BJjw/0
(involves: BALB/cAnNHsd * C57BL/6NHsd)
|
increased choroid tumor incidence
|
J:52122
|
| increased iris tumor incidence
|
J:52122
|
| increased retina tumor incidence
|
J:52122
|
Tg(Tyrp1-TAg)3434Bee/?
(involves: BALB/c * C57BL/6J)
|
increased eye tumor incidence
|
J:75629
|
Tg(UPII-SV40T)2Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:56305
|
Tg(UPII-SV40T)9Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
Tg(UPII-SV40T)29Xrw/0
(involves: FVB/N)
|
increased metastatic potential
|
J:56305
|
| increased urinary bladder carcinoma incidence
|
J:56305
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:56305
|
Tg(Upk2-HRAS*Q61L)5Xrw/?
(involves: FVB/N)
|
increased urinary system tumor incidence
|
J:69251
|
Tg(Upk2-HRAS*Q61L)12Xrw/?
(involves: FVB/N)
|
increased urinary system tumor incidence
|
J:69251
|
Tg(Upk2-TAg)1Rkl/0
(involves: C57BL/6)
|
abnormal metastatic potential
|
J:173505
|
| abnormal tumor vascularization
|
J:173505
|
| increased urinary bladder carcinoma incidence
|
J:173505
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:173505
|
Tg(Utg-TAg)7593Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Utg-TAg)7736Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Utg-TAg)#Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Vav1-Asxl1*Y588X)#Fcy/0
(C57BL/6-Tg(Vav1-Asxl1*Y588X)#Fcy)
|
increased acute myeloid leukemia incidence
|
J:257690
|
| increased myeloid sarcoma incidence
|
J:257690
|
Tg(Vav1-ERG)#Jpim/0
(involves: C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:203438,
J:174808
|
| increased leukemia incidence
|
J:203438,
J:174808
|
Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:189197
|
Tg(Vav1-NUP98/HOXD13)C1Apla/0
(FVB/N-Tg(Vav1-NUP98/HOXD13)C1Apla)
|
increased leukemia incidence
|
J:107446
|
Tg(Vav1-NUP98/HOXD13)G2Apla/0
(C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla)
|
increased leukemia incidence
|
J:107446
|
Tg(Vav1-STAT5B)731Biat/0
(C57BL/6NCrl-Tg(Vav1-STAT5B)731Biat/Biat)
|
neoplasm
|
J:257519
|
Tg(Vav1-STAT5B*N642H)726Biat/0
(C57BL/6NCrl-Tg(Vav1-STAT5B*N642H)726Biat)
|
increased leukemia incidence
|
J:257519
|
| increased lymphoma incidence
|
J:257519
|
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:88565,
J:228913
|
| increased follicular lymphoma incidence
|
J:88565,
J:228913
|
| increased histiocytic sarcoma incidence
|
J:88565
|
| increased lymphoma incidence
|
J:88565
|
| increased T cell derived lymphoma incidence
|
J:88565
|
| increased tumor incidence
|
J:88565
|
Tg(Vil1-Lin28b,-tdTomato)HiAru/0
(involves: C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:202923
|
| increased small intestine adenocarcinoma incidence
|
J:202923
|
Tg(Vil1-Lin28b,-tdTomato)MedAru/0
(involves: C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:202923
|
| increased small intestine adenocarcinoma incidence
|
J:202923
|
Tg(Vil1-PPARGC1A)#Amos/0
(involves: FVB/N)
|
decreased incidence of tumors by chemical induction
|
J:171361
|
| decreased tumor growth/size
|
J:171361
|
Tg(Vil-SLC3A2)HEMerl/0
(involves: FVB/N)
|
increased colon adenoma incidence
|
J:173946
|
| increased incidence of tumors by chemical induction
|
J:173946
|
| increased tumor growth/size
|
J:173946
|
Tg(Wap-Hgf)402Mig/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:86776
|
| increased mammary gland tumor incidence in breeding females
|
J:86776
|
| increased mammary gland tumor incidence in virgin females
|
J:86776
|
| increased metastatic potential
|
J:86776
|
Tg(Wap-Hgf)402Mig/0
(FVB/N-Tg(Wap-Hgf)402Mig)
|
increased mammary adenocarcinoma incidence
|
J:206839
|
| increased mammary gland tumor incidence in breeding females
|
J:206839
|
X/Tg(Wap-HRAS)69Lln
(involves: C57BL/6 * SJL)
|
abnormal metastatic potential
|
J:46458
|
| increased adenocarcinoma incidence
|
J:72262
|
| increased mammary gland tumor incidence
|
J:46458
|
| increased salivary adenocarcinoma incidence
|
J:46458
|
X/Tg(Wap-HRAS)69Lln
(FVB.Cg-Tg(Wap-HRAS)69Lln Chr YSJL/J)
|
increased mammary gland tumor incidence
|
J:101113
|
Tg(Wap-TAg)1Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-tAg)1Gmn/?
(involves: NMRI)
|
increased mammary adenocarcinoma incidence
|
J:69711
|
Tg(Wap-TAg)12Gmn/?
(involves: NMRI)
|
increased mammary gland tumor incidence
|
J:69711
|
Tg(Wap-TAg)NP8Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-Tsg101)4389Kuw/0
(FVB/N-Tg(Wap-Tsg101)4389Kuw)
|
increased mammary adenocarcinoma incidence
|
J:121475
|
Tg(WapMyc)212Bri/0
(FVB.Cg-Tg(WapMyc)212Bri)
|
increased mammary gland tumor incidence
|
J:114568
|
Tg(WapMyc)212Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
| increased mammary gland tumor incidence
|
J:56318
|
Tg(WapMyc)212Bri/0
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapNotch4)10Rnc/0
(involves: FVB/N)
|
increased lung tumor incidence
|
J:33193
|
| increased mammary adenocarcinoma incidence
|
J:33193
|
Tg(WapNotch4)10Rnc/Y
(involves: FVB/N)
|
neoplasm
|
J:33193
|
Tg(WapTAg)1Knw/0
(C57BL/6J-Tg(WapTAg)1Knw/J)
|
increased mammary adenocarcinoma incidence
|
J:53175
|
| increased sarcoma incidence
|
J:53175
|
Tg(WapTAg)3Knw/0
(C57BL/6J-Tg(WapTAg)3Knw)
|
increased adenocarcinoma incidence
|
J:53175
|
| increased mammary adenocarcinoma incidence
|
J:53175
|
| increased osteosarcoma incidence
|
J:53175
|
| increased sarcoma incidence
|
J:53175
|
Tg(WapTgfa)215Bri/0
(FVB.Cg-Tg(WapTgfa)215Bri)
|
increased mammary gland tumor incidence
|
J:114568
|
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
| increased mammary gland tumor incidence
|
J:56318
|
Tg(WapTgfa)215Bri/0
(B6.Cg-Tg(WapTgfa)215Bri)
|
increased lymphoma incidence
|
J:123146
|
| increased mammary gland tumor incidence
|
J:123146
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:61009
|
Tgct1MOLF/Ei/Tgct1MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct2MOLF/Ei/Tgct2MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct3MOLF/Ei/Tgct3MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct5MOLF/Ei/Tgct5MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgfb1tm1Rif/Tgfb1tm1Rif
(either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))
|
increased anal adenocarcinoma incidence
|
J:142353
|
| increased colon adenocarcinoma incidence
|
J:142353
|
| increased gastric adenocarcinoma incidence
|
J:142353
|
| increased large intestine adenocarcinoma incidence
|
J:142353
|
| increased rectum adenocarcinoma incidence
|
J:142353
|
| increased stomach tumor incidence
|
J:142353
|
| increased tumor incidence
|
J:142353
|
Tgfb1i1tm1.2Cet/Tgfb1i1tm1.2Cet
Tg(MMTV-PyVT)634Mul/0
(involves: 129S/SvEv * C57BL/6 * FVB/N)
|
decreased mammary gland tumor incidence
|
J:241234
|
| decreased metastatic potential
|
J:241234
|
Tgfbitm1.1Nap/Tgfbitm1.1Nap
(B6N.129S(FVB)-Tgfbitm1.1Nap)
|
neoplasm
|
J:230754
|
Tgfbitm1Zhao/Tgfbitm1Zhao
(involves: 129 * C57BL/6J)
|
increased incidence of tumors by chemical induction
|
J:143036
|
| increased lung adenocarcinoma incidence
|
J:143036
|
| increased lymphoma incidence
|
J:143036
|
| increased malignant tumor incidence
|
J:143036
|
| increased tumor incidence
|
J:143036
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
(involves: 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:177379
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:204736
|
| increased prostate intraepithelial neoplasia incidence
|
J:204736
|
Tgfbr2tm1Sjkm/Tgfbr2+
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:71591
|
Tgm2tm1Gml/Tgm2tm1Gml
(involves: C57BL/6)
|
increased tumor growth/size
|
J:126131
|
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor morphology
|
J:72391
|
| increased adenocarcinoma incidence
|
J:72391
|
| increased adenoma incidence
|
J:72391
|
| increased carcinoma incidence
|
J:72391
|
| increased fibrosarcoma incidence
|
J:72391
|
| increased histiocytic sarcoma incidence
|
J:72391
|
| increased liver adenocarcinoma incidence
|
J:72391
|
| increased lung adenocarcinoma incidence
|
J:72391
|
| increased lymphoma incidence
|
J:72391
|
| increased mammary adenocarcinoma incidence
|
J:72391
|
| increased osteosarcoma incidence
|
J:72391
|
| increased pancreas tumor incidence
|
J:72391
|
| increased papilloma incidence
|
J:72391
|
| increased sarcoma incidence
|
J:72391
|
| increased squamous cell carcinoma incidence
|
J:72391
|
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased adenocarcinoma incidence
|
J:72391
|
| increased carcinoma incidence
|
J:72391
|
| increased fibrosarcoma incidence
|
J:72391
|
| increased hemangiosarcoma incidence
|
J:72391
|
| increased histiocytic sarcoma incidence
|
J:72391
|
| increased lymphoma incidence
|
J:72391
|
| increased pancreas tumor incidence
|
J:72391
|
| increased sarcoma incidence
|
J:72391
|
| increased small intestine adenocarcinoma incidence
|
J:72391
|
Thbs2tm1Bst/Thbs2tm1Bst
(either: (involves: 129S4/SvJae * 129X1/SvJ) or (involves: 129X1/SvJ))
|
increased incidence of tumors by chemical induction
|
J:69756
|
ThimTg(Myh6-TGFB1)1Ljf/Thim+
(involves: C3HeB/FeJ)
|
increased T cell derived lymphoma incidence
|
J:59903
|
Thratm1Ven/Thratm1Ven
Thrbtm1Df/Thrbtm1Df
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:95391
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
increased pituitary adenoma incidence
|
J:95391
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thrbtm1Df/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thyls2BALB/c/?
(involves: BALB/c * MSM)
|
decreased incidence of tumors by ionizing radiation induction
|
J:87704
|
Thyls2MSM/Thyls2MSM
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:87704
|
Tiam1tm1Jgc/Tiam1+
(involves: 129P2/OlaHsd * FVB)
|
decreased incidence of tumors by chemical induction
|
J:77148
|
Tiam1tm1Jgc/Tiam1tm1Jgc
(involves: 129P2/OlaHsd * FVB)
|
decreased incidence of tumors by chemical induction
|
J:77148
|
| increased malignant tumor incidence
|
J:77148
|
| increased squamous cell carcinoma incidence
|
J:77148
|
Ticam1tm1Tsse/Ticam1tm1Tsse
(B6.129-Ticam1tm1Tsse)
|
increased tumor growth/size
|
J:118750
|
TigarGt(EUCE0047g05)Hmgu/TigarGt(EUCE0047g05)Hmgu
Apctm1Tno/Apctm1Tno
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
decreased tumor growth/size
|
J:198650
|
Tigittm1Sdl/Tigittm1Sdl
(involves: C57BL/6)
|
neoplasm
|
J:209990
|
Timp1tm1Pds/Timp1tm1Pds
(involves: 129S4/SvJae)
|
neoplasm
|
J:43744
|
Tlag2AKR/J/Tlag2C57L/J
(involves: AKR/J * C57L/J)
|
increased T cell derived lymphoma incidence
|
J:74369
|
Tlag2AKR/J/Tlag2C57L/J
Tlag1AKR/J/Tlag1AKR/J
(involves: AKR/J * C57L/J)
|
increased T cell derived lymphoma incidence
|
J:74369
|
Tle5tm1.1Mmt/Tle5tm1.1Mmt
Apctm1Mmt/Apc+
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S2/SvPas * C57BL/6 * DBA * SJL)
|
increased colon adenocarcinoma incidence
|
J:168065
|
| increased metastatic potential
|
J:168065
|
| increased small intestine adenocarcinoma incidence
|
J:168065
|
Tlr2tm1Aki/Tlr2tm1Aki
(B6.129P2-Tlr2tm1Aki)
|
decreased liver tumor incidence
|
J:143870
|
| decreased lung tumor incidence
|
J:143870
|
Tlr2tm1Kir/Tlr2tm1Kir
(B6.129-Tlr2tm1Kir)
|
increased carcinoma incidence
|
J:165105
|
| increased colon adenoma incidence
|
J:165105
|
| increased gastrointestinal tumor incidence
|
J:165105
|
Tlr3tm1Flv/Tlr3tm1Flv
(B6.129S1-Tlr3tm1Flv/Apb)
|
increased tumor incidence
|
J:158910
|
Tlr4tm1Aki/Tlr4tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:162097
|
Tlr4tm1Aki/Tlr4tm1Aki
(B6.129P2-Tlr4tm1Aki)
|
decreased incidence of tumors by chemical induction
|
J:135620
|
Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu)
|
increased splenic marginal zone lymphoma incidence
|
J:324448
|
Tlr7em2Anu/Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu)
|
increased splenic marginal zone lymphoma incidence
|
J:324448
|
Tlsm1AKR/JMs/Tlsm1AKR/JMs
(involves: AKR/JMs * SL/Kh)
|
increased T cell derived lymphoma incidence
|
J:21741,
J:41197,
J:33016
|
Tlsm1AKR/JMs/Tlsm1SL/Kh
(involves: AKR/JMs * SL/Kh)
|
increased T cell derived lymphoma incidence
|
J:21741,
J:41197,
J:33016
|
Tlyr1C57BL/6J/Tlyr1C57BL/6J
(involves: C57BL/6J * M. spretus)
|
decreased tumor incidence
|
J:79055
|
Tmeff2tm1Fawa/Tmeff2+
(involves: 129P2/OlaHsd)
|
neoplasm
|
J:187163
|
Tmeff2tm1Fawa/Tmeff2tm1Fawa
(involves: 129P2/OlaHsd)
|
neoplasm
|
J:187163
|
Tmem158tm1Srn/Tmem158tm1Srn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
neoplasm
|
J:121067
|
Tmem219tm1(KOMP)Vlcg/Tmem219tm1(KOMP)Vlcg
(B6J.B6N-Tmem219tm1(KOMP)Vlcg)
|
decreased metastatic potential
|
J:236976
|
Tmigd1em1Gpt/Tmigd1em1Gpt
(C57BL/6NGpt-Tmigd1em1Gpt/Gpt)
|
increased intestinal adenoma incidence
|
J:300338
|
Tmprss2tm1.1(ERG)Sho/Tmprss2tm1.1(ERG)Sho
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:212219
|
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:212219
|
Tmprss11dtm1Bug/Tmprss11dtm1Bug
(involves: 129S1/Sv * 129X1/SvJ * NIH Black Swiss)
|
increased lymphoma incidence
|
J:175364
|
Tnftm1Gkl/Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6)
|
decreased incidence of tumors by chemical induction
|
J:56068
|
Tnftm1Gkl/Tnftm1Gkl
(C.129S-Tnftm1Gkl)
|
decreased incidence of tumors by chemical induction
|
J:56068
|
Tnfaip8l1em1Huwa/Tnfaip8l1em1Huwa
(C57BL/6-Tnfaip8l1em1Huwa)
|
neoplasm
|
J:342074
|
Tnfaip8l3tm1a(KOMP)Mbp/Tnfaip8l3tm1a(KOMP)Mbp
(C57BL/6N-Atm1Brd Tnfaip8l3tm1a(KOMP)Mbp/MbpMmucd)
|
decreased incidence of tumors by chemical induction
|
J:217197
|
| decreased tumor latency
|
J:217197
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx)
|
decreased tumor incidence
|
J:66448
|
| increased skin papilloma incidence
|
J:89088
|
Tnfrsf1atm4.1(TNFRSF1A)Gkl/Tnfrsf1a+
(involves: 129P2/OlaHsd)
|
tumor regression
|
J:210950
|
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased skin papilloma incidence
|
J:89088
|
Tnfrsf10btm1.1Cjk/Tnfrsf10btm1.1Cjk
(involves: 129P2/OlaHsd * BALB/c * NIH/OlaHsd)
|
increased metastatic potential
|
J:130806
|
Tnfrsf13btm1Vmd/Tnfrsf13btm1Vmd
(involves: C57BL/6)
|
increased leukemia incidence
|
J:82331
|
Tnfsf10tm1Mjs/Tnfsf10tm1Mjs
(C.129-Tnfsf10tm1Mjs)
|
increased incidence of induced tumors
|
J:73948
|
| increased incidence of tumors by chemical induction
|
J:73948
|
Tnfsf10tm1Sdg/Tnfsf10tm1Sdg
(C.129-Tnfsf10tm1Sdg)
|
increased tumor growth/size
|
J:79085
|
Tnfsf10tm1Sdg/Tnfsf10tm1Sdg
(B6.129-Tnfsf10tm1Sdg)
|
neoplasm
|
J:79085
|
Tniktm1Teya/Tniktm1Teya
(involves: C57BL/6J)
|
decreased incidence of tumors by chemical induction
|
J:241611
|
Tnk1tm1Sksuf/Tnk1+
(involves: 129X1/SvJ * C57BL/6)
|
increased carcinoma incidence
|
J:140639
|
| increased hepatocellular carcinoma incidence
|
J:140639
|
| increased hepatoma incidence
|
J:140639
|
| increased intestinal adenocarcinoma incidence
|
J:140639
|
| increased intestinal adenoma incidence
|
J:140639
|
| increased lung adenoma incidence
|
J:140639
|
| increased lymphoma incidence
|
J:140639
|
| increased malignant tumor incidence
|
J:140639
|
| increased pancreas tumor incidence
|
J:140639
|
| increased skin tumor incidence
|
J:140639
|
| increased trichoepithelioma incidence
|
J:140639
|
| increased tumor incidence
|
J:140639
|
Tnk1tm1Sksuf/Tnk1tm1Sksuf
(involves: 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:140639
|
| increased gastrointestinal tumor incidence
|
J:140639
|
| increased hemangiosarcoma incidence
|
J:140639
|
| increased hepatocellular carcinoma incidence
|
J:140639
|
| increased lung adenocarcinoma incidence
|
J:140639
|
| increased lymphoma incidence
|
J:140639
|
| increased skin tumor incidence
|
J:140639
|
| increased trichoepithelioma incidence
|
J:140639
|
| increased tumor incidence
|
J:140639
|
Tnxbtm1Kmat/Tnxbtm1Kmat
(involves: C57BL/6 * CBA)
|
abnormal tumor susceptibility
|
J:92581
|
Tom1l2Gt(XG909)Byg/Tom1l2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung tumor incidence
|
J:133892
|
| increased prostate gland tumor incidence
|
J:133892
|
| increased skin tumor incidence
|
J:133892
|
| increased tumor incidence
|
J:133892
|
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased adenoma incidence
|
J:133892
|
| increased basal cell carcinoma incidence
|
J:133892
|
| increased lung tumor incidence
|
J:133892
|
| increased mammary gland tumor incidence
|
J:133892
|
| increased metastatic potential
|
J:133892
|
| increased ovary tumor incidence
|
J:133892
|
| increased prostate gland tumor incidence
|
J:133892
|
| increased skin tumor incidence
|
J:133892
|
| increased tumor incidence
|
J:133892
|
ToporsGt(DTM034)Byg/Topors+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased tumor incidence
|
J:325276
|
ToporsGt(DTM034)Byg/ToporsGt(DTM034)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
neoplasm
|
J:325276
|
Tpx2Gt(D028B03)Wrst/Tpx2+
(involves: 129S2/SvPas * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184948
|
| increased intestinal adenoma incidence
|
J:184948
|
| increased lung adenocarcinoma incidence
|
J:184948
|
| increased lung adenoma incidence
|
J:184948
|
| increased lymphoma incidence
|
J:184948
|
| increased metastatic potential
|
J:184948
|
| increased stomach tumor incidence
|
J:184948
|
Trap1Gt(E150H04)Wrst/Trap1Gt(E150H04)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased tumor incidence
|
J:226880
|
Trappc9tm1a(EUCOMM)Wtsi/Trappc9tm1a(EUCOMM)Wtsi
(C57BL/6N-Trappc9tm1a(EUCOMM)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Trem1tm1.1Ahoru/Trem1tm1.1Ahoru
(C57BL/6-Trem1tm1.1Ahoru)
|
decreased incidence of tumors by chemical induction
|
J:191035
|
| increased tumor latency
|
J:191035
|
Trex2tm1.2Coso/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
increased incidence of tumors by chemical induction
|
J:151766
|
Trex2tm1.2Coso/Trex2tm1.2Coso
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
increased incidence of tumors by chemical induction
|
J:151766
|
Trim11em1Bcgen/Trim11+
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
decreased tumor growth/size
|
J:329445
|
Trim16tm1Gmma/Trim16+
Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * DBA/2)
|
decreased tumor latency
|
J:290272
|
| increased incidence of tumors by chemical induction
|
J:290272
|
| increased metastatic potential
|
J:290272
|
Trim16tm1Gmma/Trim16tm1Gmma
Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * DBA/2)
|
increased tumor growth/size
|
J:290272
|
| neoplasm
|
J:290272
|
Trim24tm1.1Los/Trim24tm1.1Los
(involves: 129/Sv * C57BL/6 * SJL)
|
increased hepatocellular carcinoma incidence
|
J:130210
|
| increased liver adenoma incidence
|
J:130210
|
| increased liver tumor incidence
|
J:130210
|
Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi
(B6.129P2-Trim27Gt(XP0484)Wtsi)
|
decreased incidence of tumors by chemical induction
|
J:189317
|
| decreased tumor growth/size
|
J:189317
|
Trim37Gt(RRO307)Byg/Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg)
|
increased carcinoma incidence
|
J:232482
|
| increased lymphoma incidence
|
J:232482
|
| increased medulloblastoma incidence
|
J:232482
|
| increased ovary tumor incidence
|
J:232482
|
| increased tumor incidence
|
J:232482
|
Trim62tm1Akil/Trim62+
(involves: 129S/SvEv * C57BL/6)
|
increased adenocarcinoma incidence
|
J:204336
|
| increased hepatocellular carcinoma incidence
|
J:204336
|
| increased liver adenocarcinoma incidence
|
J:204336
|
| increased lung adenocarcinoma incidence
|
J:204336
|
| increased lymphoma incidence
|
J:204336
|
| increased mammary adenocarcinoma incidence
|
J:204336
|
| increased sarcoma incidence
|
J:204336
|
| increased spindle cell carcinoma incidence
|
J:204336
|
| increased tumor incidence
|
J:204336
|
Trim62tm1Akil/Trim62tm1Akil
(involves: 129S/SvEv * C57BL/6)
|
increased adenocarcinoma incidence
|
J:204336
|
| increased liver adenocarcinoma incidence
|
J:204336
|
| increased lung adenocarcinoma incidence
|
J:204336
|
| increased lymphoma incidence
|
J:204336
|
| increased mammary adenocarcinoma incidence
|
J:204336
|
| increased sarcoma incidence
|
J:204336
|
| increased squamous cell carcinoma incidence
|
J:204336
|
| increased tumor incidence
|
J:204336
|
Trp53Bbl/Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
|
increased brain tumor incidence
|
J:104190
|
| increased fibrosarcoma incidence
|
J:104190
|
| increased hemangiosarcoma incidence
|
J:104190
|
| increased lymphoma incidence
|
J:104190
|
| increased osteosarcoma incidence
|
J:104190
|
| increased T cell derived lymphoma incidence
|
J:104190
|
| increased teratoma incidence
|
J:104190
|
| increased tumor incidence
|
J:104190
|
Trp53Bbl/Trp53Bbl
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
|
increased B cell derived lymphoma incidence
|
J:104190
|
| increased leukemia incidence
|
J:104190
|
Trp53bhy/Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu)
|
increased brain tumor incidence
|
J:104190
|
| increased fibrosarcoma incidence
|
J:104190
|
| increased hemangiosarcoma incidence
|
J:104190
|
| increased lymphoma incidence
|
J:104190
|
| increased osteosarcoma incidence
|
J:104190
|
| increased T cell derived lymphoma incidence
|
J:104190
|
| increased teratocarcinoma incidence
|
J:104190
|
| increased tumor incidence
|
J:104190
|
Trp53bhy/Trp53bhy
(C57BL/6JSfdAnu-Trp53bhy/Anu)
|
increased leukemia incidence
|
J:104190
|
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173271
|
| increased fibrosarcoma incidence
|
J:169434
|
| increased follicular lymphoma incidence
|
J:169434
|
| increased histiocytic sarcoma incidence
|
J:173271
|
| increased incidence of tumors by ionizing radiation induction
|
J:169434
|
| increased osteosarcoma incidence
|
J:173271
|
| increased T cell derived lymphoma incidence
|
J:173271
|
Trp53tm1.1Brn/Trp53+
Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N * SKH1)
|
increased skin tumor incidence
|
J:121734
|
Trp53tm1.1Brn/Trp53tm1.1Brn
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
decreased tumor latency
|
J:73028
|
| increased tumor incidence
|
J:73028
|
Trp53tm1.1Brn/Trp53tm1.1Brn
Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N * SKH1)
|
increased skin tumor incidence
|
J:121734
|
Trp53tm1.1Brn/Trp53tm3Tyj
Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB/N * SKH1)
|
increased lymphoma incidence
|
J:121734
|
| increased skin tumor incidence
|
J:121734
|
Trp53tm1.1Dgj/Trp53tm1.1Dgj
(involves: SKH)
|
neoplasm
|
J:162466
|
Trp53tm1.1Hwan/Trp53+
(involves: C57BL/6 * C57BL/6N)
|
increased incidence of tumors by chemical induction
|
J:265556
|
Trp53tm1.1Hwan/Trp53tm1.1Hwan
(involves: C57BL/6 * C57BL/6N)
|
increased incidence of tumors by chemical induction
|
J:265556
|
Trp53tm1.1Rfo/Trp53+
(B6.129P2-Trp53tm1.1Rfo)
|
neoplasm
|
J:186114
|
Trp53tm1.1Thst/Trp53+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased tumor incidence
|
J:198482
|
Trp53tm1.1Thst/Trp53+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL)
|
increased lymphoma incidence
|
J:198482
|
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased carcinoma incidence
|
J:198482
|
| increased hemangiosarcoma incidence
|
J:198482
|
| increased leiomyosarcoma incidence
|
J:198482
|
| increased T cell derived lymphoma incidence
|
J:198482
|
| increased tumor incidence
|
J:198482
|
Trp53tm1.1Umol/Trp53tm1.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
decreased tumor latency
|
J:228632
|
| increased B cell derived lymphoma incidence
|
J:228632
|
| increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1.1Wgu/Trp53tm1.1Wgu
(involves: 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:186159
|
Trp53tm1.1Xlu/Trp53tm1.1Xlu
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
neoplasm
|
J:166152
|
Trp53tm1.1Xlu/Trp53tm1.1Xlu
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * FVB/N)
|
increased incidence of tumors by ionizing radiation induction
|
J:166152
|
| increased liver tumor incidence
|
J:166152
|
| increased lymphoma incidence
|
J:166152
|
| neoplasm
|
J:166152
|
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173271
|
| increased hamartoma incidence
|
J:173271
|
| increased hibernoma incidence
|
J:173271
|
| increased intestinal adenoma incidence
|
J:173271
|
| increased lung adenoma incidence
|
J:173271
|
| increased osteosarcoma incidence
|
J:173271
|
| increased ovary tumor incidence
|
J:173271
|
| increased tumor incidence
|
J:173271
|
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173271
|
| increased hibernoma incidence
|
J:173271
|
| increased histiocytic sarcoma incidence
|
J:173271
|
| increased intestinal adenoma incidence
|
J:173271
|
| increased lung adenoma incidence
|
J:173271
|
| increased osteosarcoma incidence
|
J:173271
|
| increased ovary tumor incidence
|
J:173271
|
| increased T cell derived lymphoma incidence
|
J:173271
|
| increased tumor incidence
|
J:173271
|
Trp53tm1Adv/Trp53+
(involves: 129S4/SvJae * C57BL/6)
|
increased skin papilloma incidence
|
J:93328
|
| increased skin tumor incidence
|
J:93328
|
Trp53tm1Adv/Trp53tm1Adv
(involves: 129S4/SvJae * C57BL/6)
|
increased skin papilloma incidence
|
J:93328
|
| increased skin tumor incidence
|
J:93328
|
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:73757
|
| increased lymphoma incidence
|
J:73757
|
| increased osteosarcoma incidence
|
J:73757
|
| increased sarcoma incidence
|
J:73757
|
| increased tumor incidence
|
J:1999,
J:73757
|
Trp53tm1Brd/Trp53+
Trp53bp2tm1Cdlo/Trp53bp2+
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased tumor incidence
|
J:146764
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:51661
|
| increased lymphoma incidence
|
J:51661
|
| increased osteosarcoma incidence
|
J:51661
|
| increased rhabdomyosarcoma incidence
|
J:51661
|
| increased sarcoma incidence
|
J:51661
|
| increased tumor incidence
|
J:186159,
J:108183
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:1999
|
| increased lymphoma incidence
|
J:1999
|
| increased osteosarcoma incidence
|
J:1999
|
| increased sarcoma incidence
|
J:1999,
J:126497
|
| increased T cell derived lymphoma incidence
|
J:126497
|
| increased tumor incidence
|
J:1999,
J:108183
|
Trp53tm1Brd/Trp53tm1Brd
(NIHOla.129S7-Trp53tm1Brd)
|
decreased incidence of tumors by chemical induction
|
J:93298
|
| decreased tumor growth/size
|
J:93298
|
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:157041
|
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:109585
|
| increased tumor incidence
|
J:109585
|
Trp53tm1Brd/Trp53tm1Brd
Wrntm1Led/Wrntm1Led
(either: (involves: 129S/SvEv) or (involves: 129S/SvEv * NIH Black Swiss))
|
decreased tumor latency
|
J:68488
|
| increased tumor incidence
|
J:68488
|
Trp53tm1Brd/Trp53tm1Brd
Xrcc4tm2.1Fwa/Xrcc4tm2Fwa
Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:109585
|
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased lymphoma incidence
|
J:141515
|
| increased medulloblastoma incidence
|
J:141515
|
Trp53tm1Brd/Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased sarcoma incidence
|
J:73757
|
| increased T cell derived lymphoma incidence
|
J:73757
|
| increased tumor incidence
|
J:73757
|
Trp53tm1Brn/Trp53+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased tumor latency
|
J:297725
|
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
| increased mammary gland tumor incidence
|
J:170898
|
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Trp53tm1Brn/Trp53tm1.1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
| neoplasm
|
J:212578
|
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased tumor latency
|
J:297725
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Cdh16-cre)91Igr/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N * ICR)
|
increased endometrial carcinoma incidence
|
J:214850,
J:215149
|
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased astrocytoma incidence
|
J:140704
|
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/N * ICR)
|
increased skin squamous cell carcinoma incidence
|
J:216813
|
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
| increased mammary gland tumor incidence
|
J:126551
|
| increased pilomatricoma incidence
|
J:116152
|
| increased skin tumor incidence
|
J:116152,
J:126551
|
| increased squamous cell carcinoma incidence
|
J:116152
|
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn)
|
increased carcinoma incidence
|
J:165292
|
| increased lung tumor incidence
|
J:165292
|
| increased mammary gland tumor incidence
|
J:165292
|
| increased squamous cell carcinoma incidence
|
J:165292
|
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
abnormal tumor morphology
|
J:162126
|
| increased lymphoma incidence
|
J:162126
|
| increased mammary gland tumor incidence
|
J:162126
|
| increased tumor incidence
|
J:162126
|
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
| increased mammary gland tumor incidence
|
J:224955
|
| increased myoepithelioma incidence
|
J:224955
|
| increased spindle cell carcinoma incidence
|
J:224955
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased brain tumor incidence
|
J:237990
|
| increased medulloblastoma incidence
|
J:237990
|
| increased tumor incidence
|
J:237990
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
increased metastatic potential
|
J:199542
|
| increased osteosarcoma incidence
|
J:199542
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Tg(Tyr-cre/ERT2)13Bos Trp53tm1Brn Tg(Tyr-NRAS*Q61K)1Bee)
|
increased cutaneous melanoma incidence
|
J:222847
|
| increased incidence of tumors by UV-induction
|
J:222847
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Upk2-cre)1Rkl/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
neoplasm
|
J:173505
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
| increased mammary gland tumor incidence
|
J:171765
|
Trp53tm1Brn/Trp53tm1Brn
Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased mesothelioma incidence
|
J:212578
|
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:102702
|
Trp53tm1Elee/Trp53+
Tg(MMTV-cre)AElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased tumor latency
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee
Tg(GFAP-cre)25Mes/0
(involves: 129S4/SvJae * FVB/N)
|
increased glioma incidence
|
J:149662
|
| increased medulloblastoma incidence
|
J:149662
|
| increased sarcoma incidence
|
J:149662
|
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)AElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased lymphoma incidence
|
J:90247
|
| increased mammary adenocarcinoma incidence
|
J:90247
|
| increased mammary gland tumor incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)BElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
| increased tumor incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee
Tg(Wap-rtTA-cre)10Whl/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
| increased tumor incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Tyj
Tg(GFAP-cre)25Mes/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased glioma incidence
|
J:149662
|
| increased medulloblastoma incidence
|
J:149662
|
| increased sarcoma incidence
|
J:149662
|
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:99305
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:61683
|
| increased fibrosarcoma incidence
|
J:61683
|
| increased hemangiosarcoma incidence
|
J:61683
|
| increased lymphoma incidence
|
J:61683
|
| increased metastatic potential
|
J:61683
|
| increased osteosarcoma incidence
|
J:61683
|
| increased sarcoma incidence
|
J:61683
|
| increased squamous cell carcinoma incidence
|
J:61683
|
| increased tumor incidence
|
J:61683
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:129627
|
| increased lymphoma incidence
|
J:129627
|
| increased osteosarcoma incidence
|
J:129627
|
| increased sarcoma incidence
|
J:129627
|
| increased squamous cell carcinoma incidence
|
J:129627
|
| increased tumor incidence
|
J:129627
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased incidence of tumors by ionizing radiation induction
|
J:172038
|
Trp53tm1Glo/Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:61683
|
| increased tumor incidence
|
J:61683
|
Trp53tm1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal tumor morphology
|
J:171821
|
| increased adenocarcinoma incidence
|
J:171821
|
| increased lipoma incidence
|
J:171821
|
| increased lymphoma incidence
|
J:171821
|
| increased sarcoma incidence
|
J:171821
|
| increased spindle cell carcinoma incidence
|
J:171821
|
| increased T cell derived lymphoma incidence
|
J:171821
|
Trp53tm1Glo/Trp53tm4Glo
Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
|
abnormal tumor pathology
|
J:171821
|
| tumor regression
|
J:171821
|
Trp53tm1Holl/Trp53tm1Holl
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:68918
|
Trp53tm1Holl/Trp53tm7.1Xu
(involves: 129P2/OlaHsd)
|
increased tumor incidence
|
J:160414
|
Trp53tm1Ldo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased tumor incidence
|
J:73757
|
| increased lung adenoma incidence
|
J:73757
|
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:36762
|
| increased tumor incidence
|
J:36762
|
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
increased T cell derived lymphoma incidence
|
J:233347
|
Trp53tm1Snj/Trp53tm1Snj
(involves: C57BL/6)
|
decreased tumor incidence
|
J:87687
|
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
neoplasm
|
J:100683
|
Trp53tm1Thst/Trp53+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased tumor incidence
|
J:198482
|
Trp53tm1Thst/Trp53+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * SJL)
|
increased lymphoma incidence
|
J:198482
|
Trp53tm1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased tumor incidence
|
J:198482
|
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
|
increased carcinoma incidence
|
J:198482
|
| increased T cell derived lymphoma incidence
|
J:198482
|
| increased teratoma incidence
|
J:198482
|
| increased tumor incidence
|
J:198482
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor morphology
|
J:17728
|
| increased adenocarcinoma incidence
|
J:72391
|
| increased adenoma incidence
|
J:72391
|
| increased carcinoma incidence
|
J:72391,
J:95318
|
| increased fibrosarcoma incidence
|
J:17728
|
| increased hemangiosarcoma incidence
|
J:72391,
J:17728
|
| increased histiocytic sarcoma incidence
|
J:72391
|
| increased leiomyosarcoma incidence
|
J:17728
|
| increased leukemia incidence
|
J:135509
|
| increased lung adenocarcinoma incidence
|
J:72391
|
| increased lymphoma incidence
|
J:72391,
J:17728
|
| increased mammary adenocarcinoma incidence
|
J:72391
|
| increased osteosarcoma incidence
|
J:72391,
J:17728
|
| increased pancreas tumor incidence
|
J:72391
|
| increased rhabdomyosarcoma incidence
|
J:17728
|
| increased sarcoma incidence
|
J:72391,
J:17728,
J:95318
|
| increased squamous cell carcinoma incidence
|
J:72391
|
| increased tumor incidence
|
J:17728,
J:135509
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
increased carcinoma incidence
|
J:95316
|
| increased incidence of tumors by chemical induction
|
J:170769
|
| increased tumor incidence
|
J:95316
|
| increased urinary system tumor incidence
|
J:170769
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal tumor incidence
|
J:108701
|
| abnormal tumor latency
|
J:108701
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/cJ * C57BL/6)
|
abnormal tumor incidence
|
J:191827
|
Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
neoplasm
|
J:243104
|
Trp53tm1Tyj/Trp53+
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J)
|
increased lymphoma incidence
|
J:108701
|
| increased tumor incidence
|
J:108701
|
Trp53tm1Tyj/Trp53+
Trp63tm1Fmc/Trp63+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:98958
|
| increased mammary adenocarcinoma incidence
|
J:98958
|
| increased metastatic potential
|
J:98958
|
| increased osteosarcoma incidence
|
J:98958
|
| increased rhabdomyosarcoma incidence
|
J:98958
|
| increased squamous cell carcinoma incidence
|
J:98958
|
| increased T cell derived lymphoma incidence
|
J:98958
|
| increased tumor incidence
|
J:98958
|
| increased urinary bladder transitional cell carcinoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+
Trp73tm1Fmc/Trp73+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:98958
|
| increased lung adenocarcinoma incidence
|
J:98958
|
| increased metastatic potential
|
J:98958
|
| increased pancreatic acinar cell carcinoma incidence
|
J:98958
|
| increased sarcoma incidence
|
J:98958
|
| increased T cell derived lymphoma incidence
|
J:98958
|
| increased tumor incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: 129S2/SvPas * BALB/cJ * C57BL/6)
|
increased incidence of tumors by ionizing radiation induction
|
J:191827
|
| increased lymphoma incidence
|
J:191827
|
| increased tumor growth/size
|
J:191827
|
Trp53tm1Tyj/Trp53+
Xpatm1Hvs/Xpatm1Hvs
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased incidence of tumors by chemical induction
|
J:170769
|
| increased urinary system tumor incidence
|
J:170769
|
Trp53tm1Tyj/Trp53+
Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
decreased tumor latency
|
J:228632
|
| increased B cell derived lymphoma incidence
|
J:228632
|
| increased carcinoma incidence
|
J:228632
|
| increased leukemia incidence
|
J:228632
|
| increased lymphoma incidence
|
J:228632
|
| increased reproductive system tumor incidence
|
J:228632
|
| increased sarcoma incidence
|
J:228632
|
| increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased carcinoma incidence
|
J:72391
|
| increased fibrosarcoma incidence
|
J:72391
|
| increased hemangioma incidence
|
J:72391
|
| increased hemangiosarcoma incidence
|
J:72391,
J:17728
|
| increased lymphoma incidence
|
J:72391,
J:17728,
J:95318
|
| increased osteosarcoma incidence
|
J:72391,
J:17728
|
| increased rhabdomyosarcoma incidence
|
J:17728
|
| increased sarcoma incidence
|
J:72391,
J:17728,
J:95318
|
| increased squamous cell carcinoma incidence
|
J:72391
|
| increased T cell derived lymphoma incidence
|
J:87501,
J:17728
|
| increased teratoma incidence
|
J:17728
|
| increased tumor incidence
|
J:72391,
J:17728
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased hemangiosarcoma incidence
|
J:95316
|
| increased lymphoma incidence
|
J:221224
|
| increased medulloblastoma incidence
|
J:102702
|
| increased T cell derived lymphoma incidence
|
J:251434,
J:221224,
J:88120,
J:95316
|
| increased tumor incidence
|
J:95316
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
decreased tumor incidence
|
J:104347
|
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased lymphoma incidence
|
J:102483
|
| increased teratoma incidence
|
J:102483
|
| increased testicular teratoma incidence
|
J:102483
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
neoplasm
|
J:243104
|
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Ly6e-MALT1)#Isg/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:185590
|
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Prrx1-FUS/DDIT3)1Mete/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased liposarcoma incidence
|
J:184491
|
| increased sarcoma incidence
|
J:184491
|
Trp53tm1Tyj/Trp53tm1Tyj
Vrk1Gt(RRR178)Byg/Vrk1Gt(RRR178)Byg
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased tumor incidence
|
J:171525
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:111068
|
| increased medulloblastoma incidence
|
J:111068
|
| increased sarcoma incidence
|
J:111068
|
| increased skin tumor incidence
|
J:111068
|
| increased T cell derived lymphoma incidence
|
J:111068
|
| increased tumor incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc4tm1Fwa/Xrcc4tm1Fwa
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased B cell derived lymphoma incidence
|
J:61973
|
Trp53tm1Tyj/Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased carcinoma incidence
|
J:95316
|
| increased hemangiosarcoma incidence
|
J:95316
|
| increased T cell derived lymphoma incidence
|
J:95316
|
| increased tumor incidence
|
J:95316
|
Trp53tm1Tyj/Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:228632
|
| increased carcinoma incidence
|
J:228632
|
| increased lymphoma incidence
|
J:228632
|
| increased reproductive system tumor incidence
|
J:228632
|
| increased sarcoma incidence
|
J:228632
|
| increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased carcinoma incidence
|
J:95316
|
| increased T cell derived lymphoma incidence
|
J:95316
|
| increased tumor incidence
|
J:95316
|
Trp53tm1Wahl/Trp53tm1Wahl
(involves: C57BL/6)
|
increased tumor incidence
|
J:108183
|
Trp53tm1Xu/Trp53tm1Xu
(involves: 129S4/SvJae)
|
neoplasm
|
J:86185
|
Trp53tm1Yjc/Trp53tm1Yjc
(B6.129S1-Trp53tm1Yjc)
|
increased sarcoma incidence
|
J:195018
|
| increased splenic marginal zone lymphoma incidence
|
J:195018
|
Trp53tm2.1Dgj/Trp53tm2.1Dgj
(involves: SKH)
|
neoplasm
|
J:162466
|
Trp53tm2.1Kasa/Trp53tm2.1Kasa
(involves: 129P2/OlaHsd * C57BL/6)
|
neoplasm
|
J:186335
|
Trp53tm2.1Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
abnormal tumor incidence
|
J:282255
|
| increased B cell derived lymphoma incidence
|
J:282255
|
| increased carcinoma incidence
|
J:282255
|
| increased sarcoma incidence
|
J:282255
|
| increased T cell derived lymphoma incidence
|
J:282255
|
| increased testis tumor incidence
|
J:282255
|
Trp53tm2.1Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased metastatic potential
|
J:95316
|
Trp53tm2.1Umol/Trp53tm2.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:228632
|
| increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm2.1Wgu/Trp53tm2.1Wgu
(involves: 129S6/SvEvTac * C57BL/6)
|
neoplasm
|
J:186159
|
Trp53tm2Brd/Trp53tm2Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased tumor incidence
|
J:80303
|
Trp53tm2Glo/Trp53tm2Glo
(involves: 129/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:87501
|
| increased sarcoma incidence
|
J:87501
|
| increased tumor incidence
|
J:87501
|
Trp53tm2Mok/Trp53tm2Mok
(involves: 129S/SvEv * C57BL/6)
|
increased tumor incidence
|
J:79629
|
Trp53tm2Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
abnormal tumor incidence
|
J:282255
|
| increased B cell derived lymphoma incidence
|
J:282255
|
| increased carcinoma incidence
|
J:282255
|
| increased sarcoma incidence
|
J:282255
|
| increased T cell derived lymphoma incidence
|
J:282255
|
| increased testis tumor incidence
|
J:282255
|
Trp53tm2Xu/Trp53tm2Xu
(involves: 129S6/SvEvTac)
|
increased tumor incidence
|
J:109354
|
| increased tumor latency
|
J:109354
|
Trp53tm2Xu/Trp53tm2Xu
Xrcc4tm1Fwa/Xrcc4tm1Fwa
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
abnormal tumor incidence
|
J:109354
|
Trp53tm3.1Glo/Trp53+
(B6.129S7-Trp53tm3.1Glo)
|
increased B cell derived lymphoma incidence
|
J:317504
|
| increased carcinoma incidence
|
J:317504,
J:95318
|
| increased lymphoma incidence
|
J:317504,
J:95318
|
| increased metastatic potential
|
J:95318
|
| increased osteosarcoma incidence
|
J:317504
|
| increased sarcoma incidence
|
J:317504,
J:95318
|
| increased T cell derived lymphoma incidence
|
J:317504
|
Trp53tm3.1Glo/Trp53tm3.1Glo
(B6.129S7-Trp53tm3.1Glo)
|
increased lymphoma incidence
|
J:95318
|
| increased sarcoma incidence
|
J:95318
|
Trp53tm3.1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal tumor morphology
|
J:171821
|
| increased adenocarcinoma incidence
|
J:171821
|
| increased lymphoma incidence
|
J:171821
|
| increased sarcoma incidence
|
J:171821
|
| increased spindle cell carcinoma incidence
|
J:171821
|
Trp53tm3.1Glo/Trp53tm4Glo
Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
|
abnormal tumor pathology
|
J:171821
|
| decreased tumor growth/size
|
J:171821
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased B cell derived lymphoma incidence
|
J:95316
|
| increased carcinoma incidence
|
J:95316
|
| increased hepatocellular carcinoma incidence
|
J:95316
|
| increased lung adenocarcinoma incidence
|
J:95316
|
| increased metastatic potential
|
J:95316
|
| increased squamous cell carcinoma incidence
|
J:95316
|
| increased tumor incidence
|
J:95316
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * SKH1)
|
increased mammary adenocarcinoma incidence
|
J:121734
|
| increased skin tumor incidence
|
J:121734
|
Trp53tm3Tyj/Trp53+
Tg(KRT14-cre)8Brn/?
(involves: 129S4/SvJae * FVB/N * SKH1)
|
increased hemangioma incidence
|
J:121734
|
| increased lymphoma incidence
|
J:121734
|
| increased skin tumor incidence
|
J:121734
|
Trp53tm3Tyj/Trp53+
Tg(Wap-cre)11738Mam/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased incidence of tumors by chemical induction
|
J:101617
|
| increased lung tumor incidence
|
J:101617
|
| increased lymphoma incidence
|
J:101617
|
| increased mammary adenocarcinoma incidence
|
J:101617
|
| increased mammary gland tumor incidence
|
J:101617
|
| increased sarcoma incidence
|
J:101617
|
Trp53tm3Wahl/Trp53tm3Wahl
(involves: 129S4/SvJae)
|
increased tumor latency
|
J:108183
|
Trp53tm4.1Glo/Trp53tm4.1Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
neoplasm
|
J:171821
|
Trp53tm4Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:171821
|
| increased lymphoma incidence
|
J:171821
|
| increased sarcoma incidence
|
J:171821
|
| increased spindle cell carcinoma incidence
|
J:171821
|
| increased T cell derived lymphoma incidence
|
J:171821
|
Trp53tm4Tyj/Trp53tm4Tyj
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:92917
|
| increased sarcoma incidence
|
J:92917
|
Trp53tm4Xu/Trp53+
(Not Specified)
|
neoplasm
|
J:126497
|
Trp53tm4Xu/Trp53tm4Xu
(Not Specified)
|
abnormal tumor incidence
|
J:126497
|
| increased lymphoma incidence
|
J:126497
|
| increased sarcoma incidence
|
J:126497
|
| increased T cell derived lymphoma incidence
|
J:126497
|
| increased tumor incidence
|
J:126497
|
Trp53tm6Xu/Trp53tm6Xu
Tg(Lck-cre)1Cwi/0
(involves: 129S4/SvJae)
|
increased lymphoma incidence
|
J:157041
|
| increased metastatic potential
|
J:157041
|
| increased T cell derived lymphoma incidence
|
J:157041
|
Trp53tm7.1Xu/Trp53tm7.1Xu
(Not Specified)
|
increased lymphoma incidence
|
J:160414
|
| increased sarcoma incidence
|
J:160414
|
| increased tumor incidence
|
J:160414
|
Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * C57BL/6)
|
increased lymphoma incidence
|
J:82512
|
| increased T cell derived lymphoma incidence
|
J:82512
|
Trp53bp2tm1Cdlo/Trp53bp2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by ionizing radiation induction
|
J:146764
|
| increased tumor incidence
|
J:146764
|
Trp53bp2tm1Cdlo/Trp53bp2+
Tg(EmuSR-tTa)83Bop/0
Tg(tetO-MYC)36aBop/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:146764
|
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:108701
|
| increased incidence of tumors by ionizing radiation induction
|
J:108701
|
| increased lymphoma incidence
|
J:108701
|
| increased rhabdomyosarcoma incidence
|
J:108701
|
| increased squamous cell carcinoma incidence
|
J:108701
|
| increased T cell derived lymphoma incidence
|
J:108701
|
| increased tumor incidence
|
J:108701
|
Trp53inp1tm1Acar/Trp53inp1tm1Acar
(involves: 129/Sv * C57BL/6)
|
increased colon adenoma incidence
|
J:118867
|
| increased incidence of tumors by chemical induction
|
J:118867
|
| neoplasm
|
J:118867
|
Trp63tm1Fmc/Trp63+
(involves: 129S4/SvJae * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:98958
|
| increased lung adenoma incidence
|
J:98958
|
| increased malignant tumor incidence
|
J:98958
|
| increased squamous cell carcinoma incidence
|
J:98958
|
| increased tumor incidence
|
J:98958
|
Trp63tm1Fmc/Trp63+
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased carcinoma incidence
|
J:98958
|
| increased chronic myelocytic leukemia incidence
|
J:98958
|
| increased hemangiosarcoma incidence
|
J:98958
|
| increased lung adenocarcinoma incidence
|
J:98958
|
| increased lung adenoma incidence
|
J:98958
|
| increased mammary adenocarcinoma incidence
|
J:98958
|
| increased metastatic potential
|
J:98958
|
| increased salivary gland adenoma incidence
|
J:98958
|
| increased squamous cell carcinoma incidence
|
J:98958
|
| increased T cell derived lymphoma incidence
|
J:98958
|
| increased tumor incidence
|
J:98958
|
Trp63tm2.1Aam/Trp63tm2.1Aam
(Not Specified)
|
neoplasm
|
J:158291
|
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:98958
|
| increased lung adenocarcinoma incidence
|
J:98958
|
| increased lung adenoma incidence
|
J:98958
|
| increased malignant tumor incidence
|
J:98958
|
| increased T cell derived lymphoma incidence
|
J:98958
|
| increased tumor incidence
|
J:98958
|
Trp73tm1Fmc/Trp73tm1Fmc
(involves: 129S4/SvJae)
|
neoplasm
|
J:60896
|
Trp73tm1Fmc/Trp73tm1Fmc
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:98958
|
Trp73tm1Mak/Trp73+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:142848
|
| increased hemangiosarcoma incidence
|
J:142848
|
| increased lung adenocarcinoma incidence
|
J:142848
|
| increased lymphoma incidence
|
J:142848
|
| increased T cell derived lymphoma incidence
|
J:142848
|
Trp73tm1Mak/Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:142848
|
| increased incidence of tumors by chemical induction
|
J:142848
|
| increased lung adenocarcinoma incidence
|
J:142848
|
| increased lymphoma incidence
|
J:142848
|
| increased T cell derived lymphoma incidence
|
J:142848
|
Trpv1tm1Jul/Trpv1tm1Jul
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:144978
|
Ts(16C-tel)1Cje/0
(involves: C57BL/6J * Rb(11.16)2H * Rb(16.17)32Lub)
|
increased follicular lymphoma incidence
|
J:174270
|
| increased lymphoma incidence
|
J:174270
|
Ts(1716)65Dn/0
(B6EiC3Sn a/A-Ts(1716)65Dn/J)
|
decreased tumor growth/size
|
J:150286
|
Ts(1716)65Dn/0
(involves: C3H/HeJ * C57BL/6J * DBA/2J)
|
increased follicular lymphoma incidence
|
J:174270
|
| increased lymphoma incidence
|
J:174270
|
| increased malignant tumor incidence
|
J:174270
|
Tsc1tm1.1Djk/Tsc1+
(either: 129S4/SvJae-Tsc1tm1Djk or (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * C57BL/6J))
|
increased hemangiosarcoma incidence
|
J:75243
|
| increased hepatic hemangioma incidence
|
J:75243
|
| increased renal carcinoma incidence
|
J:75243
|
| increased renal cystadenoma incidence
|
J:75243
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C57BL/6JOlaHsd)
|
increased hepatic hemangioma incidence
|
J:99796
|
| increased renal carcinoma incidence
|
J:99796
|
| increased renal cystadenoma incidence
|
J:99796
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * Balb/cOlaHsd * C57BL/6JOlaHsd)
|
increased hepatic hemangioma incidence
|
J:99796
|
| increased renal carcinoma incidence
|
J:99796
|
| increased renal cystadenoma incidence
|
J:99796
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C3H/HeNHsd * C57BL/6JOlaHsd)
|
increased hepatic hemangioma incidence
|
J:99796
|
| increased renal cystadenoma incidence
|
J:99796
|
Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129S4/SvJae)
|
neoplasm
|
J:212578
|
Tsc1tm1Hin/Tsc1+
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal tumor morphology
|
J:70463
|
| increased hemangioma incidence
|
J:70463
|
| increased hepatic hemangioma incidence
|
J:70463
|
| increased incidence of tumors by chemical induction
|
J:70463
|
| increased leiomyosarcoma incidence
|
J:70463
|
| increased renal carcinoma incidence
|
J:70463
|
| increased renal cystadenoma incidence
|
J:70463
|
| increased tumor incidence
|
J:70463
|
| increased uterus leiomyoma incidence
|
J:70463
|
Tsc2tm1.1Kido/Tsc2+
(involves: 129S4/SvJae * C57BL/6)
|
increased kidney tumor incidence
|
J:135811
|
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg
Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung tumor incidence
|
J:221228
|
| increased metastatic potential
|
J:221228
|
| increased uterus leiomyoma incidence
|
J:221228
|
Tsc2tm1.2Mjg/Tsc2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased adenoma incidence
|
J:121748
|
Tsc2tm1Djk/Tsc2+
(either: (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6J))
|
increased extremity angiosarcoma incidence
|
J:57631
|
| increased hepatic hemangioma incidence
|
J:57631
|
| increased lung adenoma incidence
|
J:57631
|
| increased renal carcinoma incidence
|
J:57631
|
| increased renal cystadenoma incidence
|
J:57631
|
| increased tumor incidence
|
J:57631
|
Tsc2tm1Tno/Tsc2+
(involves: 129S4/SvJae * C57BL/6J)
|
increased hepatic hemangioma incidence
|
J:52464
|
| increased renal carcinoma incidence
|
J:52464
|
Tsc2tm2.2Djk/Tsc2+
(involves: 129S4/SvJae * C57BL/6)
|
increased renal cystadenoma incidence
|
J:149326
|
Tsg101tm1.1Kuw/Tsg101+
(Not Specified)
|
neoplasm
|
J:80891
|
Tsg101tm1Kuw/Tsg101tm1Kuw
Tg(Wap-cre)11738Mam/0
(Not Specified)
|
neoplasm
|
J:80891
|
TsilTg(Myc)12ALvn/Tsil+
(involves: C57BL/6 * SJL/J)
|
increased lymphoma incidence
|
J:33857
|
Tspan3Gt(NPX312)Byg/Tspan3Gt(NPX312)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased leukemia incidence
|
J:231800
|
Tspan33tm1Stsa/Tspan33tm1Stsa
(involves: 129S1/Sv * 129X1/SvJ)
|
increased liver tumor incidence
|
J:143158
|
Tspyl2tm1Sich/Y
(involves: 129S/SvEv)
|
neoplasm
|
J:174549
|
Tspyl2tm1Sich/Tspyl2tm1Sich
(involves: 129S/SvEv)
|
neoplasm
|
J:174549
|
Ttc7fsn/Ttc7fsn
(involves: A/J)
|
increased papilloma incidence
|
J:2777
|
Ttll3tm1a(EUCOMM)Wtsi/Ttll3tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
|
increased incidence of tumors by chemical induction
|
J:216383
|
Tusc2tm1Avi/Tusc2+
(involves: 129S1/Sv * C57BL/6J)
|
abnormal tumor incidence
|
J:119985
|
| increased hemangioma incidence
|
J:119985
|
| increased hemangiosarcoma incidence
|
J:119985
|
| increased leukemia incidence
|
J:119985
|
| increased lymphoma incidence
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
|
abnormal tumor incidence
|
J:119985
|
| increased hemangioma incidence
|
J:119985
|
| increased hemangiosarcoma incidence
|
J:119985
|
| increased lymphoma incidence
|
J:119985
|
| increased squamous cell carcinoma incidence
|
J:119985
|
TxnipHyplip1/Txnip+
(involves: CAST/Ei * HcB19/Dem)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
TxnipHyplip1/TxnipHyplip1
(HcB19/Dem-TxnipHyplip1)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
TxnipHyplip1/TxnipHyplip1
(involves: CAST/Ei * HcB19/Dem)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
Uacatm1Kiy/Uacatm1Kiy
(B6.129P2-Uacatm1Kiy)
|
increased hepatocellular carcinoma incidence
|
J:157049
|
| increased incidence of tumors by chemical induction
|
J:157049
|
Ube2cem1Gpt/Ube2cem1Gpt
(C57BL/6J-Ube2cem1Gpt)
|
neoplasm
|
J:333347
|
Ube2otm1.1(KOMP)Mbp/Ube2o+
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * C57BL/6N * FVB/N)
|
decreased tumor growth/size
|
J:239679
|
| increased tumor latency
|
J:239679
|
Ube2otm1.1(KOMP)Mbp/Ube2o+
Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6N * FVB/N)
|
decreased tumor growth/size
|
J:239679
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Ptentm1Ppp/Ptentm1Ppp
(involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N)
|
increased lymphoma incidence
|
J:239679
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6N * FVB/N * SJL)
|
increased B cell derived lymphoma incidence
|
J:239679
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * C57BL/6N * FVB/N)
|
decreased tumor growth/size
|
J:239679
|
| increased tumor latency
|
J:239679
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6N * FVB/N)
|
decreased metastatic potential
|
J:239679
|
| decreased tumor growth/size
|
J:239679
|
Uimc1Gt(RRN158)Byg/Uimc1Gt(RRN158)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:188388
|
| increased tumor incidence
|
J:188388
|
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: BALB/cJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:191827
|
| increased incidence of tumors by chemical induction
|
J:191827
|
| increased incidence of tumors by ionizing radiation induction
|
J:191827
|
| increased lymphoma incidence
|
J:191827
|
| increased T cell derived lymphoma incidence
|
J:191827
|
Ungtm1Tld/Ungtm1Tld
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:85353
|
Unktm1a(KOMP)Wtsi/Unktm1a(KOMP)Wtsi
(C57BL/6N-Unktm1a(KOMP)Wtsi/Wtsi)
|
increased hemangioma incidence
|
J:239583
|
Uqcc3em1Hya/Uqcc3em1Hya
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA/2)
|
decreased incidence of induced tumors
|
J:306534
|
Urahplt2/Urahplt2
(C57BL/6-Urahplt2)
|
increased hepatocellular carcinoma incidence
|
J:164423
|
Uri1tm1.1Ndj/Uri1+
Albtm1(cre/ERT2)Mtz/Alb+
(B6.Cg-Albtm1(cre/ERT2)Mtz Uri1tm1.1Ndj)
|
decreased incidence of tumors by chemical induction
|
J:217463
|
Usp4em1Pwa/Usp4em1Pwa
(Not Specified)
|
decreased incidence of tumors by chemical induction
|
J:298778
|
Usp24Gt(XB614)Byg/Usp24+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:303991
|
| increased lipoma incidence
|
J:303991
|
| increased liver tumor incidence
|
J:303991
|
| increased lung tumor incidence
|
J:303991
|
| increased tumor incidence
|
J:303991
|
Usp28Gt(EUCE0037g10)Hmgu/Usp28Gt(EUCE0037g10)Hmgu
(involves: 129P2/OlaHsd * C57BL/6J)
|
neoplasm
|
J:215354
|
Usp44tm1.2Pjgl/Usp44tm1.2Pjgl
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
increased hepatoma incidence
|
J:193965
|
| increased lung adenoma incidence
|
J:193965
|
| increased lymphoma incidence
|
J:193965
|
| increased sarcoma incidence
|
J:193965
|
| increased tumor incidence
|
J:193965
|
Vegfatm2Gne/Vegfatm2Gne
Tg(Csf1r-cre/Esr1*)1Jwp/0
(involves: 129 * C57BL/6 * FVB/N)
|
decreased metastatic potential
|
J:186831
|
Vegfdtm1Hrl/Y
(B6.129S-Vegfdtm1Hrl)
|
decreased metastatic potential
|
J:153734
|
Vhltm1.1Jae/Vhl+
(involves: 129S4/SvJae * BALB/c)
|
increased hepatic hemangioma incidence
|
J:67505
|
Vhltm1.1Lss/Vhl+
(involves: BALB/c)
|
increased hepatic hemangioma incidence
|
J:85513
|
Vhltm1.1Wkr/Vhl+
(involves: 129S4/SvJae * C57BL/6)
|
increased adenocarcinoma incidence
|
J:157369
|
| increased incidence of tumors by chemical induction
|
J:157369
|
| preneoplasia
|
J:157369
|
Vhltm1Lss/Vhltm1.1Lss
(involves: 129X1/SvJ * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:85513
|
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
(involves: 129X1/SvJ * C3H * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:85513
|
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased pancreas adenoma incidence
|
J:148174
|
Vhltm1Mcs/Vhltm1Mcs
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
neoplasm
|
J:130780
|
Vhltm1Wml/Vhl+
(involves: 129S4/SvJae * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:88492
|
Vm/Vm+
(involves: 101/H * C3H/HeH)
|
increased tumor incidence
|
J:90559
|
Wastm1Sbs/Wastm1Sbs
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
|
neoplasm
|
J:48836
|
Wdfy4em1Jkln/Wdfy4em1Jkln
(C57BL/6J-Wdfy4em1Jkln)
|
increased tumor growth/size
|
J:326216
|
Wdr77tm1Zwan/Wdr77+
(involves: 129P2/OlaHsd * C57BL/6J)
|
neoplasm
|
J:137003
|
Wif1tm1Dmth/Wif1tm1Dmth
(involves: 129 * C57BL/6)
|
increased incidence of induced tumors
|
J:149607
|
| increased osteosarcoma incidence
|
J:149607
|
| increased sarcoma incidence
|
J:149607
|
Wrntm1Led/Wrntm1Led
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased tumor incidence
|
J:48424
|
Wrntm1Led/Wrntm1Led
(involves: 129S6/SvEvTac * Black Swiss)
|
increased tumor incidence
|
J:106446
|
Wwc1tm1Arsc/Wwc1tm1Arsc
Wwc2tm1.1Arte/Wwc2tm1.1Arte
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * C57BL/6J * DBA)
|
increased liver tumor incidence
|
J:305034
|
WwoxGt(XG218)Byg/WwoxGt(XG218)Byg
(involves: 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:132078
|
| increased malignant tumor incidence
|
J:132078
|
Wwoxtm1.1Mald/Wwoxtm1.1Mald
(involves: C57BL/6 * FVB/N)
|
neoplasm
|
J:155406
|
Wwoxtm1Ria/Wwox+
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of tumors by chemical induction
|
J:120064
|
| increased lung tumor incidence
|
J:120064
|
| increased tumor incidence
|
J:120064
|
Wwoxtm1Ria/Wwoxtm1Ria
(involves: 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:120064
|
Wwoxtm2.1Ria/Wwoxtm2.1Ria
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased skeletal tumor incidence
|
J:198845
|
Xpatm1Hvs/Xpatm1Hvs
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of induced tumors
|
J:28710
|
| increased incidence of tumors by UV-induction
|
J:112689
|
Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA)
|
increased incidence of induced tumors
|
J:28709
|
| increased incidence of tumors by chemical induction
|
J:28709
|
| increased incidence of tumors by UV-induction
|
J:28709
|
| increased lung adenocarcinoma incidence
|
J:62877
|
| increased lung adenoma incidence
|
J:62877
|
| increased papilloma incidence
|
J:28709
|
| increased skin squamous cell carcinoma incidence
|
J:28709
|
| increased tumor incidence
|
J:141237
|
Xpatm1Tnka/Xpatm1Tnka
(C3.Cg-Xpatm1Tnka)
|
increased liver adenoma incidence
|
J:76206
|
| increased liver tumor incidence
|
J:76206
|
Xpatm1Tnka/Xpatm1Tnka
Tg(KRT14-Kitl)1Takk/?
(involves: C57BL/6 * CBA * SJL)
|
increased metastatic potential
|
J:100608
|
| increased skin tumor incidence
|
J:100608
|
Xpctm1Brd/Xpctm1Brd
(involves: 129S7/SvEvBrd * C57BL)
|
increased incidence of tumors by UV-induction
|
J:28708
|
Xpctm1Ecf/Xpctm1Ecf
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:101421
|
| increased lung adenoma incidence
|
J:101421
|
| increased lung tumor incidence
|
J:101421
|
Xpnpep1tm1a(KOMP)Wtsi/Xpnpep1tm1a(KOMP)Wtsi
(C57BL/6N-Xpnpep1tm1a(KOMP)Wtsi/Wtsi)
|
embryo tumor
|
J:239583
|
| increased hemangioma incidence
|
J:239583
|
| increased trigeminal neuroma incidence
|
J:239583
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:152528
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:152528
|
Xrcc6tm1Fwa/Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:44361
|
Yap1tm2.1Dupa/Yap1tm2.1Dupa
(Not Specified)
|
increased incidence of tumors by chemical induction
|
J:223215
|
Yy1tm2.1Yshi/Yy1tm2.1Yshi
Tg(Nkx2-1-cre)2Sand/0
(involves: 129S4/SvJae * C57BL/6J)
|
increased blastoma incidence
|
J:239777
|
Zdhhc9tm1Lex/Y
Nrastm1Tyj/Nrastm1Tyj
Tg(Mx1-cre)1Cgn/0
(involves: 129S5/SvEvBrd * C57BL/6 * CBA)
|
decreased leukemia incidence
|
J:231488
|
Zeb1tm1Yhi/Zeb1tm1Yhi
(either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))
|
increased T cell derived lymphoma incidence
|
J:139194
|
Zfand2btm1Otin/Zfand2btm1Otin
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:233169
|
Zfhx3tm1.1Jtd/Zfhx3tm1.1Jtd
Tg(Pbsn-cre)4Prb/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
|
increased prostate intraepithelial neoplasia incidence
|
J:189563
|
Zfp14tm1Xch/Zfp14+
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:331393
|
| increased tumor incidence
|
J:331393
|
Zfp14tm1Xch/Zfp14tm1Xch
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:331393
|
| increased tumor incidence
|
J:331393
|
Zfp36l1tm1.1Tnr/Zfp36l1tm1.1Tnr
Zfp36l2tm1.1Tnr/Zfp36l2tm1.1Tnr
Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)
|
increased leukemia incidence
|
J:162388
|
| increased T cell derived lymphoma incidence
|
J:162388
|
Zfp280cem1Xss/Zfp280cem1Xss
(C57BL/6J-Zfp280cem1Xss)
|
decreased incidence of tumors by chemical induction
|
J:331404
|
Zfp296tm1Miya/Zfp296tm1Miya
(B6.129P2-Zfp296tm1Miya)
|
neoplasm
|
J:255491
|
Zfp639tm1.2Jaty/Zfp639tm1.2Jaty
(involves: 129 * BALB/cJ * C57BL/6 * SJL)
|
neoplasm
|
J:305874
|
Zfp746em1Jhsn/Zfp746em1Jhsn
(C57BL/6-Zfp746em1Jhsn)
|
decreased incidence of tumors by chemical induction
|
J:344819
|
Zfp871tm1a(EUCOMM)Wtsi/Zfp871+
(C57BL/6N-Zfp871tm1a(EUCOMM)Wtsi/BayMmucd)
|
decreased lymphoma incidence
|
J:317166
|
| increased B cell derived lymphoma incidence
|
J:317166
|
| neoplasm
|
J:317166
|
Zmynd8em1Lwb/Zmynd8em1Lwb
Tg(MMTV-cre)4Mam/0
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB)
|
decreased mammary gland tumor incidence
|
J:326848
|
Zmynd8em1Lwb/Zmynd8em1Lwb
Tg(MMTV-PyVT)634Mul/0
Tg(KRT14-cre)1Amc/0
(involves: C57BL/6N * CBA * FVB)
|
decreased mammary gland tumor incidence
|
J:326848
|
Analysis Tools